
<html lang="en"     class="pb-page"  data-request-id="ca1e16a3-45c4-4424-a666-486882a5ba8a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00444;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165" /></meta><meta name="dc.Creator" content="Stephen T.  Wrobleski" /></meta><meta name="dc.Creator" content="Ryan  Moslin" /></meta><meta name="dc.Creator" content="Shuqun  Lin" /></meta><meta name="dc.Creator" content="Yanlei  Zhang" /></meta><meta name="dc.Creator" content="Steven  Spergel" /></meta><meta name="dc.Creator" content="James  Kempson" /></meta><meta name="dc.Creator" content="John S.  Tokarski" /></meta><meta name="dc.Creator" content="Joann  Strnad" /></meta><meta name="dc.Creator" content="Adriana  Zupa-Fernandez" /></meta><meta name="dc.Creator" content="Lihong  Cheng" /></meta><meta name="dc.Creator" content="David  Shuster" /></meta><meta name="dc.Creator" content="Kathleen  Gillooly" /></meta><meta name="dc.Creator" content="Xiaoxia  Yang" /></meta><meta name="dc.Creator" content="Elizabeth  Heimrich" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Charu  Chaudhry" /></meta><meta name="dc.Creator" content="Javed  Khan" /></meta><meta name="dc.Creator" content="Max  Ruzanov" /></meta><meta name="dc.Creator" content="Jeffrey  Tredup" /></meta><meta name="dc.Creator" content="Dawn  Mulligan" /></meta><meta name="dc.Creator" content="Dianlin  Xie" /></meta><meta name="dc.Creator" content="Huadong  Sun" /></meta><meta name="dc.Creator" content="Christine  Huang" /></meta><meta name="dc.Creator" content="Celia  D’Arienzo" /></meta><meta name="dc.Creator" content="Nelly  Aranibar" /></meta><meta name="dc.Creator" content="Manoj  Chiney" /></meta><meta name="dc.Creator" content="Anjaneya  Chimalakonda" /></meta><meta name="dc.Creator" content="William J.  Pitts" /></meta><meta name="dc.Creator" content="Louis  Lombardo" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="James R.  Burke" /></meta><meta name="dc.Creator" content="David S.  Weinstein" /></meta><meta name="dc.Description" content="Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the cataly..." /></meta><meta name="Description" content="Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the cataly..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 18, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00444" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00444" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00444" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00444" /></link>
        
    
    

<title>Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00444" /></meta><meta property="og:title" content="Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0017.jpeg" /></meta><meta property="og:description" content="Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge. Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain. Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2. In addition to unprecedented JAK isoform and kinome selectivity, 11 shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease. On the basis of these findings, 11 appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00444"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00444">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00444&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00444&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00444&amp;href=/doi/10.1021/acs.jmedchem.9b00444" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8973-8995</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00443" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.9b00522" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Stephen T. Wrobleski</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen T. Wrobleski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For S.T.W.: phone, (609)252-4873; E-mail, <a href="/cdn-cgi/l/email-protection#7a090e1f0a121f14540d081518161f0911133a18170954191517"><span class="__cf_email__" data-cfemail="780b0c1d08101d16560f0a171a141d0b1311381a150b561b1715">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+T.++Wrobleski">Stephen T. Wrobleski</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7793-1530" title="Orcid link">http://orcid.org/0000-0001-7793-1530</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ryan Moslin</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan Moslin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><span class="conrtib-corresp"><strong>*</strong>For R.M.: E-mail, <a href="/cdn-cgi/l/email-protection#89fbf0e8e7a7e4e6fae5e0e7c9ebe4faa7eae6e4"><span class="__cf_email__" data-cfemail="91e3e8f0ffbffcfee2fdf8ffd1f3fce2bff2fefc">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan++Moslin">Ryan Moslin</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0332-4778" title="Orcid link">http://orcid.org/0000-0002-0332-4778</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuqun Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuqun Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuqun++Lin">Shuqun Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanlei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanlei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanlei++Zhang">Yanlei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven Spergel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven Spergel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Spergel">Steven Spergel</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5190-3942" title="Orcid link">http://orcid.org/0000-0002-5190-3942</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James Kempson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James Kempson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Synthesis, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James++Kempson">James Kempson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9540-3886" title="Orcid link">http://orcid.org/0000-0002-9540-3886</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John S. Tokarski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John S. Tokarski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+S.++Tokarski">John S. Tokarski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joann Strnad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joann Strnad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joann++Strnad">Joann Strnad</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adriana Zupa-Fernandez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adriana Zupa-Fernandez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adriana++Zupa-Fernandez">Adriana Zupa-Fernandez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lihong Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lihong Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lihong++Cheng">Lihong Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Shuster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Shuster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Shuster">David Shuster</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kathleen Gillooly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathleen Gillooly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Gillooly">Kathleen Gillooly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoxia Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoxia Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoxia++Yang">Xiaoxia Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth Heimrich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth Heimrich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth++Heimrich">Elizabeth Heimrich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kim W. McIntyre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kim W. McIntyre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charu Chaudhry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charu Chaudhry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Leads Discovery and Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charu++Chaudhry">Charu Chaudhry</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Javed Khan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Javed Khan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Javed++Khan">Javed Khan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Max Ruzanov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Max Ruzanov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Max++Ruzanov">Max Ruzanov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey Tredup</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey Tredup</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Tredup">Jeffrey Tredup</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dawn Mulligan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dawn Mulligan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dawn++Mulligan">Dawn Mulligan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dianlin Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dianlin Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dianlin++Xie">Dianlin Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huadong Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huadong Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huadong++Sun">Huadong Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christine Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christine Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Huang">Christine Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Celia D’Arienzo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Celia D’Arienzo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Celia++D%E2%80%99Arienzo">Celia D’Arienzo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nelly Aranibar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nelly Aranibar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nelly++Aranibar">Nelly Aranibar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manoj Chiney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manoj Chiney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manoj++Chiney">Manoj Chiney</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anjaneya Chimalakonda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anjaneya Chimalakonda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anjaneya++Chimalakonda">Anjaneya Chimalakonda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William J. Pitts</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William J. Pitts</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+J.++Pitts">William J. Pitts</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Louis Lombardo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louis Lombardo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louis++Lombardo">Louis Lombardo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Percy H. Carter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Percy H. Carter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James R. Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James R. Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Burke">James R. Burke</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">David S. Weinstein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David S. Weinstein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+S.++Weinstein">David S. Weinstein</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00444&amp;href=/doi/10.1021%2Facs.jmedchem.9b00444" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8973–8995</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 18, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 March 2019</li><li><span class="item_label"><b>Published</b> online</span>18 July 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 October 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00444" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00444</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8973%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStephen%2BT.%2BWrobleski%252C%2BRyan%2BMoslin%252C%2BShuqun%2BLin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D20%26contentID%3Dacs.jmedchem.9b00444%26title%3DHighly%2BSelective%2BInhibition%2Bof%2BTyrosine%2BKinase%2B2%2B%2528TYK2%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%253A%2BDiscovery%2Bof%2Bthe%2BAllosteric%2BInhibitor%2BBMS-986165%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8995%26publicationDate%3DOctober%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00444"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">11593</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">50</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00444" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;T. Wrobleski&quot;},{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;Moslin&quot;},{&quot;first_name&quot;:&quot;Shuqun&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Yanlei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Spergel&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Kempson&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;S. Tokarski&quot;},{&quot;first_name&quot;:&quot;Joann&quot;,&quot;last_name&quot;:&quot;Strnad&quot;},{&quot;first_name&quot;:&quot;Adriana&quot;,&quot;last_name&quot;:&quot;Zupa-Fernandez&quot;},{&quot;first_name&quot;:&quot;Lihong&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Shuster&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Gillooly&quot;},{&quot;first_name&quot;:&quot;Xiaoxia&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;Heimrich&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Charu&quot;,&quot;last_name&quot;:&quot;Chaudhry&quot;},{&quot;first_name&quot;:&quot;Javed&quot;,&quot;last_name&quot;:&quot;Khan&quot;},{&quot;first_name&quot;:&quot;Max&quot;,&quot;last_name&quot;:&quot;Ruzanov&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Tredup&quot;},{&quot;first_name&quot;:&quot;Dawn&quot;,&quot;last_name&quot;:&quot;Mulligan&quot;},{&quot;first_name&quot;:&quot;Dianlin&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Huadong&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;D’Arienzo&quot;},{&quot;first_name&quot;:&quot;Nelly&quot;,&quot;last_name&quot;:&quot;Aranibar&quot;},{&quot;first_name&quot;:&quot;Manoj&quot;,&quot;last_name&quot;:&quot;Chiney&quot;},{&quot;first_name&quot;:&quot;Anjaneya&quot;,&quot;last_name&quot;:&quot;Chimalakonda&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;J. Pitts&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;Lombardo&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Burke&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;S. Weinstein&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;8973-8995&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00444&quot;},&quot;abstract&quot;:&quot;Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge. Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain. Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (11) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2. In addition to unprecedented JAK isoform and kinome selectivity, 11 shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease. On the basis of these findings, 11 appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00444&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00444" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00444&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00444" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00444&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00444" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00444&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00444&amp;href=/doi/10.1021/acs.jmedchem.9b00444" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00444" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00444" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00444%26sid%3Dliteratum%253Aachs%26pmid%3D31318208%26genre%3Darticle%26aulast%3DWrobleski%26date%3D2019%26atitle%3DHighly%2BSelective%2BInhibition%2Bof%2BTyrosine%2BKinase%2B2%2B%2528TYK2%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BAutoimmune%2BDiseases%253A%2BDiscovery%2Bof%2Bthe%2BAllosteric%2BInhibitor%2BBMS-986165%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D20%26spage%3D8973%26epage%3D8995%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/jmcmar.2019.62.issue-20/20191024/jmcmar.2019.62.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formidable challenge. Our strategy to achieve high selectivity for TYK2 relies on targeting the TYK2 pseudokinase (JH2) domain. Herein we report the late stage optimization efforts including a structure-guided design and water displacement strategy that led to the discovery of BMS-986165 (<b>11</b>) as a high affinity JH2 ligand and potent allosteric inhibitor of TYK2. In addition to unprecedented JAK isoform and kinome selectivity, <b>11</b> shows excellent pharmacokinetic properties with minimal profiling liabilities and is efficacious in several murine models of autoimmune disease. On the basis of these findings, <b>11</b> appears differentiated from all other reported JAK inhibitors and has been advanced as the first pseudokinase-directed therapeutic in clinical development as an oral treatment for autoimmune diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Tyrosine kinase 2 (TYK2)<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> is a member of the Janus family of kinases (JAK) that also includes JAK1, JAK2, and JAK3. The JAK family of nonreceptor tyrosine kinases is known to be critical in mediating the signaling of numerous cytokines that cause inflammation.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> As a result, small molecule inhibitors of the JAK kinases offer promise as effective treatments for a variety of serious inflammatory and autoimmune diseases.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> To date, all known small molecule JAK inhibitors that have progressed into development are active site-directed inhibitors that bind to the adenosine triphosphate (ATP) site of the catalytic domain (also referred to as the JH1 or “Janus Homology 1” domain) of the JAK protein, which prevents catalytic activity of the kinase by blocking ATP, downstream phosphorylation, and resulting pathway signal transduction.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> This includes the first generation clinically approved inhibitors <b>1</b>–<b>4</b> as well as the second-generation inhibitors <b>5</b>–<b>10</b> currently in development (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In contrast, BMS-986165 (<b>11</b>) is differentiated from previous JAK inhibitors due its unique ability to selectively bind to the pseudokinase (JH2) domain of TYK2 and inhibit its function through an allosteric mechanism. This work will describe the late-stage discovery efforts that ultimately led to the identification of <b>11</b>, currently in phase III clinical trials as a potential treatment for psoriasis.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the first-generation clinically approved JAK inhibitors <b>1</b>–<b>4</b>, the second-generation experimental JAK inhibitors <b>5</b>–<b>10</b>, and the TYK2-selective allosteric inhibitor <b>11</b> in the clinic for the treatment of chronic immunological disorders. Inhibitors <b>1</b>–<b>10</b> are conventional active-site (JH1) inhibitors, whereas <b>11</b> is an allosteric (JH2) inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because of the high homology of the ATP active site across the kinome and especially within the JAK family, achieving high selectivity for a specific JAK family member while also maintaining selectivity within the kinome is a significant challenge. As a result, many JAK inhibitors that have been developed are pan-JAK inhibitors or are modestly selective for one or more JAK family member. While these inhibitors have shown encouraging results in treating autoimmune diseases, undesirable side effects leading to a narrow therapeutic index have been observed and suggests the need for improved treatments. Tofacitinib (<b>1</b>), a pan-JAK inhibitor of JAK1, JAK2, JAK3, and to a lesser extent TYK2, became the first orally available small molecule kinase inhibitor to be approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in 2012.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> However, only the lower 5 mg twice-daily dose of <b>1</b> was approved by the Food and Drug Administration (FDA) based on an unfavorable risk-to-benefit ratio observed with the higher 10 mg twice-daily dose. Efficacy was also achieved with <b>1</b> in late-stage phase III clinical trials for the treatment of psoriasis (PSO), psoriatic arthritis (PsA), and ulcerative colitis (UC) and recently gained FDA approval for the treatment of active PsA and moderately to severely active UC.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16">(8−16)</a> Despite these achievements, the FDA declined approval of <b>1</b> for the treatment of PSO in 2015 based on issues of clinical efficacy and long-term safety.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> It is currently in phase III studies for the treatment of ankylosing spondylitis (AS), phase II studies for alopecia areata (AA) and inflammatory eye disease, and phase I studies for systemic discoid lupus erythematosus (DLE), systemic lupus erythematosus (SLE), diffuse cutaneous systemic sclerosis (dcSSc), and treatment-refractory dermatomyositis.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22 ref23">(18−23)</a> Other first-generation JAK inhibitors approved include the JAK1/JAK2 selective inhibitors ruxolitinib (<b>2</b>) and the structurally related baricitinib (<b>3</b>). Inhibitor <b>2</b> has been approved as a treatment for myelofibrosis and is also being explored in phase III studies as an oral treatment for steroid-refractory graft vs host disease (GvHD) and as a topical treatment for atopic dermatitis (AD).<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Inhibitor <b>3</b> has demonstrated efficacy in RA and PSO patients in phases III and IIb, respectively, and is also being explored in SLE and atopic dermatitis in phase II trials.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27−30)</a> However, safety concerns remain as only the lower 2 mg dose of <b>3</b> was recently approved by the FDA to treat moderate-to-severely active RA patients due to a safety concern related to a potential thrombosis risk at the higher, more efficacious 4 mg dose.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The pan-JAK inhibitor peficitinib (<b>4</b>) has also shown efficacy in RA patients in two phase III trials and was recently approved in Japan.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Although these first-generation JAK inhibitors have established proof-of-concept in treating serious diseases, achieving robust efficacy while maintaining a safe therapeutic window, has been a significant challenge in the long term treatment of chronic diseases. Dose-limiting side effects such as anemia, neutropenia, and increased infection risk and dyslipidemia have been observed<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34−36)</a> and attributed to inhibition of JAK1 and JAK2, the latter of which is well-known to be involved in hematopoiesis.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> These safety concerns led to the development of second-generation JAK inhibitors that have been reported to be more selective over JAK2, including the reported JAK1-selective inhibitors filgotinib (<b>5</b>), upadacitinib (<b>6</b>), and abrocitinib (<b>7</b>).<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> These inhibitors have recently advanced into phase III clinical trials with some encouraging safety and tolerability results. Inhibitor <b>5</b> has been reported to show efficacy in RA in combination with methotrexate or as a single agent without the side effects such as anemia or changes in levels of lymphocyte, natural killer (NK) cells, or liver function tests (LFT) observed with <b>1</b>.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41−43)</a> However, increased creatinine levels and reduced neutrophil and platelet counts were observed. Inhibitor <b>5</b> was also reported to show efficacy in Crohn’s disease (CD) by meeting phase II primary end points in a 10-week interim analysis without any drug-related significant adverse events (SAEs).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> More recently, the JAK1-selective inhibitor <b>6</b> was disclosed to have met all primary and ranked secondary end points in a phase III study in RA, yet laboratory changes were shown to be very similar to those observed with <b>1</b>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> This included increased levels of liver transaminases, creatine phosphokinase, LDL cholesterol, and HDL cholesterol and decreased counts of NK cells, lymphocytes, and neutrophils. Other reported more selective inhibitors are in development, including the JAK1-selective inhibitor <b>7</b>, that has advanced to phase III studies in atopic dermatitis<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and the dual JAK3/TEC family irreversible inhibitor PF-06651600 (<b>8</b>)<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> being investigated in phase II studies in CD, UC, and AA.<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48−50)</a> Despite this progress, it is yet to be determined whether more selective JAK1 and/or JAK3 inhibition can achieve a superior therapeutic profile compared to first-generation inhibitors in these complex diseases.</div><div class="NLM_p">Selective inhibition of TYK2 has recently emerged as a potential strategy for treating various autoimmune diseases.<a onclick="showRef(event, 'ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53">(51−53)</a> A dual JAK1/TYK2 inhibitor PF-06700841 (<b>9</b>)<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> has shown efficacy in patients with plaque PSO in phase II studies<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> and is currently enrolled in additional phase II studies for CD, UC, and AA.<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48−50)</a> Yet, at maximally efficacious doses in PSO patients, <b>9</b> gave significant reductions in absolute reticulocyte and neutrophil counts as well as reduced platelet counts that was believed to be associated with JAK2 and JAK1 inhibition, respectively.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The inhibitor PF-06826647 (<b>10</b>) has recently been disclosed to be more selective for TYK2 and is currently under evaluation in phase I studies for the treatment of PSO.<a onclick="showRef(event, 'ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59">(57−59)</a></div><div class="NLM_p">Our goal was to identify a more selective TYK2 inhibitor in the hope of establishing clinical efficacy in autoimmune diseases while demonstrating an improved safety profile. Toward that goal, we were the first to report the discovery of highly selective allosteric TYK2 inhibitors that act by their unique ability to bind to and stabilize the TYK2 pseudokinase (JH2) domain to block TYK2 signaling.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> On the basis of these initial findings, we disclose in the preceding article our hit-to-lead efforts that led to a new series of <i>N</i>-methylpyridine-3-carboxamides (nicotinamides) and <i>N</i>-methyl pyridazine-3-carboxamides as allosteric TYK2 inhibitors that have demonstrated in vivo proof-of-concept in CD40 agonist-induced colitis, a murine disease model of inflammatory bowel disease (IBD).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_p">Herein, we report further optimization efforts within this series that culminated in the discovery of BMS-986165 (<b>11</b>) currently under clinical development as a potential treatment for PSO, CD, and SLE (<a href="http://Clinicaltrials.gov" class="extLink">Clinicaltrials.gov</a> identifiers NCT03624127, NCT03611751, NCT03599622, NCT03252587). Comparison of the TYK2 and other JAK family biochemical potencies of <b>11</b> relative to the classic active-site clinical JAK inhibitors <b>1</b>–<b>10</b> show a distinct selectivity profile that is envisioned to permit maximal efficacy from selective TYK2 inhibition but with decreased potential for adverse side effects that have been observed with less selective inhibitors (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). As noted, <b>11</b> is a potent allosteric inhibitor of TYK2 that acts by binding to the TYK2 JH2 domain with high affinity (IC<sub>50</sub> = 0.2 nM) and achieves remarkable selectivity over inhibition of catalytically active JH1 domains of the JAK family, a distinct profile that translates to an observed high functional selectivity for TYK2 over JAK1, JAK2, and JAK3.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Consistent with this selectivity profile, <b>11</b> has recently shown encouraging efficacy in phase II studies<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> in treating patients with active PSO without incidences of adverse effects that have commonly been observed with less selective JAK inhibitors such as neutropenia, elevations in liver enzyme levels or serum creatinine, or dyslipidemia. Furthermore, <b>11</b> has demonstrated robust efficacy in murine models of lupus nephritis and IBD.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Herein, we disclose additional preclinical studies with <b>11</b> that demonstrate robust efficacy in a murine psoriasis-like disease model that further supports the therapeutic potential of this agent as a treatment across multiple autoimmune diseases.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Reported JAK Family Biochemical Potencies for Clinical Inhibitors <b>1</b>–<b>10</b> Compared to <b>11</b><a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">assay IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">JAK1</th><th class="colsep0 rowsep0" align="center" char=".">JAK2</th><th class="colsep0 rowsep0" align="center" char=".">JAK3</th><th class="colsep0 rowsep0" align="center">TYK2 (JH1/JH2)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">55</td><td class="colsep0 rowsep0">489/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">487</td><td class="colsep0 rowsep0">30/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">787</td><td class="colsep0 rowsep0">61/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0">5/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">363</td><td class="colsep0 rowsep0" align="char" char=".">2400</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0">2600/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char=".">2304</td><td class="colsep0 rowsep0">4690/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">803</td><td class="colsep0 rowsep0" align="char" char=".">>15000</td><td class="colsep0 rowsep0">1250/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0">>10000/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">6494</td><td class="colsep0 rowsep0">23/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">383</td><td class="colsep0 rowsep0" align="char" char=".">74</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0">17/nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0">>10000/0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Assays run in the presence of 1 mM ATP according to ref <a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> for <b>1</b>–<b>3</b> and <b>5</b>, ref <a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> for <b>7</b>, ref <a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> for <b>8</b>, ref <a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> for <b>9</b>, and ref <a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> for <b>10</b>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Assays run at the <i>K</i><sub>m</sub> for ATP according to ref <a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Assays run in the presence of 0.1 mM ATP according to ref <a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a>.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Using homogeneous time-resolved fluorescence (HTRF) binding assays measuring the displacement of a probe compound (please see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">nd: not determined.</p></div></div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> A Novel Allosteric Approach to Selective TYK2 Inhibition</h3><div class="NLM_p">Small molecule TYK2 inhibitors that are able to block both the IL-23/IL-12 and the type I interferon (IFNα, IFNβ) pathways may offer the potential to safely and more efficaciously treat a broad spectrum of inflammatory and autoimmune diseases. However, a significant challenge in this regard is achieving the desired level of TYK2 selectivity to avoid undesirable off-target effects. This includes ensuring adequate selectivity over the other members of the JAK kinases as well as against the entire kinome containing >500 kinases. Despite the potential of TYK2 inhibition, identifying small molecules that are selective is challenging. Our strategy relies on small molecule allosteric inhibitors such as the <i>N</i>-deuteromethyl pyridazine carboxamide <b>12</b> that potently inhibit TYK2-dependent signaling with high specificity by binding to and stabilizing its pseudokinase JH2 domain (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref60 ref61 ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62 ref63 ref64">(60−64)</a> The JH2 domain directly precedes the catalytically active JH1 kinase domain containing the canonical ATP-binding site, a structural feature that is unique to the JAK family.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> While the TYK2 JH2 domain closely resembles its JH1 domain and contains an ATP binding site much like the JH1 domain, specific residue differences within JH2 precludes any catalytic function.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Although the precise mechanism of the allosteric inhibition of TYK2 through the JH2 domain remains to be elucidated, evidence suggests that small molecule ligand binding to JH2 stabilizes autoinhibitory intramolecular interactions between the JH2 domain and the JH1 active site. These JH2–JH1 interactions are believed to limit the conformational mobility of the JH1 active site that is required for phosphotransfer catalysis.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> A notable advantage of inhibiting TYK2 by binding to its JH2 domain is the potential to achieve maximal efficacy while maintaining a high level of selectivity over the kinome, especially with respect to the other JAKs. To that end, we have previously demonstrated in vivo proof-of-concept studies with the JH2 ligand <b>12</b> in a CD40 agonist-induced colitis murine disease model of IBD<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Inhibitor <b>12</b> has been shown to be highly selective for TYK2 over JAK1, JAK2, and JAK3 by virtue of a key deuteromethyl amide substituent. Importantly, this group provides high selectivity by binding to a pocket created by a rare alanine residue (“alanine pocket”) in the TYK2 JH2 ligand binding domain. Furthermore, deuteration of the <i>N</i>-methyl group was shown to block generation of a less selective primary amide metabolite in vivo by suppressing an <i>N</i>-demethylation metabolic pathway via deuterium kinetic isotope effect (DKIE).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In homogeneous time-resolved fluorescence (HTRF) biochemical affinity assays that measure the inhibition of binding of fluorescein-tagged probe molecules,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><b>12</b> binds to the TYK2 JH2 domain with high affinity (IC<sub>50</sub> = 0.5 nM) and specificity over binding to the TYK2, JAK1, JAK2, and JAK3 catalytically active JH1 domains (IC<sub>50</sub> values >10000 nM).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In cell-based luciferase reporter assays in T-cells that measure JAK family functional selectivity,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><b>12</b> is a selective inhibitor of IFNα-stimulated TYK2-dependent signaling (IC<sub>50</sub> = 27 nM) and is highly selective over GM-CSF stimulated JAK2-dependent signaling (∼270-fold) and IL-2 stimulated JAK1/3-dependent signaling (∼210-fold). Furthermore, <b>12</b> is also highly selective (>1000-fold) against >250 kinases in an in-house panel using similar biochemical affinity assays with the only exception being cKit (∼690-fold). On the basis of the encouraging selectivity profile and preclinical proof-of-concept studies of <b>12</b>, efforts were focused on continued optimization within this series of allosteric TYK2 inhibitors to identify potential candidates for advancement into clinical development.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustrating the general protein structure of TYK2 and depicting the <i>N</i>-deuteromethyl pyridazine carboxamide <b>12</b> that potently inhibits TYK2 dependent signaling by binding to the TYK2 pseudokinase (JH2) domain with high specificity over the JAK family kinase (JH1) domains.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13886" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13886" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Program Objectives for Further Optimization</h3><div class="NLM_p">Inhibitor <b>12</b> was a promising analogue from our initial hit-to-lead efforts that provided in vivo proof-of-concept in a murine model of IBD.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> As a result, further optimization was focused on improving potency in human whole blood (hWB) within this series. In addition, mitigation of a potential cardiovascular liability was required because <b>12</b> was shown to be an inhibitor of the human ether-á-go-go-related gene (hERG) ion channel in vitro (patch clamp IC<sub>50</sub> = 10.9 μM) that translated into an observed QT<sub>c</sub> prolongation in an in vivo telemetrized rabbit study (data not shown). Fortunately, emerging structure–activity relationships (SAR) studies in replacing the 2-aminopyridyl side chain in <b>12</b> with alkyl amide side chains, in particular cyclopropyl amide, gave reduced hERG inhibition and suggested a path forward, albeit with some decrease in potency.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Therefore, immediate optimization efforts were focused on improving potency within the series to better enable mitigation of the potential hERG liability while allowing for a lower projected human dose. Because of the aforementioned role of the deuteromethyl amide group in providing high selectivity by binding to the atypical “alanine pocket” of TYK2 JH2, this group was maintained and optimization was instead focused on modifications around the aryl methyl sulfone group of <b>12</b>. These efforts were guided by X-ray cocrystal structures of sulfone analogues such as <b>12</b> bound to TYK2 JH2 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Notably, the methyl group of the methyl sulfone of <b>12</b> favorably occupies a shallow lipophilic pocket in the C-terminal domain region that is created by Pro694, the side chain of Leu741, and the methine backbone of Asn739 at the bottom of the ligand binding site. Additional favorable interactions between <b>12</b> and TYK2 JH2 include two hydrogen bonds to the conserved Lys642 from the <i>N</i>-deuteromethyl amide carbonyl oxygen and one of the sulfone oxygens as well as the presence of a structural water molecule facilitating indirect hydrogen bond interactions between the second sulfone oxygen of <b>12</b> with the C-terminal domain Arg738 and the Gln597 of the P-loop region. On the basis of these observations, and due to our previous success in displacing a structural water resulting in improved potency in an early series of p38 kinase inhibitors,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> we were inspired to investigate ligand modifications that might displace the observed structural water. This strategy was especially attractive due to the possibility of improving potency through displacement of an energetically disfavored water molecule<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and potentially forming an additional hydrogen bond interaction with the protein.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure representation of <b>12</b> cocomplexed with TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZR">6NZR</a>). Carbons of <b>12</b> in magenta. TYK2 JH2 ribbon and carbons in green. Key hydrogen bond interactions within the ligand binding site are represented as dotted lines. Binding regions, including the unique “alanine pocket”, and the observed structural water are highlighted in blue text with other key residues labeled. The P-loop region has been partially omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> A Water Displacement Strategy</h3><div class="NLM_p">Initial SAR studies to explore the water displacement proposal were pursued within the closely related pyridine-3-carboxamide series, exemplified by <b>13</b>, that contained the methyl sulfone group at the C2′ position, a nondeuteromethyl amide, and a 5-fluoro-2-aminopyridine side chain (<a class="ref showTableEvent internalNav" data-ID="tbl1a" href="#tbl1a">Table <a class="ref showTableEvent internalNav" data-ID="tbl1a" href="#tbl1a">2</a></a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Of particular interest was a finding where the methyl sulfone group in <b>13</b> was replaced with a methoxy substituent in <b>14</b>.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Although <b>14</b> was ∼5-fold less potent compared to <b>13</b>, we envisioned that <b>14</b> may be a better starting point to explore the water displacement strategy due to its lower starting polar surface area (PSA = 88 vs 113 Å<sup>2</sup> for <b>13</b>). A proposal of particular interest from our modeling studies was incorporation of hydrogen bond accepting groups ortho to C2′ methoxy (C3′ position) that might favorably displace the structural water and form a direct hydrogen bond interaction with the Arg738 side chain. With this idea in mind, C3′ modifications were explored in the C2′ methoxy series. Gratifyingly, one of the initial analogues <b>15</b> containing a cyano group at C3′ showed a significant improvement in potency compared to the C3′ unsubstituted analogue <b>14</b>, giving comparable potency to the sulfone <b>13</b> in both the TYK2 JH2 and IFNα cellular assay. Although <b>15</b> was ∼3-fold less potent in hWB vs <b>13</b>, we were encouraged by this initial result and expanded our SAR investigation to include C3′ amides. The intermediate acid <b>16</b> was prepared and tested along with the primary amide <b>17</b> and the <i>N</i>-methyl amide <b>18</b>. All of these analogues were found to be nearly equipotent to <b>13</b> in binding and cellular potency including in hWB, with the exception of acid <b>16</b>, which did not show any activity in cells likely due to poor permeability as measured in an in vitro Caco-2 permeability assay (apical-to-basal <i>P</i><sub>c</sub> < 15 nm/s). Remarkably, removal of the C2′ methoxy group while retaining the C3′ methyl amide in <b>19</b> results in a ∼60-fold loss in TYK2 JH2 potency, ∼100-fold loss in functional potency, and no significant activity in hWB at the highest concentration tested, thereby highlighting the importance of the C2′ methoxy group. Transposition of the amide group from the C3′ position to the adjacent C4′ position was also explored while maintaining the C2′ methoxy group as in <b>20</b> and <b>21</b>. These analogues were also potent in the TYK2 JH2 assay but were noticeably less potent in the cellular assays relative to their C3′ amide counterparts <b>17</b> and <b>18</b>, possibly due to decreased permeability as observed in the Caco-2 assay (apical-to-basal <i>P</i><sub>c</sub> = 50 nm/s for <b>18</b> vs <15 nm/s for <b>21</b>).</div><div class="NLM_table-wrap" id="tbl1a"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. C4-Aminophenyl SAR Exploring C2′–C4′ Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0009.gif" alt="" id="gr4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0010.gif" alt="" id="gr5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1afn1"><div class="footnote" id="t1afn1"><sup><sup>a</sup></sup><p class="last">In vitro assays. Mean values are determined from at least three experiments unless otherwise noted.</p></div><div class="footnote" id="t1afn2"><sup><sup>b</sup></sup><p class="last">Assay measuring TYK2-dependent IFNα-induced STAT5 phosphorylation in human whole blood according to refs <a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a>.</p></div><div class="footnote" id="t1afn3"><sup><sup>c</sup></sup><p class="last">According to ref <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a>.</p></div><div class="footnote" id="t1afn4"><sup><sup>d</sup></sup><p class="last">Mean values determined from two test occasions.</p></div></div><div></div></div><div class="NLM_p">To further explore the C3′ amide SAR, additional amides were prepared in a closely related series containing a 4-methyl substituent on the pyridyl side chain (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">3</a></a>). Previous SAR efforts had shown this series to have improved selectivity over cKit (data not shown), and modeling studies suggested that larger C3′ amide substitutions would be well-tolerated due to their projection into a large open pocket beyond the Arg738 (vide infra). Consistent with these modeling results, many amide substitutions were prepared and found to be potent in the TYK2 JH2 biochemical assay. As in the previous 4-<i>des</i>-methyl pyridyl series, the primary amide (<b>22</b>) and methyl amide (<b>23</b>) were both potent (TYK2 JH2 IC<sub>50</sub> values = 0.5 nM) with very good translation into hWB (IC<sub>50</sub> values = 62 and 140 nM, respectively), with many other amides being nearly equipotent in the TYK2 JH2 biochemical assay. Unfortunately, many of the additional amides showed a decrease in potency in the IFNα cellular and/or hWB assays relative to the primary amide <b>22</b>. This included the ethyl amide <b>24</b> as well as the dimethylamide <b>25</b> that were 4–12-fold less potent in hWB relative to <b>22</b>. Larger alkyl amides containing polar groups such as the hydroxy- and morpholino-substituted alkyl amides <b>27</b> and <b>28</b> and the 2-picolinamine-derived amide <b>29</b> were also notably potent in the TYK2 JH2 assay but were still ∼3–5-fold less potent in hWB compared to <b>22</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Expansion of C3′ Amide SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0011.gif" alt="" id="gr6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0012.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">In vitro assays. Mean values determined from at least three experiments unless otherwise noted.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Assay measuring TYK2-dependent IFNα-induced STAT5 phosphorylation in human whole blood according to ref <a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a>.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_p">In addition, attempts to progress the most potent analogues in hWB were hampered by poor microsomal stability and/or poor permeability. For example, when tested in rodent microsomal assays, the C3′ <i>N</i>-alkyl substituted amides commonly afforded <50% of parent remaining after a 10 min incubation. This observed high rate of metabolism was attributed to an <i>N</i>-dealkylation metabolism pathway of the C3′ amides based on biotransformation studies, and any attempt to block this metabolic pathway with substitutions, such as the addition of fluorines, was unsuccessful (data not shown). The primary amide <b>22</b> did show improved microsomal stability relative to the substituted amides, but <b>22</b> suffered from poor permeability and high efflux in the Caco-2 assay (Caco-2 apical-to-basal <i>P</i><sub>c</sub> < 15 nm/s vs basal-to-apical <i>P</i><sub>c</sub> ∼260 nm/s). While further advancement of the C3′ amides was not pursued for these reasons, we were able to validate our water displacement strategy by solving an X-ray cocrystal structure of the 2-picolinamine-derived amide <b>29</b> bound to TYK2 JH2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). As designed, <b>29</b> bound to the hinge region in accord with previous analogues but with the newly incorporated C3′ amide forming a direct interaction with Arg738 by displacing the structural water that had been previously observed in the cocrystal structure of <b>12</b>. A direct hydrogen bond between the C3′ amide carbonyl oxygen of <b>29</b> and Arg738 side-chain N–H is observed (3.1 Å O—N distance) with the pendant 2-picolinamine group protruding into a large pocket beyond the Arg738 as had been predicted by our modeling studies. This structure is consistent with SAR that show many different amide <i>N</i>-substitutions are tolerated. Furthermore, the critical role of the C2′ methoxy group for potency can also be rationalized from this structure by noting its ability to (1) preorganize the C3′ amide conformation required for hydrogen bonding to the Arg738 through an intramolecular hydrogen bond to the C3′ amide N–H and (2) favorably position the methyl group to occupy the shallow C-terminal lipophilic pocket that was also occupied by the methyl sulfone group of <b>12</b> (vide supra).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structure of analogue <b>29</b> in TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZQ">6NZQ</a>) with surface representation of protein added and showing H-bond to Arg738 (3.1 Å) and amide <i>N</i>-substituent occupying large, open pocket. The methoxy group forms an intramolecular H-bond with the amide N–H while also occupying the shallow C-terminal pocket of TYK2 JH2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having validated our original water displacement strategy, subsequent efforts focused on further optimization to address the metabolic instability and permeability issues associated with the C3′ amides while also optimizing the interaction with Arg738. Modeling studies with a variety of heterocycles as C3′ amide replacements appeared promising in this regard. In particular, heterocycles that contained a heteroatom at the ortho position to the ring connection appeared optimal in mimicking the C3′ amides due to their ability to accept a hydrogen bond from Arg738. With this in mind, a variety of five-membered heterocycles were explored. At this point in our optimization effort, advancing compounds into mouse in vivo models for further proof-of-mechanism studies became a priority with new analogues being routinely screened for potency in a mouse whole blood (mWB) assay and for metabolic stability using a mouse liver microsomal (MLM) assay. As shown, many heterocycles in place of the C3′ amides afforded picomolar biochemical potency, with some achieving single-digit nanomolar potency in the IFNα cellular assay for the first time (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">4</a></a>). The oxadiazoles <b>30</b> and <b>31</b> and the <i>N</i>-methyl pyrazoles <b>32</b> and <b>33</b> gave cellular IFNα IC<sub>50</sub> values of 15, 12, 9, and 70 nM, respectively, but showed poor translation into whole blood, particularly mWB. In addition, these analogues suffered from only moderate stability in the MLM assay. Fortunately, exploring more polar 1,2,4-triazoles <b>34</b>–<b>38</b> resulted in improved potency in hWB. In particular, the 1-methyl-1,2,4-triazole analogue <b>38</b> was noteworthy due its potency in the IFNα cellular assay (IC<sub>50</sub> = 4 nM) and in whole blood (mWB and hWB IC<sub>50</sub> values = 130 and 12 nM, respectively). In addition, <b>38</b> gave improved stability in the MLM assay with 80% of parent remaining after a 10 min incubation time.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. C3′ Heterocycles as Amide Replacements<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0013.gif" alt="" id="gr9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0014.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">In vitro assays. Mean values determined from at least three experiments unless otherwise noted.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Mouse liver microsomal stability as percent remaining after a 10 min incubation.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Value determined from one experiment.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">nd: not determined.</p></div></div><div></div></div><div class="NLM_p">To assess as a possible candidate for advancement, <b>38</b> was profiled more extensively for potential undesirable off-target activities. From the outset of our effort in pursuing allosteric TYK2 inhibitors, we had consistently observed very high selectivity for TYK2 across a large part of the kinome due in large part to the ability of these compounds in accessing the unique “alanine pocket” of TYK2 JH2.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Gratifyingly, <b>38</b> was consistent with this trend, providing >1000-fold selectivity for TYK2 JH2 when tested in HTRF binding assays against an in-house kinase panel consisting of ∼260 diverse kinases, including the JH1 domains of TYK2, JAK1, JAK2, and JAK3. Unfortunately, additional off-target profiling of <b>38</b> in a high-throughput ion channel flux assays revealed that it was a modest inhibitor of the hERG ion channel (IC<sub>50</sub> = 31 μΜ) reminiscent of the initial lead <b>12</b>, which had shown QT<sub>c</sub> prolongation in telemetrized rabbits (vide supra). While the ∼10-fold improvement in potency in hWB was anticipated to improve the therapeutic window, we continued to explore SAR in an attempt to further reduce the hERG inhibition. These investigations focused on modifications of the C6 side chain within the potent C3′ <i>N</i>-methyl triazole series (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">5</a></a>). Differentially substituted 2-aminopyridine side chains (R<sup>1</sup>) were explored such as in <b>39</b> and <b>40</b>, however, a reduction in hERG inhibition was not realized (hERG flux IC<sub>50</sub> = 6.7 and 16 μM, respectively). More extensive modification to include more polar heterocycles, such as the substituted pyrimidine <b>41</b>, was successful in reducing activity in the hERG flux assay (IC<sub>50</sub> > 80 μM), however, unacceptably low Caco-2 permeability (apical-to-basal <i>P</i><sub>c</sub> < 15 nm/s) with high efflux was commonly observed. Fortunately, replacement of the 2-aminopyridine side chain with a cyclopropyl amide, as previously demonstrated in the methyl sulfone series,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> afforded <b>42</b> which gave reduced hERG inhibition (IC<sub>50</sub> > 80 μM) and a measurable, but low, permeability in the Caco-2 assay (apical-to-basal <i>P</i><sub>c</sub> = 23 nm/s). More surprisingly, potency in hWB for the cyclopropyl amide <b>42</b> was maintained (IC<sub>50</sub> = 16 nM), in contrast to cyclopropyl amide-containing analogues in the methyl sulfone series, which typically showed reduced potency in hWB.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Furthermore, <b>42</b> showed good in vitro mouse microsomal stability (93% remaining after 10 min incubation). Because <b>42</b> represented a promising profile for advancement, the corresponding deuterated methyl amide <b>43</b> was prepared to prevent in vivo metabolism of the <i>N</i>-methyl amide <b>42</b> by an <i>N</i>-dealkylation pathway, a strategy that had been shown to be successful in the methyl sulfone series.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Unfortunately, oral administration of <b>43</b> to C57BL/6 mice at 10 mg/kg as a solution in a PEG-300 based vehicle afforded lower than expected drug exposures due to a low initial maximum concentration (<i>C</i><sub>max</sub> = 310 nM). This finding was attributed to low permeability rather than poor metabolic stability as <b>43</b> showed reduced permeability in the Caco-2 assay (apical-to-basal <i>P</i><sub>c</sub> < 15 nm/s). To specifically address the permeability issue, the pyridazine variant of <b>43</b> was prepared because previous pyridazines within the series had routinely resulted in improved permeability relative to their pyridine counterparts.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This modification resulted in the identification of <b>11</b>, a compound with significantly improved permeability (apical-to-basal <i>P</i><sub>c</sub> = 70 nm/s) that translated to a 24-fold improvement in <i>C</i><sub>max</sub> relative to its pyridine counterpart <b>43</b> in mouse PK studies (<i>C</i><sub>max</sub> = 7.5 μM for <b>11</b> vs 310 nM for <b>43</b>). In addition, <b>11</b> maintained excellent potency in human and mouse whole blood (IC<sub>50</sub> values = 13 and 100 nM, respectively) and showed no significant hERG inhibition in the flux assay (IC<sub>50</sub> > 80 μM). Having achieved a favorable potency and selectivity profile with excellent PK properties and reduced hERG inhibition, <b>11</b> was more fully characterized as a potential candidate for advancement.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Select Analogues from C3′ <i>N</i>-Methyl Triazole Series</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0015.gif" alt="" id="gr11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0016.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">In vitro assays. Mean values determined from at least three experiments unless otherwise noted.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Value determined from one experiment.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Mouse liver microsomal stability assay measuring percent remaining after a 10 min incubation period or half-life (<i>T</i><sub>1/2</sub>) in minutes.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Mean value determined from two experiments.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> X-ray Structure Confirms Proposed Binding Mode of C3′ Triazole <b>11</b></h3><div class="NLM_p">An X-ray structure of triazole <b>11</b> bound to TYK2 JH2 was solved, confirming the proposed binding mode (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). Similar to previous X-ray cocrystal structures within the series, the pyridazine core and pendant C6 amino and C3 methyl amide side chains form a hydrogen bonding triad to the hinge region of the protein. The cyclopropyl group projects into the extended hinge region and the <i>N</i>-deuteromethyl amide group occupies the “alanine pocket” near Ala671, the binding feature critical for achieving high TYK2 JH2 selectivity.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The C2′ methoxy forms a hydrogen bond with the conserved Lys642 with the methyl group of the methoxy buried into the shallow C-terminal lipophilic pocket proximal to Pro694 and Leu741 (vide supra). Remarkably, the <i>des</i>-methoxy variant of <b>11</b> (not shown) was determined to be ∼100-fold less potent in TYK2 JH2 binding affinity compared to <b>11</b> and was inactive in hWB (IC<sub>50</sub> > 10 μM), illustrating the contribution of the C2′ group to potency. A similar finding was previously observed in comparing the C3′ amide <b>18</b> and its <i>des</i>-methoxy counterpart <b>19</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1a" href="#tbl1a">Table <a class="ref showTableEvent internalNav" data-ID="tbl1a" href="#tbl1a">2</a></a>). In this comparison, the results are reminiscent of the methyl effect in protein–ligand binding, sometimes referred to as the “magic methyl” effect, where addition of a methyl in place of hydrogen results in dramatic increase in potency due to preferred conformational biasing and burial of the methyl group in a hydrophobic pocket of the protein.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> Although, in this instance, in addition to providing favorable conformational control and hydrophobic interactions, the C2′ methoxy also forms a direct hydrogen bond interaction with the protein (Lys642) that likely contributes to the observed increase in potency. The crystal structure also confirmed that displacement of the structural water molecule observed in <b>12</b> by the newly installed C3′ triazole group of <b>11</b> was realized with the <i>N</i>-2 triazole nitrogen engaging in a direct hydrogen bond with Arg738 as designed. In an attempt to understand additional factors that may be contributing to the potency of <b>11</b>, a WaterMap simulation<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> of the TYK2 JH2 ligand binding domain was performed using the X-ray structure of <b>11</b> with the ligand present but with the methoxy group and triazole ring replaced with hydrogens. This simulation predicted the presence of an energetically unfavorable water molecule (W1) that overlapped with the structural water molecule that was shown to be displaced by the C3′ triazole of <b>11</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). In addition, several other high energy waters were predicted in the ligand binding site. Most notably are the presence of additional waters that are likely displaced by the C3′ triazole group (W2–W4) and the C2′ methoxy group (W5) of <b>11</b>. This analysis is consistent with SAR that highlights the importance of these groups for potency and suggests that displacement of energetically unfavorable waters contributes to the high affinity of <b>11</b> for binding to the TYK2 JH2 domain.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) X-ray cocrystal structure of triazole <b>11</b> in TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZP">6NZP</a>) showing key interactions including hydrogen bonds to hinge region of JH2 via <i>N</i>-methyl pyridazine amide, the <i>d</i><sub>3</sub>-<i>N</i>-methyl amide occupying the unique alanine pocket (Ala671) with the cyclopropylamide in the extended hinge region, the key triazole moiety displacing structural water present in X-ray structure of <b>12</b> to form a direct hydrogen bond to Arg738, and the orientation of the C2′ methoxy near Lys642 protruding into a shallow, C-terminal lobe pocket (displayed in gray surface representation). (b) WaterMap simulation<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> results superimposed with X-ray structure of <b>11</b> predict multiple unfavorable (Δ<i>G</i> > 2.2 kcal/mol) waters W1–W5 that are likely displaced by C3′ triazole and C2′ methoxy groups of <b>11</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Potency and Selectivity Profile of <b>11</b></h3><div class="NLM_p">Because of its high affinity approaching the lower limits of the binding assay, we evaluated <b>11</b> using a Morrison titration by varying the concentration of the fluorescent probe in the TYK2 JH2 assay.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> This analysis gave results that were consistent with competitive binding and determined a dissociation constant (<i>K</i><sub>i</sub>) of 0.02 nM for <b>11</b>.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> In addition, <b>11</b> was evaluated in both binding and human cellular assays to determine selectivity within the JAK family and across the kinome (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">6</a></a>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Consistent with earlier analogues, <b>11</b> is highly specific for binding to TYK2 JH2 and does not show any significant binding affinity in the canonical TYK2, JAK1, JAK2, and JAK3 JH1 assays (IC<sub>50</sub> values >10000 nM). Furthermore, <b>11</b> is >1000-fold selective against an in-house panel of 249 protein and lipid kinases and pseudokinases, with the exception of BMPR2 (IC<sub>50</sub> = 193 nM) and JAK1 JH2 pseudokinase domain (IC<sub>50</sub> = 1 nM). Binding affinity assays for JAK2 and JAK3 JH2 domains were not available for evaluation. Despite its potent affinity for JAK1 JH2, low functional activity in a JAK1/JAK3 dependent IL-2 stimulated cellular assay is observed as <b>11</b> is ∼300-fold less potent in the IL-2 assay (IC<sub>50</sub> = 592 nM) compared to the TYK2-dependent IFNα assay using the same pSTAT5 end point. Similarly, weak potency was measured against other JAK1-regulated pathways not dependent on TYK2, including IL-6-stimulated phosphorylation of STAT3 and IL-13-stimulated STAT6 phosphorylation.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> JAK1/JAK3 functional potency of <b>11</b> in hWB was also determined using an IL-2 stimulated STAT5 phosphorylation assay (IC<sub>50</sub> = 1900 nM), which is ∼150-fold less potent than TYK2-dependent IFNα pSTAT5 phosphorylation in hWB (IC<sub>50</sub> = 13 nM). The JAK1/JAK2-mediated IL-6-stimulated pSTAT3 response in hWB was similarly weak (IC<sub>50</sub> = 609 nM). This high functional selectivity was consistently observed within the series and suggests that either allosteric binding to JAK1 JH2 imparts decreased functional consequences relative to TYK2 JH2 binding or binding affinity determined in the JAK1 JH2 assay is overpredictive (higher) relative to JAK1 JH2 binding in cells. In addition to functional selectivity over JAK1, <b>11</b> also exhibits a high degree of functional selectivity over JAK2 relative to other reported JAK inhibitors. In a JAK2-dependent EPO-stimulated STAT5A phosphorylation assay in isolated TF-1 cells, <b>11</b> does not show any significant inhibition up to a concentration of 10 μM, indicating >5000-fold selectivity for TYK2 over JAK2 signaling. High selectivity over JAK2 signaling was also demonstrated in hWB using a JAK2-dependent TPO-stimulated STAT5 phosphorylation assay in platelets (IC<sub>50</sub> > 10 μM), establishing a functional selectivity window of >770-fold at the highest concentration tested.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Selectivity Profile of <b>11</b> in Binding and Human Cellular Assays</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">binding or cellular assay<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">stimulus (pathway)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>, nM (selectivity)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYK2 JH2</td><td class="colsep0 rowsep0" align="center">(TYK2)</td><td class="colsep0 rowsep0" align="center">0.2 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1 JH2</td><td class="colsep0 rowsep0" align="center">(JAK1)</td><td class="colsep0 rowsep0" align="center">1.0 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYK2 JH1</td><td class="colsep0 rowsep0" align="center">(TYK2)</td><td class="colsep0 rowsep0" align="center">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK1 JH1</td><td class="colsep0 rowsep0" align="center">(JAK1)</td><td class="colsep0 rowsep0" align="center">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2 JH1</td><td class="colsep0 rowsep0" align="center">(JAK2)</td><td class="colsep0 rowsep0" align="center">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK3 JH1</td><td class="colsep0 rowsep0" align="center">(JAK3)</td><td class="colsep0 rowsep0" align="center">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in-house selectivity panel of 249 kinases</td><td class="colsep0 rowsep0" align="center">(kinome selectivity)</td><td class="colsep0 rowsep0" align="center">all >1000 fold-selective except BMPR2 (∼960-fold)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="center">IFNα (TYK2)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="center">IL-23 (TYK2)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TF-1</td><td class="colsep0 rowsep0" align="center">EPO (JAK2)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">>10000 (>5000×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="center">IL-2 (JAK1/JAK3)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">592 (∼300×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="center">IL-6 (JAK1)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">615 (∼310×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PBMC</td><td class="colsep0 rowsep0" align="center">IL-13 (JAK1)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">2091 (>1000×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood</td><td class="colsep0 rowsep0" align="center">IFNα (TYK2)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">TPO (JAK2)<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">>10000 (>770×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">IL-2 (JAK1/JAK3)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">1900 (∼150×)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">IL-6 (JAK1/JAK2)<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">609 (∼47×)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">In vitro assays. Mean values determined from at least three separate experiments unless otherwise noted.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Measuring STAT5 phosphorylation in CD3<sup>+</sup> T-cells as end point.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Measuring STAT3 phosphorylation in CD161<sup>+</sup> CD3<sup>+</sup> T-cells.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Measuring STAT5A phosphorylation in TF-1 cells (<i>n</i> = 2).</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Measuring STAT6 phosphorylation in mononuclear cells (<i>n</i> = 2).</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Measuring STAT5 phosphorylation in platelets.</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">Measuring STAT3 phosphorylation in CD3<sup>+</sup> T-cells.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Triazole <b>11</b> Shows Minimal Profiling Liabilities, Excellent PK Properties, and Is Highly Efficacious in Inflammatory and Autoimmune Disease Models</h3><div class="NLM_p">Having demonstrated excellent potency and functional selectivity for inhibition of TYK2-dependent responses, <b>11</b> was further profiled in vitro and showed minimal liabilities and acceptable PK properties for further advancement (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">7</a></a>). Incubation in liver microsomes shows excellent stability (<i>T</i><sub>1/2</sub> > 120 min) across multiple species including human, mouse, rat, monkey, dog, and rabbit. Good permeability is also observed in a Caco-2 assay with moderate efflux (apical-to-basal <i>P</i><sub>c</sub> = 73 nm/s; basal to apical <i>P</i><sub>c</sub> = 740 nm/s; efflux ratio ∼10). Assessment of the potential for drug–drug interactions (DDI) indicates a low overall risk, as no significant inhibition of multiple cytochrome P450 (CYP) isozymes (1A2, 2C9, 2C19, 2D6, and 3A4) or induction of CYP3A4 is observed up to the highest concentration tested (40 μM). Testing of <b>11</b> in the hERG potassium channel patch clamp assay gives a low percent inhibition (26 ± 11% at 10 μM), suggesting a low potential for QT<sub>c</sub> prolongation-associated cardiovascular risk. Protein binding is in the moderate range (12–15% free) across species including human, monkey, and mouse. Aqueous solubility of the crystalline free base form of <b>11</b> is low at 5.2 μg/mL but was deemed acceptable for advancement into preclinical studies. Good overall PK parameters were observed with <b>11</b> in preclinical studies across multiple species (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">8</a></a>). Consistent with the observed low rate of metabolism in the microsomal assays (<i>T</i><sub>1/2</sub> > 120 min), <b>11</b> affords low to modest in vivo clearance rates in mouse, dog, and monkey of 13.2, 6.8, and 4.8 mL min<sup>–1</sup> kg<sup>–1</sup>, respectively. Low volume of distribution (<i>V</i><sub>ss</sub>) is also observed in the 2–3 L/kg range with moderate half-lives of ∼4–5 h across species. When administered orally at 10 mg/kg, <b>11</b> is well absorbed with excellent exposures and high bioavailability (%<i>F</i> > 85) in mouse, dog, and monkey. Circulating primary amide metabolite formation from N-dealkylation of the deuteromethyl amide of <b>11</b> was near the lower limits of detection (<2 nM) in these studies, consistent with the effective blocking of this metabolic pathway by deuteration as previously reported within the series.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Profiling Properties of Triazole <b>11</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">profiling assays</th><th class="colsep0 rowsep0" align="center"><b>11</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver microsomal <i>T</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">>120 all species<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 <i>P</i><sub>c</sub> (nm/s), A-to-B<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">73 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 <i>P</i><sub>c</sub> (nm/s), B-to-A<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">740 ± 140</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP450 inhibition IC<sub>50</sub>s (1A2, 2C9, 2C19, 2D6, 3A4)</td><td class="colsep0 rowsep0" align="left">all >40 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP Induction/PXR-TA EC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">>40 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG (% inhibition at 10 μM)</td><td class="colsep0 rowsep0" align="left">26 ± 11<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding (%free)</td><td class="colsep0 rowsep0" align="left">13% human, 12% cyno, 15% mouse</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aq solubility at pH 7.4</td><td class="colsep0 rowsep0" align="left">5.2 μg/mL<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Human, rat, mouse, dog, cyno, and rabbit.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">A = apical, B = basal.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last"><i>n</i> = 7 in patch clamp assay.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Crystalline free base.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vivo PK Summary for Triazole <b>11</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">iv PK parameters<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">po PK parameters<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">MRT (h)</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μM × h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char=".">13.2</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">36.4</td><td class="colsep0 rowsep0" align="char" char=".">122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">73.6</td><td class="colsep0 rowsep0" align="char" char=".">128</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">75.7</td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">IV administration at 1 mg/kg in 80% PEG 400/20% water unless otherwise noted.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">PO administration at 10 mg/kg as a solution in ethanol/TPGS/PEG 300 (5:5:90).</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">IV administration at 2 mg/kg.</p></div></div></div><div class="NLM_p">In mice, <b>11</b> was evaluated in a skin inflammation (psoriasis-like) model of IL-23-driven acanthosis whereby repetitive intradermal injections of IL-23 into the ears of mice induces a profound epidermal hyperplasia (acanthosis) and inflammatory cellular infiltration mediated by Th17 cells and IL-22, similar to the underlying mechanisms in psoriasis (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> In this model, <b>11</b> dose-dependently protects from IL-23-induced acanthosis in mice, with the 15 mg/kg oral dose of <b>11</b> administered twice-daily for 9 days proving to be as effective as an anti-IL-23 adnectin as a positive control (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The 30 mg/kg twice-daily oral dose is more effective than the anti-IL-23 adnectin at providing protection. Histological evaluation shows that the epidermal hyperplasia and the inflammatory cellular infiltration is also inhibited in a dose-dependent manner, with the high dose of 30 mg/kg twice daily providing protection more effectively than the anti-IL-23 adnectin positive control (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b). Quantitative polymerase chain reaction (PCR) analysis of skin biopsies reveals <b>11</b> to be quite effective at blocking inflammatory cytokine expression, including IL-17A, IL-21, and subunits of IL-12 and IL-23 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c). PK measurements on study animals shows that the 7.5, 15, and 30 mg/kg twice-daily doses provides drug levels at or above the in vitro mouse whole blood IC<sub>50</sub> value of 100 nM (IFNα-induced pSTAT1) for 19, 21, and 24 h, respectively. In addition to preclinical models of psoriasis, <b>11</b> has also been shown to be highly efficacious in murine models of colitis and lupus.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> These results demonstrate in an anti-CD40-induced colitis model in severe-combined-immunodeficient-diseased (SCID) mice, <b>11</b> administered 50 mg/kg twice-daily provides inhibition of peak weight loss (IL-12 driven) by 99% and inhibition of histological scores by 70% comparable to an anti-p40 monoclonal antibody control. Furthermore, when orally administered up to a maximum 30 mg/kg once-daily dose in a three-month lupus disease model using NZB/W lupus-prone mice, <b>11</b> is well-tolerated and highly efficacious in protecting from nephritis. In this latter study, efficacy is well-correlated with inhibition of type I IFN-dependent gene expression in both whole blood and kidneys in study mice and is at least as effective as a blocking anti-IFNαR antibody.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Dose–response of <b>11</b> showing inhibitory effect in an IL-23 induced psoriasis-like acanthosis mouse model<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> compared to an anti-IL-23 adnectin as a positive control.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Values are presented as means ± SEM, eight mice per group. Statistical analysis was performed with one-way ANOVA. Vehicle, 5:5:90, EtOH:TGPS:PEG300. (b) Dose–response of histological scores showing dose-dependent inhibition of epidermal hyperplasia (acanthosis) and inflammatory cellular infiltration. (c) Inflammatory cytokine expression by quantitative PCR analysis of skin biopsies showing dose-dependent inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, <b>11</b> is efficacious against both type I IFN-, IL-12-, and IL-23-dependent pathobiology in preclinical studies in mice. Efficacy from oral administration of <b>11</b> in all disease models studied is well correlated with coverage of the whole blood IC<sub>50</sub> value over the dosing intervals and is at least as effective as the blocking antibody controls used in these studies.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div class="NLM_p">Preparation of the <i>N</i>-methyl nicotinamide and <i>N</i>-methyl pyridazine-3-carboxamide analogues in this work utilized similar chemistry methods as previously reported.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The analogues were prepared from the 4,6-dichloro-<i>N</i>-(methyl)nicotinamide (X = C) or pyridazine-3-carboxamide (X = N) intermediate <b>44</b> as the nondeuteromethyl amide (R = CH<sub>3</sub>) or deuteromethyl variant (R = CD<sub>3</sub>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Various substituted anilines (ArNH<sub>2</sub>) were coupled under basic conditions and in moderate to high yields using lithium or sodium hexamethylsilazide in THF at ambient temperature to give coupling at the C4 position exclusively to afford <b>45</b>. A second coupling to install the C6 amino substituents was performed using the palladium-catalyzed Buchwald–Hartwig amination reaction<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> to afford the final compounds <b>46</b>. Initial C6 couplings were performed using XantPhos as the palladium ligand under high temperatures (130–145 °C), which resulted in low yields in some cases. However, more efficient coupling for problematic cases could be performed at lower temperatures (85–110 °C) using BrettPhos as the palladium ligand or 1,1′-bis(dicyclohexylphosphino)ferrocene (dppf) as a ligand in the case of cyclopropyl amide couplings. Specific substitutions (R′) were explored by either incorporating on the aniline before C-4 coupling to afford <b>45</b> or at a later stage after C6-coupling depending on functional group compatibility and/or ease of intermediate isolations. This synthetic route proved to be highly versatile for both SAR exploration as well as larger scale preparation of key compounds for advancing through preclinical studies.</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Preparation of <i>N</i>-Methyl Nicotinamides and <i>N</i>-Methyl Pyridazine-3-Carboxamides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHMDS or LiHMDS, ArNH<sub>2</sub>, THF, rt; 53–92%; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3,</sub> DMA or 1,4-dioxane, 130–145 °C, 1 h, 23–64%; (c) Pd(OAc)<sub>2</sub> or Pd<sub>2</sub>(dba)<sub>3</sub> BrettPhos or dppf, K<sub>2</sub>CO<sub>3</sub> or Cs<sub>2</sub>CO<sub>3</sub> or LiHMDS, 1,4-dioxane, 85–110 °C, 1 h, 40–97%.</p></p></figure><div class="NLM_p">As an example, the synthesis of <b>11</b> is highlighted (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Beginning with commercially available methyl-2-hydroxy-3-nitrobenzoate (<b>47</b>), methylation followed by ammonolysis of the intermediate methyl ester afforded amide <b>48</b>. The triazole group was readily installed by reaction of <b>48</b> with DMF-DMA followed by condensation with hydrazine hydrate to afford <b>49</b>. Methylation of the triazole with methyl iodide in the presence of potassium carbonate afforded a 2:1 mixture of the desired regioisomer <b>50</b> and undesired regioisomer <b>51</b>, respectively. The regioisomers could be separated by supercritical fluid chromatography (SFC) to afford the desired, isomerically pure <b>50</b> in 67% overall yield. Attempts to improve the alkylation regioselectivity found that using potassium hexamethylsilazide as the base in place of potassium carbonate and using THF in place of DMF, as the solvent afforded an improved regioselectivity of ∼8:1 in favor of the desired isomer <b>50</b>. This result obviated separation of the isomers by SFC chromatography on a larger scale, as the crude product enriched in the desired isomer could be crystallized to afford isomerically pure <b>50</b>. With pure <b>50</b> in hand, nitro group reduction under standard palladium-catalyzed hydrogenation conditions afforded aniline <b>52</b> in 92%, which was subsequently coupled to <b>53</b><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> using lithium hexamethyldisilazide as the base at ambient temperature to afford the penultimate intermediate <b>54</b> in 66% yield. Coupling of <b>54</b> with cyclopropyl amide (<b>55</b>) under palladium-catalyzed Buchwald–Hartwig reaction conditions<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> using XantPhos as the palladium ligand afforded <b>11</b> in 46% yield. A significant improvement in this final coupling reaction was identified by replacing the XantPhos as a ligand with 1,1′-bis(dicyclohexylphosphino)ferrocene (dppf) and using aqueous potassium triphosphate in place of cesium carbonate as the base. These modified conditions permitted a lower reaction temperature and afforded an improved 76% yield in the preparation of multigram quantities of <b>11</b> for advanced preclinical studies.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0008.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Clinical TYK2 Inhibitor <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 98%; (b) aq NH<sub>4</sub>OH, NH<sub>3</sub> in MeOH, rt, 86%; (c) (i) DMF-DMA, 95 °C, (ii) hydrazine hydrate, EtOH, AcOH, rt, 69% over 2 steps; (d) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 91%, (∼2:1 mixture); (e) KHMDS, CH<sub>3</sub>I, THF, rt, 58% of pure <b>50</b>; (f) 5% Pd-C, 1 atm H<sub>2</sub>, EtOH, rt, 92%; (g) LiHMDS, THF, rt, 66%; (h) Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 130 °C, 46%; (i) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, K<sub>3</sub>PO<sub>4,</sub> dioxane, 85 °C, 76%.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The discovery of the TYK2 inhibitor <b>11</b> as the first known pseudokinase-specific ligand to enter clinical development has been described. This work was achieved through optimization of a series of highly selective <i>N</i>-methyl nicotinamides and <i>N</i>-methyl pyridazine-3-carboxamides as a novel class of potent allosteric inhibitors that act by binding to and stabilizing the pseudokinase (JH2) domain of TYK2. As a result of this unique mechanism, <b>11</b> is highly differentiated from all other reported JAK/TYK2 inhibitors due to its ability to achieve an unprecedented level of selectivity for TYK2, especially over JAK1, JAK2, and JAK3. Notably, several key discoveries and innovative strategies were important in identifying <b>11</b> as a suitable candidate for clinical development. A chemogenomics approach was used to find initial lead molecules that allosterically inhibit TYK2-dependent IL-23 signaling by virtue of their binding to the TYK2 pseudokinase domain.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This key discovery spawned a medicinal chemistry effort that identified additional novel leads for optimization including the <i>N</i>-methyl nicotinamide series.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> A critical methyl amide group within this series was discovered that surprisingly afforded a high level of selectivity by accessing an atypical pocket created by a rare alanine residue (“alanine pocket”) in the ligand binding domain of TYK2 JH2. To preserve the selectivity of the methyl amides in vivo, deuterium was incorporated into the methyl group to block an <i>N</i>-demethylation metabolic pathway that generated a less selective primary amide metabolite. While incorporation of deuterium into drug molecules is not an uncommon practice, the large majority of known examples typically involve deuterium incorporation into already existing drug developmental candidates or marketed drugs in an attempt to decrease overall clearance rates and improve PK properties.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Our approach is unique from these strategies in that deuterium was incorporated during the de novo design and optimization process to shunt a metabolic pathway in vivo and address a specific metabolite concern. Other notable strategies in our efforts include heterocyclic core modifications (pyridine to pyridazine) to provide optimal permeability and bioavailability and the use of a cyclopropyl carboxamide as a replacement for the C6 amino heterocycles to reduce undesirable hERG ion channel activity.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The versatility of the cyclopropane fragment in overcoming multiple roadblocks in drug discovery has been previously reported.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> In this instance, it is notable that the cyclopropyl carboxamide group was found to be an effective replacement for the 2-aminopyridine side chain and reduced hERG affinity, likely due to decreased aromaticity and increased sp<sup>3</sup> character.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Finally, an innovative structure-based drug design strategy targeted at displacing a structural water molecule observed within the TYK2 JH2 binding site led to C3′ substituted analogues having significantly enhanced potency and ultimately resulting in the identification of <b>11</b> containing a C3′ <i>N</i>-methyl triazole group. These results highlight the potential of targeting the displacement of water molecules from ligand binding sites as a successful strategy for drug design and optimization and suggests the application of computational methods to predict hydration thermodynamics as potentially useful tools in directing medicinal chemistry efforts.<a onclick="showRef(event, 'ref81 ref82 ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref81 ref82 ref83 ref84 ref85">(81−85)</a> Additional allosteric TYK2 inhibitors from our efforts will be reported in due course. In summary, <b>11</b> has been identified as a highly potent and selective allosteric TYK2 inhibitor having excellent PK properties across species with minimal profiling liabilities and is orally efficacious with dose-dependent activity in a murine disease model of psoriasis. Significant activity has also been observed with <b>11</b> in other murine autoimmune disease models of colitis and lupus.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> On the basis of these findings, <b>11</b> has been advanced into clinical studies as a potential treatment for patients suffering from a spectrum of IFN- and IL-12/IL-23 driven inflammatory and autoimmune diseases.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58734" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58734" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All animal research was conducted in accordance with institutional guidelines as defined by Institutional Animal Care and Use Committee for U.S. institutions and with the approval of the Bristol-Myers Squibb Animal Care and Use Committee. Mice were housed under a 12 h/12 h light/dark cycle and provided standard access to rodent chow diet and fresh drinking water ad libitum.</div><div class="NLM_p">All biochemical potencies and selectivities were determined using homogeneous time-resolved fluorescence (HTRF) assays where compounds were shown to compete with a fluorescent probe for binding to human recombinant JAK1, JAK2, JAK3, and TYK2 JH1 domain proteins in addition to TYK2 and JAK1 JH2 protein domains. Dose–response curves were generated to determine the concentration required for inhibiting 50% of the HTRF signal (IC<sub>50</sub>) as derived by nonlinear regression analysis. Cellular potencies and selectivities were determined using stably integrated STAT-dependent luciferase reporter assays in T-cells using IFNα-stimulation for measuring TYK2/JAK1 dependent signaling and IL-23 stimulation for measuring TYK2/JAK1 dependent signaling. JAK2 dependent signaling was measured in TF-1 cells using GM-CSF stimulation. Dose–response curves were generated to determine the concentration required to inhibit 50% of cellular response (IC<sub>50</sub>) as derived by nonlinear regression analysis. Potencies and selectivities for JAK-dependent signaling were also measured in human and mouse whole blood using specific cytokine stimulations and measuring the phosphorylation of specific STAT proteins by cellular staining and flow cytometry. Experimental details for all assays have been previously reported.<a onclick="showRef(event, 'ref60 ref63'); return false;" href="javascript:void(0);" class="ref ref60 ref63">(60,63)</a> All compounds active in biological assays were electronically filtered for structural attributes common to pan assay interference compounds (PAINS) and were found to be negative.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Synthesis</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Chemistry General Methods and Compound Characterization</h4><div class="NLM_p last">All reagents and starting materials were obtained from commercial suppliers and used without further purification unless otherwise stated. Reactions were run under an atmosphere of nitrogen and at ambient temperature unless otherwise noted. Reaction progress was monitored using a variety of LC instruments equipped with electrospray positive ionization detectors. Reported liquid chromatography retention times (<i>R</i><sub>T</sub>) were established using the following conditions: Column, Waters Acquity UPLC BEH C18, 2.1 mm × 50 mm, 1.7 μm particles. Mobile phase A: 2:98 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 98:2 acetonitrile:water with 10 mM ammonium acetate. Temperature: 50 °C. Gradient: 0–100% B over 1 min, then a 0.5 min hold at 100% B. Flow: 0.8 mL/min. Detection: MS and UV (220 nm). In some cases, alternative liquid chromatography conditions (specified as condition B or condition C) were used. Condition B = column: Waters Acquity BEH C18, 2.1 mm× 50 mm, 1.7 μm particles. Mobile phase A: water. Mobile phase B: acetonitrile with buffer, 0.05% TFA. Temperature: 50 °C. Gradient range: 2%–98% B (0–1 min), 98% B (to 1.5 min), then 98%–2% B (to 1.6 min). Flow: 1.11 mL/min. Detection: MS and UV (220 nm). Condition C = column: Waters Acquity UPLC BEH C18, 2.1 mm× 50 mm, 1.7 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Temperature: 50 °C. Gradient: 2–98% B over 1 min, then a 0.6 min hold at 98% B. Flow: 0.8 mL/min. Detection: MS and UV (220 nm). Proton (<sup>1</sup>H NMR) magnetic resonance spectra were obtained in CDCl<sub>3</sub>, CD<sub>3</sub>OD, or DMSO-<i>d</i><sub>6</sub> at 400 MHz at 298 K unless otherwise noted. The following abbreviations were utilized to describe peak patterns when appropriate: br = broad, s = singlet, d = doublet, q = quartet, t = triplet, and m = multiplet. All final compounds used for testing in assays and biological studies had purities that were determined to be >95% by HPLC or LCMS based on ultraviolet detection at 220 nm.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Synthesis of 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)-amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>)pyridazine-3-carboxamide (<b>11</b>)</h4><div class="NLM_p last">A mixture of <b>54</b> (2.3 g, 6.2 mmol) and cyclopropane carboxamide (<b>55</b>, 1.05 g, 12.3 mmol) was dissolved in dioxane (62 mL), and Pd<sub>2</sub>(dba)<sub>3</sub> (564 mg, 0.616 mmol), XantPhos (534 mg, 0.924 mmol), and cesium carbonate (4.01 g, 12.3 mmol) were added. The vessel was evacuated three times (backfilling with nitrogen) and then sealed and heated to 130 °C using a preheated oil bath for 140 min. The reaction was filtered through diatomaceous earth (washing with ethyl acetate), and the resulting filtrate was concentrated to obtain the crude product. This material was adsorbed onto diatomaceous earth using dichloromethane and was purified using automated chromatography (100% ethyl acetate) to provide <b>11</b> as a near-white solid (1.22 g, 46% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.99 (s, 1H), 9.81 (s, 1H), 8.23 (s, 1H), 8.11 (s, 1H), 8.03 (s, 1H), 7.80 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.52 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.26 (t, <i>J</i> = 7.8 Hz, 1H), 4.00 (s, 3H), 3.81 (s, 3H), 1.88–1.82 (m, 1H), 1.16–1.06 (m, 2H), 0.94–0.83 (m, 2H). <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) δ 173.2, 166.8, 160.3, 155.8, 151.5, 146.1, 143.9, 134.9, 132.4, 127.0, 126.0, 124.5, 123.4, 97.9, 61.5, 36.4, 26.0–24.1 (m, <i>J</i> = 21.8 Hz, 1C), 15.9, 8.7 (s, 2C). LCMS (E+) <i>m</i>/<i>z</i>: 426.1 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.62 min. An analytically pure sample was obtained by SFC. Anal. Calcd for C<sub>20</sub>H<sub>19</sub>D<sub>3</sub>N<sub>8</sub>O<sub>3</sub>·0.06H<sub>2</sub>O·0.03CH<sub>3</sub>OH: C 56.24; H 5.32; N 26.20. Found: C 55.86; H 5.22; N 26.12. HRMS calcd for C<sub>20</sub>H<sub>20</sub>D<sub>3</sub>N<sub>8</sub>O<sub>3</sub>[M + H]<sup>+</sup>, 426.20759; found, 426.20734.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Alternative Coupling Conditions for Synthesis of <b>11</b></h4><div class="NLM_p last">A mixture of <b>54</b> (17.52 g, 46.5 mmol) and cyclopropane carboxamide <b>55</b> (4.75 g, 55.8 mmol) were taken up in 1,4-dioxane (186 mL) and nitrogen bubbled through the slurry for about 10–15 min. Pd<sub>2</sub>(dba)<sub>3</sub> (1.06 g, 1.16 mmol) and 1,1′-bis(dicyclohexylphosphino)ferrocene (1.34 g, 2.32 mmol) were then added with a continued nitrogen flow for an additional ∼5 min. An aqueous solution of potassium phosphate tribasic (2 M, 58.1 mL, 116 mmol) was then added in one portion and the reaction heated to 85 °C for 48 h. The reaction was allowed to cool to room temperature before diluting with ethyl acetate (200 mL) and water (200 mL). The separated aqueous phase was further extracted with ethyl acetate (3 × 200 mL), and the combined organic layers were then dried (MgSO<sub>4</sub>) and concentrated under vacuum to give the crude product. The crude product was then taken up in Me-THF (400 mL) and ethyl acetate (400 mL), then <i>N</i>-acetyl cysteine (10% aqueous solution, 300 mL) was added and the biphasic mixture was allowed to stir at room temperature overnight. The layers were separated and the aqueous phase was extracted with ethyl acetate (3 × 200 mL). The combined organics were washed with 10% ammonium hydroxide solution (500 mL), and the organic layer then dried (MgSO<sub>4</sub>) and evaporated under vacuum to afford the crude product which was purified by MPLC using a RediSep 750 g gold silica gel column and eluting with a gradient of solvent A (dichloromethane) and solvent B (20% methanol in dichloromethane) at a flow rate of 300 mL/min. The desired product was collected at 30% A to B concentration and fractions were concentrated under vacuum to afford <b>11</b> as a cream-colored solid (15.0 g, 76% yield).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-((3-Cyano-2-methoxyphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)-<i>N</i>-methyl-nicotinamide (<b>15</b>)</h4><div class="NLM_p last">To a suspension of 4-((3-carbamoyl-2-methoxyphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>17</b>, 21 mg, 0.051 mmol) in dichloromethane (0.2 mL) and THF (0.2 mL) was added Burgess reagent (24.4 mg, 0.10 mmol) in one portion under nitrogen, and the resulting mixture was allowed to stir overnight at room temperature. HPLC and LCMS indicated only ∼15% conversion of starting material to afford the desired product (observed MH<sup>+</sup> of 393). Therefore, the reaction was concentrated to remove the THF and dichloromethane and acetonitrile (0.3 mL) was added followed by additional Burgess reagent (24.4 mg, 0.10 mmol). After 4 h at room temperature, the reaction mixture became a clear solution and HPLC analysis indicated completed conversion of starting material to the desired product. The reaction was concentrated, diluted with DMF (1 mL), filtered, and was purified by reverse phase preparative LCMS with the following conditions: Column, Waters XBridge C18, 19 mm × 200 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Gradient: 15–100% B over 20 min, then a 5 min hold at 100% B. Flow: 25 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford 7.2 mg (35%) of <b>15</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79 (s, 1H), 9.87 (br s, 1H), 8.58 (br d, <i>J</i> = 3.1 Hz, 1H), 8.50 (s, 1H), 8.17 (d, <i>J</i> = 3.1 Hz, 1H), 7.87 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H), 7.77–7.58 (m, 3H), 7.50 (d, <i>J</i> = 7.9 Hz, 1H), 7.43–7.33 (m, 1H), 3.92 (s, 3H), 2.79 (d, <i>J</i> = 4.9 Hz, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 393.1 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.53 min.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-((2-((5-Fluoropyridin-2-yl)amino)-5-(methylcarbamoyl)pyridin-4-yl)amino)-2-methoxy-benzoic Acid (<b>16</b>)</h4><div class="NLM_p">A solution of 4,6-dichloro-<i>N</i>-methylnicotinamide<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (2 g, 9.75 mmol) and 3-amino-2-methoxybenzoic acid<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> (1.96 g, 11.7 mmol) in 20 mL of DMA was cooled in an ice bath, and a solution of lithium bis(trimethylsilyl)amide (1 M in THF, 39.0 mL, 39.0 mmol) was added dropwise via syringe over 3–5 min. After the addition was complete, the ice bath was removed and the dark-brown mixture was allowed to warm to room temperature and stir for ∼30 min. LCMS analysis at this time indicated the complete conversion to afford a single major component that was consistent with the formation of the desired coupled intermediate (observed MH<sup>+</sup> 336/338). The reaction was cooled in an ice bath and was quenched by the slow addition of cold water (∼150 mL), giving a dark-amber colored solution. The pH of the solution was made acidic (pH ∼ 1–2) by a dropwise addition of 6 N aq HCl, causing a heavy tan precipitate to form. The resulting slurry was allowed to stir for 1 h, then the solid was collected by vacuum filtration and the solid was rinsed with additional water (∼50 mL). The solid was allowed to partially air-dry in the funnel for 2–3 h and then was slurried in methanol (∼50 mL). Ethyl acetate (∼100 mL) was added initially, giving complete dissolution followed by precipitation of a solid. The solid was collected by vacuum filtration and dried in a funnel overnight to afford 1.0 g of an off-white solid. The resulting filtrate was concentrated under vacuum to afford an additional 2 g of additional solid (overall yield 3 g, 92%). MS (E+) <i>m</i>/<i>z</i>: 336/338 (MH<sup>+</sup> with chloride isotope pattern).</div><div class="NLM_p last">A reaction vial was charged with solid obtained from previous step (130 mg, 0.39 mmol), 5-fluoropyridin-2-amine (60.8 mg, 0.54 mmol), BrettPhos (8.31 mg, 0.015 mmol), and Pd<sub>2</sub>(dba)<sub>3</sub> (7.1 mg, 7.8 μmol), and the contents were flushed with nitrogen. Dioxane (1.5 mL) and DMA (0.5 mL) were then added, and the resulting slurry was sparged with additional nitrogen for ∼1 min. A solution of lithium bis(trimethylsilyl)amide (1 M in THF, 0.85 mL, 0.85 mmol) was added, and the resulting dark-amber-colored solution was heated in a preheated heating block at 110 °C for 2 h. The reaction mixture was cooled to room temperature and was analyzed by LCMS, which indicated formation of a major product that was consistent with the desired product (observed MH<sup>+</sup> 412). The reaction mixture was diluted with water (10 mL) and made slightly acidic (pH ∼ 3) by slowly adding 1N aq HCl dropwise, causing a solid to precipitate. The slurry was allowed to stir at room temperature overnight, and then the solid was collected by vacuum filtration and dried under vacuum to afford 128 mg (80%) of <b>16</b> as a beige solid. MS (E+) <i>m</i>/<i>z</i>: 412.1 (MH<sup>+</sup>). An analytical sample for testing was prepared by purification by preparative LC/MS with the following conditions: Column, Waters XBridge C18, 19 mm × 250 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Gradient: 0–100% B over 25 min, then a 5 min hold at 100% B. Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford pure <b>16</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (s, 1H), 9.81 (s, 1H), 8.52 (q, <i>J</i> = 4.1 Hz, 1H), 8.47 (s, 1H), 8.15 (d, <i>J</i> = 3.1 Hz, 1H), 7.74–7.67 (m, 3H), 7.66–7.60 (m, 1H), 7.41–7.37 (m, 1H), 7.31–7.26 (m, 1H), 3.76 (s, 3H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 412.1 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.75 min.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-((3-Carbamoyl-2-methoxyphenyl)amino)-6-((5-fluoropyridin-2-yl)amino)-<i>N</i>-methyl-nicotinamide (<b>17</b>)</h4><div class="NLM_p last">3-((2-((5-Fluoropyridin-2-yl)amino)-5-(methylcarbamoyl)pyridin-4-5-yl)-amino)-2-methoxybenzoic acid (<b>16</b>, 15 mg, 0.036 mmol), Hunig’s base (0.019 mL, 0.109 mmol), and ammonium chloride (3.90 mg, 0.073 mmol) were stirred in DMF at room temperature for a few minutes, then BOP (20.96 mg, 0.047 mmol) was added to the resulting slurry. After stirring at room temperature for 1 h, methanol (0.1 mL) and DMF (1.0 mL) were successively added and the solution was filtered through a Millipore filter. The resulting solution was subjected to purification by reverse-phase preparative LCMS using the following conditions: Column, Waters XBridge C18, 19 mm × 200 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Gradient: 100% B over 20 min, then a 5 min hold at 100% B. Flow: 25 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford 7.6 mg (48%) of <b>17</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (s, 1H), 10.06 (s, 1H), 8.55 (br s, 1H), 8.45 (s, 1H), 8.21–8.11 (m, 1H), 7.75 (br s, 1H), 7.63 (br dd, <i>J</i> = 7.6, 1.5 Hz, 4H), 7.56 (br s, 1H), 7.36–7.30 (m, 1H), 7.29–7.24 (m, 1H), 3.73 (s, 3H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 411.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.23 min.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-((5-Fluoropyridin-2-yl)amino)-4-((2-methoxy-3-(methylcarbamoyl)phenyl)-amino)-<i>N</i>-methylnicotinamide (<b>18</b>)</h4><div class="NLM_p last">Prepared from <b>16</b> in a manner similar to <b>17</b> using methylamine in place of ammonium chloride to afford 7.6 mg of <b>18</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (s, 1H), 9.78 (s, 1H), 8.51 (br d, <i>J</i> = 4.3 Hz, 1H), 8.45 (s, 1H), 8.28–8.19 (m, 1H), 8.14 (d, <i>J</i> = 3.1 Hz, 1H), 7.74–7.57 (m, 4H), 7.30–7.20 (m, 2H), 3.71 (s, 3H), 2.78 (dd, <i>J</i> = 8.2, 4.6 Hz, 6H). LCMS (E+) <i>m</i>/<i>z</i>: 425.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.17 min.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 6-((5-Fluoropyridin-2-yl)amino)-4-((3-(methylcarbamoyl)phenyl)-amino)-<i>N</i>-methyl-nicotinamide (<b>19</b>)</h4><div class="NLM_p last">Prepared from 4,6-dichloro-<i>N</i>-methylnicotinamide<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> using similar procedures as described for the preparation of <b>17</b> and using 3-amino-<i>N</i>-methylbenzamide in place of 3-amino-2-methoxybenzoic acid to afford 8.7 mg of <b>19</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 9.81 (s, 1H), 8.48 (s, 2H), 8.56–8.43 (m, 1H), 8.10 (d, <i>J</i> = 2.5 Hz, 1H), 7.78 (s, 1H), 7.76–7.72 (m, 1H), 7.68–7.59 (m, 2H), 7.57–7.53 (m, 1H), 7.49 (t, <i>J</i> = 7.7 Hz, 1H), 7.42 (d, <i>J</i> = 8.9 Hz, 1H), 2.81–2.76 (m, 6H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 4-(4-Carbamoyl-2-methoxyphenylamino)-6-(5-fluoropyridin-2-ylamino)-<i>N</i>-methyl-nicotinamide (<b>20</b>)</h4><div class="NLM_p">To a stirred solution of 4,6-dichloro-<i>N</i>-methylnicotinamide<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (1.0 g, 4.9 mmol) in DMA (30 mL) was added 4-amino-3-methoxybenzoic acid (1.22 g, 7.32 mmol) followed by addition of a solution of sodium bis(trimethylsilyl)amide (1 M in THF, 36.6 mL, 36.6 mmol). The reaction mixture was stirred for 2 h, at which point the THF was removed in vacuo and HCl (1 M aq) was added to adjust pH to ∼5. The resulting heterogeneous slurry was filtered to collect the solid as crude 4-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-3-methoxybenzoic acid. The filtrate was extracted with dichloromethane and washed with water (3×), dried, concentrated, and purified by automated silica gel chromatography (0–100% MeOH/DCM) to yield additional 4-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-3-methoxybenzoic acid (0.87 g total, 53%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 9.81 (s, 1H), 8.48 (s, 2H), 8.56–8.43 (m, 1H), 8.10 (d, <i>J</i> = 2.5 Hz, 1H), 7.78 (s, 1H), 7.76–7.72 (m, 1H), 7.68–7.59 (m, 2H), 7.57–7.53 (m, 1H), 7.49 (t, <i>J</i> = 7.7 Hz, 1H), 7.42 (d, <i>J</i> = 8.9 Hz, 1H), 2.81–2.76 (m, 6H). LCMS (E+) <i>m</i>/<i>z</i>: 336 (MH<sup>+</sup>).</div><div class="NLM_p">To a mixture of 5-fluoropyridin-2-amine (217 mg, 1.94 mmol) and 4-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-3-methoxybenzoic acid (500 mg, 1.49 mmol) was added DMA (10 mL) followed by Pd<sub>2</sub>(dba)<sub>3</sub> (136 mg, 0.15 mmol), XantPhos (172 mg, 0.30 mmol), and cesium carbonate (0.970 g, 2.98 mmol). The vessel was then evacuated and backfilled with nitrogen three times and then heated to 145 °C for 2 h. The crude product was filtered and then concentrated to afford an oil as the crude product. This material was adsorbed onto silica gel, dried and then purified using automated chromatography (0–100% MeOH/DCM) to provide 300 mg (49%) of 4-((2-((5-fluoropyridin-2-yl)amino)-5-(methylcarbamoyl)pyridin-4-yl)amino)-3-methoxybenzoic acid. LCMS (E+) <i>m</i>/<i>z</i>: 412 (MH<sup>+</sup>).</div><div class="NLM_p last">To a DMF (1 mL) solution containing 4-((2-((5-fluoropyridin-2-yl)amino)-5-(methylcarbamoyl)-pyridin-4-yl)amino)-3-methoxybenzoic acid (30 mg, 0.073 mmol), ammonium chloride (7.8 mg, 0.15 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (51 μL, 0.29 mmol) was added <i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate (HATU, 36 mg, 0.095 mmol) and the reaction stirred for 1 h. The reaction was filtered and purified by preparative HPLC, providing <b>20</b> (12 mg, 40%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.66 (s, 1H), 9.86 (s, 1H), 8.53–8.48 (m, 1H), 8.47 (s, 1H), 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.95 (s, 1H), 7.87 (s, 1H), 7.69–7.63 (m, 2H), 7.60–7.55 (m, 3H), 7.31 (br s, 1H), 3.91 (s, 3H), 2.77 (d, <i>J</i> = 4.5 Hz, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 411.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.09 min.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 6-((5-Fluoropyridin-2-yl)amino)-4-((2-methoxy-4-(methylcarbamoyl)phenyl)-amino)-<i>N</i>-methylnicotinamide (<b>21</b>)</h4><div class="NLM_p last">Prepared from 4,6-dichloro-<i>N</i>-methylnicotinamide<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> using similar procedures as described for the preparation of <b>20</b> and using methylamine in place ammonium chloride to afford 18.3 mg of <b>21</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69–10.57 (m, 1H), 9.86 (br s, 1H), 8.51 (br s, 1H), 8.45 (s, 1H), 8.40 (br d, <i>J</i> = 4.4 Hz, 1H), 8.18 (s, 1H), 7.82 (br s, 1H), 7.69–7.50 (m, 5H), 3.91 (s, 3H), 2.81 (br d, <i>J</i> = 4.2 Hz, 3H), 2.77 (br d, <i>J</i> = 4.1 Hz, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 425.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.25 min.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-((3-Carbamoyl-2-methoxyphenyl)amino)-6-((5-fluoro-4-methylpyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>22</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoic acid as described for the preparation of <b>17</b> and using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine to afford 9.1 mg of <b>22</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.66 (s, 1H), 9.69 (s, 1H), 8.53–8.43 (m, 2H), 8.04 (s, 1H), 7.77–7.66 (m, 2H), 7.63 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.58–7.53 (m, 2H), 7.32–7.23 (m, 2H), 3.74 (s, 3H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H), 2.23 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 425.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.20 min.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(methylcarbamoyl)phenyl)-amino)-<i>N</i>-methylnicotinamide (<b>23</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoic acid using similar procedures as described for the preparation of <b>18</b> using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine to afford 7.6 mg of <b>23</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (s, 1H), 9.65 (br s, 1H), 8.55 (br s, 1H), 8.46 (s, 1H), 8.29–8.18 (m, 1H), 8.07 (s, 1H), 7.66–7.58 (m, 2H), 7.50 (br s, 1H), 7.26 (br d, <i>J</i> = 4.9 Hz, 2H), 3.72 (s, 3H), 2.83–2.75 (m, 6H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 439.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.29 min.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 4-((3-(Ethylcarbamoyl)-2-methoxyphenyl)amino)-6-((5-fluoro-4-methylpyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>24</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoic acid using similar procedures as described for the preparation of <b>17</b> and using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine and ethylamine hydrochloride in place of ammonium chloride to afford 9.7 mg of <b>24</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (s, 1H), 9.71 (br s, 1H), 8.54–8.48 (m, 1H), 8.48 (s, 1H), 8.29 (br s, 1H), 8.05 (s, 1H), 7.70 (br s, 1H), 7.62 (br d, <i>J</i> = 7.4 Hz, 1H), 7.56 (br s, 1H), 7.32–7.14 (m, 2H), 3.72 (s, 3H), 3.35 (m, 2H), 2.78 (br d, <i>J</i> = 4.0 Hz, 3H), 2.24 (s, 3H), 1.13 (br t, <i>J</i> = 7.1 Hz, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 453.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.56 min.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 4-((3-(Dimethylcarbamoyl)-2-methoxyphenyl)amino)-6-((5-fluoro-4-methylpyridin-2-yl)-amino)-<i>N</i>-methylnicotinamide (<b>25</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoic acid using similar procedures as described for the preparation of <b>17</b> and using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine and dimethylamine in place of ammonium chloride to afford 6.8 mg of <b>25</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67–10.54 (m, 1H), 9.71–9.63 (m, 1H), 8.54–8.42 (m, 2H), 8.04 (s, 1H), 7.68 (br s, 1H), 7.62–7.46 (m, 2H), 7.29–7.15 (m, 1H), 6.92 (br d, <i>J</i> = 7.5 Hz, 1H), 3.68–3.65 (m, 3H), 2.81–2.75 (m, 9H), 2.23 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 453.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> (condition B) = 0.69 min.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-((3-((Cyclopropylmethyl)carbamoyl)-2-methoxyphenyl)amino)-6-((5-fluoro-4-methyl-pyridin-2-yl)amino)-<i>N</i>-methylnicotinamide (<b>26</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)-pyridin-4-ylamino)-2-methoxybenzoic acid using similar procedures as described for the preparation of <b>17</b> and using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine and cyclopropylmethylamine in place of ammonium chloride to afford 6.3 mg of <b>26</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (s, 1H), 9.72 (br s, 1H), 8.51 (br d, <i>J</i> = 3.7 Hz, 1H), 8.48 (s, 1H), 8.37 (t, <i>J</i> = 5.5 Hz, 1H), 8.05 (s, 1H), 7.70 (br s, 1H), 7.64 (dd, <i>J</i> = 7.6, 2.1 Hz, 1H), 7.56 (br d, <i>J</i> = 4.3 Hz, 1H), 7.33–7.17 (m, 2H), 3.74 (s, 3H), 3.16 (t, <i>J</i> = 6.4 Hz, 2H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H), 2.24 (s, 3H), 1.11–0.98 (m, 1H), 0.48–0.42 (m, 2H), 0.28–0.21 (m, 2H). LCMS (E+) <i>m</i>/<i>z</i>: 479.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.57 min.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((3-((2-hydroxyethyl)carbamoyl)-2-methoxy-phenyl)amino)-<i>N</i>-methylnicotinamide (<b>27</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoic acid using similar procedures as described for the preparation of <b>17</b> and using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine and 2-hydroxyethylamine in place of ammonium chloride to afford 6.5 mg of <b>27</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H), 9.71 (br s, 1H), 8.51 (br d, <i>J</i> = 4.3 Hz, 1H), 8.48 (s, 1H), 8.30 (br t, <i>J</i> = 5.5 Hz, 1H), 8.05 (s, 1H), 7.70 (br s, 1H), 7.65 (br d, <i>J</i> = 6.7 Hz, 1H), 7.57 (br d, <i>J</i> = 4.9 Hz, 1H), 7.35–7.23 (m, 2H), 4.79 (t, <i>J</i> = 5.5 Hz, 1H), 3.73 (s, 3H), 3.54 (q, <i>J</i> = 5.9 Hz, 2H), 3.36 (m, 2H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 469.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.18 min.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-((2-morpholinoethyl)-carbamoyl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>28</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoic acid using similar procedures as described for the preparation of <b>17</b> and using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine and 2-morpholinylethylamine in place of ammonium chloride to afford 8.3 mg of <b>28</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (s, 1H), 9.71 (s, 1H), 8.54–8.49 (m, 1H), 8.48 (s, 1H), 8.36–8.29 (m, 1H), 8.05–8.02 (m, 1H), 7.69 (s, 1H), 7.65 (d, <i>J</i> = 7.9 Hz, 1H), 7.59–7.54 (m, 1H), 7.36–7.32 (m, 1H), 7.31–7.25 (m, 1H), 3.76 (s, 3H), 3.60–3.54 (m, 4H), 3.45–3.38 (m, 5H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H), 2.46–2.37 (m, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 538.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.32 min.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-((pyridin-2-ylmethyl)-carbamoyl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>29</b>)</h4><div class="NLM_p last">Prepared from 3-(2-chloro-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoic acid using similar procedures as described for the preparation of <b>17</b> and using 2-amino-4-methyl-5-fluoropyridine in place of 2-amino-5-fluoropyridine and pyridin-2-ylmethanamine in place of ammonium chloride to afford 11.2 mg of <b>29</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (s, 1H), 9.72 (br s, 1H), 9.02 (br t, <i>J</i> = 5.8 Hz, 1H), 8.53 (br dd, <i>J</i> = 11.3, 4.6 Hz, 2H), 8.49 (s, 1H), 8.05 (s, 1H), 7.83–7.78 (m, 1H), 7.70 (br s, 1H), 7.67 (br d, <i>J</i> = 7.9 Hz, 1H), 7.57 (br d, <i>J</i> = 4.9 Hz, 1H), 7.42 (d, <i>J</i> = 7.3 Hz, 1H), 7.37 (br d, <i>J</i> = 6.7 Hz, 1H), 7.33–7.26 (m, 2H), 4.61 (d, <i>J</i> = 5.5 Hz, 2H), 3.75 (s, 3H), 2.79 (d, <i>J</i> = 4.3 Hz, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 516.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.44 min.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Preparation of 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(1,3,4-oxadiazol-2-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>30</b>)</h4><div class="NLM_p">Intermediate 3-((2-((5-fluoropyridin-2-yl)amino)-5-(methylcarbamoyl)pyridin-4–5-yl)amino)-2-methoxybenzoic acid (60 mg, 0.141 mmol) from the preparation of <b>22</b>, Hunig’s base (0.074 mL, 0.423 mmol), and <i>tert</i>-butyl hydrazinecarboxylate (22.4 mg, 0.169 mmol) was stirred in DMF (0.6 mL) for a few minutes at room temperature, then (benzotriazol-1- yloxy)tris(dimethylamino)-phosphonium hexafluorophosphate (BOP, 81 mg, 0.183 mmol) was added. After stirring the resulting slurry at room temperature for 1 h, the reaction mixture was slowly diluted with water (∼3 mL), and the resulting suspension was sonicated briefly and the precipitated solid was collected by vacuum filtration and dried under vacuum to afford 64 mg (84%) of <i>tert</i>-butyl 2-(3-(2-(5-fluoro-4-methylpyridin-2-ylamino)-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoyl)-hydrazinecarboxylate as a light-tan solid. LCMS (E+) <i>m</i>/<i>z</i>: 540.2 (MH<sup>+</sup>).</div><div class="NLM_p">To a slurry of <i>tert</i>-butyl 2-(3-(2-(5-fluoro-4-methylpyridin-2-ylamino)-5-(methylcarbamoyl)pyridin-4-ylamino)-2-methoxybenzoyl)-hydrazinecarboxylate (64 mg, 0.119 mmol) in dichloromethane (0.5 mL) was added trifluoroacetic acid (0.18 mL, 2.4 mmol) to give a clear solution This mixture was stirred at room temperature for 1 h then was concentrated and redissolved in DCM (10 mL). The solution was reconcentrated, and the process was repeated one additional time to remove residual trifluoroacetic acid. The resulting material was triturated with ether (2 × 5 mL) to give an oil, which foamed and solidified under vacuum to afford 55 mg of 6-(5-fluoro-4-methylpyridin-2-ylamino)-4-(3-(hydrazinecarbonyl)-2-methoxyphenylamino)-<i>N</i>-methylnicotinamide as a pale-yellow solid. LCMS (E+) <i>m</i>/<i>z</i>: 440.2 (MH<sup>+</sup>).</div><div class="NLM_p last">A portion of 6-(5-fluoro-4-methylpyridin-2-ylamino)-4-(3-(hydrazinecarbonyl)-2-methoxyphenylamino)-<i>N</i>-methylnicotinamide from the previous step (15 mg, 0.027 mmol) was dissolved in trimethoxymethane (144 mg, 1.36 mmol) and was heated to 105 °C for 2 h using a preheated heating block. The reaction mixture was concentrated to remove excess trimethoxymethane, diluted with DMF (∼1 mL), filtered, and was purified by preparative reverse phase LCMS with the following conditions: column, Waters XBridge C18, 19 mm × 200 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Gradient: 15–100% B over 20 min, then a 5 min hold at 100% B. Flow: 25 mL/mins. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford 7.2 mg (59%) of <b>30</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (s, 1H), 9.75 (br s, 1H), 9.41 (s, 1H), 8.59–8.53 (m, 1H), 8.50 (s, 1H), 8.07 (s, 1H), 7.82 (d, <i>J</i> = 7.4 Hz, 1H), 7.78–7.68 (m, 1H), 7.63 (br d, <i>J</i> = 7.4 Hz, 1H), 7.60–7.51 (m, 1H), 7.43 (t, <i>J</i> = 7.9 Hz, 1H), 3.79 (s, 3H), 2.79 (d, <i>J</i> = 4.4 Hz, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 450.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.40 min.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>31</b>)</h4><div class="NLM_p last">Prepared using similar procedures as described for the preparation of <b>30</b> and using trimethoxyorthoacetate in place of trimethoxymethane to afford 7.5 mg (59%) of <b>31</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (s, 1H), 9.73 (s, 1H), 8.53 (br d, <i>J</i> = 4.4 Hz, 1H), 8.50 (s, 1H), 8.06 (s, 1H), 7.79 (d, <i>J</i> = 7.7 Hz, 1H), 7.73 (s, 1H), 7.57 (br d, <i>J</i> = 6.7 Hz, 2H), 7.41 (t, <i>J</i> = 8.1 Hz, 1H), 3.78 (s, 3H), 2.79 (d, <i>J</i> = 4.4 Hz, 3H), 2.60 (s, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 464.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.46 min.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>32</b>) and 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-5-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>33</b>)</h4><div class="NLM_p">A slurry of l-(2-methoxy-3-nitrophenyl)ethanone<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> (450 mg, 2.306 mmol) in <i>Ν</i>,<i>Ν</i>-dimethylformamide dimethyl acetal (DMF-DMA, 8.15 g, 68.4 mmol) was heated to 80 °C, giving a clear solution. After stirring at this temperature for ∼30 min, the reaction was cooled, diluted with 100 mL of ethyl acetate, washed with water (3×), then brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 432 mg of a tan oil. This material was dissolved in ethanol (4.0 mL) and was cooled in an ice bath, then hydrazine hydrate (0.22 mL, 6.9 mmol) was added dropwise with good stirring. After the addition was complete, the reaction was allowed to warm to room temperature and stirred overnight (∼16 h). The resulting mixture was concentrated to remove the ethanol, diluted with 100 mL of ethyl acetate, washed with water (3×), then brine, dried over sodium sulfate, filtered, and concentrated to afford a tan semisolid. To this material was added 4 mL of acetone and potassium carbonate (956 mg, 6.92 mmol), and the resulting mixture was stirred at room temperature for 10 min before adding iodomethane (0.577 mL, 9.22 mmol) dropwise. After stirring the reaction mixture at room temperature overnight, the mixture was concentrated and was partitioned between ethyl acetate and water. The layers were separated, and the organic portion was washed with water (3×), dried over sodium sulfate, filtered, and concentrated under vacuum to afford tan oil. This material was purified by flash silica gel chromatography using hexanes/ethyl acetate mixtures as the eluent. Fractions containing the major uv active component were combined and concentrated under vacuum to afford 155 mg (29% overall yield) of a ∼4:1 isomeric mixture of 3-(2-methoxy-3-nitrophenyl)-1-methyl-1<i>H</i>-pyrazole and 5-(2-methoxy-3-nitrophenyl)-1-methyl-1<i>H</i>-pyrazole, respectively, which was used directly in the next reaction. LCMS (E+) <i>m</i>/<i>z</i>: 235 (MH<sup>+</sup>).</div><div class="NLM_p">To a solution of a ∼4:1 isomeric mixture of 3-(2-methoxy-3-nitrophenyl)-1-methyl-1<i>H</i>-pyrazole and 5-(2-methoxy-3-nitrophenyl)-1-methyl-1<i>H</i>-pyrazole (0.15 g, 0.643 mmol) in ethanol (10 mL) was added 10% palladium on carbon (0.021 g, 0.019 mmol), and the flask was evacuated and supplied with hydrogen gas from a balloon for 3 h. After the reaction was complete, the hydrogen balloon was removed and the flask was flushed with nitrogen before adding 50 mL of additional ethanol. The mixture was filtered to remove the catalyst, and the resulting clear filtrate was concentrated to afford 120 mg (92%) of a ∼4:1 isomeric mixture of 2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-3-yl)aniline and 2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-5-yl)aniline, respectively. LCMS (E+) <i>m</i>/<i>z</i>: 204 (MH<sup>+</sup>).</div><div class="NLM_p">To a solution of 4,6-dichloro-<i>N</i>-methylnicotinamide<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (110 mg, 0.54 mmol) and a ∼4:1 isomeric mixture of 2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-3-yl)aniline and 2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-5-yl)aniline (120 mg, 0.59 mmol) in DMA (1 mL) was added a solution of lithium bis(trimethylsilyl)amide (1 M in THF, 1.34 mL, 1.34 mmol) dropwise via syringe at room temperature over ∼5 min. After stirring for ∼30 min at room temperature, additional lithium bis(trimethylsilyl)amide (1 M in THF, 0.6 mL, 0.6 mmol) was added and the mixture was stirred for an additional 30 min. Water was then added, and the resulting mixture was concentrated to remove most of the volatiles. The resulting aqueous solution was acidified to a pH of ∼4 by slowly adding 1N aq HCl dropwise with stirring, causing a solid to precipitate from solution. The resulting slurry was stirred at room temperature for ∼1 h. The resulting solid was collected by vacuum filtration, rinsed with water, and dried to afford 155 mg (78%) of a tan solid as a ∼4:1 isomeric mixture of 6-chloro-4-(2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-3-yl)phenylamino)-<i>N</i>-methylnicotinamide and 6-chloro-4-(2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-5-yl)phenylamino)-<i>N</i>-methylnicotinamide, respectively. LCMS <i>m</i>/<i>z</i>: 204 (MH<sup>+</sup>) for both isomers.</div><div class="NLM_p">A ∼4:1 isomeric mixture of 6-chloro-4-(2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-3-yl)phenylamino)-<i>N</i>-methylnicotinamide and 6-chloro-4-(2-methoxy-3-(1-methyl-1<i>H</i>-pyrazol-5-yl)phenylamino)-<i>N</i>-methylnicotinamide (25 mg, 0.067 mmol), 5-fluoro-4-methylpyridin-2-amine (12.7 mg, 0.10 mmol), cesium carbonate (43.8 mg, 0.134 mmol), and 2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-l, I′-biphenyl (BrettPhos, 5.4 mg, 10.1 μmol) in dioxane (0.5 mL) was sparged with nitrogen for 5 min, then Pd<sub>2</sub>(dba)<sub>3</sub> (9.2 mg, 10.1 μmol) was added and the reaction was placed into a preheated 110 °C heating block for 1 h. The reaction was cooled to room temperature, diluted with DMSO, filtered, and subjected to purification by reverse phase preparative LCMS with the following conditions: column, XBridge C18, 19 mm × 200 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate. Gradient: 25–65% B over 20 min, then a 0 min hold at 100% B. Flow: 20 mL/min. Fractions containing the resolved isomeric products were combined and dried via centrifugal evaporation to afford 13.2 mg (40%) of the major isomer <b>32</b> and 3.0 mg (9%) of the minor isomer <b>33</b>.</div><div id="sec4_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Data for the Major Isomer <b>32</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.79–10.59 (m, 1H), 9.68 (s, 1H), 8.49 (d, <i>J</i> = 4.9 Hz, 1H), 8.48 (s, 1H), 8.04 (s, 1H), 7.77 (d, <i>J</i> = 1.8 Hz, 1H), 7.72 (s, 1H), 7.63–7.55 (m, 2H), 7.49 (d, <i>J</i> = 1.9 Hz, 1H), 7.23 (t, <i>J</i> = 1.9 Hz, 1H), 6.73 (d, <i>J</i> = 2.4 Hz, 1H), 3.91 (s, 3H), 3.64–3.58 (m, 3H), 2.79 (d, <i>J</i> = 4.3 Hz, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 462.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.66 min.</div></div><div id="sec4_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> Data for the Minor Isomer <b>33</b></h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (s, 1H), 9.85 (br s, 1H), 8.56 (br s, 1H), 8.47 (s, 1H), 8.09 (s, 1H), 7.67 (d, <i>J</i> = 8.5 Hz, 2H), 7.51 (s, 2H), 7.32 (t, <i>J</i> = 1.6 Hz, 1H), 7.07 (d, <i>J</i> = 7.3 Hz, 1H), 6.38 (s, 1H), 3.69 (s, 3H), 3.47 (br s, 3H), 2.78 (d, <i>J</i> = 3.7 Hz, 3H), 2.25 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 462.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.65 min.</div></div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>34</b>)</h4><div class="NLM_p last">A slurry of <b>22</b> (25 mg, 0.06 mmol) in DMF-DMA (1.5 mL, 11.2 mmol) was heated to 110 °C, giving a clear solution initially then eventually becoming a heterogeneous slurry after stirring at this temperature for 30 min. The resulting mixture was then cooled slightly and concentrated to remove the DMF-DMA to afford a solid which was dried further under vacuum. To this residue was added acetic acid (0.12 mL) and ethanol (0.6 mL), giving a clear solution which was immediately by cooled in a −10 °C brine/ice bath, giving a slurry. At this time, 60 μL (∼10 equiv) of hydrazine hydrate was added dropwise via syringe with good stirring to afford light-pink slurry. After addition was complete, the reaction was slowly heated to 60 °C and stirring was continued for 2 h. The reaction mixture was then cooled to room temperature and allowed to stir overnight. The reaction mixture was diluted with ∼2 mL of DMSO and was subjected to reverse phase preparative LCMS purification with the following conditions: column, Waters XBridge C18, 19 mm × 200 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Gradient: 10–100% B over 25 min, then a 5 min hold at 100% B. Flow: 25 mL/min. Fractions containing the major product were combined and dried via centrifugal evaporation to afford 8.6 mg (33%) of <b>34</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (s, 1H), 9.71 (s, 1H), 8.54 (br d, <i>J</i> = 3.7 Hz, 1H), 8.49 (s, 1H), 8.29 (br s, 1H), 8.04 (s, 1H), 7.70 (s, 1H), 7.68–7.61 (m, 3H), 7.58 (br d, <i>J</i> = 4.9 Hz, 1H), 7.34 (br t, <i>J</i> = 7.9 Hz, 1H), 3.69 (s, 3H), 2.79 (br d, <i>J</i> = 3.8 Hz, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 449.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.25 min.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(5-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>35</b>)</h4><div class="NLM_p last">Prepared from <b>22</b> using a similar procedure as described for the preparation of <b>34</b> and using <i>N</i>,<i>N</i>-dimethylacetamide dimethyl acetal in place of DMF-DMA to afford 12.3 mg (34%) of <b>35</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.43 (s, 1H), 7.99 (s, 1H), 7.74 (d, <i>J</i> = 7.7 Hz, 2H), 7.64 (br s, 1H), 7.44–7.31 (m, 2H), 3.79 (s, 3H), 3.00 (s, 3H), 2.54 (s, 3H), 2.34 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 463.4 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.66 min (condition C).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(4-methyl-4<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>36</b>)</h4><div class="NLM_p last">Prepared from <b>22</b> using a similar procedure as described for the preparation of <b>34</b> and using <i>N</i>,<i>N</i>-dimethylacetamide dimethyl acetal in place of DMF-DMA and <i>N</i>-methyl hydrazine in place of hydrazine hydrate to afford 4.8 mg (10%) of <b>36</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.40 (s, 1H), 7.99 (d, <i>J</i> = 1.1 Hz, 1H), 7.84 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.74 (s, 1H), 7.40 (t, <i>J</i> = 7.9 Hz, 1H), 7.31 (d, <i>J</i> = 5.5 Hz, 1H), 7.26 (dd, <i>J</i> = 7.7, 1.6 Hz, 1H), 3.76 (s, 3H), 3.58 (s, 3H), 2.94 (s, 3H), 2.43 (s, 3H), 2.33 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 477.4 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.68 min (condition C).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 6-((4,5-Dimethylpyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-5-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>37</b>)</h4><div class="NLM_p last">Prepared from <b>22</b> using a similar procedure as described for the preparation of <b>34</b> and using <i>N</i>-methyl hydrazine in place of hydrazine hydrate to afford 15 mg (42%) of <b>37</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.43 (s, 1H), 8.11 (s, 1H), 8.01 (br s, 1H), 7.88 (d, <i>J</i> = 7.7 Hz, 1H), 7.78 (s, 1H), 7.43 (t, <i>J</i> = 7.8 Hz, 1H), 7.34 (d, <i>J</i> = 5.5 Hz, 1H), 7.29 (d, <i>J</i> = 7.7 Hz, 1H), 3.86 (s, 3H), 3.59 (s, 3H), 2.97 (s, 3H), 2.35 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 463.1 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 0.69 min (condition C).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 6-((5-Fluoro-4-methylpyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>38</b>)</h4><div class="NLM_p last">Prepared from 3-((2-chloro-5-(methylcarbamoyl)pyridin-4-yl)amino)-2-methoxybenzoic acid by amide formation using a similar procedure as described in the preparation of <b>17</b> to afford 4-((3-carbamoyl-2-methoxyphenyl)amino)-6-chloro-<i>N</i>-methylnicotinamide. Reaction of 4-((3-carbamoyl-2-methoxyphenyl)amino)-6-chloro-<i>N</i>-methylnicotinamide with DMF-DMA followed by hydrazine hydrate using a similar procedure as described for the preparation of <b>34</b> afforded 6-chloro-4-((2-methoxy-3-(1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide. Methylation of 6-chloro-4-((2-methoxy-3-(1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide using a similar procedure as described for the preparation of <b>50</b> afforded 6-chloro-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methyl-nicotinamide. Final coupling of 6-chloro-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide with 2-amino-4-methyl-5-fluoropyridine using a similar procedure as described for the preparation of <b>32</b> and <b>33</b> afforded <b>38</b>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (s, 1H), 9.70 (br s, 1H), 8.55 (s, 1H), 8.51 (br s, 1H), 8.48 (s, 1H), 8.06 (s, 1H), 7.78–7.68 (m, 1H), 7.65–7.57 (m, 2H), 7.53 (br d, <i>J</i> = 7.3 Hz, 1H), 7.28 (t, <i>J</i> = 7.9 Hz, 1H), 3.95 (s, 3H), 3.74 (s, 3H), 2.81–2.77 (m, 3H), 2.24 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 463.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.32 min.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 6-((5-Cyanopyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>39</b>)</h4><div class="NLM_p last">Prepared using similar procedures as described for the preparation of <b>38</b> by using 2-amino-5-cyanopyridine in place of 2-amino-4-methyl-5-fluoropyridine to afford 4.2 mg of <b>39</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.54–8.51 (m, 2H), 8.45 (s, 1H), 7.91 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.78 (s, 1H), 7.71–7.70 (m, 1H), 7.68 (d, <i>J</i> = 1.1 Hz, 1H), 7.64 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 4.06 (s, 3H), 3.77 (s, 3H), 2.96 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 456.0 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.64 min (condition C).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-((2-Methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methyl-6-((5-(trifluoromethyl)pyridin-2-yl)amino)nicotinamide (<b>40</b>)</h4><div class="NLM_p last">Prepared using similar procedures described for the preparation of <b>38</b> by using 2-amino-5-trifluoromethylpyridine in place of 2-amino-5-fluoropyridine to afford 6.9 mg of <b>40</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.51 (s, 1H), 8.47–8.45 (m, 1H), 8.45 (s, 1H), 7.89 (dd, <i>J</i> = 8.7, 2.3 Hz, 1H), 7.82 (s, 1H), 7.74–7.62 (m, 3H), 7.34 (t, <i>J</i> = 7.9 Hz, 1H), 4.06 (s, 3H), 3.78 (s, 3H), 2.97 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 499.0 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 0.73 min (condition C).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 6-((2,6-Dimethylpyrimidin-4-yl)amino)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>41</b>)</h4><div class="NLM_p last">Prepared using similar procedures described for the preparation of <b>38</b> by using 2,6-dimethylpyrimidin-4-amine in place of 2-amino-5-fluoropyridine to afford 13 mg of <b>41</b>. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.50 (s, 1H), 8.49 (s, 1H), 7.72 (br d, <i>J</i> = 7.9 Hz, 1H), 7.60 (d, <i>J</i> = 7.9 Hz, 1H), 7.33 (t, <i>J</i> = 7.9 Hz, 1H), 4.02 (s, 3H), 3.73 (s, 3H), 2.95 (s, 3H), 2.59 (s, 3H), 2.47 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 460.3 (MH<sup>+</sup>). <i>R</i><sub>T</sub> = 0.53 min (condition C).</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Preparation of 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylnicotinamide (<b>42</b>)</h4><div class="NLM_p last">Prepared by a sequential coupling of 2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)aniline (<b>52</b>) and cyclopropylamide (<b>55</b>) to 4,6-dichloro-<i>N</i>-methylnicotinamide<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> using similar procedures as described in the preparation of <b>11</b> to afford 17.8 mg (36% over 2 steps) of <b>42</b> as an off-white solid. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.54 (s, 1H), 8.38 (s, 1H), 7.83 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.59 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.38 (t, <i>J</i> = 7.9 Hz, 1Η), 6.94 (br s, 1H), 4.06 (d, <i>J</i> = 0.4 Hz, 3H), 3.75 (s, 3H), 2.98 (s, 3H), 1.87–1.76 (m, 1H), 1.15–1.07 (m, 2H), 1.06–0.97 (m, 2H). LCMS (E+) <i>m</i>/<i>z</i>: 422.2 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.57 min (condition C).</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 6-(Cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-(methyl-<i>d</i><sub>3</sub>-nicotinamide (<b>43</b>)</h4><div class="NLM_p last">Prepared by a sequential coupling of 2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)aniline (<b>52</b>) and cyclopropylamide to <b>53</b><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> using similar procedures as described in the preparation of <b>11</b> to afford 26.3 mg (60% over 2 steps) of <b>43</b> as an off-white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (br s, 1H), 10.61 (br s, 1H), 8.58 (br s, 1H), 8.52 (br s, 1H), 8.48 (br s, 1H), 8.03 (br s, 1H), 7.62–7.42 (m, 2H), 7.22 (t, <i>J</i> = 7.4 Hz, 1H), 3.93 (br s, 3H), 3.69 (br s, 3H), 2.01–1.88 (m, 1H), 0.85–0.69 (m, <i>J</i> = 4.4 Hz, 4H). LCMS (E+) <i>m</i>/<i>z</i>: 425.3 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 1.09 min.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-Methoxy-3-nitrobenzamide (<b>48</b>)</h4><div class="NLM_p">To a solution of 10 g (51 mmol) of commercially available methyl 2-hydroxy-3-nitrobenzoate (<b>47</b>) in DMF (100 mL) at room temperature was added potassium carbonate (14 g, 101 mmol) followed by addition of methyl iodide (6.34 mL, 101 mmol), and the resulting orange mixture was heated to 60 °C for 1 h. LCMS analysis at this time showed complete and clean conversion to a major product consistent with the expected product (observed MH<sup>+</sup> 212). The reaction mixture was allowed to cool to room temperature and crushed ice (∼100 mL) was added followed by water to a total volume of ∼400 mL, causing a yellow solid to crystallize from the solution. The solution was stirred for a few minutes to give a slurry, then the solid was collected by vacuum filtration. The resulting solid was rinsed with additional water (∼100 mL) to afford a white solid, which was partially air-dried then transferred to a round-bottom flask and further dried under vacuum overnight to afford 10.5 g (98%) of a pale-yellow solid as the intermediate methyl 2-methoxy-3-nitrobenzoate. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.92 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 7.31–7.28 (m, 1H), 4.02 (s, 3H), 3.97 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 212 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.83 min.</div><div class="NLM_p last">Methyl 2-methoxy-3-nitrobenzoate (11 g, 52 mmol) was dissolved in a cold solution of ammonia in methanol (7 N, 250 mL), and concentrated aqueous ammonium hydroxide (100 mL) was added. The flask was sealed, and the resulting solution was allowed to gently stir at room temperature overnight (∼17 h). The reaction mixture was concentrated in vacuo under mild warming using a water bath to yield an aqueous slurry. This slurry was diluted with additional water (∼300 mL) and was briefly sonicated. The resulting yellow solid was collected by vacuum filtration and was rinsed with additional water (∼100 mL) and air-dried in the funnel for several hours then under vacuum to afford 7.12 g of <b>48</b> as a yellow solid. A second crop was obtained by extracting the filtrate with ethyl acetate (3 × 100 mL), followed by washing the extracts with brine, drying over anhydrous sodium sulfate, decanting, and concentration under vacuum to afford 1.67 g of additional <b>48</b> as a yellow solid (86% overall combined yield). LCMS (E+) <i>m</i>/<i>z</i>: 197 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.58 min.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 3-(2-Methoxy-3-nitrophenyl)-1<i>H</i>-1,2,4-triazole (<b>49</b>)</h4><div class="NLM_p last">A slurry of <b>48</b> (7.1 g, 36 mmol) in dimethylformamide dimethyl acetal (DMF-DMA, 48.5 mL, 362 mmol) was heated to 95 °C. giving a clear, pale-yellow solution. After heating for ∼30 min at this temperature, the reaction was cooled and concentrated in vacuo. The resulting yellow oil was azeotroped twice with 1,2-dichloroethane (40 mL portions) to ensure complete removal of any residual DMF-DMA. The oil containing the crude DMF-DMA adduct was dissolved in 35 mL of ethanol and was immediately used in the following step. In a separate flask was prepared a mixture of ethanol (150 mL) and acetic acid (35 mL), and the resulting solution was cooled in an ice bath. Once cooled, hydrazine hydrate (17.6 mL, 362 mmol) was added dropwise, followed by a dropwise addition of the previously prepared ethanol solution of the crude DMF-DMA adduct via cannula over ∼15 min with stirring. During the addition, a pale-yellow solid formed in the solution. After the addition was complete, the resulting cloudy yellow mixture was allowed to warm to room temperature and stir for ∼4 h. The reaction mixture was concentrated in vacuo to remove the ethanol, diluted with additional water, and filtered to collect the solid. The solid was washed with additional portions of water and was air-dried in the funnel, then under vacuum to afford 5.5 g (69%) of <b>49</b> as a pale-yellow solid. LCMS (E+) <i>m</i>/<i>z</i>: 221 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.61 min.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 3-(2-Methoxy-3-nitrophenyl)-1-methyl-1<i>H</i>-1,2,4-triazole (<b>50</b>)</h4><div class="NLM_p last">A solution of <b>49</b> (2.2 g, 10.1 mmol) in DMF (20 mL) was treated with potassium carbonate (4.2 g, 30 mmol). After cooling, the resulting mixture in an ice bath, and a solution of iodomethane (0.86 mL, 13.7 mmol) in DMF (5 mL) was slowly added dropwise by syringe over 2 min. After the addition was complete, the ice bath was removed and the reaction mixture was allowed to warm to room temperature. After stirring at room temperature for ∼4 h, LCMS analysis indicated complete and clean conversion to a regioisomeric mixture of products in ∼2:1 ratio. The reaction was cooled in an ice bath and was diluted with water (∼ 50 mL), and the solution was extracted with ethyl acetate (3 × 40 mL) and the combined extracts were washed with 10% aq lithium chloride (2 × 20 mL), water (20 mL), then brine before concentrating to afford 2.2 g (91%) of a yellow oil as the crude product, which solidified to a yellow solid upon standing. This crude material was combined with another batch of additional crude product (∼0.45 g) obtained from a previous similar reaction using <b>49</b>, and the combined material was purified by SFC to resolve the isomers [conditions: column = chiral IC 3 cm 5 cm, 5 μm; column temp = 35 °C; flow rate = 200 mL/min; mobile phase = CO<sub>2</sub>/MeOH = 80/20; injection program = stacked (2.3 min/cycle), 2.5 mL/per injection; sampler conc (mg/mL), 60 mg/mL; detector wavelength = 220 nm] to afford 1.87 g (66%) of the major isomer <b>50</b> as a pale-yellow solid and 0.7 g (25%) of the minor isomer <b>51</b> as a pale-yellow oil. Data for major (desired) isomer <b>50</b>: <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>: δ 8.50 (s, 1H), 8.11 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 7.38 (t, <i>J</i> = 8.0 Hz, 1H), 4.03 (s, 3H), 3.83 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 235 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.74 min.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Alternative Conditions for Synthesis of <b>50</b></h4><div class="NLM_p last">To a yellow suspension of <b>49</b> (49.3 g, 224 mmol) in THF (1000 mL) under nitrogen at room temperature was added a 1 M solution of potassium bis(trimethylsilyl)amide in THF (269 mmol) dropwise over 20 min. During the addition, the reaction turned dark-red to ultimately dark-brown in color. The temperature of the reaction at the end of addition was 27 °C. The reaction was left to stir at room temperature for 4 h, then methyl iodide (28.0 mL, 448 mmol) was added dropwise over a period of 15 min. The reaction was then left to stir at room temperature overnight. After 20 h, the reaction was checked by LCMS, indicating complete conversion had occurred. The reaction was then slowly quenched with water (350 mL) and ethyl acetate (650 mL) was added. The layers were partitioned in a separatory funnel. The organic layer was washed with brine (200 mL) and then dried over solid magnesium sulfate. Filtration and concentrating afforded 49 g (93%) of a crude yellow oil that solidified upon standing. The crude solid was then suspended in 30–40 mL of ethanol and warmed slowly to 45 °C with a heating mantle. Once all the solid has dissolved, the heat was shut off and the solution was allowed to slowly cool. When the solution reached 30 °C, it was seeded to initiate crystallization. The mixture was stirred for 1 h at room temperature, then the slurry was filtered through Whatman 2 filter paper to collect the crystalline solid. The filter cake was washed with cold (−30 °C) ethanol and was dried under vacuum overnight to afford 12 g (51.3 mmol, 23%) of the major isomer <b>50</b> as an off-white solid. The mother liquor from the filtration was concentrated, and the crystallization step was repeated with stirring overnight. Filtration and drying the collected crystalline solid afforded an additional 8.38 g (35.8 mmol, 16%) of the major isomer <b>50</b> as an off-white solid. The mother liquor was once again concentrated to an oil (29.3 g) and purified on an Isco RediSep Silica 1.5 kg Gold column. The isomers were eluted with a gradient of 100% A for 1 column volume then to 18% B over 10 column volumes where A = dichloromethane and B = 80/20 dichloromethane/methanol to afford 20.38 g of an isomeric mixture. The material was then purified by SFC using previously described conditions to yield an additional 10 g (19%) of <b>50</b> as a white solid.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-Methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)aniline (<b>52</b>)</h4><div class="NLM_p last">A solution of <b>50</b> (1.87 g, 7.98 mmol) in ethanol (50 mL) was sparged with nitrogen for a few minutes and charged with 5% Pd-C (0.85 g, 0.40 mmol). The reaction mixture was then sparged with hydrogen from a balloon for a few minutes and allowed to stir under a balloon of hydrogen for 1.5 h at room temperature. The mixture was then sparged with nitrogen to deactivate the catalyst and the mixture was filtered through a pad of diatomaceous earth washing with additional amounts of ethanol, and the resulting clear, colorless filtrate containing the product was concentrated under vacuum to afford a colorless oil. This material was azeotroped with two portions of dry toluene (∼25 mL each) to afford an off-white solid which was dried further under vacuum to afford 1.5 g (92%) of <b>52</b> as a free-flowing white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.09 (s, 1H), 7.35 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 7.00 (t, <i>J</i> = 7.8 Hz, 1H), 6.82 (dd, <i>J</i> = 7.8, 1.7 Hz, 1H), 4.00 (s, 3H), 3.94 (br s, 2H), 3.78 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 205 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.44 min.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 6-Chloro-4-((2-methoxy-3-(1-methyl-1<i>H</i>-1,2,4-triazol-3-yl)phenyl)amino)-<i>N</i>-methylpyridazine-3-carboxamide (<b>54</b>)</h4><div class="NLM_p last">To a solution of <b>52</b> (10.26 g, 50.2 mmol) and <b>53</b><a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (10.5 g, 50.2 mmol) in THF (120 mL) was added a 1 M solution of lithium bis(trimethylsilyl)amide in THF (151 mL, 151 mmol) in a dropwise manner using a pressure equalized addition funnel. The reaction was run for 10 min after the completion of the addition and then quenched with HCl (1 M aq, 126 mL, 126 mmol). The reaction was concentrated in vacuo until the majority of the THF was removed and a precipitate prevailed throughout the vessel. Water (∼500 mL) was then added, and the slurry was sonicated for 5 min and stirred for 15 min. The solid was collected by vacuum filtration, rinsed with water, and then air-dried for 30 min. The powder was collected and dissolved in dichloromethane. The organic layer was washed with water and brine and then dried over sodium sulfate, filtered, and concentrated to provide 12.5 g (66%) of <b>54</b> as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.11 (s, 1H), 9.36 (s, 1H), 8.56 (s, 1H), 7.72 (dd, <i>J</i> = 7.8, 1.6 Hz, 1H), 7.60 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.29 (t, <i>J</i> = 7.9 Hz, 1H), 7.19 (s, 1H), 3.95 (s, 3H), 3.72 (s, 3H). LCMS (E+) <i>m</i>/<i>z</i>: 377 (MH<sup>+</sup>), <i>R</i><sub>T</sub> = 0.83 min.</div></div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> IL-23-Induced Acanthosis in Mice</h3><div class="NLM_p last">Acanthosis was induced in 6–8-week-old C57BL/6 female mice (19–20 g average weight, Jackson Laboratories) by intradermal injection of dual chain, recombinant human IL-23 into the right ear. IL-23 injections were administered every other day from day 0 through day 9 of the study. Treatment groups consisted of eight mice per group. Compound <b>11</b> at 7.5, 15, and 30 mg/kg BID in vehicle (EtOH:TPGS:PEG300, 5:5:90) and vehicle alone dosed BID by oral gavage, with the first dose given the evening before the first IL-23 injection. An anti-IL-23 adnectin (3 mg/kg) and PBS control were administered subcutaneously approximately 1 h prior to the first IL-23 injection and then twice a week thereafter. Ear thickness was measured using a Mitutoyo (no. 2412F) dial caliper and calculated as the percent change in thickness from the baseline measurement taken on day 0 before initial IL-23 injections for each animal. At the end of the study, IL-23-injected ears as well as naïve control ears were collected from four animals per group for histological examination and gene expression analyses. Terminal blood samples collected via the retro-orbital sinus were used for PK determinations. Statistical analyses were performed using Student’s <i>t</i> tests or ANOVA with Dunnett’s post test. At the end of the study, ears were removed and fixed in 10% neutral-buffered formalin for 24–48 h. The fixed ears were then cut longitudinally, and two pieces were parallel embedded to make the paraffin blocks. The paraffin blocks were then sectioned and placed on microscope slides for H&E staining for histological evaluation. Severity of ear inflammation was scored using an objective scoring system based on the following parameters: extent of the lesion, severity of hyperkeratosis, number and size of pustules, height of epidermal hyperplasia (acanthosis, measured in interfollicular epidermis), and the amount of inflammatory infiltrate in the dermis and soft tissue. The latter two parameters, acanthosis and inflammatory infiltrate, were scored independently on a scale from 0 to 4: 0, none; 1, minimal; 2, mild; 3, moderate; 4, marked. The histological changes were blindly evaluated by a pathologist. Statistical analyses was performed using one-way ANOVA with Dunnett’s test for comparison of each treatment versus the vehicle control.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> X-ray Crystallography</h3><div class="NLM_p last">Protein production and purification of TYK2 JH2 (575-869) was carried out as previously reported.<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60−62)</a> Cocrystals of TYK2 JH2 in complex with a previously reported BMS compound<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> was first grown under conditions similar to that reported earlier.<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60−62)</a> These cocrystals were subsequently used for soaking inhibitors of interest. Compounds <b>11</b>, <b>12</b>, and <b>29</b> was soaked into the TYK2 JH2 cocrystals (24 h soak) by adding 5 mM inhibitor (final concentration) to a 10 μL well of harvest mother liquor. Crystals were frozen from mother liquor solution containing 25% glycerol. Structure determination was as described previously.<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60−62)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00444" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10182" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10182" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00444" class="ext-link">10.1021/acs.jmedchem.9b00444</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray crystallographic data and refinement statistics for compounds <b>11</b>, <b>12</b>, and <b>29</b> in TYK2 JH2 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings list (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_001.pdf">jm9b00444_si_001.pdf (146.23 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_002.csv">jm9b00444_si_002.csv (2.96 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>11</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZP">6NZP</a>), <b>12</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZR">6NZR</a>), and <b>29</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZQ">6NZQ</a>) in TYK2 JH2 are available from the RCSB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00444" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72601" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72601" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen T. Wrobleski</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7793-1530" title="Orcid link">http://orcid.org/0000-0001-7793-1530</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ea999e8f9a828f84c49d988588868f998183aa888799c4898587"><span class="__cf_email__" data-cfemail="8cfff8e9fce4e9e2a2fbfee3eee0e9ffe7e5cceee1ffa2efe3e1">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan Moslin</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0332-4778" title="Orcid link">http://orcid.org/0000-0002-0332-4778</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a0d2d9c1ce8ecdcfd3ccc9cee0c2cdd38ec3cfcd"><span class="__cf_email__" data-cfemail="afddd6cec181c2c0dcc3c6c1efcdc2dc81ccc0c2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuqun Lin</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanlei Zhang</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Spergel</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5190-3942" title="Orcid link">http://orcid.org/0000-0002-5190-3942</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Kempson</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Synthesis, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9540-3886" title="Orcid link">http://orcid.org/0000-0002-9540-3886</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John S. Tokarski</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joann Strnad</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adriana Zupa-Fernandez</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihong Cheng</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Shuster</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Gillooly</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoxia Yang</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth Heimrich</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charu Chaudhry</span> - <span class="hlFld-Affiliation affiliation">Leads Discovery
and Optimization, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Javed Khan</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Max Ruzanov</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Tredup</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dawn Mulligan</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dianlin Xie</span> - <span class="hlFld-Affiliation affiliation">Molecular Structure
and Design, Molecular Discovery Technologies, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huadong Sun</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate
Optimization, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Huang</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate
Optimization, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia D’Arienzo</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate
Optimization, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nelly Aranibar</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate
Optimization, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manoj Chiney</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate
Optimization, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anjaneya Chimalakonda</span> - <span class="hlFld-Affiliation affiliation">Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate
Optimization, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William J. Pitts</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis Lombardo</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Burke</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Biology, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David S. Weinstein</span> - <span class="hlFld-Affiliation affiliation">Immunosciences Discovery Chemistry, , , , , , Bristol-Myers Squibb Research
& Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>S.W. and R. M. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was funded by Bristol-Myers Squibb Company. We thank Dr. Robert Borzilleri, Dr. Joseph Tino, and Dr. John Hynes Jr., and Dr. Murali Dhar for helpful comments in the writing of this manuscript, Dr. Phil Baran for useful discussions, Dr. Andrew Tebben and Charlotte Raymond for their assistance in the design of the proposed cover art illustration, Sylwia Stachura for assistance in the preparation of analogues, the Synthesis and Analysis Technology Team and the Department of Discovery Synthesis (DDS) including Dr. Dauh-Rurng Wu, Shiuhang Yip, Richard Rampulla, and the Biocon Bristol-Myers Squibb Research and Development Center (BBRC) DDS team for assistance in the synthesis and purification of compounds. Finally, the we acknowledge the beamline staff at the IMCA-CAT beamline 17-ID at the Advanced Photon Source and the CLS 08ID at Canadian Light Source for their support in diffraction data collection.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">JH1</td><td class="NLM_def"><p class="first last">Janus homology 1</p></td></tr><tr><td class="NLM_term">JH2</td><td class="NLM_def"><p class="first last">Janus homology 2</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">pSTAT</td><td class="NLM_def"><p class="first last">phospho signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">hWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">mWB</td><td class="NLM_def"><p class="first last">mouse whole blood</p></td></tr><tr><td class="NLM_term">IC</td><td class="NLM_def"><p class="first last">Inhibitory concentration</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">μM</td><td class="NLM_def"><p class="first last">micromolar</p></td></tr><tr><td class="NLM_term">mM</td><td class="NLM_def"><p class="first last">millimolar</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">GM-CSF</td><td class="NLM_def"><p class="first last">granulocyte-macrophage colony-stimulatory factor</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">TPO</td><td class="NLM_def"><p class="first last">thrombopoietin</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">PSO</td><td class="NLM_def"><p class="first last">psoriasis</p></td></tr><tr><td class="NLM_term">PsA</td><td class="NLM_def"><p class="first last">psoriatic arthritis</p></td></tr><tr><td class="NLM_term">UC</td><td class="NLM_def"><p class="first last">ulcerative colitis</p></td></tr><tr><td class="NLM_term">AS</td><td class="NLM_def"><p class="first last">ankylosing spondylitis</p></td></tr><tr><td class="NLM_term">AA</td><td class="NLM_def"><p class="first last">alopecia areata</p></td></tr><tr><td class="NLM_term">DLE</td><td class="NLM_def"><p class="first last">discoid lupus erythematosus</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term">dcSSc</td><td class="NLM_def"><p class="first last">diffuse cutaneous systemic sclerosis</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">Crohn’s disease</p></td></tr><tr><td class="NLM_term">SAEs</td><td class="NLM_def"><p class="first last">significant adverse events</p></td></tr><tr><td class="NLM_term">mg</td><td class="NLM_def"><p class="first last">milligram</p></td></tr><tr><td class="NLM_term">g</td><td class="NLM_def"><p class="first last">gram</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer</p></td></tr><tr><td class="NLM_term">LFT</td><td class="NLM_def"><p class="first last">liver function tests</p></td></tr><tr><td class="NLM_term">LDL</td><td class="NLM_def"><p class="first last">low density lipoprotein</p></td></tr><tr><td class="NLM_term">HDL</td><td class="NLM_def"><p class="first last">high density lipoprotein</p></td></tr><tr><td class="NLM_term">CD40</td><td class="NLM_def"><p class="first last">cluster of differentiation 40</p></td></tr><tr><td class="NLM_term">compd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">SPA</td><td class="NLM_def"><p class="first last">scintillation proximity assay</p></td></tr><tr><td class="NLM_term">Th1</td><td class="NLM_def"><p class="first last">T-helper 1</p></td></tr><tr><td class="NLM_term">Th17</td><td class="NLM_def"><p class="first last">T-helper 17</p></td></tr><tr><td class="NLM_term">SH2</td><td class="NLM_def"><p class="first last">Src homology 2</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">inflammatory bowel disease</p></td></tr><tr><td class="NLM_term">Pro</td><td class="NLM_def"><p class="first last">proline</p></td></tr><tr><td class="NLM_term">Leu</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">Asn</td><td class="NLM_def"><p class="first last">asparagine</p></td></tr><tr><td class="NLM_term">Lys</td><td class="NLM_def"><p class="first last">lysine</p></td></tr><tr><td class="NLM_term">Gln</td><td class="NLM_def"><p class="first last">glutamine</p></td></tr><tr><td class="NLM_term">Thr</td><td class="NLM_def"><p class="first last">threonine;</p></td></tr><tr><td class="NLM_term">Val</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">Ala</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">Arg</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">s</td><td class="NLM_def"><p class="first last">seconds</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>c</sub></td><td class="NLM_def"><p class="first last">permeability coefficient</p></td></tr><tr><td class="NLM_term">Å</td><td class="NLM_def"><p class="first last">angstroms</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">Het</td><td class="NLM_def"><p class="first last">heterocycle</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether a-go-go-related gene</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">kcal</td><td class="NLM_def"><p class="first last">kilocalories</p></td></tr><tr><td class="NLM_term">BMPR2</td><td class="NLM_def"><p class="first last">bone morphogenetic receptor type 2</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interactions</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome p450</p></td></tr><tr><td class="NLM_term">mL</td><td class="NLM_def"><p class="first last">milliliter</p></td></tr><tr><td class="NLM_term">kg</td><td class="NLM_def"><p class="first last">kilogram</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">L</td><td class="NLM_def"><p class="first last">liter</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term">A</td><td class="NLM_def"><p class="first last">apical</p></td></tr><tr><td class="NLM_term">B</td><td class="NLM_def"><p class="first last">basal</p></td></tr><tr><td class="NLM_term">PXR-TA</td><td class="NLM_def"><p class="first last">pregnane X receptor trans-activation</p></td></tr><tr><td class="NLM_term">EC</td><td class="NLM_def"><p class="first last">efficacious concentration</p></td></tr><tr><td class="NLM_term">Aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous administration</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">oral administration</p></td></tr><tr><td class="NLM_term">TPGS</td><td class="NLM_def"><p class="first last">tocopheryl polyethylene glycol</p></td></tr><tr><td class="NLM_term">PCR</td><td class="NLM_def"><p class="first last">quantitative chain reaction</p></td></tr><tr><td class="NLM_term">SCID</td><td class="NLM_def"><p class="first last">severe-combined immunodeficient</p></td></tr><tr><td class="NLM_term">IFNαR</td><td class="NLM_def"><p class="first last">interferon-α receptor</p></td></tr><tr><td class="NLM_term">ng</td><td class="NLM_def"><p class="first last">nanogram</p></td></tr><tr><td class="NLM_term">WB</td><td class="NLM_def"><p class="first last">whole blood</p></td></tr><tr><td class="NLM_term">LLQ</td><td class="NLM_def"><p class="first last">lower limit of detection</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">mpk</td><td class="NLM_def"><p class="first last">milligrams per kilogram</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice-daily administration</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once-daily administration</p></td></tr><tr><td class="NLM_term">Ar</td><td class="NLM_def"><p class="first last">aryl</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(dicyclohexylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term"><i>R</i><sub>T</sub></td><td class="NLM_def"><p class="first last">retention times</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">LC</td><td class="NLM_def"><p class="first last">liquid chromatography</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectrometer</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">K</td><td class="NLM_def"><p class="first last">Kelvin</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometer</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">br</td><td class="NLM_def"><p class="first last">broad</p></td></tr><tr><td class="NLM_term">s</td><td class="NLM_def"><p class="first last">singlet</p></td></tr><tr><td class="NLM_term">d</td><td class="NLM_def"><p class="first last">doublet</p></td></tr><tr><td class="NLM_term">dd</td><td class="NLM_def"><p class="first last">doublet of doublet</p></td></tr><tr><td class="NLM_term">m</td><td class="NLM_def"><p class="first last">multiplet</p></td></tr><tr><td class="NLM_term">Hz</td><td class="NLM_def"><p class="first last">hertz</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">conc</td><td class="NLM_def"><p class="first last">concentration</p></td></tr><tr><td class="NLM_term">MH<sup>+</sup></td><td class="NLM_def"><p class="first last">molecular ion</p></td></tr><tr><td class="NLM_term">mmol</td><td class="NLM_def"><p class="first last">millimolar</p></td></tr><tr><td class="NLM_term">MPLC</td><td class="NLM_def"><p class="first last">medium pressure liquid chromatography</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 88 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firmbach-Kraft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shows, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalla-Favera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krolewski, J. J.</span></span> <span> </span><span class="NLM_article-title">Tyk2, Prototype of a Novel Class of Non-Receptor Tyrosine Kinase Genes</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=2216457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=1329-1336&author=I.+Firmbach-Kraftauthor=M.+Byersauthor=T.+Showsauthor=R.+Dalla-Faveraauthor=J.+J.+Krolewski&title=Tyk2%2C+Prototype+of+a+Novel+Class+of+Non-Receptor+Tyrosine+Kinase+Genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">tyk2, Prototype of a novel class of non-receptor tyrosine kinase genes</span></div><div class="casAuthors">Firmbach-Kraft, Iris; Byers, Mary; Shows, Thomas; Dalla-Favera, Riccardo; Krolewski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-36</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The authors previously identified a novel protein tyrosine kinase gene, tyk2, by screening a human lymphoid cDNA library with a tyrosine kinase domain specific c-fms restriction fragment under low stringency hybridization conditions.  They now isolated and sequenced a full length tyk2 cDNA clone; demonstrated that this gene is widely expressed in hematopoietic and non-hematopoietic cell lines; and mapped it to chromosome 19p13.2.  The cDNA clone is 4176 nucleotides long and codes for a putative protein with a mol. wt. of 134 kilodaltons.  Hydrophobicity anal. of the sequence does not identify a transmembrane domain, which is found in all members of the receptor class of protein tyrosine kinases; nor can the authors detect an SH2 domain, found in all previously identified non-receptor protein kinases.  They propose that tyk2 is the prototype of a new class of non-receptor protein tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLoFCW2FDWrVg90H21EOLACvtfcHk0lhxtL7yuwGY8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D&md5=c7a4180a140f0bcdc98140a265fb4cb4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirmbach-Kraft%26aufirst%3DI.%26aulast%3DByers%26aufirst%3DM.%26aulast%3DShows%26aufirst%3DT.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DKrolewski%26aufirst%3DJ.%2BJ.%26atitle%3DTyk2%252C%2520Prototype%2520of%2520a%2520Novel%2520Class%2520of%2520Non-Receptor%2520Tyrosine%2520Kinase%2520Genes%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D1329%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raivola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span> <span> </span><span class="NLM_article-title">The Regulation of JAKs in Cytokine Signaling and its Breakdown in Disease</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2Fj.cyto.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29685781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2019&pages=48-63&author=H.+M.+Hammar%C3%A9nauthor=A.+T.+Virtanenauthor=J.+Raivolaauthor=O.+Silvennoinen&title=The+Regulation+of+JAKs+in+Cytokine+Signaling+and+its+Breakdown+in+Disease&doi=10.1016%2Fj.cyto.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of JAKs in cytokine signaling and its breakdown in disease</span></div><div class="casAuthors">Hammaren, Henrik M.; Virtanen, Anniina T.; Raivola, Juuli; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-63</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The JAK-STAT signal transduction pathway is responsible for mediating signals of over fifty cytokines, growth factors and hormones.  Signaling through the JAK-STAT pathway is regulated on multiple levels, including intramol. regulation by the JAK pseudokinase domain, and intermol. regulation by a host of regulatory proteins.  The advent of accessible genomic tools have provided a wealth of information on disease-assocd. mutations in the JAK-STAT pathway and its regulatory components.  The vast no. of these mutations in diseases ranging from immunodeficiencies and obesity to many cancers highlight the importance of correct regulation of JAK-STAT signaling for biol. processes such as hematopoiesis, regulation of the immune system, metab., and growth.  Simultaneously, JAK inhibitors are gaining traction in clin. use, both for treatment of diseases driven by JAK mutations, and for a host of inflammatory disorders, in which proinflammatory cytokine signaling through the JAK-STAT pathway is an integral part of pathogenesis.  The elucidation of mol. mechanisms in the pathogenesis of complex diseases has also, however, brought the limitations of our current understanding on the regulation of cytokine signaling to the foreground.  Indeed, deeper understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of pharmacol. modulators of the JAK-STAT pathway.  In this review we discuss the current state of knowledge of the intra- and intermol. regulation of the JAK-STAT pathway, with a focus on diseases arising from disruptions in the regulatory app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RzQKF2IxZbVg90H21EOLACvtfcHk0lhxtL7yuwGY8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D&md5=f640078513fdd7e86a122d5d1172f76b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DVirtanen%26aufirst%3DA.%2BT.%26aulast%3DRaivola%26aufirst%3DJ.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520Regulation%2520of%2520JAKs%2520in%2520Cytokine%2520Signaling%2520and%2520its%2520Breakdown%2520in%2520Disease%26jtitle%3DCytokine%26date%3D2019%26volume%3D118%26spage%3D48%26epage%3D63%26doi%3D10.1016%2Fj.cyto.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II Cytokines, JAKs, and New Strategies for Treating Autoimmune Diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+Cytokines%2C+JAKs%2C+and+New+Strategies+for+Treating+Autoimmune+Diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0lhxtL7yuwGY8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520Cytokines%252C%2520JAKs%252C%2520and%2520New%2520Strategies%2520for%2520Treating%2520Autoimmune%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span> <span> </span><span class="NLM_article-title">JAK Kinases in Health and Disease: An Update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+Kinases+in+Health+and+Disease%3A+An+Update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0ljim7O-r5QM0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520Kinases%2520in%2520Health%2520and%2520Disease%253A%2520An%2520Update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0ljim7O-r5QM0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9030</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+Inhibitors+for+the+Treatment+of+Immunological+Disorders%3A+Recent+Advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0ljim7O-r5QM0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Immunological%2520Disorders%253A%2520Recent%2520Advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, K.</span></span> <span> </span><span class="NLM_article-title">FDA Approves Tofacitinib for Rheumatoid Arthritis</span>. <i>Am. J. Health Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2120</span>, <span class="refDoi"> DOI: 10.2146/news120088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.2146%2Fnews120088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2120&author=K.+Traynor&title=FDA+Approves+Tofacitinib+for+Rheumatoid+Arthritis&doi=10.2146%2Fnews120088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2146%2Fnews120088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews120088%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520Approves%2520Tofacitinib%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D2120%26doi%3D10.2146%2Fnews120088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Lernia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardazzi, F.</span></span> <span> </span><span class="NLM_article-title">Profile of Tofacitinib Citrate and its Potential in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S82599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.2147%2FDDDT.S82599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26889081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BC28jitFemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=533-539&author=V.+Di+Lerniaauthor=F.+Bardazzi&title=Profile+of+Tofacitinib+Citrate+and+its+Potential+in+the+Treatment+of+Moderate-to-Severe+Chronic+Plaque+Psoriasis&doi=10.2147%2FDDDT.S82599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis</span></div><div class="casAuthors">Di Lernia V; Bardazzi F</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies.  Cytokines exert their effects by activating intracellular signaling and transcription pathways, among which there are Janus kinases (JAKs) and signal transducers and activators of transcription (STAT) pathways.  JAKs are intracellular second messengers that are crucial for transmitting extracellular cytokine signals to the cell.  JAK inhibition interrupts intracellular signaling and can suppress immune cell activation and inflammation in T-cell-mediated disorders, such as psoriasis.  Consequently, JAKs are the subject of intensive research activity, since they represent possible therapeutic targets.  Tofacitinib is an orally available compound belonging to a novel category of nonbiologic drugs, the "JAK inhibitors", which target JAKs.  Recently, oral and topical formulations of tofacitinib have been demonstrated to be safe and effective for the treatment of plaque psoriasis in randomized clinical trials.  In particular, a 10 mg bid dose of tofacitinib was shown to be noninferior to etanercept 50 mg subcutaneously twice weekly.  Questions remain unresolved regarding the safety risk beyond the 5 mg bid dose.  This review, assessing the available scientific literature, focuses on the profile of tofacitinib, as investigational compound in the treatment of plaque psoriasis.  An overview of the efficacy and safety data from randomized clinical trials is provided.  In addition, the authors highlight future potential applications of tofacitinib in other skin diseases, in particular alopecia areata and vitiligo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7YQipRf1dUZcXNb62YGmbfW6udTcc2eZw0v3YEwic8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jitFemtg%253D%253D&md5=10cd4d4272d8e0dce01575df59f73662</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S82599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S82599%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLernia%26aufirst%3DV.%26aulast%3DBardazzi%26aufirst%3DF.%26atitle%3DProfile%2520of%2520Tofacitinib%2520Citrate%2520and%2520its%2520Potential%2520in%2520the%2520Treatment%2520of%2520Moderate-to-Severe%2520Chronic%2520Plaque%2520Psoriasis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D533%26epage%3D539%26doi%3D10.2147%2FDDDT.S82599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonanno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">and for the OPT Pivotal 1 and OPT Pivotal 2 Investigators. Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Results from Two, Randomised, Placebo-Controlled, Phase 3</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-961&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=and+for+the+OPT+Pivotal+1+and+OPT+Pivotal+2+Investigators.+Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+for+the+Treatment+of+Chronic+Plaque+Psoriasis%3A+Results+from+Two%2C+Randomised%2C+Placebo-Controlled%2C+Phase+3&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving ≥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41·9% and 59·2% vs. 9·0%; OPT Pivotal 2, 46·0% and 59·1% vs. 10·9%; all P < 0·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46·0%, 59·6% and 11·4%; all P < 0·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0lg7YxX-v3gd0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3Dand%2520for%2520the%2520OPT%2520Pivotal%25201%2520and%2520OPT%2520Pivotal%25202%2520Investigators.%2520Tofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Plaque%2520Psoriasis%253A%2520Results%2520from%2520Two%252C%2520Randomised%252C%2520Placebo-Controlled%252C%2520Phase%25203%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D949%26epage%3D961%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gladman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigby, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaszuba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrikx, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanik, K. S.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1615977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1615977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29045207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGlt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1525-1536&author=D.+Gladmanauthor=W.+Rigbyauthor=V.+F.+Azevedoauthor=F.+Behrensauthor=R.+Blancoauthor=A.+Kaszubaauthor=E.+Kudlaczauthor=C.+Wangauthor=S.+Menonauthor=T.+Hendrikxauthor=K.+S.+Kanik&title=Tofacitinib+for+Psoriatic+Arthritis+in+Patients+with+an+Inadequate+Response+to+TNF+Inhibitors&doi=10.1056%2FNEJMoa1615977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors</span></div><div class="casAuthors">Gladman, Dafna; Rigby, William; Azevedo, Valderilio F.; Behrens, Frank; Blanco, Ricardo; Kaszuba, Andrzej; Kudlacz, Elizabeth; Wang, Cunshan; Menon, Sujatha; Hendrikx, Thijs; Kanik, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1525-1536</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis.  We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors. methods In this 6-mo randomized, placebo-controlled, double-blind, phase 3 trial, we randomly assigned 395 patients, in a 2:2:1:1 ratio, to four regimens: 5 mg of tofacitinib administered orally twice daily (132 patients); 10 mg of tofacitinib twice daily (132 patients); placebo, with a switch to 5 mg of tofacitinib twice daily at 3 mo (66 patients); or placebo, with a switch to 10 mg of tofacitinib twice daily at 3 mo (65 patients).  Data from the patients who received placebo during the first 3 mo of the trial were pooled.  The primary end points were the percentage of patients who had at least 20% improvement according to the criteria of the American College of Rheumatol. (ACR20 response) and the change from baseline score on the Health Assessment Questionnaire-Disability Index (HAQ-DI; scores range from 0 to 3, with higher scores indicating greater disability) at the month 3 anal. results At 3 mo, the rates of ACR20 response were 50% with the 5-mg dose of tofacitinib and 47% with the 10-mg dose, as compared with 24% with placebo (P<0.001 for both comparisons); the corresponding mean changes from baseline in HAQ-DI score were -0.39 and -0.35, as compared with -0.14 (P<0.001 for both comparisons).  Serious adverse events occurred in 4% of the patients who received the 5-mg dose of tofacitinib continuously and in 6% who received the 10-mg dose continuously.  Over the course of 6 mo, there were four serious infections, three herpes zoster infections, one myocardial infarction, and one ischemic stroke among the patients who received tofacitinib continuously.  Elevations of aspartate and alanine aminotransferase concns. of three or more times the upper limit of the normal range occurred in more patients who received tofacitinib continuously than in patients who received placebo followed by tofacitinib. conclusions In this trial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhibitors, tofacitinib was more effective than placebo over 3 mo in reducing disease activity.  Adverse events were more frequent with tofacitinib than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbGiFUjTAPrVg90H21EOLACvtfcHk0lgZPdPTs5WNgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGlt7bE&md5=a38f9b9fc29590f98f94fe599a13df74</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1615977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1615977%26sid%3Dliteratum%253Aachs%26aulast%3DGladman%26aufirst%3DD.%26aulast%3DRigby%26aufirst%3DW.%26aulast%3DAzevedo%26aufirst%3DV.%2BF.%26aulast%3DBehrens%26aufirst%3DF.%26aulast%3DBlanco%26aufirst%3DR.%26aulast%3DKaszuba%26aufirst%3DA.%26aulast%3DKudlacz%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DHendrikx%26aufirst%3DT.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26atitle%3DTofacitinib%2520for%2520Psoriatic%2520Arthritis%2520in%2520Patients%2520with%2520an%2520Inadequate%2520Response%2520to%2520TNF%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1525%26epage%3D1536%26doi%3D10.1056%2FNEJMoa1615977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachelez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Kerkhof, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakusevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papacharalambous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawadrous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">and for the OPT Compare Investigators. Tofacitinib versus Etanercept or Placebo in Moderate-to-Severe Chronic Plaque Psoriasis: a Phase 3 Randomised Non-Inferiority Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26051365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-561&author=H.+Bachelezauthor=P.+C.+Van+de+Kerkhofauthor=R.+Strohalauthor=A.+Kubanovauthor=F.+Valenzuelaauthor=J.-H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=and+for+the+OPT+Compare+Investigators.+Tofacitinib+versus+Etanercept+or+Placebo+in+Moderate-to-Severe+Chronic+Plaque+Psoriasis%3A+a+Phase+3+Randomised+Non-Inferiority+Trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span></div><div class="casAuthors">Bachelez, Herve; van de Kerkhof, Peter C. M.; Strohal, Robert; Kubanov, Alexey; Valenzuela, Fernando; Lee, Joo-Heung; Yakusevich, Vladimir; Chimenti, Sergio; Papacharalambous, Jocelyne; Proulx, James; Gupta, Pankaj; Tan, Huaming; Tawadrous, Margaret; Valdez, Hernan; Wolk, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9993</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New therapeutic options are needed for patients with psoriasis.  Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis.  In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.  In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-wk, non-inferiority trial, adult patients with chronic stable plaque psoriasis (for ≥12 mo) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index (PASI) score of 12 or higher and a Physician's Global Assessment (PGA) of moderate or severe, and had failed to respond to, had a contraindication to, or were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational dermatol. centers worldwide.  Eligible patients were randomly assigned in a 3:3:3:1 ratio to receive tofacitinib 5 mg or 10 mg twice daily at about 12 h intervals, etanercept 50 mg s.c. twice weekly at about 3-4 day intervals, or placebo.  Randomisation was done by a computer-generated randomisation schedule, and all patients and study personnel were masked to treatment assignment.  The co-primary endpoints were the proportion of patients at week 12 with at least a 75% redn. in the PASI score from baseline (PASI75 response) and the proportion of patients achieving a PGA score of "clear" or "almost clear" (PGA response), analyzed in the full anal. set (all patients who were randomised and received at least one dose of study drug).  This study is registered with ClinicalTrials.gov, no. NCT01241591.  Between Nov 29, 2010, and Sept 13, 2012, we enrolled 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four treatment groups (330 to tofacitinib 5 mg twice daily, 332 to tofacitinib 10 mg twice daily, 336 to etanercept 50 mg twice weekly, and 108 to placebo).  Of these patients, 1101 actually received their assigned study medication (329 in the tofactinib 5 mg group, 330 in the tofacitinib 10 mg group, 335 in the etanercept group, and 107 in the placebo group).  At week 12, PASI75 responses were recorded in 130 (39·5%) of 329 patients in the tofacitinib 5 mg group, 210 (63·6%) of 330 in the tofacitinib 10 mg group, 197 (58·8%) of 335 in the etanercept group, and six (5·6%) of 107 in the placebo group.  A PGA response was achieved by 155 (47·1%) of 329 patients in the tofacitinib 5 mg group, 225 (68·2%) of 330 in the tofacitinib 10 mg group, 222 (66·3%) of 335 in the etanercept group, and 16 (15·0%) of 107 in the placebo group.  The rate of adverse events was similar across the four groups, with serious adverse events occurring in seven (2%) of 329 patients in the tofacitinib 5 mg group, five (2%) of 330 in the tofacitinib 10 mg group, seven (2%) of 335 in the etanercept group, and two (2%) of 107 in the placebo group.  Three (1%) of 329 patients in the tofacitinib 5 mg group, ten (3%) of 330 in the tofacitinib 10 mg group, 11 (3%) of 335 in the etanercept group, and four (4%) of 107 patients in the placebo group discontinued their assigned treatment because of adverse events.  In patients with moderate-to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50 mg twice weekly.  The adverse event rates over 12 wk were similar for tofacitinib and etanercept.  This study indicates that in the future tofacitinib could provide a convenient and well-tolerated therapeutic option for patients with moderate-to-severe plaque psoriasis.Pfizer Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYcpF-XDavrVg90H21EOLACvtfcHk0lgZPdPTs5WNgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J&md5=797adf1a67423e82ce47d96aa87daa6b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3DVan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3DKubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3Dand%2520for%2520the%2520OPT%2520Compare%2520Investigators.%2520Tofacitinib%2520versus%2520Etanercept%2520or%2520Placebo%2520in%2520Moderate-to-Severe%2520Chronic%2520Plaque%2520Psoriasis%253A%2520a%2520Phase%25203%2520Randomised%2520Non-Inferiority%2520Trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D552%26epage%3D561%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asahina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imafuku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomochika, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsuki, M.</span></span> <span> </span><span class="NLM_article-title">and study investigators. Oral Tofacitinib Efficacy, Safety and Tolerability in Japanese Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: A Randomized, Double-Blind, Phase 3 Study</span>. <i>J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1111/1346-8138.13258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1111%2F1346-8138.13258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26875540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ehtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=869-880&author=A.+Asahinaauthor=T.+Etohauthor=A.+Igarashiauthor=S.+Imafukuauthor=H.+Saekiauthor=Y.+Shibasakiauthor=Y.+Tomochikaauthor=S.+Toyoizumiauthor=M.+Nagaokaauthor=M.+Ohtsuki&title=and+study+investigators.+Oral+Tofacitinib+Efficacy%2C+Safety+and+Tolerability+in+Japanese+Patients+with+Moderate-to-Severe+Plaque+Psoriasis+and+Psoriatic+Arthritis%3A+A+Randomized%2C+Double-Blind%2C+Phase+3+Study&doi=10.1111%2F1346-8138.13258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study</span></div><div class="casAuthors">Asahina, Akihiko; Etoh, Takafumi; Igarashi, Atsuyuki; Imafuku, Shinichi; Saeki, Hidehisa; Shibasaki, Yoshiyuki; Tomochika, Yukiko; Toyoizumi, Shigeyuki; Nagaoka, Makoto; Ohtsuki, Mamitaro; the study investigators</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-880</span>CODEN:
                <span class="NLM_cas:coden">JDMYAG</span>;
        ISSN:<span class="NLM_cas:issn">0385-2407</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis and psoriatic arthritis.  Japanese patients aged 20 years or more with moderate to severe plaque psoriasis and/or psoriatic arthritis were double-blindly randomized 1:1 to tofacitinib 5 or 10 mg b.i.d. for 16 wk, open-label 10 mg b.i.d. for 4 wk, then variable 5 or 10 mg b.i.d. to Week 52.  Primary end-points at Week 16 were the proportion of patients achieving at least a 75% redn. in Psoriasis Area and Severity Index (PASI75) and Physician's Global Assessment of "clear" or "almost clear" (PGA response) for psoriasis, and 20% or more improvement in American College of Rheumatol. criteria (ACR20) for patients with psoriatic arthritis.  Safety was assessed throughout.  Eighty-seven patients met eligibility criteria for moderate to severe plaque psoriasis (5 mg b.i.d., n = 43; 10 mg b.i.d., n = 44), 12 met eligibility criteria for psoriatic arthritis (5 mg b.i.d., n = 4; 10 mg b.i.d., n = 8) including five who met both criteria (10 mg b.i.d.).  At Week 16, 62.8% and 72.7% of patients achieved PASI75 with tofacitinib 5 and 10 mg b.i.d., resp.; 67.4% and 68.2% achieved PGA responses; all patients with psoriatic arthritis achieved ACR20.  Responses were maintained through Week 52.  Adverse events occurred in 83% of patients through Week 52, including four (4.3%) serious adverse events and three (3.2%) serious infections (all herpes zoster).  No malignancies, cardiovascular events or deaths occurred.  Tofacitinib (both doses) demonstrated efficacy in patients with moderate to severe plaque psoriasis and/or psoriatic arthritis through 52 wk; safety findings were generally consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNrigERixmbVg90H21EOLACvtfcHk0ligpU5tWEZeKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ehtLzP&md5=b8151e6cdee3c1496b633e8b115156e4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2F1346-8138.13258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1346-8138.13258%26sid%3Dliteratum%253Aachs%26aulast%3DAsahina%26aufirst%3DA.%26aulast%3DEtoh%26aufirst%3DT.%26aulast%3DIgarashi%26aufirst%3DA.%26aulast%3DImafuku%26aufirst%3DS.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DShibasaki%26aufirst%3DY.%26aulast%3DTomochika%26aufirst%3DY.%26aulast%3DToyoizumi%26aufirst%3DS.%26aulast%3DNagaoka%26aufirst%3DM.%26aulast%3DOhtsuki%26aufirst%3DM.%26atitle%3Dand%2520study%2520investigators.%2520Oral%2520Tofacitinib%2520Efficacy%252C%2520Safety%2520and%2520Tolerability%2520in%2520Japanese%2520Patients%2520with%2520Moderate-to-Severe%2520Plaque%2520Psoriasis%2520and%2520Psoriatic%2520Arthritis%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Phase%25203%2520Study%26jtitle%3DJ.%2520Dermatol.%26date%3D2016%26volume%3D43%26spage%3D869%26epage%3D880%26doi%3D10.1111%2F1346-8138.13258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Haens, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feagan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawendy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panés, J.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1736</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1606910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1606910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=28467869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOns7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1723-1736&author=W.+J.+Sandbornauthor=C.+Suauthor=B.+E.+Sandsauthor=G.+R.+D%E2%80%99Haensauthor=S.+Vermeireauthor=S.+Schreiberauthor=S.+Daneseauthor=B.+G.+Feaganauthor=W.+Reinischauthor=W.+Niezychowskiauthor=G.+Friedmanauthor=N.+Lawendyauthor=D.+Yuauthor=D.+Woodworthauthor=A.+Mukherjeeauthor=H.+Zhangauthor=P.+Healeyauthor=J.+Pan%C3%A9s&title=Tofacitinib+as+Induction+and+Maintenance+Therapy+for+Ulcerative+Colitis&doi=10.1056%2FNEJMoa1606910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib as induction and maintenance therapy for ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Su, Chinyu; Sands, Bruce E.; D'Haens, Geert R.; Vermeire, Severine; Schreiber, Stefan; Danese, Silvio; Feagan, Brian G.; Reinisch, Walter; Niezychowski, Wojciech; Friedman, Gary; Lawendy, Nervin; Yu, Dahong; Woodworth, Deborah; Mukherjee, Arnab; Zhang, Haiying; Healey, Paul; Panes, Julian</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1723-1736</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Tofacitinib, an oral, small-mol. Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.  We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.  METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.  In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, resp., who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 wk.  The primary end point was remission at 8 wk.  In the OCTAVE Sustain trial, 593 patients who had a clin. response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 wk.  The primary end point was remission at 52 wk.  RESULTS: In the OCTAVE Induction 1 trial, remission at 8 wk occurred in 18.5% of the patients in the tofacitinib group vs. 8.2% in the placebo group (P = 0.007); in the OCTAVE Induction 2 trial, remission occurred in 16.6% vs. 3.6% (P<0.001).  In the OCTAVE Sustain trial, remission at 52 wk occurred in 34.3% of the patients in the 5-mg tofacitinib group and 40.6% in the 10-mg tofacitinib group vs. 11.1% in the placebo group (P<0.001 for both comparisons with placebo).  In the OCTAVE Induction 1 and 2 trials, the rates of overall infection and serious infection were higher with tofacitinib than with placebo.  In the OCTAVE Sustain trial, the rate of serious infection was similar across the three treatment groups, and the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo.  Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was assocd. with increased lipid levels.  CONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohzKgMAVSZh7Vg90H21EOLACvtfcHk0ligpU5tWEZeKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOns7jP&md5=3e56aba6c1cba05688f4c59d8e66f0de</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1606910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1606910%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%2BR.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DFeagan%26aufirst%3DB.%2BG.%26aulast%3DReinisch%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DG.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWoodworth%26aufirst%3DD.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHealey%26aufirst%3DP.%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26atitle%3DTofacitinib%2520as%2520Induction%2520and%2520Maintenance%2520Therapy%2520for%2520Ulcerative%2520Colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1723%26epage%3D1736%26doi%3D10.1056%2FNEJMoa1606910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span> </span><span class="NLM_article-title">A Multicentre,
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
of Oral CP-690,550 as an Induction Therapy in Subjects with Moderate-to-Severe
Ulcerative Colitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT01465763</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT01465763?term=nct01465763&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01465763?term=nct01465763&rank=1</a>   (first posted Oct. 21, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Multicentre%2C%0ARandomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Parallel-Group+Study%0Aof+Oral+CP-690%2C550+as+an+Induction+Therapy+in+Subjects+with+Moderate-to-Severe%0AUlcerative+Colitis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT01465763%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01465763%3Fterm%3Dnct01465763%26rank%3D1+%28first+posted+Oct.+21%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Multicentre%252C%250ARandomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Parallel-Group%2520Study%250Aof%2520Oral%2520CP-690%252C550%2520as%2520an%2520Induction%2520Therapy%2520in%2520Subjects%2520with%2520Moderate-to-Severe%250AUlcerative%2520Colitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT01465763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span> </span><span class="NLM_article-title">Pfizer Announces FDA Approval
of Xeljanz (Tofacitinib) and Xeljanz XR for the Treatment of Active
Psoriatic Arthritis</span>.  <i>Pfizer Press Release</i>; <span class="NLM_publisher-name">Pfizer</span>, Dec 14, 2017; <a href="https://press.pfizer.com/press-release/pfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor" class="extLink">https://press.pfizer.com/press-release/pfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor</a> (accessed Aug 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Announces+FDA+Approval%0Aof+Xeljanz+%28Tofacitinib%29+and+Xeljanz+XR+for+the+Treatment+of+Active%0APsoriatic+Arthritis.+Pfizer+Press+Release%3B+Pfizer%2C+Dec+14%2C+2017%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor+%28accessed+Aug+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Announces%2520FDA%2520Approval%250Aof%2520Xeljanz%2520%2528Tofacitinib%2529%2520and%2520Xeljanz%2520XR%2520for%2520the%2520Treatment%2520of%2520Active%250APsoriatic%2520Arthritis%26jtitle%3DPfizer%2520Press%2520Release%26pub%3DPfizer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span> </span><span class="NLM_article-title">Pfizer Announces U.S. FDA Approves Xeljanz
(Tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative
Colitis</span>.  <i>Pfizer Press Release</i>; <span class="NLM_publisher-name">Pfizer</span>, May 30, 2018; <a href="https://press.pfizer.com/press-release/pfizer-announces-us-fda-approves-xeljanz-tofacitinib-treatment-moderately-severely-act" class="extLink">https://press.pfizer.com/press-release/pfizer-announces-us-fda-approves-xeljanz-tofacitinib-treatment-moderately-severely-act</a> (accessed Aug 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Announces+U.S.+FDA+Approves+Xeljanz%0A%28Tofacitinib%29+for+the+Treatment+of+Moderately+to+Severely+Active+Ulcerative%0AColitis.+Pfizer+Press+Release%3B+Pfizer%2C+May+30%2C+2018%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-announces-us-fda-approves-xeljanz-tofacitinib-treatment-moderately-severely-act+%28accessed+Aug+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Announces%2520U.S.%2520FDA%2520Approves%2520Xeljanz%250A%2528Tofacitinib%2529%2520for%2520the%2520Treatment%2520of%2520Moderately%2520to%2520Severely%2520Active%2520Ulcerative%250AColitis%26jtitle%3DPfizer%2520Press%2520Release%26pub%3DPfizer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span> </span><span class="NLM_article-title">Pfizer Receives Complete Response Letter
from FDA for Oral Xeljanz (Tofacitinib Citrate) Supplemental New Drug
Application for Moderate to Severe Chronic Plaque Psoriasis</span>.  <i>Pfizer Press Release</i>; <span class="NLM_publisher-name">Pfizer</span>, Oct 14, 2015; <a href="https://press.pfizer.com/press-release/pfizer-receives-complete-response-letter-fda-oral-xeljanz-tofacitinib-citrate-suppleme" class="extLink">https://press.pfizer.com/press-release/pfizer-receives-complete-response-letter-fda-oral-xeljanz-tofacitinib-citrate-suppleme</a> (accessed Dec 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Receives+Complete+Response+Letter%0Afrom+FDA+for+Oral+Xeljanz+%28Tofacitinib+Citrate%29+Supplemental+New+Drug%0AApplication+for+Moderate+to+Severe+Chronic+Plaque+Psoriasis.+Pfizer+Press+Release%3B+Pfizer%2C+Oct+14%2C+2015%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-receives-complete-response-letter-fda-oral-xeljanz-tofacitinib-citrate-suppleme+%28accessed+Dec+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Receives%2520Complete%2520Response%2520Letter%250Afrom%2520FDA%2520for%2520Oral%2520Xeljanz%2520%2528Tofacitinib%2520Citrate%2529%2520Supplemental%2520New%2520Drug%250AApplication%2520for%2520Moderate%2520to%2520Severe%2520Chronic%2520Plaque%2520Psoriasis%26jtitle%3DPfizer%2520Press%2520Release%26pub%3DPfizer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span> </span><span class="NLM_article-title">Efficacy and Safety of Tofacitinib in Subjects
with Active Ankylosing Spondylitis (AS)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03502616</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03502616?term=NCT03502616&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03502616?term=NCT03502616&rank=1</a> (first posted April 18, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy+and+Safety+of+Tofacitinib+in+Subjects%0Awith+Active+Ankylosing+Spondylitis+%28AS%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03502616%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03502616%3Fterm%3DNCT03502616%26rank%3D1+%28first+posted+April+18%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tofacitinib%2520in%2520Subjects%250Awith%2520Active%2520Ankylosing%2520Spondylitis%2520%2528AS%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03502616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span> </span><span class="NLM_article-title">Topical Tofacitinib for the Treatment
of Alopecia Areata and Variants</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02812342</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02812342?term=NCT02812342&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02812342?term=NCT02812342&rank=1</a> (first posted June 24, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Topical+Tofacitinib+for+the+Treatment%0Aof+Alopecia+Areata+and+Variants.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02812342%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02812342%3Fterm%3DNCT02812342%26rank%3D1+%28first+posted+June+24%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DTopical%2520Tofacitinib%2520for%2520the%2520Treatment%250Aof%2520Alopecia%2520Areata%2520and%2520Variants%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02812342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span> </span><span class="NLM_article-title">Tofacitinib for Inflammatory Eye
Disease</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03580343</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03580343?term=NCT03580343&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03580343?term=NCT03580343&rank=1</a> (first posted July 9, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tofacitinib+for+Inflammatory+Eye%0ADisease.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03580343%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03580343%3Fterm%3DNCT03580343%26rank%3D1+%28first+posted+July+9%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DTofacitinib%2520for%2520Inflammatory%2520Eye%250ADisease%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03580343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span> </span><span class="NLM_article-title">Oral Tofacitinib in Adult Subjects
with Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus
(SLE)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03159936</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03159936?term=NCT03159936&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03159936?term=NCT03159936&rank=1</a> (first posted May 19, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+Tofacitinib+in+Adult+Subjects%0Awith+Discoid+Lupus+Erythematosus+%28DLE%29+and+Systemic+Lupus+Erythematosus%0A%28SLE%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03159936%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03159936%3Fterm%3DNCT03159936%26rank%3D1+%28first+posted+May+19%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DOral%2520Tofacitinib%2520in%2520Adult%2520Subjects%250Awith%2520Discoid%2520Lupus%2520Erythematosus%2520%2528DLE%2529%2520and%2520Systemic%2520Lupus%2520Erythematosus%250A%2528SLE%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03159936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span> </span><span class="NLM_article-title">Evaluation of Tofacitinib in Early
Diffuse Cutaneous Systemic Sclerosis (dcSSc) (TOFA-SSc)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03274076</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03274076?term=NCT03274076&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03274076?term=NCT03274076&rank=1</a> (first posted Sept. 6, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Evaluation+of+Tofacitinib+in+Early%0ADiffuse+Cutaneous+Systemic+Sclerosis+%28dcSSc%29+%28TOFA-SSc%29.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03274076%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03274076%3Fterm%3DNCT03274076%26rank%3D1+%28first+posted+Sept.+6%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DEvaluation%2520of%2520Tofacitinib%2520in%2520Early%250ADiffuse%2520Cutaneous%2520Systemic%2520Sclerosis%2520%2528dcSSc%2529%2520%2528TOFA-SSc%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03274076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span> </span><span class="NLM_article-title">Study of Tofacitinib in Refractory
Dermatomyositis (STIR)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT03002649</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03002649?term=NCT03002649&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03002649?term=NCT03002649&rank=1</a> (first posted Dec. 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+of+Tofacitinib+in+Refractory%0ADermatomyositis+%28STIR%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT03002649%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03002649%3Fterm%3DNCT03002649%26rank%3D1+%28first+posted+Dec.+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520of%2520Tofacitinib%2520in%2520Refractory%250ADermatomyositis%2520%2528STIR%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT03002649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R. U.S.</span></span> <span> </span><span class="NLM_article-title">Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3212</span>– <span class="NLM_lpage">3217</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1158%2F1078-0432.CCR-12-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=22544377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3212-3217&author=A.+Deisserothauthor=E.+Kaminskasauthor=J.+Grilloauthor=W.+Chenauthor=H.+Saberauthor=H.+L.+Luauthor=M.+D.+Rothmannauthor=S.+Brarauthor=J.+Wangauthor=C.+Garnettauthor=J.+Bullockauthor=L.+B.+Burkeauthor=A.+Rahmanauthor=R.+Sridharaauthor=A.+Farrellauthor=R.+U.S.+Pazdur&title=Food+and+Drug+Administration+Approval%3A+Ruxolitinib+for+the+Treatment+of+Patients+with+Intermediate+and+High-Risk+Myelofibrosis&doi=10.1158%2F1078-0432.CCR-12-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span></div><div class="casAuthors">Deisseroth, Albert; Kaminskas, Edvardas; Grillo, Joseph; Chen, Wei; Saber, Haleh; Lu, Hong L.; Rothmann, Mark D.; Brar, Satjit; Wang, Jian; Garnett, Christine; Bullock, Julie; Burke, Laurie B.; Rahman, Atiqur; Sridhara, Rajeshwari; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3212-3217</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the U.S.  Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.  This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2).  The primary efficacy endpoint was the proportion of patients who experienced a redn. in spleen vol. of ≥35% at 24 wk (study 1) or 48 wk (study 2).  The key secondary endpoint in study 1 was the proportion of patients who experienced a ≥50% improvement from baseline in myelofibrosis total symptom score at 24 wk.  The results of these studies showed that a greater proportion of patients treated with ruxolitinib experienced a ≥35% redn. in spleen vol. as compared with those treated with placebo (42% vs. 1%, P < 0.0001) or best available therapy (29% vs. 0%, P < 0.0001).  A greater proportion of patients in study 1 experienced a ≥50% redn. in the myelofibrosis total symptom score during treatment with ruxolitinib than with placebo (46% vs. 5%, P < 0.0001).  Ruxolitinib treatment was assocd. with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia.  This is the first drug approved for myelofibrosis.  Clin Cancer Res; 18(12); 3212-7. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44NYcMOixiLVg90H21EOLACvtfcHk0ljohw1g2IoP0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D&md5=6ed7731730708b8a8cbdc5d766065ddb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0653%26sid%3Dliteratum%253Aachs%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%2BL.%26aulast%3DRothmann%26aufirst%3DM.%2BD.%26aulast%3DBrar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DL.%2BB.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%2BU.S.%26atitle%3DFood%2520and%2520Drug%2520Administration%2520Approval%253A%2520Ruxolitinib%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Intermediate%2520and%2520High-Risk%2520Myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3212%26epage%3D3217%26doi%3D10.1158%2F1078-0432.CCR-12-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span> </span><span class="NLM_article-title">A Study
of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory
Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation
(REACH3)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03112603</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03112603?term=NCT03112603&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03112603?term=NCT03112603&rank=1v</a> (first posted April 13, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+Ruxolitinib+vs+Best+Available+Therapy+%28BAT%29+in+Patients+With+Steroid-refractory%0AChronic+Graft+vs.+Host+Disease+%28GvHD%29+After+Bone+Marrow+Transplantation%0A%28REACH3%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03112603%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03112603%3Fterm%3DNCT03112603%26rank%3D1v+%28first+posted+April+13%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%250Aof%2520Ruxolitinib%2520vs%2520Best%2520Available%2520Therapy%2520%2528BAT%2529%2520in%2520Patients%2520With%2520Steroid-refractory%250AChronic%2520Graft%2520vs.%2520Host%2520Disease%2520%2528GvHD%2529%2520After%2520Bone%2520Marrow%2520Transplantation%250A%2528REACH3%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03112603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span> </span><span class="NLM_article-title">TRuE AD2—An Efficacy and
Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic
Dermatitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03745651</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03745651?term=NCT03745651&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03745651?term=NCT03745651&rank=1</a> (first posted November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=TRuE+AD2%E2%80%94An+Efficacy+and%0ASafety+Study+of+Ruxolitinib+Cream+in+Adolescents+and+Adults+With+Atopic%0ADermatitis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03745651%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03745651%3Fterm%3DNCT03745651%26rank%3D1+%28first+posted+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DTRuE%2520AD2%25E2%2580%2594An%2520Efficacy%2520and%250ASafety%2520Study%2520of%2520Ruxolitinib%2520Cream%2520in%2520Adolescents%2520and%2520Adults%2520With%2520Atopic%250ADermatitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03745651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludivico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogulec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span> <span> </span><span class="NLM_article-title">Baricitinib in Patients with Refractory Rheumatoid Arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1507247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27028914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1243-1252&author=M.+C.+Genoveseauthor=J.+Kremerauthor=O.+Zamaniauthor=C.+Ludivicoauthor=M.+Krogulecauthor=L.+Xieauthor=S.+D.+Beattieauthor=A.+E.+Kochauthor=T.+E.+Cardilloauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=S.+de+Bonoauthor=D.+E.+Schlichtingauthor=J.+S.+Smolen&title=Baricitinib+in+Patients+with+Refractory+Rheumatoid+Arthritis&doi=10.1056%2FNEJMoa1507247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib in patients with refractory rheumatoid arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Kremer, Joel; Zamani, Omid; Ludivico, Charles; Krogulec, Marek; Xie, Li; Beattie, Scott D.; Koch, Alisa E.; Cardillo, Tracy E.; Rooney, Terence P.; Macias, William L.; de Bono, Stephanie; Schlichting, Douglas E.; Smolen, Josef S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1243-1252</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biol. disease-modifying antirheumatic drugs (DMARDs).  METHODS In this phase 3 study involving 527 patients with an inadequate response to or unacceptable side effects assocd. with one or more tumor necrosis factor inhibitors, other biol. DMARDs, or both, we randomly assigned the patients in a 1:1:1 ratio to baricitinib at a dose of 2 or 4 mg daily or placebo for 24 wk.  End points, tested hierarchically at week 12 to control type 1 error, were the American College of Rheumatol. 20% (ACR20) response (primary end point), the Health Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP), and a Simplified Disease Activity Index (SDAI) score of 3.3 or less (on a scale of 0.1 to 86.0, with a score of 3.3 or less indicating remission).  Comparisons with placebo were made first with the 4-mg dose of baricitinib and then with the 2-mg dose.  RESULTS Significantly more patients receiving baricitinib at the 4-mg dose than those receiving placebo had an ACR20 response at week 12 (55% vs. 27%, P<0.001).  Differences between the higher-dose baricitinib group and the placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score of 3.3 or less.  Adverse-event rates through 24 wk were higher for patients receiving the 2-mg dose of baricitinib and those receiving the 4-mg dose than for patients receiving placebo (71% and 77%, resp., vs. 64%), including infections (44% and 40%, vs. 31%).  The rates of serious adverse events were 4%, 10%, and 7% in the three groups, resp.  Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke, occurred in the higher-dose group.  Baricitinib was assocd. with a small redn. in neutrophil levels and increases in serum creatinine and low-d. lipoprotein cholesterol levels.  CONCLUSIONS In patients with rheumatoid arthritis and an inadequate response to biol. DMARDs, baricitinib at a daily dose of 4 mg was assocd. with clin. improvement at 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj72FQTLOsQLVg90H21EOLACvtfcHk0lhQ6OOEDyumgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E&md5=d7d317ee88fae38379b3b07c420349f6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507247%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZamani%26aufirst%3DO.%26aulast%3DLudivico%26aufirst%3DC.%26aulast%3DKrogulec%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DBaricitinib%2520in%2520Patients%2520with%2520Refractory%2520Rheumatoid%2520Arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1243%26epage%3D1252%26doi%3D10.1056%2FNEJMoa1507247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. M.</span></span> <span> </span><span class="NLM_article-title">A Randomized Phase 2b Trial of Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Moderate-to-Severe Psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1111/bjd.14403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1111%2Fbjd.14403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26800231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=1266-1276&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Ramanauthor=D.+Dischauthor=D.+E.+Schlichtingauthor=C.+Gaichauthor=W.+Maciasauthor=X.+Zhangauthor=J.+M.+Janes&title=A+Randomized+Phase+2b+Trial+of+Baricitinib%2C+an+Oral+Janus+Kinase+%28JAK%29+1%2FJAK2+Inhibitor%2C+in+Patients+with+Moderate-to-Severe+Psoriasis&doi=10.1111%2Fbjd.14403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Raman, M.; Disch, D.; Schlichting, D. E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.  Objectives : To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.  Methods : Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 wk (Part A).  Dose adjustment for 12 addnl. weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score.  The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 wk for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population.  Results : At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75.  All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 wk and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 wk.  More than 81% of PASI-75 responders maintained their scores through 24 wk.  During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, resp.  No opportunistic infections were obsd. in any treatment group.  Dose-dependent changes in lab. values were obsd.  Conclusions : Patients with moderate-to-severe psoriasis treated with baricitinib for 12 wk achieved significant improvements in PASI-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVPv2558vrrVg90H21EOLACvtfcHk0lhQ6OOEDyumgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN&md5=37df34807683b4742548f192f99654f6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14403%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DDisch%26aufirst%3DD.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DGaich%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJanes%26aufirst%3DJ.%2BM.%26atitle%3DA%2520Randomized%2520Phase%25202b%2520Trial%2520of%2520Baricitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520%2528JAK%2529%25201%252FJAK2%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Moderate-to-Severe%2520Psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D174%26spage%3D1266%26epage%3D1276%26doi%3D10.1111%2Fbjd.14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span> </span><span class="NLM_article-title">A Study of Baricitinib (LY3009104) in Participants with Systemic
Lupus Erythematosus (SLE)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02708095</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02708095?term=NCT02708095&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02708095?term=NCT02708095&rank=1</a>  (first posted Mar 15, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+Baricitinib+%28LY3009104%29+in+Participants+with+Systemic%0ALupus+Erythematosus+%28SLE%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02708095%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02708095%3Fterm%3DNCT02708095%26rank%3D1+%28first+posted+Mar+15%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520Baricitinib%2520%2528LY3009104%2529%2520in%2520Participants%2520with%2520Systemic%250ALupus%2520Erythematosus%2520%2528SLE%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02708095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span> </span><span class="NLM_article-title">A Study of Baricitinib (LY3009104)
in Participants with Moderate-to-Severe Atopic Dermatitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2015</span>;  <span class="NLM_fpage">NCT02576938</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02576938?term=NCT02576938&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02576938?term=NCT02576938&rank=1</a> (first posted Oct 15, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+Baricitinib+%28LY3009104%29%0Ain+Participants+with+Moderate-to-Severe+Atopic+Dermatitis.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+NCT02576938%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02576938%3Fterm%3DNCT02576938%26rank%3D1+%28first+posted+Oct+15%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520Baricitinib%2520%2528LY3009104%2529%250Ain%2520Participants%2520with%2520Moderate-to-Severe%2520Atopic%2520Dermatitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2015%26spage%3DNCT02576938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span> </span><span class="NLM_article-title">FDA Approves Olumiant (Baricitinib)
2-mg tablets for the Treatment of Adults with Moderately-to-Severely
Active Rheumatoid Arthritis</span>.  <i>Lilly Press Release</i>; <span class="NLM_publisher-name">Eli Lilly and Company</span>, June 1, <span class="NLM_year">2018</span>; <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults" class="extLink">https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults</a> (accessed Sept. 5, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Olumiant+%28Baricitinib%29%0A2-mg+tablets+for+the+Treatment+of+Adults+with+Moderately-to-Severely%0AActive+Rheumatoid+Arthritis.+Lilly+Press+Release%3B+Eli+Lilly+and+Company%2C+June+1%2C+2018%3B+https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Ffda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults+%28accessed+Sept.+5%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Olumiant%2520%2528Baricitinib%2529%250A2-mg%2520tablets%2520for%2520the%2520Treatment%2520of%2520Adults%2520with%2520Moderately-to-Severely%250AActive%2520Rheumatoid%2520Arthritis%26jtitle%3DLilly%2520Press%2520Release%26pub%3DEli%2520Lilly%2520and%2520Company%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span> </span><span class="NLM_article-title">Oral JAK Inhibitor Smyraf Tablets Approved
in Japan for the Treatment of Rheumatoid Arthritis (including prevention
of structural joint damage) in Patients Who Have an Inadequate Response
to Conventional Therapies</span>.  <i>Astellas Press
Release</i>; <span class="NLM_publisher-name">Astellas Pharma, Inc.</span>, March 26, <span class="NLM_year">2019</span>; <a href="https://www.astellas.com/en/news/14651" class="extLink">https://www.astellas.com/en/news/14651</a> (accessed April 26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+JAK+Inhibitor+Smyraf+Tablets+Approved%0Ain+Japan+for+the+Treatment+of+Rheumatoid+Arthritis+%28including+prevention%0Aof+structural+joint+damage%29+in+Patients+Who+Have+an+Inadequate+Response%0Ato+Conventional+Therapies.+Astellas+Press%0ARelease%3B+Astellas+Pharma%2C+Inc.%2C+March+26%2C+2019%3B+https%3A%2F%2Fwww.astellas.com%2Fen%2Fnews%2F14651+%28accessed+April+26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DOral%2520JAK%2520Inhibitor%2520Smyraf%2520Tablets%2520Approved%250Ain%2520Japan%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%2520%2528including%2520prevention%250Aof%2520structural%2520joint%2520damage%2529%2520in%2520Patients%2520Who%2520Have%2520an%2520Inadequate%2520Response%250Ato%2520Conventional%2520Therapies%26jtitle%3DAstellas%2520Press%250ARelease%26pub%3DAstellas%2520Pharma%252C%2520Inc%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrzycka-Sienkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardiel, M. H.</span></span> <span> </span><span class="NLM_article-title">Peficitinib, a JAK Inhibitor, in Combination with Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">932</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1002/art.40054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fart.40054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=28118538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=932-942&author=M.+C.+Genoveseauthor=M.+Greenwaldauthor=C.+Coddingauthor=A.+Zubrzycka-Sienkiewiczauthor=A.+J.+Kivitzauthor=A.+Wangauthor=K.+Shayauthor=X.+Wangauthor=J.+P.+Gargauthor=M.+H.+Cardiel&title=Peficitinib%2C+a+JAK+Inhibitor%2C+in+Combination+with+Limited+Conventional+Synthetic+Disease-Modifying+Antirheumatic+Drugs+in+the+Treatment+of+Moderate-to-Severe+Rheumatoid+Arthritis&doi=10.1002%2Fart.40054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Greenwald, Maria; Codding, Christine; Zubrzycka-Sienkiewicz, Anna; Kivitz, Alan J.; Wang, Annie; Shay, Kathyjo; Wang, Xuegong; Garg, Jay P.; Cardiel, Mario H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">932-942</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA).  Methods : In this randomized, double-blind, phase IIb trial, patients with RA (n = 289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 wk.  The primary end point was the percentage of patients who met the American College of Rheumatol. 20% improvement criteria (achieved an ACR20 response) at week 12.  Results : ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (P < 0.05), 56.3% (P < 0.01), and 29.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, resp.  Patients in the peficitinib 100 mg and 150 mg groups achieved a rapid and statistically significant ACR20 response compared with those in the placebo group (P < 0.05), reaching statistical significance by week 2.  Overall, the incidence of adverse events (AEs) was similar between patients receiving peficitinib and those receiving placebo.  The most common AEs were upper respiratory tract infection (5% [n = 15]), nausea (4% [n = 12]), and urinary tract infection (4% [n = 10]).  There was 1 case of herpes zoster in the placebo group, and 1 serious infection (limb abscess) in the peficitinib 25 mg group.  There were no incidences of grade 2 or higher neutropenia or lymphopenia.  Conclusion : In patients with moderate-to-severe RA, orally administered once-daily peficitinib in combination with limited csDMARDs resulted in a dose-dependent ACR20 response rate over 12 wk with satisfactory tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAtngQf8klmrVg90H21EOLACvtfcHk0liPskIzDLpUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D&md5=761c5b89cdbbe60108a1bceb1d699ecd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fart.40054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40054%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DCodding%26aufirst%3DC.%26aulast%3DZubrzycka-Sienkiewicz%26aufirst%3DA.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DShay%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGarg%26aufirst%3DJ.%2BP.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26atitle%3DPeficitinib%252C%2520a%2520JAK%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Limited%2520Conventional%2520Synthetic%2520Disease-Modifying%2520Antirheumatic%2520Drugs%2520in%2520the%2520Treatment%2520of%2520Moderate-to-Severe%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D932%26epage%3D942%26doi%3D10.1002%2Fart.40054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R. J.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+Efficacy+of+Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+for+the+Treatment+of+Rheumatoid+Arthritis+in+Open-label&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0liPskIzDLpUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Tofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%2520in%2520Open-label%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, W. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, C. S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worsley, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. C. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span>. <i>BMC Musculoskelet. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi"> DOI: 10.1186/1471-2474-14-298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1186%2F1471-2474-14-298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=24139404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVWnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=298&author=Y.+Heauthor=A.Y.+S.+Wongauthor=E.+W.+Chanauthor=W.+C.+Y.+Lauauthor=K.+K.+C.+Manauthor=C.+S.+L.+Chuiauthor=A.+J.+Worsleyauthor=I.+C.+K.+Wong&title=Efficacy+and+Safety+of+Tofacitinib+in+the+Treatment+of+Rheumatoid+Arthritis%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1186%2F1471-2474-14-298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis</span></div><div class="casAuthors">He, Ying; Wong, Angel Y. S.; Chan, Esther W.; Lau, Wallis C. Y.; Man, Kenneth K. C.; Chui, Celine S. L.; Worsley, Alan J.; Wong, Ian C. K.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Musculoskeletal Disorders</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298/1-298/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">BMDMCE</span>;
        ISSN:<span class="NLM_cas:issn">1471-2474</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US Food and Drug Administration (FDA).  There are several randomized clin. trials (RCTs) that have investigated the efficacy and safety of tofacitinib in adult patients with rheumatoid arthritis (RA).  A systematic review with a meta-anal. of RCTs was undertaken to det. the efficacy and safety of tofacitinib in treating patients with RA.  Methods: Electronic and clin. trials register databases were searched for published RCTs of tofacitinib between 2009 and 2013.  Outcomes of interest include 20% and 50% improvement in the American College of Rheumatol. Scale (ACR20 and ACR50) response rates, rates of infection, the no. of immunol./haematol. adverse events (AEs), deranged lab. results (hepatic, renal, haematol. tests and lipoprotein level) and the incidence of drug withdrawal.  Results: Eight RCTs (n = 3,791) were reviewed.  Significantly greater ACR20 response rates were obsd. in patients receiving tofacitinib 5 and 10 mg bid (twice daily) vs. placebo at week 12, with risk ratios (RR) of 2.20 (95% CI 1.58, 3.07) and 2.38 (95% CI 1.81, 3.14) resp.  The effect was maintained at week 24 for 5 mg bid (RR 1.94; 95% CI 1.55, 2.44) and 10 mg bid (RR 2.20; 95% CI 1.76, 2.75).  The ACR50 response rate was also significantly higher for patients receiving tofacitinib 5 mg bid (RR 2.91; 95% CI 2.03, 4.16) and 10 mg bid (RR 3.32; 95% CI 2.33, 4.72) compared to placebo at week 12.  Patients in the tofacitinib group had significantly lower mean neutrophil counts, higher serum creatinine, higher percentage change of LDL/HDL and a higher risk of ALT/AST > 1 ULN (upper limit of normal) vs. placebo.  There were no significant differences in AEs and withdrawal due to AEs compared to placebo.  Conclusion: Tofacitinib is efficacious and well tolerated in patients with MTX-resistant RA up to a period of 24 wk.  However, haematol., liver function tests and lipoproteins should be monitored.  Long-term efficacy and pharmacovigilance studies are recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUBb07WA5QhLVg90H21EOLACvtfcHk0liPskIzDLpUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVWnsLk%253D&md5=91b198e3c0af406dee90bf105ee2a27c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2F1471-2474-14-298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2474-14-298%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DA.Y.%2BS.%26aulast%3DChan%26aufirst%3DE.%2BW.%26aulast%3DLau%26aufirst%3DW.%2BC.%2BY.%26aulast%3DMan%26aufirst%3DK.%2BK.%2BC.%26aulast%3DChui%26aufirst%3DC.%2BS.%2BL.%26aulast%3DWorsley%26aufirst%3DA.%2BJ.%26aulast%3DWong%26aufirst%3DI.%2BC.%2BK.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tofacitinib%2520in%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DBMC%2520Musculoskelet.%2520Disord.%26date%3D2013%26volume%3D14%26spage%3D298%26doi%3D10.1186%2F1471-2474-14-298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomonte, A. B.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib for the Treatment of Rheumatoid Arthritis</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1586/eci.12.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1586%2Feci.12.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=22607178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=319-331&author=C.+A.+Zerbiniauthor=A.+B.+Lomonte&title=Tofacitinib+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1586%2Feci.12.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Zerbini, Cristiano A. F.; Lomonte, Andrea Barranjard Vannucci</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-331</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approx. 1% of the worldwide population.  It primarily targets the synovial membrane of joints, leading to a synovial proliferation, joint cartilage lesion and erosions in the adjacent bone tissue.  The disease is usually progressive and if the inflammatory process is not adequately suppressed, joint deformity takes place, leading to a significant functional disability and work incapacity.  Over the last decade, biol. therapy was established as a major step towards disease control in those patients who experienced failure after treatment with disease-modifying antirheumatic drugs.  Despite the growing no. of biol. agents with different immunol. targets, a significant no. of patients do not receive appropriate disease control, or have the use of these agents limited because of adverse events.  As such, the search for new mols. with a higher efficacy and better safety profile is ongoing.  This article focuses on a new drug, tofacitinib, which is a synthetic disease-modifying antirheumatic drug for treatment of RA.  Preclin. studies in arthritis and transplantation animal models are reviewed as a background for the possible use of tofacitinib treatment in humans.  Four Phase II (one A and three B dose-ranging) trials lasting from 6 to 24 wk in RA patients showed significant American College of Rheumatol. 20 improvements as early as week 2 and sustained at week 24 in two studies.  Tofacitinib Phase III studies in RA are included in a clin. program called ORAL Trials'.  Long-term follow-up from ongoing studies will contribute to a more accurate tofacitinib efficacy and safety profile.  Trials in other illness such as psoriasis, psoriatic arthritis, renal transplant rejection prevention, inflammatory bowel diseases and dry eye are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHpLt7-aROnLVg90H21EOLACvtfcHk0lijFrizn8C6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D&md5=ad557fe321ab93878f9eace579afcadf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1586%2Feci.12.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Feci.12.19%26sid%3Dliteratum%253Aachs%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DLomonte%26aufirst%3DA.%2BB.%26atitle%3DTofacitinib%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2012%26volume%3D8%26spage%3D319%26epage%3D331%26doi%3D10.1586%2Feci.12.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffstadt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, K.</span></span> <span> </span><span class="NLM_article-title">Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0092-8674%2800%2981168-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=9590174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+Deficiency+Defines+an+Essential+Developmental+Checkpoint+in+Definitive+Hematopoiesis&doi=10.1016%2FS0092-8674%2800%2981168-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span></div><div class="casAuthors">Neubauer, Hans; Cumano, Ana; Muller, Mathias; Wu, Hong; Huffstadt, Ulrike; Pfeffer, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors.  A targeted inactivation of Jak2 was performed.  Jak2-/- embryos are anemic and die around day 12.5 postcoitum.  Primitive erythrocytes are found, but definitive erythropoiesis is absent.  Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe.  Fetal liver BFU-E and CFU-E colonies are completely absent.  However, multilineage hematopoietic stem cells (CD34low, c-kitpos) can be found, and B lymphopoiesis appears intact.  In contrast to IFNα stimulation, Jak2-/- cells do not respond to IFNγ.  Jak2-/- embryonic stem cells are competent for LIF signaling.  The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8oeTh0n3FcbVg90H21EOLACvtfcHk0lijFrizn8C6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D&md5=74275b73c807331170c096145e69af94</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981168-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520Deficiency%2520Defines%2520an%2520Essential%2520Developmental%2520Checkpoint%2520in%2520Definitive%2520Hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409%26doi%3D10.1016%2FS0092-8674%2800%2981168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lommen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannigot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9323</span>– <span class="NLM_lpage">9342</span>, <span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+Selective+JAK1+Inhibitors%3A+From+Hit+Identification+to+GLPG0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0lijFrizn8C6oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520Selective%2520JAK1%2520Inhibitors%253A%2520From%2520Hit%2520Identification%2520to%2520GLPG0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494)</span>. <i>BMC Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=23&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+Vitro+and+In+Vivo+Characterization+of+the+JAK1+Selectivity+of+Upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNγ, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2ebhUxZyKKas0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520Upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatology%26date%3D2018%26volume%3D2%26spage%3D23%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+A+Selective+JAK1+Clinical+Candidate+for+the+Treatment+of+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lhASI_dep7hhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520A%2520Selective%2520JAK1%2520Clinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westhovens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enriquez-Sosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P.</span></span> <span> </span><span class="NLM_article-title">Filgotinib (GLPG0634/GS-6034), an Oral JAK1 Selective Inhibitor, is Effective in Combination with Methotrexate (MTX) in Patients with Active Rheumatoid Arthritis and Insufficient Response to MTX: Results from a Randomised, Dose-Finding Study (DARWIN 1)</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-210104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1136%2Fannrheumdis-2016-210104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27993829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=998-1008&author=R.+Westhovensauthor=P.+C.+Taylorauthor=R.+Altenauthor=D.+Pavlovaauthor=F.+Enriquez-Sosaauthor=M.+Mazurauthor=M.+Greenwaldauthor=A.+Van+der+Aaauthor=F.+Vanhoutteauthor=C.+Tassetauthor=P.+Harrison&title=Filgotinib+%28GLPG0634%2FGS-6034%29%2C+an+Oral+JAK1+Selective+Inhibitor%2C+is+Effective+in+Combination+with+Methotrexate+%28MTX%29+in+Patients+with+Active+Rheumatoid+Arthritis+and+Insufficient+Response+to+MTX%3A+Results+from+a+Randomised%2C+Dose-Finding+Study+%28DARWIN+1%29&doi=10.1136%2Fannrheumdis-2016-210104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)</span></div><div class="casAuthors">Westhovens, R.; Taylor, P. C.; Alten, R.; Pavlova, D.; Enriquez-Sosa, F.; Mazur, M.; Greenwald, M.; Van der Aa, A.; Vanhoutte, F.; Tasset, C.; Harrison, P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">998-1009</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.  In this 24-wk phase IIb study, patients with moderate-to-severe active RA receiving a stable dose of MTX were randomised (1:1:1:1:1:1:1) to receive placebo or 50, 100 or 200 mg filgotinib, administered once daily or twice daily.  Primary end point was the percentage of patients achieving a week 12 American College of Rheumatol. (ACR)20 response.  Overall, 594 patients were randomised and treated.  At week 12, significantly more patients receiving filgotinib 100 mg once daily or 200 mg daily (both regimens) achieved an ACR20 response vs. placebo.  For other key end points at week 12 (ACR50, ACR-N, Disease Activity Score based on 28 joints and C reactive protein value, Clin. Disease Activity Index, Simplified Disease Activity Index and Health Assessment Questionnaire-Disability Index), differences in favor of 100 or 200 mg filgotinib daily were seen vs. placebo; responses were maintained or improved through to week 24.  Rapid onset of action and dosedependent responses were obsd. for most efficacy end points and were assocd. with an increased Hb concn.  No significant differences between once-daily and twice-daily regimens were seen.  Treatment-emergent adverse event rates were similar in placebo and filgotinib groups.  Serious infections occurred in one and five patients in the placebo and filgotinib groups, resp.  No tuberculosis or opportunistic infections were reported.  Filgotinib as add-on to MTX improved the signs and symptoms of active RA over 24 wk and was assocd. with a rapid onset of action.  Filgotinib was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSL1GnhmEyfLVg90H21EOLACvtfcHk0lgbZqFnwVofEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FM&md5=be3caaaf07ed3981f50545e651630b69</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-210104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-210104%26sid%3Dliteratum%253Aachs%26aulast%3DWesthovens%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DAlten%26aufirst%3DR.%26aulast%3DPavlova%26aufirst%3DD.%26aulast%3DEnriquez-Sosa%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DP.%26atitle%3DFilgotinib%2520%2528GLPG0634%252FGS-6034%2529%252C%2520an%2520Oral%2520JAK1%2520Selective%2520Inhibitor%252C%2520is%2520Effective%2520in%2520Combination%2520with%2520Methotrexate%2520%2528MTX%2529%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%2520and%2520Insufficient%2520Response%2520to%2520MTX%253A%2520Results%2520from%2520a%2520Randomised%252C%2520Dose-Finding%2520Study%2520%2528DARWIN%25201%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2017%26volume%3D76%26spage%3D998%26epage%3D1008%26doi%3D10.1136%2Fannrheumdis-2016-210104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cseuz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reshetko, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P.</span></span> <span> </span><span class="NLM_article-title">Filgotinib (GLPG0634/GS-6034), an Oral Selective JAK1 Inhibitor, is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Randomised, Dose-Finding Study (DARWIN 2)</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-210105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1136%2Fannrheumdis-2016-210105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27993828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWgtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=1009-1019&author=A.+Kavanaughauthor=J.+Kremerauthor=L.+Ponceauthor=R.+Cseuzauthor=O.+V.+Reshetkoauthor=M.+Stanislavchukauthor=M.+Greenwaldauthor=A.+Van+der+Aaauthor=F.+Vanhoutteauthor=C.+Tassetauthor=P.+Harrison&title=Filgotinib+%28GLPG0634%2FGS-6034%29%2C+an+Oral+Selective+JAK1+Inhibitor%2C+is+Effective+as+Monotherapy+in+Patients+with+Active+Rheumatoid+Arthritis%3A+Results+from+a+Randomised%2C+Dose-Finding+Study+%28DARWIN+2%29&doi=10.1136%2Fannrheumdis-2016-210105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)</span></div><div class="casAuthors">Kavanaugh, A.; Kremer, J.; Ponce, L.; Cseuz, R.; Reshetko, O. V.; Stanislavchuk, M.; Greenwald, M.; Van der Aa, A.; Vanhoutte, F.; Tasset, C.; Harrison, P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1009-1020</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX).  Methods: In this 24-wk phase IIb study, patients with moderately to severely active RA were randomised (1:1:1:1) to receive 50, 100 or 200 mg filgotinib once daily, or placebo, after a ≥4-wk washout from MTX.  The primary end point was the percentage of patients achieving an American College of Rheumatol. (ACR)20 response at week 12.  Results: Overall, 283 patients were randomised and treated.  At week 12, significantly more patients receiving filgotinib at any dose achieved ACR20 responses vs. placebo (≥65% vs 29%, p<0.001).  For other key end points at week 12 (ACR50, ACR70, ACR-N, Disease Activity Score based on 28 joints and C reactive protein, Clin. Disease Activity Index, Simplified Disease Activity Index and Health Assessment Questionnaire-Disability Index) significant differences from baseline in favor of filgotinib 100 and 200 mg vs. placebo were seen; responses were maintained or improved through week 24.  Rapid onset of action was obsd. for most efficacy end points.  Dose-dependent increases in Hb were obsd.  The percentage of patients with treatment-emergent adverse events (TEAE) was similar in the placebo and filgotinib groups (∼40%).  Eight patients on filgotinib and one on placebo had a serious TEAE, and four patients, all of whom received filgotinib, experienced a serious infection.  No tuberculosis or opportunistic infections were reported.  Conclusions: Over 24 wk, filgotinib as monotherapy was efficacious in treating the signs and symptoms of active RA, with a rapid onset of action.  Filgotinib was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLpycEqtJBZLVg90H21EOLACvtfcHk0lgbZqFnwVofEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWgtbvN&md5=157b24f3a339ba9837a7fa79d2a209b8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-210105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-210105%26sid%3Dliteratum%253Aachs%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DPonce%26aufirst%3DL.%26aulast%3DCseuz%26aufirst%3DR.%26aulast%3DReshetko%26aufirst%3DO.%2BV.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DP.%26atitle%3DFilgotinib%2520%2528GLPG0634%252FGS-6034%2529%252C%2520an%2520Oral%2520Selective%2520JAK1%2520Inhibitor%252C%2520is%2520Effective%2520as%2520Monotherapy%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%253A%2520Results%2520from%2520a%2520Randomised%252C%2520Dose-Finding%2520Study%2520%2528DARWIN%25202%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2017%26volume%3D76%26spage%3D1009%26epage%3D1019%26doi%3D10.1136%2Fannrheumdis-2016-210105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voloshyn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleners, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective Janus Kinase 1 Inhibitor, after Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.1002/art.40186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fart.40186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=28622463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1949-1959&author=F.+Vanhoutteauthor=M.+Mazurauthor=O.+Voloshynauthor=M.+Stanislavchukauthor=A.+Van+der+Aaauthor=F.+Namourauthor=R.+Galienauthor=L.+Meulenersauthor=G.+van%E2%80%99t+Klooster&title=Efficacy%2C+Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Filgotinib%2C+a+Selective+Janus+Kinase+1+Inhibitor%2C+after+Short-Term+Treatment+of+Rheumatoid+Arthritis%3A+Results+of+Two+Randomized+Phase+IIa+Trials&doi=10.1002%2Fart.40186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span></div><div class="casAuthors">Vanhoutte, Frederic; Mazur, Minodora; Voloshyn, Oleksandr; Stanislavchuk, Mykola; Van der Aa, Annegret; Namour, Florence; Galien, Rene; Meuleners, Luc; van 't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : JAK inhibitors have shown efficacy in rheumatoid arthritis (RA).  We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors.  Methods : In two 4-wk exploratory, double-blind, placebo-controlled phase IIa trials, 127 RA patients with an insufficient response to methotrexate (MTX) received filgotinib (GLPG0634, GS-6034) oral capsules (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily) or placebo, added onto a stable regimen of MTX, to evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of filgotinib.  The primary efficacy end point was the no. and percentage of patients in each treatment group meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 4.  Results : Treatment with filgotinib at 75-300 mg met the primary end point and showed early onset of efficacy.  ACR20 response rates progressively increased to week 4, and the Disease Activity Score in 28 joints using the C-reactive protein (CRP) level decreased.  Marked and sustained improvements were obsd. in serum CRP level and other PD markers.  The PK of filgotinib and its major metabolite was dose proportional over the 30-300 mg range.  Early side effects seen with other less selective JAK inhibitors were not obsd. (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-d. lipoprotein or total cholesterol).  A limited decrease in neutrophils without neutropenia was consistent with immunomodulatory effects through JAK-1 inhibition.  There were no infections.  Overall, filgotinib was well tolerated.  Events related to study drug were mild or moderate and transient during therapy, and the most common such event was nausea.  Conclusion : Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7oTo2cM5so7Vg90H21EOLACvtfcHk0lg-3JaZJbk8hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP&md5=b704bd2b69231f1aa95815120b8cf922</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fart.40186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40186%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVoloshyn%26aufirst%3DO.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DMeuleners%26aufirst%3DL.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DEfficacy%252C%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Filgotinib%252C%2520a%2520Selective%2520Janus%2520Kinase%25201%2520Inhibitor%252C%2520after%2520Short-Term%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520Results%2520of%2520Two%2520Randomized%2520Phase%2520IIa%2520Trials%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D1949%26epage%3D1959%26doi%3D10.1002%2Fart.40186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petryka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehbacher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebuterne, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roblin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klopocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewska-Jarosinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sike, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoyanova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P.</span></span> <span> </span><span class="NLM_article-title">Clinical Remission in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib (the FITZROY Study): Results from a Phase 2, Double-Blind, Randomised</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(16)32537-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0140-6736%2816%2932537-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27988142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSmu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=266-275&author=S.+Vermeireauthor=S.+Schreiberauthor=R.+Petrykaauthor=T.+Kuehbacherauthor=X.+Hebuterneauthor=X.+Roblinauthor=M.+Klopockaauthor=A.+Goldisauthor=M.+Wisniewska-Jarosinskaauthor=A.+Baranovskyauthor=R.+Sikeauthor=K.+Stoyanovaauthor=C.+Tassetauthor=A.+Van+der+Aaauthor=P.+Harrison&title=Clinical+Remission+in+Patients+with+Moderate-to-Severe+Crohn%E2%80%99s+Disease+Treated+with+Filgotinib+%28the+FITZROY+Study%29%3A+Results+from+a+Phase+2%2C+Double-Blind%2C+Randomised&doi=10.1016%2FS0140-6736%2816%2932537-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial</span></div><div class="casAuthors">Vermeire, Severine; Schreiber, Stefan; Petryka, Robert; Kuehbacher, Tanja; Hebuterne, Xavier; Roblin, Xavier; Klopocka, Maria; Goldis, Adrian; Wisniewska-Jarosinska, Maria; Baranovsky, Andrey; Sike, Robert; Stoyanova, Kremena; Tasset, Chantal; Van der Aa, Annegret; Harrison, Pille</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10066</span>),
    <span class="NLM_cas:pages">266-275</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.  The FITZROY study examd. the efficacy and safety of filgotinib for the treatment of moderate-to-severe Crohn's disease.  We did a randomised, double-blind, placebo-controlled phase 2 study, which recruited patients from 52 centers in nine European countries.  We enrolled eligible patients aged 18-75 years with a documented history of ileal, colonic, or ileocolonic Crohn's disease for 3 mo or more before screening, as assessed by colonoscopy and supported by histol., and a Crohn's Disease Activity Index (CDAI) score during screening between 220 and 450 inclusive.  Patients were randomly assigned (3:1) to receive filgotinib 200 mg once a day or placebo for 10 wk.  Patients were stratified according to previous anti-tumor necrosis factor alpha exposure, C-reactive protein concn. at screening (≤10 mg/L or >10 mg/L), and oral corticosteroid use at baseline, using an interactive web-based response system.  The primary endpoint was clin. remission, defined as CDAI less than 150 at week 10.  After week 10, patients were assigned based on responder status to filgotinib 100 mg once a day, filgotinib 200 mg once a day, or placebo for an observational period lasting a further 10 wk.  The filgotinib and placebo treatment groups were compared using ANCOVA models and logistic regression models contg. baseline values and randomisation stratification factors as fixed effects.  Analyses were done on the intention-to-treat non-responder imputation set.  The trial was registered at ClinicalTrials.gov, no. NCT02048618.  Between Feb 3, 2014, and July 10, 2015, we enrolled 174 patients with active Crohn's disease confirmed by centrally read endoscopy (130 in the filgotinib 200 mg group and 44 in the placebo group).  In the intention-to-treat population, 60 (47%) of 128 patients treated with filgotinib 200 mg achieved clin. remission at week 10 vs. ten (23%) of 44 patients treated with placebo (difference 24 percentage points [95% CI 9-39], p=0·0077).  In a pooled anal. of all periods of filgotinib and placebo exposure over 20 wk, serious treatment-emergent adverse effects were reported in 14 (9%) of 152 patients treated with filgotinib and three (4%) of 67 patients treated with placebo.  Filgotinib induced clin. remission in significantly more patients with active Crohn's disease compared with placebo, and had an acceptable safety profile.Galapagos.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMvAPgtQG5WbVg90H21EOLACvtfcHk0lg-3JaZJbk8hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSmu7jL&md5=1b70edfe4ba93e35a35974a0ca52b149</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932537-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932537-5%26sid%3Dliteratum%253Aachs%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DPetryka%26aufirst%3DR.%26aulast%3DKuehbacher%26aufirst%3DT.%26aulast%3DHebuterne%26aufirst%3DX.%26aulast%3DRoblin%26aufirst%3DX.%26aulast%3DKlopocka%26aufirst%3DM.%26aulast%3DGoldis%26aufirst%3DA.%26aulast%3DWisniewska-Jarosinska%26aufirst%3DM.%26aulast%3DBaranovsky%26aufirst%3DA.%26aulast%3DSike%26aufirst%3DR.%26aulast%3DStoyanova%26aufirst%3DK.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DP.%26atitle%3DClinical%2520Remission%2520in%2520Patients%2520with%2520Moderate-to-Severe%2520Crohn%25E2%2580%2599s%2520Disease%2520Treated%2520with%2520Filgotinib%2520%2528the%2520FITZROY%2520Study%2529%253A%2520Results%2520from%2520a%2520Phase%25202%252C%2520Double-Blind%252C%2520Randomised%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D266%26epage%3D275%26doi%3D10.1016%2FS0140-6736%2816%2932537-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubbert-Roth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, M.-E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangan, A. L.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Upadacitinib in Patients with Active Rheumatoid Arthritis Refractory to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-BEYOND): a Double-Blind, Randomised Controlled Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">2513</span>– <span class="NLM_lpage">2524</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31116-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0140-6736%2818%2931116-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29908670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=2513-2524&author=M.+C.+Genoveseauthor=R.+Fleischmannauthor=B.+Combeauthor=S.+Hallauthor=A.+Rubbert-Rothauthor=Y.+Zhangauthor=Y.+Zhouauthor=M.-E.+F.+Mohamedauthor=S.+Meerweinauthor=A.+L.+Pangan&title=Safety+and+Efficacy+of+Upadacitinib+in+Patients+with+Active+Rheumatoid+Arthritis+Refractory+to+Biologic+Disease-Modifying+Anti-Rheumatic+Drugs+%28SELECT-BEYOND%29%3A+a+Double-Blind%2C+Randomised+Controlled+Phase+3+Trial&doi=10.1016%2FS0140-6736%2818%2931116-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial</span></div><div class="casAuthors">Genovese, Mark C.; Fleischmann, Roy; Combe, Bernard; Hall, Stephen; Rubbert-Roth, Andrea; Zhang, Ying; Zhou, Yijie; Mohamed, Mohamed-Eslam F.; Meerwein, Sebastian; Pangan, Aileen L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10139</span>),
    <span class="NLM_cas:pages">2513-2524</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis.  We did this study to further assess the safety and efficacy of upadacitinib in patients with an inadequate response to biol. disease-modifying anti-rheumatic drugs (bDMARDs).  We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries.  Patients were aged 18 years or older, had active rheumatoid arthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs).  We randomly assigned patients (2:2:1:1) by interactive response technol. to receive once-daily oral extended-release upadacitinib 15 mg or 30 mg or placebo for 12 wk, followed by upadacitinib 15 mg or 30 mg from week 12 onwards.  The two sep. primary endpoints were the proportions of patients achieving a 20% improvement in American College of Rheumatol. criteria (ACR20) at week 12 and the proportion of patients achieving a 28-joint disease activity score using C-reactive protein (DAS28[CRP]) of 3·2 or less at week 12.  Efficacy and safety analyses were done in the modified intention-to-treat population of all patients who received at least one dose of study drug.  Data are presented up to week 24 of this ongoing study.  The trial is registered with ClinicalTrials.gov (NCT02706847).  Between March 15, 2016, and Jan 10, 2017, 499 patients were randomly assigned (n=165 upadacitinib 15 mg; n=165 upadacitinib 30 mg; n=85 placebo then upadacitinib 15 mg; and n=84 placebo then upadacitinib 30 mg) and one patient was withdrawn from the 15 mg upadacitinib group before the start of study treatment.  Mean disease duration was 13·2 years (SD 9·5); 235 (47%) of 498 patients had received one previous bDMARD, 137 (28%) had received two, and 125 (25%) had received at least three; 451 (91%) patients completed treatment up to week 12 and 419 (84%) patients completed treatment up to week 24.  At week 12, ACR20 was achieved by 106 (65%; 95% CI 57-72) of 164 patients receiving upadacitinib 15 mg and 93 (56%; 49-64) of 165 patients receiving upadacitinib 30 mg compared with 48 (28%; 22-35) of 169 patients receiving placebo (p<0·0001 for each dose vs placebo).  DAS28(CRP) of 3·2 or less was achieved by 71 (43%; 95% CI 36-51) of 164 patients receiving upadacitinib 15 mg and 70 (42%; 35-50) of 165 patients receiving upadacitinib 30 mg vs. 24 (14%; 9-20) of 169 patients receiving placebo (p<0·0001 for each dose vs placebo).  Up to week 12, overall nos. of patients with adverse events were similar for the placebo group (95 [56%] of 169) and the upadacitinib 15 mg group (91 [55%] of 164), but higher in the upadacitinib 30 mg group (111 [67%] of 165).  At week 12, the most common adverse events occurring in at least 5% of patients in any treatment group were upper respiratory tract infection (13 [8%] of 169 in the placebo group; 13 [8%] of 164 in the upadacitinib 15 mg group; ten [6%] of 165 in the upadacitinib 30 mg group), nasopharyngitis (11 [7%]; seven [4%]; nine [5%]), urinary tract infection (ten [6%]; 15 [9%]; nine [5%]), and worsening of rheumatoid arthritis (ten [6%]; four [2%]; six [4%]).  The no. of patients with serious adverse events was higher in the upadacitinib 30 mg group (12 [7%]) than in the upadacitinib 15 mg group (eight [5%]); no serious adverse events were reported in patients receiving placebo.  More patients in the upadacitinib 30 mg group had serious infections, herpes zoster, and adverse events leading to discontinuation than in the upadacitinib 15 mg and placebo groups.  During the placebo-controlled phase of the study, one case of pulmonary embolism, three malignancies, one major adverse cardiovascular event, and one death were reported in patients receiving upadacitinib; none were reported in patients receiving placebo.  Both doses of upadacitinib led to rapid and significant improvements compared with placebo over 12 wk in patients with refractory rheumatoid arthritis.AbbVie Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNKODcAMc3erVg90H21EOLACvtfcHk0lg-3JaZJbk8hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb3E&md5=d7bcea909b5dfb3a25fe64a22beca3a0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931116-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931116-4%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCombe%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DRubbert-Roth%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMohamed%26aufirst%3DM.-E.%2BF.%26aulast%3DMeerwein%26aufirst%3DS.%26aulast%3DPangan%26aufirst%3DA.%2BL.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Upadacitinib%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%2520Refractory%2520to%2520Biologic%2520Disease-Modifying%2520Anti-Rheumatic%2520Drugs%2520%2528SELECT-BEYOND%2529%253A%2520a%2520Double-Blind%252C%2520Randomised%2520Controlled%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D2513%26epage%3D2524%26doi%3D10.1016%2FS0140-6736%2818%2931116-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span> </span><span class="NLM_article-title">Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842,
an Oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe
Atopic Dermatitis</span>.  <i>Pfizer News Release</i>; <span class="NLM_publisher-name">Pfizer</span>, Feb 14, <span class="NLM_year">2018</span>; <a href="https://press.pfizer.com/press-release/pfizer-receives-breakthrough-therapy-designation-fda-pf-04965842-oral-jak1-inhibitor-t" class="extLink">https://press.pfizer.com/press-release/pfizer-receives-breakthrough-therapy-designation-fda-pf-04965842-oral-jak1-inhibitor-t</a> (accessed Sep 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Receives+Breakthrough+Therapy+Designation+from+FDA+for+PF-04965842%2C%0Aan+Oral+JAK1+Inhibitor%2C+for+the+Treatment+of+Patients+with+Moderate-to-Severe%0AAtopic+Dermatitis.+Pfizer+News+Release%3B+Pfizer%2C+Feb+14%2C+2018%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-receives-breakthrough-therapy-designation-fda-pf-04965842-oral-jak1-inhibitor-t+%28accessed+Sep+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Receives%2520Breakthrough%2520Therapy%2520Designation%2520from%2520FDA%2520for%2520PF-04965842%252C%250Aan%2520Oral%2520JAK1%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Moderate-to-Severe%250AAtopic%2520Dermatitis%26jtitle%3DPfizer%2520News%2520Release%26pub%3DPfizer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seneviratne, U. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Point, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1242</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlels70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1235-1242&author=H.+Xuauthor=M.+I.+Jessonauthor=U.+I.+Seneviratneauthor=T.+H.+Linauthor=M.+N.+Sharifauthor=L.+Xueauthor=C.+Nguyenauthor=R.+A.+Everleyauthor=J.+I.+Trujilloauthor=D.+S.+Johnsonauthor=G.+R.+Pointauthor=A.+Thorarensenauthor=I.+Kiltyauthor=J.-B.+Telliez&title=PF-06651600%2C+a+Dual+JAK3%2FTEC+Family+Kinase+Inhibitor&doi=10.1021%2Facschembio.9b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor</span></div><div class="casAuthors">Xu, Hua; Jesson, Michael I.; Seneviratne, Uthpala I.; Lin, Tsung H.; Sharif, M. Nusrat; Xue, Liang; Nguyen, Chuong; Everley, Robert A.; Trujillo, John I.; Johnson, Douglas S.; Point, Gary R.; Thorarensen, Atli; Kilty, Iain; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1242</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-06651600 was developed as an irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms.  A high level of selectivity toward JAK3 is achieved by the covalent interaction of PF-06651600 with a unique cysteine residue (Cys-909) in the catalytic domain of JAK3, which is replaced by a serine residue in the other JAK isoforms.  Importantly, 10 other kinases in the kinome have a cysteine at the equiv. position of Cys-909 in JAK3.  Five of those kinases belong to the TEC kinase family including BTK, BMX, ITK, RLK, and TEC and are also inhibited by PF-06651600.  Preclin. data demonstrate that inhibition of the cytolytic function of CD8+ T cells and NK cells by PF-06651600 is driven by the inhibition of TEC kinases.  On the basis of the underlying pathophysiol. of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, alopecia areata, and vitiligo, the dual activity of PF-06651600 toward JAK3 and the TEC kinase family may provide a beneficial inhibitory profile for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeuSFXH1umLVg90H21EOLACvtfcHk0liA52hFyTMZDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlels70%253D&md5=6b687d02201c599e4e724885f5ecc93b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00188%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DSeneviratne%26aufirst%3DU.%2BI.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DSharif%26aufirst%3DM.%2BN.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DEverley%26aufirst%3DR.%2BA.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DPoint%26aufirst%3DG.%2BR.%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DPF-06651600%252C%2520a%2520Dual%2520JAK3%252FTEC%2520Family%2520Kinase%2520Inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D1235%26epage%3D1242%26doi%3D10.1021%2Facschembio.9b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span> </span><span class="NLM_article-title">Study to Evaluate the Efficacy
and Safety of Oral PF-06651600 and PF-06700841 in Subjects with Moderate
to Severe Crohn’s Disease</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03395184</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03395184?term=NCT03395184&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03395184?term=NCT03395184&rank=1</a>  (first posted Jan 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+to+Evaluate+the+Efficacy%0Aand+Safety+of+Oral+PF-06651600+and+PF-06700841+in+Subjects+with+Moderate%0Ato+Severe+Crohn%E2%80%99s+Disease.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03395184%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03395184%3Fterm%3DNCT03395184%26rank%3D1+%28first+posted+Jan+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520to%2520Evaluate%2520the%2520Efficacy%250Aand%2520Safety%2520of%2520Oral%2520PF-06651600%2520and%2520PF-06700841%2520in%2520Subjects%2520with%2520Moderate%250Ato%2520Severe%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03395184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span> </span><span class="NLM_article-title">Study to Compare Oral PF-06651600,
PF-06700841 and Placebo in Subjects with Moderate to Severe Ulcerative
Colitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02958865</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02958865?term=NCT02958865&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02958865?term=NCT02958865&rank=1</a>  (first posted Nov 8, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+to+Compare+Oral+PF-06651600%2C%0APF-06700841+and+Placebo+in+Subjects+with+Moderate+to+Severe+Ulcerative%0AColitis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02958865%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02958865%3Fterm%3DNCT02958865%26rank%3D1+%28first+posted+Nov+8%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520to%2520Compare%2520Oral%2520PF-06651600%252C%250APF-06700841%2520and%2520Placebo%2520in%2520Subjects%2520with%2520Moderate%2520to%2520Severe%2520Ulcerative%250AColitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02958865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span> </span><span class="NLM_article-title">Study To Evaluate The Efficacy
And Safety Profile Of PF-06651600 And PF-06700841 In Subjects with
Alopecia Areata</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02974868</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02974868?term=NCT02974868&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02974868?term=NCT02974868&rank=1</a> (first posted Nov 29, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+To+Evaluate+The+Efficacy%0AAnd+Safety+Profile+Of+PF-06651600+And+PF-06700841+In+Subjects+with%0AAlopecia+Areata.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02974868%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02974868%3Fterm%3DNCT02974868%26rank%3D1+%28first+posted+Nov+29%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520To%2520Evaluate%2520The%2520Efficacy%250AAnd%2520Safety%2520Profile%2520Of%2520PF-06651600%2520And%2520PF-06700841%2520In%2520Subjects%2520with%250AAlopecia%2520Areata%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02974868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 Locus Genotype-to-Phenotype Differences in Autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+Locus+Genotype-to-Phenotype+Differences+in+Autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520Locus%2520Genotype-to-Phenotype%2520Differences%2520in%2520Autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Selective Tyk2 Inhibitors as Potential Therapeutic Agents: A Patent Review (2015–2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1567713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1080%2F13543776.2019.1567713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30621465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=137-149&author=X.+Heauthor=X.+Chenauthor=H.+Zhangauthor=T.+Xieauthor=X.-Y.+Ye&title=Selective+Tyk2+Inhibitors+as+Potential+Therapeutic+Agents%3A+A+Patent+Review+%282015%E2%80%932018%29&doi=10.1080%2F13543776.2019.1567713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)</span></div><div class="casAuthors">He, Xingrui; Chen, Xiabin; Zhang, Hancheng; Xie, Tian; Ye, Xiang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene.  Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family.  Before 2014, far more publications and patents appeared in public domain attributing to the development of selective Jak2 and Jak3 inhibitors than those for selective Tyk2 and Jak1 inhibitors.  This review sought to give an overview of patents related to small mol. selective Tyk2 inhibitors published from 2015 to 2018.  The article also covers clin. activities of small mol. selective Tyk2 inhibitors in recent years.  As a key component of the JAK-STAT signaling pathway, Tyk2 regulates INFα, IL12, and IL23.  Selective inhibition of Tyk2 can provide pharmacol. benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.  The selectivity against other Jak family subtypes (such as Jak2) is crucial in order to minimize the potential side effects and to maximize the desired pharmacol. effects.  In this context, this review of recent selective Tyk2 inhibitor patents may prove valid, interesting, and promising within the therapeutic paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrer4xPnKRtvrVg90H21EOLACvtfcHk0lgQMhQRzo_SMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D&md5=cf7fa5e5f7a92eb951886f7951f7da4b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1567713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1567713%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DX.-Y.%26atitle%3DSelective%2520Tyk2%2520Inhibitors%2520as%2520Potential%2520Therapeutic%2520Agents%253A%2520A%2520Patent%2520Review%2520%25282015%25E2%2580%25932018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D137%26epage%3D149%26doi%3D10.1080%2F13543776.2019.1567713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward Selective TYK2 Inhibitors as Therapeutic Agents for the Treatment of Inflammatory Diseases</span>. <i>Pharm. Pat. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.4155/ppa.14.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.4155%2Fppa.14.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=25291316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=449-466&author=C.+J.+Menet&title=Toward+Selective+TYK2+Inhibitors+as+Therapeutic+Agents+for+the+Treatment+of+Inflammatory+Diseases&doi=10.4155%2Fppa.14.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-466</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target.  The role of JAK is central to cytokine signaling pathways.  It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biol. therapies.  Consequently, selective JAK inhibition has become a major focus area of drug discovery research.  A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors.  Importantly, despite the increasing no. of published patents, none of these drugs have yet made it to the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmMgH3Z8Ff7Vg90H21EOLACvtfcHk0lgQMhQRzo_SMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF&md5=0a79df697117246c840c559260d8e7ba</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.23%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520Selective%2520TYK2%2520Inhibitors%2520as%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26spage%3D449%26epage%3D466%26doi%3D10.4155%2Fppa.14.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+Inhibition+of+TYK2+and+JAK1+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29-pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lgQMhQRzo_SMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520Inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529-pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span> </span><span class="NLM_article-title">Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects
with Moderate to Severe Plaque Psoriasis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes
of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02969018</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02969018?term=NCT02969018&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02969018?term=NCT02969018&rank=1</a> (first posted Nov 21, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+to+Evaluate+Safety+and+Efficacy+of+PF-06700841+in+Subjects%0Awith+Moderate+to+Severe+Plaque+Psoriasis.+ClinicalTrials.gov%3B+U.S.+National+Institutes%0Aof+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02969018%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02969018%3Fterm%3DNCT02969018%26rank%3D1+%28first+posted+Nov+21%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520to%2520Evaluate%2520Safety%2520and%2520Efficacy%2520of%2520PF-06700841%2520in%2520Subjects%250Awith%2520Moderate%2520to%2520Severe%2520Plaque%2520Psoriasis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%250Aof%2520Health%26date%3D2016%26spage%3DNCT02969018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkle, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients with Plaque Psoriasis</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1002/jcph.1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fjcph.1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29266308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=434-447&author=C.+Banfieldauthor=M.+Scaramozzaauthor=W.+Zhangauthor=E.+Kierasauthor=K.+M.+Pageauthor=A.+Fensomeauthor=M.+Vincentauthor=M.+E.+Dowtyauthor=K.+Gotetiauthor=P.+J.+Winkleauthor=E.+Peeva&title=The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+TYK2%2FJAK1+Inhibitor+%28PF-06700841%29+in+Healthy+Subjects+and+Patients+with+Plaque+Psoriasis&doi=10.1002%2Fjcph.1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span></div><div class="casAuthors">Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M.; Fensome, Andrew; Vincent, Michael; Dowty, Martin E.; Goteti, Kosalaram; Winkle, Peter J.; Peeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-447</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis.  The single ascending dose (1, 3, 10, 30, 100, or 200 mg) and multiple ascending dose (MAD; PF-06700841; up to 175 mg once daily or 50 mg twice daily for 10 days) periods included 54 healthy participants.  In addn., 30 patients with psoriasis received PF-06700841 30 or 100 mg or placebo once daily for 28 days.  Single PF-06700841 doses were rapidly absorbed, with peak plasma concns. ≤ 1 h, proportional exposure up to 100 mg, and mean half-life 3.8-7.5 h.  On day 10 of MAD, plasma concns. peaked at ≤1.5 h postdose (10-175 mg once daily).  Elimination half-life was 4.9-10.7 h; steady state was reached by day 8.  In psoriasis patients on day 28, peak plasma concns. occurred at 1-2 h.  Biomarkers IP-10 and high-sensitivity C-reactive protein were reduced and returned to near baseline levels after dosing.  Maximal mean percent change from baseline in the Psoriasis Area and Severity Index scores for PF-06700841 30 mg once daily and 100 mg once daily were -67.92% and -96.31%, resp., in week 4.  All adverse events were mild/moderate.  PF-06700841 was safe and well tolerated up to 200 mg once daily in healthy subjects and 100 mg once daily in patients with psoriasis, suggesting potential therapeutic utility in plaque psoriasis and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHMconrLwJf7Vg90H21EOLACvtfcHk0lgTFv5Jl2dgGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D&md5=a907c91ff2d50db9cba930c2249ed37b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1046%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DScaramozza%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DK.%2BM.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DM.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DGoteti%26aufirst%3DK.%26aulast%3DWinkle%26aufirst%3DP.%2BJ.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DThe%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520Inhibitor%2520%2528PF-06700841%2529%2520in%2520Healthy%2520Subjects%2520and%2520Patients%2520with%2520Plaque%2520Psoriasis%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D434%26epage%3D447%26doi%3D10.1002%2Fjcph.1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span>; <span class="NLM_string-name">Arnold, E. P.</span>; <span class="NLM_string-name">Banker, M. E.</span>; <span class="NLM_string-name">Brown, M. F.</span>; <span class="NLM_string-name">Clark, J. D.</span>; <span class="NLM_string-name">Dermenci, A.</span>; <span class="NLM_string-name">Dowty, M.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Hayward, M. M.</span>; <span class="NLM_string-name">Hegen, M.</span>; <span class="NLM_string-name">Hollingshead, B. D.</span>; <span class="NLM_string-name">Knafels, J. D.</span>; <span class="NLM_string-name">Lin, D. W.</span>; <span class="NLM_string-name">Lin, T.</span>; <span class="NLM_string-name">Owen, D.</span>; <span class="NLM_string-name">Saiah, E.</span>; <span class="NLM_string-name">Sharma, R.</span>; <span class="NLM_string-name">Vajdos, F. F.</span>; <span class="NLM_string-name">Vincent, F.</span>; <span class="NLM_string-name">Wright, S. W.</span>; <span class="NLM_string-name">Xing, L.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of the TYK2 Selective Inhibitor PF-6826647 for the Treatment of Crohn’s Disease, and Other Autoimmune Conditions</span>.  <i>Presented at 256th ACS National Meeting, Boston, MA,, Aug. 19–23, 2018</i>; <span class="NLM_publisher-name">American Chemical Society</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">MEDI 319</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=MEDI+319&author=B.+S.+Gerstenberger&author=E.+P.+Arnold&author=M.+E.+Banker&author=M.+F.+Brown&author=J.+D.+Clark&author=A.+Dermenci&author=M.+Dowty&author=A.+Fensome&author=M.+M.+Hayward&author=M.+Hegen&author=B.+D.+Hollingshead&author=J.+D.+Knafels&author=D.+W.+Lin&author=T.+Lin&author=D.+Owen&author=E.+Saiah&author=R.+Sharma&author=F.+F.+Vajdos&author=F.+Vincent&author=S.+W.+Wright&author=L.+Xing&author=X.+Yang&author=X.+Yang&author=L.+Zhang&title=Discovery+of+the+TYK2+Selective+Inhibitor+PF-6826647+for+the+Treatment+of+Crohn%E2%80%99s+Disease%2C+and+Other+Autoimmune+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26atitle%3DDiscovery%2520of%2520the%2520TYK2%2520Selective%2520Inhibitor%2520PF-6826647%2520for%2520the%2520Treatment%2520of%2520Crohn%25E2%2580%2599s%2520Disease%252C%2520and%2520Other%2520Autoimmune%2520Conditions%26jtitle%3DPresented%2520at%2520256th%2520ACS%2520National%2520Meeting%252C%2520Boston%252C%2520MA%252C%252C%2520Aug.%252019%25E2%2580%259323%252C%25202018%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2018%26spage%3DMEDI%2520319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span>; <span class="NLM_string-name">Dermenci, A.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Gerstenberger, B. S.</span>; <span class="NLM_string-name">Hayward, M. M.</span>; <span class="NLM_string-name">Owen, D. R.</span>; <span class="NLM_string-name">Wright, S. W.</span>; <span class="NLM_string-name">Xing, L. H.</span>; <span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[l,5-<i>a</i>]pyrazin-4-yl Derivatives</span>. U.S. Patent <span class="NLM_patent">2017/0240552 A1</span>, Feb 21, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+F.+Brown&author=A.+Dermenci&author=A.+Fensome&author=B.+S.+Gerstenberger&author=M.+M.+Hayward&author=D.+R.+Owen&author=S.+W.+Wright&author=L.+H.+Xing&author=X.+Yang&title=Pyrazolo%5Bl%2C5-a%5Dpyrazin-4-yl+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BF.%26atitle%3DPyrazolo%255Bl%252C5-a%255Dpyrazin-4-yl%2520Derivatives%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span> </span><span class="NLM_article-title">A First in Human Study to Evaluate
Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects
and Subjects with Plaque Psoriasis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03210961</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03210961?term=NCT03210961&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03210961?term=NCT03210961&rank=1</a> (first posted July 7, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+First+in+Human+Study+to+Evaluate%0ASafety%2C+Tolerability%2C+and+Pharmacology+of+PF-06826647+in+Healthy+Subjects%0Aand+Subjects+with+Plaque+Psoriasis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03210961%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03210961%3Fterm%3DNCT03210961%26rank%3D1+%28first+posted+July+7%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520First%2520in%2520Human%2520Study%2520to%2520Evaluate%250ASafety%252C%2520Tolerability%252C%2520and%2520Pharmacology%2520of%2520PF-06826647%2520in%2520Healthy%2520Subjects%250Aand%2520Subjects%2520with%2520Plaque%2520Psoriasis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03210961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edavettal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2-Mediated Signal Transduction in T Lymphocytes is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">11061</span>– <span class="NLM_lpage">11074</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.619502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1074%2Fjbc.M114.619502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=25762719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=11061-11074&author=J.+S.+Tokarskiauthor=A.+Zupa-Fernandezauthor=J.+A.+Tredupauthor=K.+Pikeauthor=C.+Changauthor=D.+Xieauthor=L.+Chengauthor=D.+Pedicordauthor=J.+Muckelbauerauthor=S.+R.+Johnsonauthor=S.+Wuauthor=S.+C.+Edavettalauthor=Y.+Hongauthor=M.+R.+Witmerauthor=L.+L.+Elkinauthor=Y.+Blatauthor=W.+J.+Pittsauthor=D.+S.+Weinsteinauthor=J.+R.+Burke&title=Tyrosine+Kinase+2-Mediated+Signal+Transduction+in+T+Lymphocytes+is+Blocked+by+Pharmacological+Stabilization+of+Its+Pseudokinase+Domain&doi=10.1074%2Fjbc.M114.619502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</span></div><div class="casAuthors">Tokarski, John S.; Zupa-Fernandez, Adriana; Tredup, Jeffrey A.; Pike, Kristen; Chang, Chieh Ying; Xie, Dianlin; Cheng, Lihong; Pedicord, Donna; Muckelbauer, Jodi; Johnson, Stephen R.; Wu, Sophie; Edavettal, Suzanne C.; Hong, Yang; Witmer, Mark R.; Elkin, Lisa L.; Blat, Yuval; Pitts, William J.; Weinstein, David S.; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11061-11074</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of signal transduction downstream of the IL-23 receptor represents an intriguing approach to the treatment of autoimmunity.  Using a chemogenomics approach marrying kinome-wide inhibitory profiles of a compd. library with the cellular activity against an IL-23-stimulated transcriptional response in T lymphocytes, a class of inhibitors was identified that bind to and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of receptor-mediated activation of the adjacent catalytic domain.  These Tyk2 pseudokinase domain stabilizers were also shown to inhibit Tyk2-dependent signaling through the Type I interferon receptor but not Tyk2-independent signaling and transcriptional cellular assays, including stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high functional selectivity of this approach.  A crystal structure of the pseudokinase domain liganded with a representative example showed the compd. bound to a site analogous to the ATP-binding site in catalytic kinases with features consistent with high ligand selectivity.  The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions.  Tyk2 pseudokinase stabilizers, therefore, represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSl_Zer56d7Vg90H21EOLACvtfcHk0liYIO-UeguiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D&md5=49e10a7c3e430c8be198c119b26bb16b</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.619502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.619502%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DPike%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DEdavettal%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DTyrosine%2520Kinase%25202-Mediated%2520Signal%2520Transduction%2520in%2520T%2520Lymphocytes%2520is%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520Its%2520Pseudokinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D11061%26epage%3D11074%26doi%3D10.1074%2Fjbc.M114.619502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine TYK2 Pseudokinase Ligands as Potent and Selective Allosteric Inhibitors of TYK2 Signalling</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1039/C6MD00560H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1039%2FC6MD00560H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30108788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=700-712&author=R.+Moslinauthor=D.+Gardnerauthor=J.+Santellaauthor=Y.+Zhangauthor=J.+V.+Dunciaauthor=C.+Liuauthor=J.+Linauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=D.+Pedicordauthor=J.+Chenauthor=Y.+Blatauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+TYK2+Pseudokinase+Ligands+as+Potent+and+Selective+Allosteric+Inhibitors+of+TYK2+Signalling&doi=10.1039%2FC6MD00560H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span></div><div class="casAuthors">Moslin, R.; Gardner, D.; Santella, J.; Zhang, Y.; Duncia, J. V.; Liu, C.; Lin, J.; Tokarski, J. S.; Strnad, J.; Pedicord, D.; Chen, J.; Blat, Y.; Zupa-Fernandez, A.; Cheng, L.; Sun, H.; Chaudhry, C.; Huang, C.; D'Arienzo, C.; Sack, J. S.; Muckelbauer, J. K.; Chang, C.; Tredup, J.; Xie, D.; Aranibar, N.; Burke, J. R.; Carter, P. H.; Weinstein, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-712</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role.  Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-b]pyridazine (IZP) 7 was identified as a promising hit compd.  Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain.  These studies led to the discovery of the JH2-selective TYK2 inhibitor 29, which provided encouraging systemic exposures after oral dosing in mice.  Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors detd. from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX5_XfvLHsLVg90H21EOLACvtfcHk0liYIO-UeguiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN&md5=67b06413866ee6096810903f62edd901</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1039%2FC6MD00560H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00560H%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520TYK2%2520Pseudokinase%2520Ligands%2520as%2520Potent%2520and%2520Selective%2520Allosteric%2520Inhibitors%2520of%2520TYK2%2520Signalling%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D700%26epage%3D712%26doi%3D10.1039%2FC6MD00560H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Mertzman, M.</span>; <span class="NLM_string-name">Tokarski, J. S.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Gillooly, K.</span>; <span class="NLM_string-name">McIntyre, K. W.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Chaudhry, C.</span>; <span class="NLM_string-name">Huang, C.</span>; <span class="NLM_string-name">D’Arienzo, C.</span>; <span class="NLM_string-name">Heimrich, E.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Muckelbauer, J. K.</span>; <span class="NLM_string-name">Chang, C.-Y.</span>; <span class="NLM_string-name">Tredup, J.</span>; <span class="NLM_string-name">Mulligan, D.</span>; <span class="NLM_string-name">Xie, D.</span>; <span class="NLM_string-name">Aranibar, N.</span>; <span class="NLM_string-name">Chiney, M.</span>; <span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Lombardo, L.</span>; <span class="NLM_string-name">Carter, P. H.</span>; <span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-carboxamide Pseudokinase Domain Ligands as Highly Selective Inhibitors of Tyrosine Kinase 2 (TYK2)</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+Moslin&author=Y.+Zhang&author=S.+T.+Wrobleski&author=S.+Lin&author=M.+Mertzman&author=J.+S.+Tokarski&author=J.+Strnad&author=K.+Gillooly&author=K.+W.+McIntyre&author=A.+Zupa-Fernandez&author=L.+Cheng&author=H.+Sun&author=C.+Chaudhry&author=C.+Huang&author=C.+D%E2%80%99Arienzo&author=E.+Heimrich&author=X.+Yang&author=J.+K.+Muckelbauer&author=C.-Y.+Chang&author=J.+Tredup&author=D.+Mulligan&author=D.+Xie&author=N.+Aranibar&author=M.+Chiney&author=J.+R.+Burke&author=L.+Lombardo&author=P.+H.+Carter&author=D.+S.+Weinstein&title=Identification+of+N-Methyl+Nicotinamide+and+N-Methyl+Pyridazine-3-carboxamide+Pseudokinase+Domain+Ligands+as+Highly+Selective+Inhibitors+of+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1021%2Facs.jmedchem.9b00443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00443%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-Methyl%2520Nicotinamide%2520and%2520N-Methyl%2520Pyridazine-3-carboxamide%2520Pseudokinase%2520Domain%2520Ligands%2520as%2520Highly%2520Selective%2520Inhibitors%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26doi%3D10.1021%2Facs.jmedchem.9b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Gillooly, K. M.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Catlett, I. M.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Heimrich, E. M.</span>; <span class="NLM_string-name">McIntyre, K. W.</span>; <span class="NLM_string-name">Cunningham, M. D.</span>; <span class="NLM_string-name">Carman, J. A.</span>; <span class="NLM_string-name">Zhou, X.</span>; <span class="NLM_string-name">Banas, D.</span>; <span class="NLM_string-name">Chaudhry, C.</span>; <span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">D’Arienzo, C.</span>; <span class="NLM_string-name">Chimalakonda, A.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Xie, J. H.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Rose, S. M.</span></span>;; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>.; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span>; <span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Weinstein, D. S.</span>; <span class="NLM_string-name">Salter-Cid, L. M.</span></span> <span> </span><span class="NLM_article-title">Autoimmune Pathways in Mice and Humans are Blocked by Pharmacological Stabilization of the TYK2 Pseudokinase Domain</span>,  <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, in press.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1126%2Fscitranslmed.aaw1736" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+R.+Burke&author=L.+Cheng&author=K.+M.+Gillooly&author=J.+Strnad&author=A.+Zupa-Fernandez&author=I.+M.+Catlett&author=Y.+Zhang&author=E.+M.+Heimrich&author=K.+W.+McIntyre&author=M.+D.+Cunningham&author=J.+A.+Carman&author=X.+Zhou&author=D.+Banas&author=C.+Chaudhry&author=S.+Li&author=C.+D%E2%80%99Arienzo&author=A.+Chimalakonda&author=X.+Yang&author=J.+H.+Xie&author=J.+Pang&author=Q.+Zhao&author=S.+M.+Roseauthor=J.+Huangauthor=R.+M.+Moslin&author=S.+T.+Wrobleski&author=D.+S.+Weinstein&author=L.+M.+Salter-Cid&title=Autoimmune+Pathways+in+Mice+and+Humans+are+Blocked+by+Pharmacological+Stabilization+of+the+TYK2+Pseudokinase+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw1736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw1736%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAutoimmune%2520Pathways%2520in%2520Mice%2520and%2520Humans%2520are%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520the%2520TYK2%2520Pseudokinase%2520Domain%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaçi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgis, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span> <span> </span><span class="NLM_article-title">Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1806382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1806382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30205746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1313-1321&author=K.+Pappauthor=K.+Gordonauthor=D.+Tha%C3%A7iauthor=A.+Moritaauthor=M.+Gooderhamauthor=P.+Foleyauthor=I.+G.+Girgisauthor=S.+Kunduauthor=S.+Banerjee&title=Phase+2+Trial+of+Selective+Tyrosine+Kinase+2+Inhibition+in+Psoriasis&doi=10.1056%2FNEJMoa1806382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span></div><div class="casAuthors">Papp, Kim; Gordon, Kenneth; Thaci, Diamant; Morita, Akimichi; Gooderham, Melinda; Foley, Peter; Girgis, Ihab G.; Kundu, Sudeep; Banerjee, Subhashis</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiol. of psoriasis.  Selective inhibitors of TYK2 may be effective in treating psoriasis. methods We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway.  Patients were randomly assigned to receive the drug orally at a dose of 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo.  The primary end point was a 75% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (higher scores indicate greater severity of psoriasis). results A total of 267 patients received at least one dose in an intervention group of the trial.  At week 12, the percentage of patients with a 75% or greater redn. in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P = 0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P<0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P<0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P<0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P<0.001 vs. placebo).  There were three serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment. conclusions Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 wk.  Larger and longer-duration trials of this drug are required to det. its safety and durability of effect in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqWANKhDdt7Vg90H21EOLACvtfcHk0ljqtAVNUABQvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE&md5=ededd5d925dd557cceacc472839a966a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1806382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1806382%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DTha%25C3%25A7i%26aufirst%3DD.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGirgis%26aufirst%3DI.%2BG.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26atitle%3DPhase%25202%2520Trial%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520Inhibition%2520in%2520Psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1313%26epage%3D1321%26doi%3D10.1056%2FNEJMoa1806382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">The Janus Kinase Family of Protein Tyrosine Kinases and their Role in Signaling</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1007/s000180050392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1007%2Fs000180050392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10526570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK1MXmtF2msLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=1523-1534&author=T.+C.+Yehauthor=S.+Pellegrini&title=The+Janus+Kinase+Family+of+Protein+Tyrosine+Kinases+and+their+Role+in+Signaling&doi=10.1007%2Fs000180050392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase family of protein tyrosine kinases and their role in signaling</span></div><div class="casAuthors">Yeh, T. C.; Pellegrini, S.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1523-1534</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review is given with 143 refs. on the Jaks with particular emphasis on structure-function studies aimed at revealing how this family of tyrosine kinases is regulated.  In the early 1990s, the search for protein kinases led to the discovery of a novel family of non-receptor Tyr kinases, the Janus kinases or JAKs.  These proteins were unusual because they contained 2 kinase homol. domains and no other known signaling modules.  It soon became clear that these were not 'just another' type of kinase.  Their ability to complement mutant cells insensitive to interferons and to be activated by a variety of cytokines demonstrated their central signaling function.  Now, as the authors approach the end of the decade, it is evident from biochem. studies to knockout mice that JAKs play non-redundant functions in development, differentiation, and host defense mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuWb3drPf_OrVg90H21EOLACvtfcHk0ljT3lZLDP0Rhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtF2msLo%253D&md5=f6887b6510043e3814c3fb1b3581c69f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs000180050392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000180050392%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DThe%2520Janus%2520Kinase%2520Family%2520of%2520Protein%2520Tyrosine%2520Kinases%2520and%2520their%2520Role%2520in%2520Signaling%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D1999%26volume%3D55%26spage%3D1523%26epage%3D1534%26doi%3D10.1007%2Fs000180050392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">27261</span>– <span class="NLM_lpage">27270</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.672048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1074%2Fjbc.M115.672048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26359499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=27261-27270&author=X.+Minauthor=D.+Ungureanuauthor=S.+Maxwellauthor=H.+Hammar%C3%A9nauthor=S.+Thibaultauthor=E.-K.+Hillertauthor=M.+Ayresauthor=B.+Greenfieldauthor=J.+Eksterowiczauthor=C.+Gabelauthor=N.+Walkerauthor=O.+Silvennoinenauthor=Z.+Wang&title=Structural+and+Functional+Characterization+of+the+JH2+Pseudokinase+Domain+of+JAK+Family+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1074%2Fjbc.M115.672048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Min, Xiaoshan; Ungureanu, Daniela; Maxwell, Sarah; Hammaren, Henrik; Thibault, Steve; Hillert, Ellin-Kristina; Ayres, Merrill; Greenfield, Brad; Eksterowicz, John; Gabel, Chris; Walker, Nigel; Silvennoinen, Olli; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27261-27270</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation.  JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2).  The majority of disease-assocd. mutations in JAKs map to JH2, demonstrating its central regulatory function.  JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity.  Whether the other JAK JH2s share ATP binding and enzymic activity has been unclear.  Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5'-O-(thiotriphosphate) (ATP-γS) and characterize its nucleotide binding by biochem. and biophys. methods.  TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes.  Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling.  The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing mol. interactions around helix αAL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s.  The structural and biochem. data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2.  Finally, the co-crystal structure of TYK2 JH2 complexed with a small mol. inhibitor demonstrates that JH2 is accessible to ATP-competitive compds., which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ZJIkM0pXXbVg90H21EOLACvtfcHk0ljT3lZLDP0Rhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO&md5=2933fa07a5bdbea19f3d434591613070</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.672048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.672048%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DX.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DMaxwell%26aufirst%3DS.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DHillert%26aufirst%3DE.-K.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DGreenfield%26aufirst%3DB.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGabel%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructural%2520and%2520Functional%2520Characterization%2520of%2520the%2520JH2%2520Pseudokinase%2520Domain%2520of%2520JAK%2520Family%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D27261%26epage%3D27270%26doi%3D10.1074%2Fjbc.M115.672048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition</span>. <i>Proc. Nat. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">8025</span>– <span class="NLM_lpage">8030</span>, <span class="refDoi"> DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=24843152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+Pseudokinase-Kinase+Domains+from+Protein+Kinase+TYK2+Reveals+a+Mechanism+for+Janus+Kinase+%28JAK%29+Autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition</span></div><div class="casAuthors">Lupardus Patrick J; Ultsch Mark; Wallweber Heidi; Eigenbrot Charles; Bir Kohli Pawan; Johnson Adam R</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8025-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinases (JAKs) are receptor-associated multidomain tyrosine kinases that act downstream of many cytokines and interferons.  JAK kinase activity is regulated by the adjacent pseudokinase domain via an unknown mechanism.  Here, we report the 2.8-ÅA structure of the two-domain pseudokinase-kinase module from the JAK family member TYK2 in its autoinhibited form.  We find that the pseudokinase and kinase interact near the kinase active site and that most reported mutations in cancer-associated JAK alleles cluster in or near this interface.  Mutation of residues near the TYK2 interface that are analogous to those in cancer-associated JAK alleles, including the V617F and "exon 12" JAK2 mutations, results in increased kinase activity in vitro.  These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsxgEXiV6j3TQLBVDQn4bCfW6udTcc2eZA-VQoqVedEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D&md5=47f1d528f736376c9e02add92839ac67</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Pseudokinase-Kinase%2520Domains%2520from%2520Protein%2520Kinase%2520TYK2%2520Reveals%2520a%2520Mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520Autoinhibition%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisouard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoda, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span> <span> </span><span class="NLM_article-title">ATP Binding to the Pseudokinase Domain of JAK2 is Critical for Pathogenic Activation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">4642</span>– <span class="NLM_lpage">4647</span>, <span class="refDoi"> DOI: 10.1073/pnas.1423201112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1073%2Fpnas.1423201112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=25825724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=4642-4647&author=H.+M.+Hammar%C3%A9nauthor=D.+Ungureanuauthor=J.+Grisouardauthor=R.+C.+Skodaauthor=S.+R.+Hubbardauthor=O.+Silvennoinen&title=ATP+Binding+to+the+Pseudokinase+Domain+of+JAK2+is+Critical+for+Pathogenic+Activation&doi=10.1073%2Fpnas.1423201112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation</span></div><div class="casAuthors">Hammaren, Henrik M.; Ungureanu, Daniela; Grisouard, Jean; Skoda, Radek C.; Hubbard, Stevan R.; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4642-4647</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Pseudokinases lack conserved motifs typically required for kinase activity.  Nearly half of pseudokinases bind ATP, but only few retain phosphotransfer activity, leaving the functional role of nucleotide binding in most cases unknown.  Janus kinases (JAKs) are nonreceptor tyrosine kinases with a tandem pseudokinase-kinase domain configuration, where the pseudokinase domain (JAK homol. 2, JH2) has important regulatory functions and harbors mutations underlying hematol. and immunol. diseases.  JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance of this is unclear.  We characterize the role of nucleotide binding in normal and pathogenic JAK signaling using comprehensive structure-based mutagenesis.  Disruption of JH2 ATP binding in wild-type JAK2 has only minor effects, and in the presence of type I cytokine receptors, the mutations do not affect JAK2 activation.  However, JH2 mutants devoid of ATP binding ameliorate the hyperactivation of JAK2 V617F.  Disrupting ATP binding in JH2 also inhibits the hyperactivity of other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in a JAK2 V617F myeloproliferative neoplasm mouse model.  Mol. dynamic simulations and thermal-shift anal. indicate that ATP binding stabilizes JH2, with a pronounced effect on the C helix region, which plays a crit. role in pathogenic activation of JAK2.  Taken together, our results suggest that ATP binding to JH2 serves a structural role in JAKs, which is required for aberrant activity of pathogenic JAK mutants.  The inhibitory effect of abrogating JH2 ATP binding in pathogenic JAK mutants may warrant novel therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowpDHSf5yGQ7Vg90H21EOLACvtfcHk0lgiPiiD3UyCsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOntL8%253D&md5=7cb7b90a1978ef02628f9ce9e85622ad</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1423201112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1423201112%26sid%3Dliteratum%253Aachs%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DGrisouard%26aufirst%3DJ.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DATP%2520Binding%2520to%2520the%2520Pseudokinase%2520Domain%2520of%2520JAK2%2520is%2520Critical%2520for%2520Pathogenic%2520Activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D4642%26epage%3D4647%26doi%3D10.1073%2Fpnas.1423201112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftheris, K.</span></span> <span> </span><span class="NLM_article-title">5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6261</span>– <span class="NLM_lpage">6270</span>, <span class="refDoi"> DOI: 10.1021/jm0503594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFSnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6261-6270&author=C.+Liuauthor=S.+T.+Wrobleskiauthor=J.+Linauthor=G.+Ahmedauthor=A.+Metzgerauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=D.+J.+Shusterauthor=K.+W.+McIntyreauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=H.+Zhangauthor=A.+M.+Doweykoauthor=D.+Dillerauthor=I.+Hendersonauthor=J.+C.+Barrishauthor=J.+H.+Doddauthor=G.+L.+Schievenauthor=K.+Leftheris&title=5-Cyanopyrimidine+Derivatives+as+a+Novel+Class+of+Potent%2C+Selective%2C+and+Orally+Active+Inhibitors+of+p38%CE%B1+MAP+Kinase&doi=10.1021%2Fjm0503594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase</span></div><div class="casAuthors">Liu, Chunjian; Wrobleski, Stephen T.; Lin, James; Ahmed, Gulzar; Metzger, Axel; Wityak, John; Gillooly, Kathleen M.; Shuster, David J.; McIntyre, Kim W.; Pitt, Sidney; Shen, Ding Ren; Zhang, Rosemary F.; Zhang, Hongjian; Doweyko, Arthur M.; Diller, David; Henderson, Ian; Barrish, Joel C.; Dodd, John H.; Schieven, Gary L.; Leftheris, Katerina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6261-6270</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of 5-cyanopyrimidine-based inhibitors of p38α MAP kinase has been investigated.  Analogs optimized through SAR iterations display low nanomolar enzymic and cellular activity.  The in vivo efficacy of this class of p38 inhibitors was demonstrated by 3a and 3b (>50% redn. in TNF levels when orally dosed at 5 mg/kg, 5 h prior to LPS administration in an acute murine model of inflammation).  For 3a and 3b, the previously identified N-methoxybenzamide moiety (1) was replaced with N-(isoxazol-3-yl)benzamide, thereby providing increased metabolic stability.  Cyanopyrimidine 3a demonstrated 100% oral bioavailability in mouse.  High p38 kinase selectivity vs. over 20 kinases was obsd. for analog 3b.  Direct hydrogen bonding of the cyano nitrogen of the 5-cyanopyrimidine core to the backbone NH of Met109 was confirmed by x-ray crystallog. anal. of 3a bound to p38α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjJgNQ1DS8nrVg90H21EOLACvtfcHk0lgiPiiD3UyCsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFSnu7Y%253D&md5=f293bdf26280ffe475eb22ba509488f1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm0503594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503594%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DAhmed%26aufirst%3DG.%26aulast%3DMetzger%26aufirst%3DA.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DDiller%26aufirst%3DD.%26aulast%3DHenderson%26aufirst%3DI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3D5-Cyanopyrimidine%2520Derivatives%2520as%2520a%2520Novel%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Active%2520Inhibitors%2520of%2520p38%25CE%25B1%2520MAP%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6261%26epage%3D6270%26doi%3D10.1021%2Fjm0503594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">15403</span>– <span class="NLM_lpage">15411</span>, <span class="refDoi"> DOI: 10.1021/ja906058w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja906058w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=15403-15411&author=J.+Michelauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Energetics+of+Displacing+Water+Molecules+from+Protein+Binding+Sites%3A+Consequences+for+Ligand+Optimization&doi=10.1021%2Fja906058w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization</span></div><div class="casAuthors">Michel, Julien; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15403-15411</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy in drug design is to consider enhancing the affinity of lead mols. with structural modifications that displace water mols. from a protein binding site.  Because success of the approach is uncertain, clarification of the assocd. energetics was sought in cases where similar structural modifications yield qual. different outcomes.  Specifically, free-energy perturbation calcns. were carried out in the context of Monte Carlo statistical mechanics simulations to investigate ligand series that feature displacement of ordered water mols. in the binding sites of scytalone dehydratase, p38-αMAP kinase, and EGFR kinase.  The change in affinity for a ligand modification is found to correlate with the ease of displacement of the ordered water mol.  However, as in the EGFR example, the binding affinity may diminish if the free-energy increase due to the removal of the bound water mol. is not more than compensated by the addnl. interactions of the water-displacing moiety.  For accurate computation of the effects of ligand modifications, a complete thermodn. anal. is shown to be needed.  It requires identification of the location of water mols. in the protein-ligand interface and evaluation of the free-energy changes assocd. with their removal and with the introduction of the ligand modification.  Direct modification of the ligand in free-energy calcns. is likely to trap the ordered mol. and provide misleading guidance for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoULCMKgzc8SLVg90H21EOLACvtfcHk0lgiPiiD3UyCsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI&md5=598676ea350be074bc2adea75eae9948</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fja906058w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja906058w%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DJ.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DEnergetics%2520of%2520Displacing%2520Water%2520Molecules%2520from%2520Protein%2520Binding%2520Sites%253A%2520Consequences%2520for%2520Ligand%2520Optimization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D15403%26epage%3D15411%26doi%3D10.1021%2Fja906058w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl Effects in Protein–Ligand Binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4500</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-4500&author=C.+S.+Leungauthor=S.+S.+F.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+Effects+in+Protein%E2%80%93Ligand+Binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0ljwSCctOK8ylQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520Effects%2520in%2520Protein%25E2%2580%2593Ligand%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D4500%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schönherr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span> <span> </span><span class="NLM_article-title">Profound Methyl Effects in Drug Discovery and a Call for New C–H Methylation Reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12256</span>– <span class="NLM_lpage">12267</span>, <span class="refDoi"> DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Sch%C3%B6nherrauthor=T.+Cernak&title=Profound+Methyl+Effects+in+Drug+Discovery+and+a+Call+for+New+C%E2%80%93H+Methylation+Reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span></div><div class="casAuthors">Schonherr Heike; Cernak Tim</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">12256-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The methyl group is one of the most commonly occurring carbon fragments in small-molecule drugs.  This simplest alkyl fragment appears in more than 67 % of the top-selling drugs of 2011 and can modulate both the biological and physical properties of a molecule.  This Review focuses on so-called magic methyl effects on binding potency, where the seemingly mundane change of C H to C Me improves the IC50  value of a drug candidate more than 100-fold.  This discussion is followed by a survey of recent advances in synthetic chemistry that allow the direct methylation of C(sp(2) ) H and C(sp(3) ) H bonds.  It is our hope that the relevance of the meager methyl group to drug discovery as presented herein will inspire reports on new C H methylation reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyoLZDDgvsMh0LsK7uFuY7fW6udTcc2eY8sD_5TvoFmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D&md5=ef08f80e55b2c530b49e4306da024902</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520Methyl%2520Effects%2520in%2520Drug%2520Discovery%2520and%2520a%2520Call%2520for%2520New%2520C%25E2%2580%2593H%2520Methylation%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span> <i>Small Molecule Drug Discovery Suite 2016-3, WaterMap</i>, <span class="NLM_edition">version 2.8</span>; <span class="NLM_publisher-name">Schrodinger, LLC</span>; <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Small+Molecule+Drug+Discovery+Suite+2016-3%2C+WaterMap%2C+version+2.8%3B+Schrodinger%2C+LLC%3B+New+York%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSmall%2520Molecule%2520Drug%2520Discovery%2520Suite%25202016-3%252C%2520WaterMap%26pub%3DSchrodinger%252C%2520LLC%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilenko, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastham-Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span> <span> </span><span class="NLM_article-title">Interleukin-22, a T(H)17 Cytokine, Mediates IL-23-Induced Dermal Inflammation and Acanthosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>445</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1038/nature05505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1038%2Fnature05505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=17187052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=648-651&author=Y.+Zhengauthor=D.+M.+Danilenkoauthor=P.+Valdezauthor=I.+Kasmanauthor=J.+Eastham-Andersonauthor=J.+Wuauthor=W.+Ouyang&title=Interleukin-22%2C+a+T%28H%2917+Cytokine%2C+Mediates+IL-23-Induced+Dermal+Inflammation+and+Acanthosis&doi=10.1038%2Fnature05505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis</span></div><div class="casAuthors">Zheng, Yan; Danilenko, Dimitry M.; Valdez, Patricia; Kasman, Ian; Eastham-Anderson, Jeffrey; Wu, Jianfeng; Ouyang, Wenjun</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7128</span>),
    <span class="NLM_cas:pages">648-651</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Psoriasis is a chronic inflammatory skin disease characterized by hyperplasia of the epidermis (acanthosis), infiltration of leukocytes into both the dermis and epidermis, and dilation and growth of blood vessels.  The underlying cause of the epidermal acanthosis in psoriasis is still largely unknown.  Recently, interleukin (IL)-23, a cytokine involved in the development of IL-17-producing T helper cells (TH17 cells), was found to have a potential function in the pathogenesis of psoriasis.  Here the authors show that IL-22 is preferentially produced by TH17 cells and mediates the acanthosis induced by IL-23.  The authors found that IL-23 or IL-6 can directly induce the prodn. of IL-22 from both murine and human naive T cells.  However, the prodn. of IL-22 and IL-17 from TH17 cells is differentially regulated.  Transforming growth factor-β, although crucial for IL-17 prodn., actually inhibits IL-22 prodn.  Furthermore, IL-22 mediates IL-23-induced acanthosis and dermal inflammation through the activation of Stat3 (signal transduction and activators of transcription 3) in vivo.  The authors' results suggest that TH17 cells, through the prodn. of both IL-22 and IL-17, might have essential functions in host defense and in the pathogenesis of autoimmune diseases such as psoriasis.  IL-22, as an effector cytokine produced by T cells, mediates the crosstalk between the immune system and epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUsvRYRPqQbVg90H21EOLACvtfcHk0ljwSCctOK8ylQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrtLk%253D&md5=492a413528aa035cbdc6a7ad683610c5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnature05505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05505%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDanilenko%26aufirst%3DD.%2BM.%26aulast%3DValdez%26aufirst%3DP.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DEastham-Anderson%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DW.%26atitle%3DInterleukin-22%252C%2520a%2520T%2528H%252917%2520Cytokine%252C%2520Mediates%2520IL-23-Induced%2520Dermal%2520Inflammation%2520and%2520Acanthosis%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D648%26epage%3D651%26doi%3D10.1038%2Fnature05505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, R.</span>; <span class="NLM_string-name">Sheriff, S.</span>; <span class="NLM_string-name">Wei, A.</span>; <span class="NLM_string-name">Ramamurthy, V.</span>; <span class="NLM_string-name">Bush, A.</span>; <span class="NLM_string-name">Russo, K. A.</span>; <span class="NLM_string-name">Engle, L.</span></span> <span> </span><span class="NLM_article-title">Fibronectin Based Scaffold Domain Proteins that Bind IL-23</span>. U.S. Patent <span class="NLM_patent">9,260,496 B2</span>, Dec 20, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Dasgupta&author=S.+Sheriff&author=A.+Wei&author=V.+Ramamurthy&author=A.+Bush&author=K.+A.+Russo&author=L.+Engle&title=Fibronectin+Based+Scaffold+Domain+Proteins+that+Bind+IL-23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDasgupta%26aufirst%3DR.%26atitle%3DFibronectin%2520Based%2520Scaffold%2520Domain%2520Proteins%2520that%2520Bind%2520IL-23%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guram, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Aromatic Aminations with in Situ Generated Aminostannanes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">7901</span>– <span class="NLM_lpage">7902</span>, <span class="refDoi"> DOI: 10.1021/ja00096a059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00096a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK2cXmvVSgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=7901-7902&author=A.+S.+Guramauthor=S.+L.+Buchwald&title=Palladium-Catalyzed+Aromatic+Aminations+with+in+Situ+Generated+Aminostannanes&doi=10.1021%2Fja00096a059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Aromatic Aminations with in situ Generated Aminostannanes</span></div><div class="casAuthors">Guram, Anil S.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7901-2</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Aminostannes, generated in situ by the transamination reactions of N,N-diethylaminotributyltin with primary and secondary amines, undergo Pd-catalyzed reactions with aryl bromides to afford aryl amines in good yields.  Thus, e.g., in situ generation of Bu3SnNMeCH2Ph via transamination of Bu3SnNEt2 with HNMeCH2Ph, followed by reaction with 4-EtO2CC6H4Br in presence of PdCl2[P(o-tolyl)3]2 afforded 88% 4-EtO2CC6H4NMeCH2Ph.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbgxIJwAw2rVg90H21EOLACvtfcHk0ljXEwTSeQooCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvVSgs74%253D&md5=01e7d965aef985f90b78c7c7bda73c9d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fja00096a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00096a059%26sid%3Dliteratum%253Aachs%26aulast%3DGuram%26aufirst%3DA.%2BS.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-Catalyzed%2520Aromatic%2520Aminations%2520with%2520in%2520Situ%2520Generated%2520Aminostannanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D7901%26epage%3D7902%26doi%3D10.1021%2Fja00096a059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J. F.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Formation of Carbon-Nitrogen Bonds. Reaction Intermediates and Catalyst Improvements in the Hetero Cross-Coupling of Aryl Halides and Tin Amides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">5969</span>– <span class="NLM_lpage">5970</span>, <span class="refDoi"> DOI: 10.1021/ja00092a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00092a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK2cXltlCnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=5969-5970&author=F.+Paulauthor=J.+Pattauthor=J.+F.+Hartwig&title=Palladium-Catalyzed+Formation+of+Carbon-Nitrogen+Bonds.+Reaction+Intermediates+and+Catalyst+Improvements+in+the+Hetero+Cross-Coupling+of+Aryl+Halides+and+Tin+Amides&doi=10.1021%2Fja00092a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed formation of carbon-nitrogen bonds. Reaction intermediates and catalyst improvements in the hetero cross-coupling of aryl halides and tin amides</span></div><div class="casAuthors">Paul, Frederic; Patt, Joe; Hartwig, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5969-70</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The hetero cross-coupling of aryl bromides and Sn amides by Pd catalysts was studied to understand transition metal mediated C-N bond forming processes and to find more efficient and more general catalysts for this coupling process.  The Pd(II) compd. [(o-MeC6H4)3P]2PdX2 (X = Cl 1-Cl, Br 1-Br) is known to catalyze the hetero cross-coupling of Bu3SnNMe2 and phenyl- or p-alkylphenyl bromides at 90-110° in arene solvents to form N,N-dimethylanilines in 75-85% yields.  Three complexes were isolated and are kinetically competent intermediates in this catalytic process.  The mixed amine/phosphine complexes [(o-tolyl)3P](NHR2)PdCl2 (2) were formed by reaction of 1 with Sn dialkyl amides.  These amine complexes were sol. in toluene, catalyzed the coupling process in yields comparable to 1, and were characterized crystallog.  The Pd(0) species [(o-tolyl)3P]2Pd (3) was prepd. in pure form by addn. of (o-tolyl)3P to Pd(dba)2 and was also characterized crystallog.  This complex catalyzed the coupling chem. with rates that were faster than those involving 1 or 2.  The isolation of this pure Pd(0) species allowed a mechanistic anal. of the coupling process.  3 Reacted with aryl halides to yield the dimeric {[(o-tolyl)3P]Pd(Br)(Ar)}2 (4) which was also characterized spectroscopically, crystallog., and by soln. mol. wt.  The dimeric form appears to be retained in soln.  4 Reacted with Sn and Li amides to produce the arylamine products in yields comparable to those of the catalytic process.  This coupling step involved direct reaction of 4 with the main group amides, strongly suggesting that transmetalation and reductive elimination are the steps that provide coupled product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5cbOkyGCp7Vg90H21EOLACvtfcHk0ljXEwTSeQooCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltlCnsrY%253D&md5=e322f59a309f7f377857fa5b61626aaf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fja00092a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00092a058%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DF.%26aulast%3DPatt%26aufirst%3DJ.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DPalladium-Catalyzed%2520Formation%2520of%2520Carbon-Nitrogen%2520Bonds.%2520Reaction%2520Intermediates%2520and%2520Catalyst%2520Improvements%2520in%2520the%2520Hetero%2520Cross-Coupling%2520of%2520Aryl%2520Halides%2520and%2520Tin%2520Amides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D5969%26epage%3D5970%26doi%3D10.1021%2Fja00092a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halford, B.</span></span> <span> </span><span class="NLM_article-title">Deuterium Switcheroo Breathes Life into Old Drugs</span>. <i>Chem. Eng. News</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=32-36&author=B.+Halford&title=Deuterium+Switcheroo+Breathes+Life+into+Old+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalford%26aufirst%3DB.%26atitle%3DDeuterium%2520Switcheroo%2520Breathes%2520Life%2520into%2520Old%2520Drugs%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2016%26volume%3D94%26spage%3D32%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T.
T.</span></span> <span> </span><span class="NLM_article-title">The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8712</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8712-8756&author=T.%0AT.+Talele&title=The+%E2%80%9CCyclopropyl+Fragment%E2%80%9D+is+a+Versatile+Player+that+Frequently+Appears+in+Preclinical%2FClinical+Drug+Molecules&doi=10.1021%2Facs.jmedchem.6b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8712-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclin. to clin. stage.  Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes.  The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs contg. it.  Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflux ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIJAG1XVRG7Vg90H21EOLACvtfcHk0ljXEwTSeQooCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D&md5=b5586458ec4ab5e2d7586f5739663d1f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DThe%2520%25E2%2580%259CCyclopropyl%2520Fragment%25E2%2580%259D%2520is%2520a%2520Versatile%2520Player%2520that%2520Frequently%2520Appears%2520in%2520Preclinical%252FClinical%2520Drug%2520Molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8712%26epage%3D8756%26doi%3D10.1021%2Facs.jmedchem.6b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The Impact of Aromatic Ring Count on Compound Developability: Further Insights by Examining Carbo- and Hetero-Aromatic and -Aliphatic Ring Types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+Impact+of+Aromatic+Ring+Count+on+Compound+Developability%3A+Further+Insights+by+Examining+Carbo-+and+Hetero-Aromatic+and+-Aliphatic+Ring+Types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0ljgVl9BIHeN6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520Impact%2520of%2520Aromatic%2520Ring%2520Count%2520on%2520Compound%2520Developability%253A%2520Further%2520Insights%2520by%2520Examining%2520Carbo-%2520and%2520Hetero-Aromatic%2520and%2520-Aliphatic%2520Ring%2520Types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spyrakis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayden, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzarelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellogg, G. E.</span></span> <span> </span><span class="NLM_article-title">The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6781</span>– <span class="NLM_lpage">6827</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6781-6827&author=F.+Spyrakisauthor=M.+H.+Ahmedauthor=A.+S.+Baydenauthor=P.+Cozziniauthor=A.+Mozzarelliauthor=G.+E.+Kellogg&title=The+Roles+of+Water+in+the+Protein+Matrix%3A+A+Largely+Untapped+Resource+for+Drug+Discovery&doi=10.1021%2Facs.jmedchem.7b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery</span></div><div class="casAuthors">Spyrakis, Francesca; Ahmed, Mostafa H.; Bayden, Alexander S.; Cozzini, Pietro; Mozzarelli, Andrea; Kellogg, Glen E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6781-6827</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The value of thoroughly understanding the thermodn. specific to a drug discovery/design study is well known.  Over the past decade, the crucial roles of water mols. in protein structure, function, and dynamics have also become increasingly appreciated.  This Perspective explores water in the biol. environment by adopting its point of view in such phenomena.  The prevailing thermodn. models of the past, where water was seen largely in terms of an entropic gain after its displacement by a ligand, are now known to be much too simplistic.  We adopt a set of terminol. that describes water mols. as being "hot" and "cold", which we have defined as being easy and difficult to displace, resp.  The basis of these designations, which involve both enthalpic and entropic water contributions, are explored in several classes of biomols. and structural motifs.  The hallmarks for characterizing water mols. are examd., and computational tools for evaluating water-centric thermodn. are reviewed.  This Perspective's summary features guidelines for exploiting water mols. in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD8mT4Z7V7P7Vg90H21EOLACvtfcHk0ljgVl9BIHeN6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVyru7s%253D&md5=1e6f76629bf2eeabf8b491f8814cfc69</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00057%26sid%3Dliteratum%253Aachs%26aulast%3DSpyrakis%26aufirst%3DF.%26aulast%3DAhmed%26aufirst%3DM.%2BH.%26aulast%3DBayden%26aufirst%3DA.%2BS.%26aulast%3DCozzini%26aufirst%3DP.%26aulast%3DMozzarelli%26aufirst%3DA.%26aulast%3DKellogg%26aufirst%3DG.%2BE.%26atitle%3DThe%2520Roles%2520of%2520Water%2520in%2520the%2520Protein%2520Matrix%253A%2520A%2520Largely%2520Untapped%2520Resource%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6781%26epage%3D6827%26doi%3D10.1021%2Facs.jmedchem.7b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krimmer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein-Bound Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10530</span>– <span class="NLM_lpage">10548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10530-10548&author=S.+G.+Krimmerauthor=J.+Cramerauthor=M.+Betzauthor=V.+Fridhauthor=R.+Karlssonauthor=A.+Heineauthor=G.+Klebe&title=Rational+Design+of+Thermodynamic+and+Kinetic+Binding+Profiles+by+Optimizing+Surface+Water+Networks+Coating+Protein-Bound+Ligands&doi=10.1021%2Facs.jmedchem.6b00998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein-Bound Ligands</span></div><div class="casAuthors">Krimmer, Stefan G.; Cramer, Jonathan; Betz, Michael; Fridh, Veronica; Karlsson, Robert; Heine, Andreas; Klebe, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10530-10548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A previously studied congeneric series of thermolysin inhibitors addressing the solvent-accessible S2' pocket with different hydrophobic substituents showed modulations of the surface water layers coating the protein-bound inhibitors.  Increasing stabilization of water mols. resulted in enthalpically more favorable binding signature, overall enhancing affinity.  Based on this observation, the authors optimized the series by designing tailored P2' substituents to improve and further stabilize the surface water network.  MD simulations were applied to predict the putative water pattern around the bound ligands.  Subsequently, the inhibitors were synthesized and characterized by high-resoln. crystallog., microcalorimetry and surface plasmon resonance.  One of the designed inhibitors established the most pronounced water network of all inhibitors tested so far, composed of several fused water polygons, and showed 50-fold affinity enhancement with respect to the original methylated parent ligand.  Notably, the inhibitor forming the most perfect water network also showed significantly prolonged residence time compared to the other tested inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKAWUpfEr2WbVg90H21EOLACvtfcHk0ljgVl9BIHeN6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjsL%252FN&md5=37092339ddcbe5a1ec6a10572b1a3213</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00998%26sid%3Dliteratum%253Aachs%26aulast%3DKrimmer%26aufirst%3DS.%2BG.%26aulast%3DCramer%26aufirst%3DJ.%26aulast%3DBetz%26aufirst%3DM.%26aulast%3DFridh%26aufirst%3DV.%26aulast%3DKarlsson%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DRational%2520Design%2520of%2520Thermodynamic%2520and%2520Kinetic%2520Binding%2520Profiles%2520by%2520Optimizing%2520Surface%2520Water%2520Networks%2520Coating%2520Protein-Bound%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10530%26epage%3D10548%26doi%3D10.1021%2Facs.jmedchem.6b00998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Water, S.</span></span> <span> </span><span class="NLM_article-title">Water, Everywhere···It’s Time to Stop and Think</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2Fj.drudis.2016.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27210724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XoslWltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1139-1146&author=M.+Bodnarchukauthor=S.+Water&title=Water%2C+Everywhere%C2%B7%C2%B7%C2%B7It%E2%80%99s+Time+to+Stop+and+Think&doi=10.1016%2Fj.drudis.2016.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Water, water, everywhere... It's time to stop and think</span></div><div class="casAuthors">Bodnarchuk, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite the numerous methods available for predicting the location and affinity of water mols., there is still a degree of scepticism and reluctance towards using such information within a drug discovery program.  Here, I review some of the most common and popular methods to assess whether these apparent concerns are justified.  I suggest that the field is approaching maturity and that some methods are capable of giving quant. predictions, which are confirmed exptl.  This suggests that water-placement methods should be used more widely to help direct chem. efforts, although more successful examples are required to help validate the techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxfKWV5PXTkrVg90H21EOLACvtfcHk0ljGSGkaXHLgvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XoslWltb4%253D&md5=dc2a72fa764bb19cd0c0ca2921fc974a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DBodnarchuk%26aufirst%3DM.%26aulast%3DWater%26aufirst%3DS.%26atitle%3DWater%252C%2520Everywhere%25C2%25B7%25C2%25B7%25C2%25B7It%25E2%2580%2599s%2520Time%2520to%2520Stop%2520and%2520Think%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1139%26epage%3D1146%26doi%3D10.1016%2Fj.drudis.2016.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightstone, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. E.</span></span> <span> </span><span class="NLM_article-title">Approaches to Efficiently Estimate Solvation and Explicit Water Energetics in Ligand Binding: The Use of WaterMap</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.749853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1517%2F17460441.2013.749853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=23286874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtF2htb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=277-287&author=Y.+Yangauthor=F.+C.+Lightstoneauthor=S.+E.+Wong&title=Approaches+to+Efficiently+Estimate+Solvation+and+Explicit+Water+Energetics+in+Ligand+Binding%3A+The+Use+of+WaterMap&doi=10.1517%2F17460441.2013.749853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: the use of WaterMap</span></div><div class="casAuthors">Yang, Yue; Lightstone, Felice C.; Wong, Sergio E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Water displacement plays crit. role in several phases of drug discovery.  Proper treatment of displacing water could improve enrichment in virtual screening and could lead to more successes in lead optimization.  WaterMap has recently emerged as a promising approach in this regard; recent implementations of this protocol successfully explained various binding activity that were poorly understood previously, including the well-known super affinity assocd. with biotin binding to streptavidin.Areas covered: The review briefly discusses implicit and explicit solvent models and focuses on an application of inhomogeneous solvation theory - WaterMap.  Furthermore, the review discusses various successful cases where the use of WaterMap explained selectivity in protein-ligand binding and provides discussion of the fundamentals and recently successful implementations of WaterMap.  The authors also discuss the limitations of this protocol and list a few approaches that could extend its implementation to more cases.Expert opinion: WaterMap is a powerful tool for calcg. the cost of desolvation for structural waters.  In some cases, it proved useful in predicting relative binding free energy differences for congeneric ligands.  The practical utility of WaterMap hinges in adequate application of the results in the context of all the thermodn. contributions to binding.  Potential improvements as well as integration into methods such like MM-GB/SA could extend its success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTt0Lv5MkEN7Vg90H21EOLACvtfcHk0ljGSGkaXHLgvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtF2htb8%253D&md5=b63980bbfbea61c076be0d10704e2e91</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.749853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.749853%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLightstone%26aufirst%3DF.%2BC.%26aulast%3DWong%26aufirst%3DS.%2BE.%26atitle%3DApproaches%2520to%2520Efficiently%2520Estimate%2520Solvation%2520and%2520Explicit%2520Water%2520Energetics%2520in%2520Ligand%2520Binding%253A%2520The%2520Use%2520of%2520WaterMap%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D277%26epage%3D287%26doi%3D10.1517%2F17460441.2013.749853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightstone, F. C.</span></span> <span> </span><span class="NLM_article-title">Accounting for Water Molecules in Drug Design</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1517/17460441.2011.534452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1517%2F17460441.2011.534452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=22646827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=65-74&author=S.+E.+Wongauthor=F.+C.+Lightstone&title=Accounting+for+Water+Molecules+in+Drug+Design&doi=10.1517%2F17460441.2011.534452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Accounting for water molecules in drug design</span></div><div class="casAuthors">Wong, Sergio E.; Lightstone, Felice C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-74</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Water mols. often appear around ligands in protein crystal structures.  Reliable prediction of the effects of water on ligand binding remains a challenge.  Solvation effects are crucial for lead optimization where a 100-fold difference in binding affinity is significant but correspond to only ∼ 3 kcal/mol in binding free energy.  Well-known examples, such as nonpeptidic urea inhibitors of HIV protease, prove that careful examn. of water mols. and their energetics can contribute significantly to a successful drug design campaign.  Areas covered in this review: In this review, we examine methods to account for the effect of water in ligand binding at two stages of drug discovery: lead identification via docking calcns. and lead optimization.  We provide a survey of the models and techniques available to account for water in drug design.  What the reader will gain: The reader will become aware of common practices and pitfalls in dealing with water mols. in structure-based drug design.  Take home message: Although solvation effects are not fully understood, some pragmatic recommendations at the end of the article provide guidance for modelers in this area as well as new practitioners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp69CF6zImq0rVg90H21EOLACvtfcHk0ljGSGkaXHLgvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvN&md5=9dddf1105c78b0e29b416016a4e328ab</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.534452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.534452%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BE.%26aulast%3DLightstone%26aufirst%3DF.%2BC.%26atitle%3DAccounting%2520for%2520Water%2520Molecules%2520in%2520Drug%2520Design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D65%26epage%3D74%26doi%3D10.1517%2F17460441.2011.534452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljlY4gg1fe4fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span> <span> </span><span class="NLM_article-title">One-Pot Synthesis of Hybrid Macrocyclic Pentamers with Variable Functionalizations around the Periphery</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2270</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1021/ol200538d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol200538d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlOls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=2270-2273&author=B.+Qinauthor=C.+Sunauthor=Y.+Liuauthor=J.+Shenauthor=R.+Yeauthor=J.+Zhuauthor=X.-F.+Duanauthor=H.+Zeng&title=One-Pot+Synthesis+of+Hybrid+Macrocyclic+Pentamers+with+Variable+Functionalizations+around+the+Periphery&doi=10.1021%2Fol200538d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">One-Pot Synthesis of Hybrid Macrocyclic Pentamers with Variable Functionalizations around the Periphery</span></div><div class="casAuthors">Qin, Bo; Sun, Chang; Liu, Ying; Shen, Jie; Ye, Ruijuan; Zhu, Jia; Duan, Xin-Fang; Zeng, Huaqiang</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2270-2273</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rather than four- or six-residue macrocycles, one-pot macrocyclization of m-anthranilic acid derivs. allows for the highly selective formation of five-residue macrocycles rigidified by intramol. hydrogen bonds.  Variable functionalizations around the pentameric periphery were achieved by reacting monomers with higher oligomers bearing different exterior side chains.  The formation of these hybrid pentamers suggests a chain-growth mechanism for the one-pot macrocyclization where the successive addn. of monomers onto higher oligomers is faster than those between two monomers or two higher oligomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz4Sn6GF_id7Vg90H21EOLACvtfcHk0ljlY4gg1fe4fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlOls74%253D&md5=e3479232a4b2bceec7909f0132d92d56</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fol200538d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol200538d%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DDuan%26aufirst%3DX.-F.%26aulast%3DZeng%26aufirst%3DH.%26atitle%3DOne-Pot%2520Synthesis%2520of%2520Hybrid%2520Macrocyclic%2520Pentamers%2520with%2520Variable%2520Functionalizations%2520around%2520the%2520Periphery%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D2270%26epage%3D2273%26doi%3D10.1021%2Fol200538d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span>; <span class="NLM_string-name">Weinstein, D. S.</span>; <span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Tokarski, J. S.</span>; <span class="NLM_string-name">Spergel, S. H.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Amide-Substituted Heterocyclic Compounds Useful as Modulators of IL-12, IL-23 and/or IFNα Responses</span>. U.S. Patent <span class="NLM_patent">9,505,748 B2</span>, Nov 7, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+M.+Moslin&author=D.+S.+Weinstein&author=S.+T.+Wrobleski&author=J.+S.+Tokarski&author=S.+H.+Spergel&author=S.+Lin&author=Y.+Zhang&title=Amide-Substituted+Heterocyclic+Compounds+Useful+as+Modulators+of+IL-12%2C+IL-23+and%2For+IFN%CE%B1+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAmide-Substituted%2520Heterocyclic%2520Compounds%2520Useful%2520as%2520Modulators%2520of%2520IL-12%252C%2520IL-23%2520and%252For%2520IFN%25CE%25B1%2520Responses%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 50 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Priyadeep Bhutani, Gaurav Joshi, Nivethitha Raja, Namrata Bachhav, Prabhakar K. Rajanna, Hemant Bhutani, Atish T. Paul, <span class="NLM_string-name hlFld-ContribAuthor">Raj Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">U.S. FDA Approved Drugs from 2015–June 2020: A Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2339-2381. <a href="https://doi.org/10.1021/acs.jmedchem.0c01786" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01786%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DU.S.%252BFDA%252BApproved%252BDrugs%252Bfrom%252B2015%2525E2%252580%252593June%252B2020%25253A%252BA%252BPerspective%26aulast%3DBhutani%26aufirst%3DPriyadeep%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12102020%26date%3D22022021%26volume%3D64%26issue%3D5%26spage%3D2339%26epage%3D2381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chufeng Zhang, Wenyan Qi, Yong Li, Minghai Tang, Tao Yang, Kongjun Liu, Yong Chen, Dexin Deng, Mingli Xiang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 1966-1988. <a href="https://doi.org/10.1021/acs.jmedchem.0c01468" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01468</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01468%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-%2525284-%2525282-%252528%2525281H-Indol-5-yl%252529amino%252529-5-fluoropyrimidin-4-yl%252529-1H-pyrazol-1-yl%252529propanenitrile%252BDerivatives%252Bas%252BSelective%252BTYK2%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BInflammatory%252BBowel%252BDisease%26aulast%3DZhang%26aufirst%3DChufeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28082020%26date%3D16022021%26volume%3D64%26issue%3D4%26spage%3D1966%26epage%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chunjian Liu, James Lin, Charles Langevine, Daniel Smith, Jianqing Li, John S. Tokarski, Javed Khan, Max Ruzanov, Joann Strnad, Adriana Zupa-Fernandez, Lihong Cheng, Kathleen M. Gillooly, David Shuster, Yifan Zhang, Anil Thankappan, Kim W. McIntyre, Charu Chaudhry, Paul A. Elzinga, Manoj Chiney, Anjaneya Chimalakonda, Louis J. Lombardo, John E. Macor, Percy H. Carter, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">David S. Weinstein</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 677-694. <a href="https://doi.org/10.1021/acs.jmedchem.0c01698" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01698%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBMS-986202%25253A%252BA%252BClinical%252BTyk2%252BInhibitor%252Bthat%252BBinds%252Bto%252BTyk2%252BJH2%26aulast%3DLiu%26aufirst%3DChunjian%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D28092020%26date%3D28122020%26volume%3D64%26issue%3D1%26spage%3D677%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Brian S. Gerstenberger, Catherine Ambler, Eric P. Arnold, Mary-Ellen Banker, Matthew F. Brown, James D. Clark, Alpay Dermenci, Martin E. Dowty, Andrew Fensome, Susan Fish, Matthew M. Hayward, Martin Hegen, Brett D. Hollingshead, John D. Knafels, David W. Lin, Tsung H. Lin, Dafydd R. Owen, Eddine Saiah, Raman Sharma, Felix F. Vajdos, Li Xing, Xiaojing Yang, Xin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Stephen W. Wright</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13561-13577. <a href="https://doi.org/10.1021/acs.jmedchem.0c00948" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00948</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00948%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252BInhibitor%252B%252528PF-06826647%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DGerstenberger%26aufirst%3DBrian%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03062020%26date%3D25082020%26date%3D05082020%26volume%3D63%26issue%3D22%26spage%3D13561%26epage%3D13577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bingsong Han, Francesco G. Salituro, <span class="NLM_string-name hlFld-ContribAuthor">Maria-Jesus Blanco</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1810-1819. <a href="https://doi.org/10.1021/acsmedchemlett.9b00655" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00655</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00655%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DImpact%252Bof%252BAllosteric%252BModulation%252Bin%252BDrug%252BDiscovery%25253A%252BInnovation%252Bin%252BEmerging%252BChemical%252BModalities%26aulast%3DHan%26aufirst%3DBingsong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D26122019%26date%3D10032020%26date%3D20032020%26date%3D10032020%26volume%3D11%26issue%3D10%26spage%3D1810%26epage%3D1819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuqin Zhu, Yuxiang Ma, Weidong Zu, Jianing Song, Hua Wang, You Zhong, Hongmei Li, Yanmin Zhang, Qianqian Gao, Bo Kong, Junyu Xu, Fei Jiang, Xinren Wang, Shuwen Li, Chenhe Liu, Haichun Liu, Tao Lu, <span class="NLM_string-name hlFld-ContribAuthor">Yadong Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6748-6773. <a href="https://doi.org/10.1021/acs.jmedchem.0c00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BN-Phenyl-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252BDerivatives%252Bas%252BNovel%25252C%252BPotent%25252C%252Band%252BSelective%252BNF-%2525CE%2525BAB%252BInducing%252BKinase%252B%252528NIK%252529%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BPsoriasis%26aulast%3DZhu%26aufirst%3DYuqin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12012020%26date%3D16062020%26date%3D01062020%26volume%3D63%26issue%3D13%26spage%3D6748%26epage%3D6773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew A. Cerny, Amit S. Kalgutkar, R. Scott Obach, Raman Sharma, Douglas K. Spracklin, <span class="NLM_string-name hlFld-ContribAuthor">Gregory S. Walker</span>. </span><span class="cited-content_cbyCitation_article-title">Effective Application of Metabolite Profiling in Drug Design and Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (12)
                                     , 6387-6406. <a href="https://doi.org/10.1021/acs.jmedchem.9b01840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEffective%252BApplication%252Bof%252BMetabolite%252BProfiling%252Bin%252BDrug%252BDesign%252Band%252BDiscovery%26aulast%3DCerny%26aufirst%3DMatthew%2BA.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D06112019%26date%3D06032020%26date%3D25022020%26volume%3D63%26issue%3D12%26spage%3D6387%26epage%3D6406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jeremy A. Turkett, Anna E. Ringuette, Craig W. Lindsley, <span class="NLM_string-name hlFld-ContribAuthor">Aaron M. Bender</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Substituted 6,7-Dihydro-5H-pyrrolo[2,3-c]pyridazines/pyrazines via Catalyst-Free Tandem Hydroamination–Aromatic Substitution. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (9)
                                     , 6123-6130. <a href="https://doi.org/10.1021/acs.joc.9b03463" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03463%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BSubstituted%252B6%25252C7-Dihydro-5H-pyrrolo%25255B2%25252C3-c%25255Dpyridazines%25252Fpyrazines%252Bvia%252BCatalyst-Free%252BTandem%252BHydroamination%2525E2%252580%252593Aromatic%252BSubstitution%26aulast%3DTurkett%26aufirst%3DJeremy%2BA.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D23122019%26date%3D09042020%26date%3D31032020%26volume%3D85%26issue%3D9%26spage%3D6123%26epage%3D6130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu Chang, Shilin Xu, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (20)
                                     , 8951-8952. <a href="https://doi.org/10.1021/acs.jmedchem.9b01612" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01612</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01612%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTyrosine%252BKinase%252B2%252B%252528TYK2%252529%252BAllosteric%252BInhibitors%252BTo%252BTreat%252BAutoimmune%252BDiseases%26aulast%3DChang%26aufirst%3DYu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D28092019%26date%3D11102019%26volume%3D62%26issue%3D20%26spage%3D8951%26epage%3D8952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maciej  Gonciarz</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Pawlak-Buś</span>, <span class="hlFld-ContribAuthor ">Piotr  Leszczyński</span>, <span class="hlFld-ContribAuthor ">Witold  Owczarek</span>. </span><span class="cited-content_cbyCitation_article-title">TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. </span><span class="cited-content_cbyCitation_journal-name">Immunotherapy</span><span> <strong>2021,</strong> <em>53 </em><a href="https://doi.org/10.2217/imt-2021-0096" title="DOI URL">https://doi.org/10.2217/imt-2021-0096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/imt-2021-0096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fimt-2021-0096%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunotherapy%26atitle%3DTYK2%252Bas%252Ba%252Btherapeutic%252Btarget%252Bin%252Bthe%252Btreatment%252Bof%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%26aulast%3DGonciarz%26aufirst%3DMaciej%26date%3D2021%26date%3D2021%26volume%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominika  Hromadová</span>, <span class="hlFld-ContribAuthor ">Dirk  Elewaut</span>, <span class="hlFld-ContribAuthor ">Robert D.  Inman</span>, <span class="hlFld-ContribAuthor ">Birgit  Strobl</span>, <span class="hlFld-ContribAuthor ">Eric  Gracey</span>. </span><span class="cited-content_cbyCitation_article-title">From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Genetics</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fgene.2021.685280" title="DOI URL">https://doi.org/10.3389/fgene.2021.685280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fgene.2021.685280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffgene.2021.685280%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Genetics%26atitle%3DFrom%252BScience%252Bto%252BSuccess%25253F%252BTargeting%252BTyrosine%252BKinase%252B2%252Bin%252BSpondyloarthritis%252Band%252BRelated%252BChronic%252BInflammatory%252BDiseases%26aulast%3DHromadov%25C3%25A1%26aufirst%3DDominika%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>, <span class="hlFld-ContribAuthor ">Upendra A.  Argikar</span>, <span class="hlFld-ContribAuthor ">James P.  Driscoll</span>, <span class="hlFld-ContribAuthor ">Carley J. S.  Heck</span>, <span class="hlFld-ContribAuthor ">Lloyd  King</span>, <span class="hlFld-ContribAuthor ">Klarissa D.  Jackson</span>, <span class="hlFld-ContribAuthor ">Wenying  Jian</span>, <span class="hlFld-ContribAuthor ">Amit S.  Kalgutkar</span>, <span class="hlFld-ContribAuthor ">Grover P.  Miller</span>, <span class="hlFld-ContribAuthor ">Valerie  Kramlinger</span>, <span class="hlFld-ContribAuthor ">Ivonne M. C. M.  Rietjens</span>, <span class="hlFld-ContribAuthor ">Aaron M.  Teitelbaum</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Cong  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Novel advances in biotransformation and bioactivation research – 2020 year in review. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2021,</strong> <em>48 </em>, 1-50. <a href="https://doi.org/10.1080/03602532.2021.1916028" title="DOI URL">https://doi.org/10.1080/03602532.2021.1916028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2021.1916028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2021.1916028%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DNovel%252Badvances%252Bin%252Bbiotransformation%252Band%252Bbioactivation%252Bresearch%252B%2525E2%252580%252593%252B2020%252Byear%252Bin%252Breview%26aulast%3DKhojasteh%26aufirst%3DS.%2BCyrus%26date%3D2021%26date%3D2021%26volume%3D48%26spage%3D1%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvio  Danese</span>, <span class="hlFld-ContribAuthor ">Laurent  Peyrin-Biroulet</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise. </span><span class="cited-content_cbyCitation_journal-name">Inflammatory Bowel Diseases</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1093/ibd/izab135" title="DOI URL">https://doi.org/10.1093/ibd/izab135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ibd/izab135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fibd%2Fizab135%26sid%3Dliteratum%253Aachs%26jtitle%3DInflammatory%2520Bowel%2520Diseases%26atitle%3DSelective%252BTyrosine%252BKinase%252B2%252BInhibition%252Bfor%252BTreatment%252Bof%252BInflammatory%252BBowel%252BDisease%25253A%252BNew%252BHope%252Bon%252Bthe%252BRise%26aulast%3DDanese%26aufirst%3DSilvio%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Andrew  Tebben</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Robert  Borzilleri</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Jonathan  Lippy</span>, <span class="hlFld-ContribAuthor ">Litao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 1115-1125. <a href="https://doi.org/10.1016/j.drudis.2021.01.018" title="DOI URL">https://doi.org/10.1016/j.drudis.2021.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2021.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2021.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DAn%252Binnovative%252Bkinome%252Bplatform%252Bto%252Baccelerate%252Bsmall-molecule%252Binhibitor%252Bdiscovery%252Band%252Boptimization%252Bfrom%252Bhits%252Bto%252Bleads%26aulast%3DChaudhry%26aufirst%3DCharu%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D1115%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Yu  Tang</span>, <span class="hlFld-ContribAuthor ">Zhixuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Ping  Lin</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2021,</strong> <em>137 </em>, 111373. <a href="https://doi.org/10.1016/j.biopha.2021.111373" title="DOI URL">https://doi.org/10.1016/j.biopha.2021.111373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2021.111373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2021.111373%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DStudies%252Bon%252Bthe%252Banti-psoriasis%252Beffects%252Band%252Bits%252Bmechanism%252Bof%252Ba%252Bdual%252BJAK2%25252FFLT3%252Binhibitor%252Bflonoltinib%252Bmaleate%26aulast%3DZhu%26aufirst%3DJiali%26date%3D2021%26volume%3D137%26spage%3D111373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Borzilleri</span>, <span class="hlFld-ContribAuthor ">Amy C.  Hart</span>, <span class="hlFld-ContribAuthor ">Ryan  Moslin</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Stephen T.  Wrobleski</span>. </span><span class="cited-content_cbyCitation_article-title">JAK
              Family Inhibitors for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-86. <a href="https://doi.org/10.1002/0471266949.bmc279" title="DOI URL">https://doi.org/10.1002/0471266949.bmc279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc279%26sid%3Dliteratum%253Aachs%26atitle%3DJAK%252BFamily%252BInhibitors%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DBorzilleri%26aufirst%3DRobert%2BM.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D86%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D64" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John E.  Bell</span>, <span class="hlFld-ContribAuthor ">Jessica K.  Bell</span>. </span><span class="cited-content_cbyCitation_article-title">Allosterism and Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-78. <a href="https://doi.org/10.1002/0471266949.bmc299" title="DOI URL">https://doi.org/10.1002/0471266949.bmc299</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc299%26sid%3Dliteratum%253Aachs%26atitle%3DAllosterism%252Band%252BDrug%252BDiscovery%26aulast%3DBell%26aufirst%3DJohn%2BE.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D78%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonie C S  De Vries</span>, <span class="hlFld-ContribAuthor ">Mohammed  Ghiboub</span>, <span class="hlFld-ContribAuthor ">Patricia H P  van Hamersveld</span>, <span class="hlFld-ContribAuthor ">Olaf  Welting</span>, <span class="hlFld-ContribAuthor ">Caroline  Verseijden</span>, <span class="hlFld-ContribAuthor ">Matthew J  Bell</span>, <span class="hlFld-ContribAuthor ">Inmaculada  Rioja</span>, <span class="hlFld-ContribAuthor ">Rabinder K  Prinjha</span>, <span class="hlFld-ContribAuthor ">Pim J  Koelink</span>, <span class="hlFld-ContribAuthor ">Birgit  Strobl</span>, <span class="hlFld-ContribAuthor ">Mathias  Müller</span>, <span class="hlFld-ContribAuthor ">Geert R  D’Haens</span>, <span class="hlFld-ContribAuthor ">Manon E  Wildenberg</span>, <span class="hlFld-ContribAuthor ">Wouter J  De Jonge</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2021,</strong> <em>15 </em>
                                    (4)
                                     , 617-630. <a href="https://doi.org/10.1093/ecco-jcc/jjaa199" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjaa199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjaa199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjaa199%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DTyrosine%252BKinase%252B2%252BSignalling%252BDrives%252BPathogenic%252BT%252Bcells%252Bin%252BColitis%26aulast%3DDe%2BVries%26aufirst%3DLeonie%2BC%2BS%26date%3D2021%26date%3D2020%26volume%3D15%26issue%3D4%26spage%3D617%26epage%3D630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karima  Alim</span>, <span class="hlFld-ContribAuthor ">Arnaud  Bruyère</span>, <span class="hlFld-ContribAuthor ">Alain  Lescoat</span>, <span class="hlFld-ContribAuthor ">Elodie  Jouan</span>, <span class="hlFld-ContribAuthor ">Valérie  Lecureur</span>, <span class="hlFld-ContribAuthor ">Marc  Le Vée</span>, <span class="hlFld-ContribAuthor ">Olivier  Fardel</span>. </span><span class="cited-content_cbyCitation_article-title">Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Metabolism & Toxicology</span><span> <strong>2021,</strong> <em>17 </em>
                                    (3)
                                     , 259-271. <a href="https://doi.org/10.1080/17425255.2021.1862084" title="DOI URL">https://doi.org/10.1080/17425255.2021.1862084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17425255.2021.1862084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17425255.2021.1862084%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Metabolism%2520%2526%2520Toxicology%26atitle%3DInteractions%252Bof%252Bjanus%252Bkinase%252Binhibitors%252Bwith%252Bdrug%252Btransporters%252Band%252Bconsequences%252Bfor%252Bpharmacokinetics%252Band%252Btoxicity%26aulast%3DAlim%26aufirst%3DKarima%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D3%26spage%3D259%26epage%3D271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lori S.  Kim</span>, <span class="hlFld-ContribAuthor ">Jashin J.  Wu</span>, <span class="hlFld-ContribAuthor ">George  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Deucravacitinib for Psoriasis. </span><span class="cited-content_cbyCitation_journal-name">Current Dermatology Reports</span><span> <strong>2021,</strong> <em>10 </em>
                                    (1)
                                     , 1-5. <a href="https://doi.org/10.1007/s13671-020-00326-x" title="DOI URL">https://doi.org/10.1007/s13671-020-00326-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13671-020-00326-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13671-020-00326-x%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Dermatology%2520Reports%26atitle%3DDeucravacitinib%252Bfor%252BPsoriasis%26aulast%3DKim%26aufirst%3DLori%2BS.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D1%26spage%3D1%26epage%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhaogang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiangyu  Ren</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A practical synthesis of deuterated methylamine and dimethylamine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2021,</strong> <em>45 </em>
                                    (3-4)
                                     , 265-268. <a href="https://doi.org/10.1177/1747519820969636" title="DOI URL">https://doi.org/10.1177/1747519820969636</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1747519820969636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1747519820969636%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DA%252Bpractical%252Bsynthesis%252Bof%252Bdeuterated%252Bmethylamine%252Band%252Bdimethylamine%26aulast%3DLiu%26aufirst%3DZhaogang%26date%3D2021%26date%3D2020%26volume%3D45%26issue%3D3-4%26spage%3D265%26epage%3D268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamran  Ghoreschi</span>, <span class="hlFld-ContribAuthor ">Anna  Balato</span>, <span class="hlFld-ContribAuthor ">Charlotta  Enerbäck</span>, <span class="hlFld-ContribAuthor ">Robert  Sabat</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. </span><span class="cited-content_cbyCitation_journal-name">The Lancet</span><span> <strong>2021,</strong> <em>397 </em>
                                    (10275)
                                     , 754-766. <a href="https://doi.org/10.1016/S0140-6736(21)00184-7" title="DOI URL">https://doi.org/10.1016/S0140-6736(21)00184-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S0140-6736(21)00184-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS0140-6736%2821%2900184-7%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%26atitle%3DTherapeutics%252Btargeting%252Bthe%252BIL-23%252Band%252BIL-17%252Bpathway%252Bin%252Bpsoriasis%26aulast%3DGhoreschi%26aufirst%3DKamran%26date%3D2021%26volume%3D397%26issue%3D10275%26spage%3D754%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Poelzl</span>, <span class="hlFld-ContribAuthor ">Caroline  Lassnig</span>, <span class="hlFld-ContribAuthor ">Simone  Tangermann</span>, <span class="hlFld-ContribAuthor ">Dominika  Hromadová</span>, <span class="hlFld-ContribAuthor ">Ursula  Reichart</span>, <span class="hlFld-ContribAuthor ">Riem  Gawish</span>, <span class="hlFld-ContribAuthor ">Kristina  Mueller</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Andreas  Linkermann</span>, <span class="hlFld-ContribAuthor ">Martin  Glösmann</span>, <span class="hlFld-ContribAuthor ">Lukas  Kenner</span>, <span class="hlFld-ContribAuthor ">Mathias  Mueller</span>, <span class="hlFld-ContribAuthor ">Birgit  Strobl</span>. </span><span class="cited-content_cbyCitation_article-title">TYK2 licenses non-canonical inflammasome activation during endotoxemia. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Differentiation</span><span> <strong>2021,</strong> <em>28 </em>
                                    (2)
                                     , 748-763. <a href="https://doi.org/10.1038/s41418-020-00621-x" title="DOI URL">https://doi.org/10.1038/s41418-020-00621-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41418-020-00621-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41418-020-00621-x%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Differentiation%26atitle%3DTYK2%252Blicenses%252Bnon-canonical%252Binflammasome%252Bactivation%252Bduring%252Bendotoxemia%26aulast%3DPoelzl%26aufirst%3DAndrea%26date%3D2021%26date%3D2020%26volume%3D28%26issue%3D2%26spage%3D748%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juuli  Raivola</span>, <span class="hlFld-ContribAuthor ">Teemu  Haikarainen</span>, <span class="hlFld-ContribAuthor ">Bobin George  Abraham</span>, <span class="hlFld-ContribAuthor ">Olli  Silvennoinen</span>. </span><span class="cited-content_cbyCitation_article-title">Janus Kinases in Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 800. <a href="https://doi.org/10.3390/cancers13040800" title="DOI URL">https://doi.org/10.3390/cancers13040800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040800%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DJanus%252BKinases%252Bin%252BLeukemia%26aulast%3DRaivola%26aufirst%3DJuuli%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nayana  Devang</span>, <span class="hlFld-ContribAuthor ">Adyashree  Pani</span>, <span class="hlFld-ContribAuthor ">G.K.  Rajanikant</span>. </span><span class="cited-content_cbyCitation_article-title">Pseudokinases: Prospects for expanding the therapeutic targets armamentarium. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 121-185. <a href="https://doi.org/10.1016/bs.apcsb.2020.09.004" title="DOI URL">https://doi.org/10.1016/bs.apcsb.2020.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.apcsb.2020.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.apcsb.2020.09.004%26sid%3Dliteratum%253Aachs%26atitle%3DPseudokinases%25253A%252BProspects%252Bfor%252Bexpanding%252Bthe%252Btherapeutic%252Btargets%252Barmamentarium%26aulast%3DDevang%26aufirst%3DNayana%26date%3D2021%26spage%3D121%26epage%3D185%26pub%3DElsevier%26atitle%3DProtein%252BKinases%252Bin%252BDrug%252BDiscovery%26date%3D2021%26volume%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Xu</span>, <span class="hlFld-ContribAuthor ">Dapeng  Zou</span>, <span class="hlFld-ContribAuthor ">Qijie  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Ag-catalyzed decarboxylative acylation of pyridazines using α-keto acids in aqueous media. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>62 </em>, 152691. <a href="https://doi.org/10.1016/j.tetlet.2020.152691" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.152691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.152691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.152691%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DAg-catalyzed%252Bdecarboxylative%252Bacylation%252Bof%252Bpyridazines%252Busing%252B%2525CE%2525B1-keto%252Bacids%252Bin%252Baqueous%252Bmedia%26aulast%3DWang%26aufirst%3DShengqiang%26date%3D2021%26volume%3D62%26spage%3D152691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hermann  AM Mucke</span>. </span><span class="cited-content_cbyCitation_article-title">Patent highlights August–September 2020. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Patent Analyst</span><span> <strong>2021,</strong> <em>10 </em>
                                    (1)
                                     , 1-7. <a href="https://doi.org/10.4155/ppa-2020-0032" title="DOI URL">https://doi.org/10.4155/ppa-2020-0032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/ppa-2020-0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fppa-2020-0032%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Patent%2520Analyst%26atitle%3DPatent%252Bhighlights%252BAugust%2525E2%252580%252593September%252B2020%26aulast%3DAM%25C2%25A0Mucke%26aufirst%3DHermann%26date%3D2021%26volume%3D10%26issue%3D1%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Chinigo</span>, <span class="hlFld-ContribAuthor ">Yiqing  Feng</span>, <span class="hlFld-ContribAuthor ">Susan  Hoy</span>, <span class="hlFld-ContribAuthor ">Ricardo  Lira</span>, <span class="hlFld-ContribAuthor ">Matthew  Perry</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazines and Their Benzo Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00082-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00082-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00082-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00082-2%26sid%3Dliteratum%253Aachs%26atitle%3DPyridazines%252Band%252BTheir%252BBenzo%252BDerivatives%26aulast%3DChinigo%26aufirst%3DGary%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Bellinato</span>, <span class="hlFld-ContribAuthor ">Paolo  Gisondi</span>, <span class="hlFld-ContribAuthor ">Giampiero  Girolomoni</span>. </span><span class="cited-content_cbyCitation_article-title">Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules. </span><span class="cited-content_cbyCitation_journal-name">Biologics: Targets and Therapy</span><span> <strong>2021,</strong> <em>Volume 15 </em>, 247-253. <a href="https://doi.org/10.2147/BTT.S290309" title="DOI URL">https://doi.org/10.2147/BTT.S290309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/BTT.S290309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FBTT.S290309%26sid%3Dliteratum%253Aachs%26jtitle%3DBiologics%253A%2520Targets%2520and%2520Therapy%26atitle%3DLatest%252BAdvances%252Bfor%252Bthe%252BTreatment%252Bof%252BChronic%252BPlaque%252BPsoriasis%252Bwith%252BBiologics%252Band%252BOral%252BSmall%252BMolecules%26aulast%3DBellinato%26aufirst%3DFrancesco%26date%3D2021%26date%3D2021%26volume%3DVolume%252015%26spage%3D247%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 33-74. <a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26spage%3D33%26epage%3D74%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter D.  Mace</span>, <span class="hlFld-ContribAuthor ">James M.  Murphy</span>. </span><span class="cited-content_cbyCitation_article-title">There’s more to death than life: Noncatalytic functions in kinase and pseudokinase signaling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2021,</strong> <em>296 </em>, 100705. <a href="https://doi.org/10.1016/j.jbc.2021.100705" title="DOI URL">https://doi.org/10.1016/j.jbc.2021.100705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jbc.2021.100705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jbc.2021.100705%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DThere%2525E2%252580%252599s%252Bmore%252Bto%252Bdeath%252Bthan%252Blife%25253A%252BNoncatalytic%252Bfunctions%252Bin%252Bkinase%252Band%252Bpseudokinase%252Bsignaling%26aulast%3DMace%26aufirst%3DPeter%2BD.%26date%3D2021%26volume%3D296%26spage%3D100705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristian  Hernandez-Rocha</span>, <span class="hlFld-ContribAuthor ">Niels  Vande Casteele</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2020,</strong> <em>55 </em>, 99-109. <a href="https://doi.org/10.1016/j.coph.2020.10.010" title="DOI URL">https://doi.org/10.1016/j.coph.2020.10.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2020.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2020.10.010%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DJAK%252Binhibitors%25253A%252Bcurrent%252Bposition%252Bin%252Btreatment%252Bstrategies%252Bfor%252Buse%252Bin%252Binflammatory%252Bbowel%252Bdisease%26aulast%3DHernandez-Rocha%26aufirst%3DCristian%26date%3D2020%26volume%3D55%26spage%3D99%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Onisha  Patel</span>, <span class="hlFld-ContribAuthor ">Michael J.  Roy</span>, <span class="hlFld-ContribAuthor ">James M.  Murphy</span>, <span class="hlFld-ContribAuthor ">Isabelle S.  Lucet</span>. </span><span class="cited-content_cbyCitation_article-title">The PEAK family of pseudokinases, their role in cell signalling and cancer. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2020,</strong> <em>287 </em>
                                    (19)
                                     , 4183-4197. <a href="https://doi.org/10.1111/febs.15087" title="DOI URL">https://doi.org/10.1111/febs.15087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.15087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.15087%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DThe%252BPEAK%252Bfamily%252Bof%252Bpseudokinases%25252C%252Btheir%252Brole%252Bin%252Bcell%252Bsignalling%252Band%252Bcancer%26aulast%3DPatel%26aufirst%3DOnisha%26date%3D2020%26date%3D2019%26volume%3D287%26issue%3D19%26spage%3D4183%26epage%3D4197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Allosterische Kinaseinhibitoren – Erwartungen und Chancen. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (33)
                                     , 13868-13881. <a href="https://doi.org/10.1002/ange.201914525" title="DOI URL">https://doi.org/10.1002/ange.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAllosterische%252BKinaseinhibitoren%252B%2525E2%252580%252593%252BErwartungen%252Bund%252BChancen%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D33%26spage%3D13868%26epage%3D13881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">New Promise and Opportunities for Allosteric Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (33)
                                     , 13764-13776. <a href="https://doi.org/10.1002/anie.201914525" title="DOI URL">https://doi.org/10.1002/anie.201914525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201914525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201914525%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DNew%252BPromise%252Band%252BOpportunities%252Bfor%252BAllosteric%252BKinase%252BInhibitors%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D33%26spage%3D13764%26epage%3D13776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gerhard  Rogler</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of JAK inhibitors in Crohn’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Crohn's and Colitis</span><span> <strong>2020,</strong> <em>14 </em>
                                    (Supplement_2)
                                     , S746-S754. <a href="https://doi.org/10.1093/ecco-jcc/jjz186" title="DOI URL">https://doi.org/10.1093/ecco-jcc/jjz186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/ecco-jcc/jjz186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fecco-jcc%2Fjjz186%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Crohn%2527s%2520and%2520Colitis%26atitle%3DEfficacy%252Bof%252BJAK%252Binhibitors%252Bin%252BCrohn%2525E2%252580%252599s%252BDisease%26aulast%3DRogler%26aufirst%3DGerhard%26date%3D2020%26date%3D2019%26volume%3D14%26issue%3DSupplement_2%26spage%3DS746%26epage%3DS754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua B.  Sheetz</span>, <span class="hlFld-ContribAuthor ">Sebastian  Mathea</span>, <span class="hlFld-ContribAuthor ">Hanna  Karvonen</span>, <span class="hlFld-ContribAuthor ">Ketan  Malhotra</span>, <span class="hlFld-ContribAuthor ">Deep  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Wilhelmiina  Niininen</span>, <span class="hlFld-ContribAuthor ">Robert  Perttilä</span>, <span class="hlFld-ContribAuthor ">Franziska  Preuss</span>, <span class="hlFld-ContribAuthor ">Krishna  Suresh</span>, <span class="hlFld-ContribAuthor ">Steven E.  Stayrook</span>, <span class="hlFld-ContribAuthor ">Yuko  Tsutsui</span>, <span class="hlFld-ContribAuthor ">Ravi  Radhakrishnan</span>, <span class="hlFld-ContribAuthor ">Daniela  Ungureanu</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>, <span class="hlFld-ContribAuthor ">Mark A.  Lemmon</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cell</span><span> <strong>2020,</strong> <em>79 </em>
                                    (3)
                                     , 390-405.e7. <a href="https://doi.org/10.1016/j.molcel.2020.06.018" title="DOI URL">https://doi.org/10.1016/j.molcel.2020.06.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molcel.2020.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molcel.2020.06.018%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cell%26atitle%3DStructural%252BInsights%252Binto%252BPseudokinase%252BDomains%252Bof%252BReceptor%252BTyrosine%252BKinases%26aulast%3DSheetz%26aufirst%3DJoshua%2BB.%26date%3D2020%26volume%3D79%26issue%3D3%26spage%3D390%26epage%3D405.e7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda  Garrido</span>, <span class="hlFld-ContribAuthor ">Alban  Lepailleur</span>, <span class="hlFld-ContribAuthor ">Serge M.  Mignani</span>, <span class="hlFld-ContribAuthor ">Patrick  Dallemagne</span>, <span class="hlFld-ContribAuthor ">Christophe  Rochais</span>. </span><span class="cited-content_cbyCitation_article-title">hERG toxicity assessment: Useful guidelines for drug design. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>195 </em>, 112290. <a href="https://doi.org/10.1016/j.ejmech.2020.112290" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112290%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DhERG%252Btoxicity%252Bassessment%25253A%252BUseful%252Bguidelines%252Bfor%252Bdrug%252Bdesign%26aulast%3DGarrido%26aufirst%3DAmanda%26date%3D2020%26volume%3D195%26spage%3D112290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Pan</span>, <span class="hlFld-ContribAuthor ">Feng  Jin</span>, <span class="hlFld-ContribAuthor ">Rui  Fu</span>, <span class="hlFld-ContribAuthor ">Ke  Gao</span>, <span class="hlFld-ContribAuthor ">Shaofang  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">Oxidative Ring-Opening of 1
              H
              -Pyrazol-5-amines and Its Application in Constructing Pyrazolo-Pyrrolo-Pyrazine Scaffolds by Domino Cyclization. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (19)
                                     , 2956-2961. <a href="https://doi.org/10.1002/ejoc.202000265" title="DOI URL">https://doi.org/10.1002/ejoc.202000265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202000265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202000265%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOxidative%252BRing-Opening%252Bof%252B1%252BH%252B-Pyrazol-5-amines%252Band%252BIts%252BApplication%252Bin%252BConstructing%252BPyrazolo-Pyrrolo-Pyrazine%252BScaffolds%252Bby%252BDomino%252BCyclization%26aulast%3DPan%26aufirst%3DLei%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D19%26spage%3D2956%26epage%3D2961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Fensome</span>, <span class="hlFld-ContribAuthor ">Catherine M.  Ambler</span>, <span class="hlFld-ContribAuthor ">Eric  Arnold</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Ivan V.  Efremov</span>, <span class="hlFld-ContribAuthor ">Andrew  Flick</span>, <span class="hlFld-ContribAuthor ">Brian S.  Gerstenberger</span>, <span class="hlFld-ContribAuthor ">Roger S.  Gifford</span>, <span class="hlFld-ContribAuthor ">Ariamala  Gopalsamy</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">David C.  Limburg</span>, <span class="hlFld-ContribAuthor ">Tsung H.  Lin</span>, <span class="hlFld-ContribAuthor ">Betsy S.  Pierce</span>, <span class="hlFld-ContribAuthor ">Raman  Sharma</span>, <span class="hlFld-ContribAuthor ">John I.  Trujillo</span>, <span class="hlFld-ContribAuthor ">Felix F.  Vajdos</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Zhao-Kui  Wan</span>, <span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (10)
                                     , 115481. <a href="https://doi.org/10.1016/j.bmc.2020.115481" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115481</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115481%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Boptimization%252Bof%252Ba%252Bseries%252Bof%252B4-%2525283-azabicyclo%25255B3.1.0%25255Dhexan-3-yl%252529pyrimidin-2-amines%25253A%252BDual%252Binhibitors%252Bof%252BTYK2%252Band%252BJAK1%26aulast%3DFensome%26aufirst%3DAndrew%26date%3D2020%26volume%3D28%26issue%3D10%26spage%3D115481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Xinying  Cheng</span>, <span class="hlFld-ContribAuthor ">Qiuyu  Chen</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112155. <a href="https://doi.org/10.1016/j.ejmech.2020.112155" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112155%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DJanus%252Bkinases%252B%252528JAKs%252529%25253A%252BThe%252Befficient%252Btherapeutic%252Btargets%252Bfor%252Bautoimmune%252Bdiseases%252Band%252Bmyeloproliferative%252Bdisorders%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2020%26volume%3D192%26spage%3D112155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junhong  Qin</span>, <span class="hlFld-ContribAuthor ">Xiaofei  Shen</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Da  Jia</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric inhibitors of the STAT3 signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112122. <a href="https://doi.org/10.1016/j.ejmech.2020.112122" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112122%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAllosteric%252Binhibitors%252Bof%252Bthe%252BSTAT3%252Bsignaling%252Bpathway%26aulast%3DQin%26aufirst%3DJunhong%26date%3D2020%26volume%3D190%26spage%3D112122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean Jacques  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Jérôme  Leprince</span>, <span class="hlFld-ContribAuthor ">Yasu-Taka  Azuma</span>, <span class="hlFld-ContribAuthor ">Alfonso T.  García-Sosa</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Paula A. C.  Gomes</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>, <span class="hlFld-ContribAuthor ">F. Javier  Luque</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Mariana  Spetea</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Ivan  Kosalec</span>, <span class="hlFld-ContribAuthor ">Catherine  Guillou</span>, <span class="hlFld-ContribAuthor ">M. Helena  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Maria Emília  de Sousa</span>, <span class="hlFld-ContribAuthor ">Clementina  Manera</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>, <span class="hlFld-ContribAuthor ">Stefano  Mangani</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">Cristóbal  de los Ríos</span>, <span class="hlFld-ContribAuthor ">Luigi A.  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Rita C.  Guedes</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (1)
                                     , 119. <a href="https://doi.org/10.3390/molecules25010119" title="DOI URL">https://doi.org/10.3390/molecules25010119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25010119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25010119%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525936%26aulast%3DVanden%2BEynde%26aufirst%3DJean%2BJacques%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D1%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Justin D.  Singleton</span>, <span class="hlFld-ContribAuthor ">Reuben  Dass</span>, <span class="hlFld-ContribAuthor ">Nathaniel R.  Neubert</span>, <span class="hlFld-ContribAuthor ">Rachel M.  Smith</span>, <span class="hlFld-ContribAuthor ">Zak  Webber</span>, <span class="hlFld-ContribAuthor ">Marc D.H.  Hansen</span>, <span class="hlFld-ContribAuthor ">Matt A.  Peterson</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel pyrazolo[1,5-a]pyrimidines: Discovery of a selective inhibitor of JAK1 JH2 pseudokinase and VPS34. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (2)
                                     , 126813. <a href="https://doi.org/10.1016/j.bmcl.2019.126813" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126813</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126813%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrazolo%25255B1%25252C5-a%25255Dpyrimidines%25253A%252BDiscovery%252Bof%252Ba%252Bselective%252Binhibitor%252Bof%252BJAK1%252BJH2%252Bpseudokinase%252Band%252BVPS34%26aulast%3DSingleton%26aufirst%3DJustin%2BD.%26date%3D2020%26volume%3D30%26issue%3D2%26spage%3D126813" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">F.  Solimani</span>, <span class="hlFld-ContribAuthor ">F. J.  Hilke</span>, <span class="hlFld-ContribAuthor ">K.  Ghoreschi</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmakologie der Januskinaseinhibitoren. </span><span class="cited-content_cbyCitation_journal-name">Der Hautarzt</span><span> <strong>2019,</strong> <em>70 </em>
                                    (12)
                                     , 934-941. <a href="https://doi.org/10.1007/s00105-019-04509-x" title="DOI URL">https://doi.org/10.1007/s00105-019-04509-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00105-019-04509-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00105-019-04509-x%26sid%3Dliteratum%253Aachs%26jtitle%3DDer%2520Hautarzt%26atitle%3DPharmakologie%252Bder%252BJanuskinaseinhibitoren%26aulast%3DSolimani%26aufirst%3DF.%26date%3D2019%26date%3D2019%26volume%3D70%26issue%3D12%26spage%3D934%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katharina  Wöss</span>, <span class="hlFld-ContribAuthor ">Natalija  Simonović</span>, <span class="hlFld-ContribAuthor ">Birgit  Strobl</span>, <span class="hlFld-ContribAuthor ">Sabine  Macho-Maschler</span>, <span class="hlFld-ContribAuthor ">Mathias  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">TYK2: An Upstream Kinase of STATs in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (11)
                                     , 1728. <a href="https://doi.org/10.3390/cancers11111728" title="DOI URL">https://doi.org/10.3390/cancers11111728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11111728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11111728%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTYK2%25253A%252BAn%252BUpstream%252BKinase%252Bof%252BSTATs%252Bin%252BCancer%26aulast%3DW%25C3%25B6ss%26aufirst%3DKatharina%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D11%26spage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Hart S.  Dengler</span>, <span class="hlFld-ContribAuthor ">Naomi S.  Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126658. <a href="https://doi.org/10.1016/j.bmcl.2019.126658" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126658%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhaled%252BJanus%252BKinase%252B%252528JAK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Basthma%26aulast%3DZak%26aufirst%3DMark%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">I-Tsu  Chyuan</span>, <span class="hlFld-ContribAuthor ">Hong-Tai  Tzeng</span>, <span class="hlFld-ContribAuthor ">Ji-Yih  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (9)
                                     , 963. <a href="https://doi.org/10.3390/cells8090963" title="DOI URL">https://doi.org/10.3390/cells8090963</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8090963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8090963%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DSignaling%252BPathways%252Bof%252BType%252BI%252Band%252BType%252BIII%252BInterferons%252Band%252BTargeted%252BTherapies%252Bin%252BSystemic%252BLupus%252BErythematosus%26aulast%3DChyuan%26aufirst%3DI-Tsu%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D9%26spage%3D963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the first-generation clinically approved JAK inhibitors <b>1</b>–<b>4</b>, the second-generation experimental JAK inhibitors <b>5</b>–<b>10</b>, and the TYK2-selective allosteric inhibitor <b>11</b> in the clinic for the treatment of chronic immunological disorders. Inhibitors <b>1</b>–<b>10</b> are conventional active-site (JH1) inhibitors, whereas <b>11</b> is an allosteric (JH2) inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustrating the general protein structure of TYK2 and depicting the <i>N</i>-deuteromethyl pyridazine carboxamide <b>12</b> that potently inhibits TYK2 dependent signaling by binding to the TYK2 pseudokinase (JH2) domain with high specificity over the JAK family kinase (JH1) domains.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray crystal structure representation of <b>12</b> cocomplexed with TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZR">6NZR</a>). Carbons of <b>12</b> in magenta. TYK2 JH2 ribbon and carbons in green. Key hydrogen bond interactions within the ligand binding site are represented as dotted lines. Binding regions, including the unique “alanine pocket”, and the observed structural water are highlighted in blue text with other key residues labeled. The P-loop region has been partially omitted for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structure of analogue <b>29</b> in TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZQ">6NZQ</a>) with surface representation of protein added and showing H-bond to Arg738 (3.1 Å) and amide <i>N</i>-substituent occupying large, open pocket. The methoxy group forms an intramolecular H-bond with the amide N–H while also occupying the shallow C-terminal pocket of TYK2 JH2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) X-ray cocrystal structure of triazole <b>11</b> in TYK2 JH2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZP">6NZP</a>) showing key interactions including hydrogen bonds to hinge region of JH2 via <i>N</i>-methyl pyridazine amide, the <i>d</i><sub>3</sub>-<i>N</i>-methyl amide occupying the unique alanine pocket (Ala671) with the cyclopropylamide in the extended hinge region, the key triazole moiety displacing structural water present in X-ray structure of <b>12</b> to form a direct hydrogen bond to Arg738, and the orientation of the C2′ methoxy near Lys642 protruding into a shallow, C-terminal lobe pocket (displayed in gray surface representation). (b) WaterMap simulation<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> results superimposed with X-ray structure of <b>11</b> predict multiple unfavorable (Δ<i>G</i> > 2.2 kcal/mol) waters W1–W5 that are likely displaced by C3′ triazole and C2′ methoxy groups of <b>11</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Dose–response of <b>11</b> showing inhibitory effect in an IL-23 induced psoriasis-like acanthosis mouse model<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> compared to an anti-IL-23 adnectin as a positive control.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Values are presented as means ± SEM, eight mice per group. Statistical analysis was performed with one-way ANOVA. Vehicle, 5:5:90, EtOH:TGPS:PEG300. (b) Dose–response of histological scores showing dose-dependent inhibition of epidermal hyperplasia (acanthosis) and inflammatory cellular infiltration. (c) Inflammatory cytokine expression by quantitative PCR analysis of skin biopsies showing dose-dependent inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Preparation of <i>N</i>-Methyl Nicotinamides and <i>N</i>-Methyl Pyridazine-3-Carboxamides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHMDS or LiHMDS, ArNH<sub>2</sub>, THF, rt; 53–92%; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3,</sub> DMA or 1,4-dioxane, 130–145 °C, 1 h, 23–64%; (c) Pd(OAc)<sub>2</sub> or Pd<sub>2</sub>(dba)<sub>3</sub> BrettPhos or dppf, K<sub>2</sub>CO<sub>3</sub> or Cs<sub>2</sub>CO<sub>3</sub> or LiHMDS, 1,4-dioxane, 85–110 °C, 1 h, 40–97%.</p></p></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/medium/jm-2019-00444x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0008.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Clinical TYK2 Inhibitor <b>11</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00444/20191018/images/large/jm-2019-00444x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00444&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 98%; (b) aq NH<sub>4</sub>OH, NH<sub>3</sub> in MeOH, rt, 86%; (c) (i) DMF-DMA, 95 °C, (ii) hydrazine hydrate, EtOH, AcOH, rt, 69% over 2 steps; (d) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, rt, 91%, (∼2:1 mixture); (e) KHMDS, CH<sub>3</sub>I, THF, rt, 58% of pure <b>50</b>; (f) 5% Pd-C, 1 atm H<sub>2</sub>, EtOH, rt, 92%; (g) LiHMDS, THF, rt, 66%; (h) Pd<sub>2</sub>(dba)<sub>3</sub>, XantPhos, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 130 °C, 46%; (i) Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, K<sub>3</sub>PO<sub>4,</sub> dioxane, 85 °C, 76%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i71">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34528" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34528" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 88 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firmbach-Kraft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shows, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalla-Favera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krolewski, J. J.</span></span> <span> </span><span class="NLM_article-title">Tyk2, Prototype of a Novel Class of Non-Receptor Tyrosine Kinase Genes</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1329</span>– <span class="NLM_lpage">1336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=2216457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=1329-1336&author=I.+Firmbach-Kraftauthor=M.+Byersauthor=T.+Showsauthor=R.+Dalla-Faveraauthor=J.+J.+Krolewski&title=Tyk2%2C+Prototype+of+a+Novel+Class+of+Non-Receptor+Tyrosine+Kinase+Genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">tyk2, Prototype of a novel class of non-receptor tyrosine kinase genes</span></div><div class="casAuthors">Firmbach-Kraft, Iris; Byers, Mary; Shows, Thomas; Dalla-Favera, Riccardo; Krolewski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-36</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The authors previously identified a novel protein tyrosine kinase gene, tyk2, by screening a human lymphoid cDNA library with a tyrosine kinase domain specific c-fms restriction fragment under low stringency hybridization conditions.  They now isolated and sequenced a full length tyk2 cDNA clone; demonstrated that this gene is widely expressed in hematopoietic and non-hematopoietic cell lines; and mapped it to chromosome 19p13.2.  The cDNA clone is 4176 nucleotides long and codes for a putative protein with a mol. wt. of 134 kilodaltons.  Hydrophobicity anal. of the sequence does not identify a transmembrane domain, which is found in all members of the receptor class of protein tyrosine kinases; nor can the authors detect an SH2 domain, found in all previously identified non-receptor protein kinases.  They propose that tyk2 is the prototype of a new class of non-receptor protein tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLoFCW2FDWrVg90H21EOLACvtfcHk0lilPoGJ_J1nXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D&md5=c7a4180a140f0bcdc98140a265fb4cb4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirmbach-Kraft%26aufirst%3DI.%26aulast%3DByers%26aufirst%3DM.%26aulast%3DShows%26aufirst%3DT.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DKrolewski%26aufirst%3DJ.%2BJ.%26atitle%3DTyk2%252C%2520Prototype%2520of%2520a%2520Novel%2520Class%2520of%2520Non-Receptor%2520Tyrosine%2520Kinase%2520Genes%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D1329%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raivola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span> <span> </span><span class="NLM_article-title">The Regulation of JAKs in Cytokine Signaling and its Breakdown in Disease</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2Fj.cyto.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29685781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2019&pages=48-63&author=H.+M.+Hammar%C3%A9nauthor=A.+T.+Virtanenauthor=J.+Raivolaauthor=O.+Silvennoinen&title=The+Regulation+of+JAKs+in+Cytokine+Signaling+and+its+Breakdown+in+Disease&doi=10.1016%2Fj.cyto.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of JAKs in cytokine signaling and its breakdown in disease</span></div><div class="casAuthors">Hammaren, Henrik M.; Virtanen, Anniina T.; Raivola, Juuli; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-63</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The JAK-STAT signal transduction pathway is responsible for mediating signals of over fifty cytokines, growth factors and hormones.  Signaling through the JAK-STAT pathway is regulated on multiple levels, including intramol. regulation by the JAK pseudokinase domain, and intermol. regulation by a host of regulatory proteins.  The advent of accessible genomic tools have provided a wealth of information on disease-assocd. mutations in the JAK-STAT pathway and its regulatory components.  The vast no. of these mutations in diseases ranging from immunodeficiencies and obesity to many cancers highlight the importance of correct regulation of JAK-STAT signaling for biol. processes such as hematopoiesis, regulation of the immune system, metab., and growth.  Simultaneously, JAK inhibitors are gaining traction in clin. use, both for treatment of diseases driven by JAK mutations, and for a host of inflammatory disorders, in which proinflammatory cytokine signaling through the JAK-STAT pathway is an integral part of pathogenesis.  The elucidation of mol. mechanisms in the pathogenesis of complex diseases has also, however, brought the limitations of our current understanding on the regulation of cytokine signaling to the foreground.  Indeed, deeper understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of pharmacol. modulators of the JAK-STAT pathway.  In this review we discuss the current state of knowledge of the intra- and intermol. regulation of the JAK-STAT pathway, with a focus on diseases arising from disruptions in the regulatory app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RzQKF2IxZbVg90H21EOLACvtfcHk0lilPoGJ_J1nXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D&md5=f640078513fdd7e86a122d5d1172f76b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DVirtanen%26aufirst%3DA.%2BT.%26aulast%3DRaivola%26aufirst%3DJ.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520Regulation%2520of%2520JAKs%2520in%2520Cytokine%2520Signaling%2520and%2520its%2520Breakdown%2520in%2520Disease%26jtitle%3DCytokine%26date%3D2019%26volume%3D118%26spage%3D48%26epage%3D63%26doi%3D10.1016%2Fj.cyto.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span> <span> </span><span class="NLM_article-title">Type I/II Cytokines, JAKs, and New Strategies for Treating Autoimmune Diseases</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrrheum.2015.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1038%2Fnrrheum.2015.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26633291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=25-36&author=D.+M.+Schwartzauthor=M.+Bonelliauthor=M.+Gadinaauthor=J.+J.+O%E2%80%99Shea&title=Type+I%2FII+Cytokines%2C+JAKs%2C+and+New+Strategies+for+Treating+Autoimmune+Diseases&doi=10.1038%2Fnrrheum.2015.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases</span></div><div class="casAuthors">Schwartz, Daniella M.; Bonelli, Michael; Gadina, Massimo; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-36</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cytokines are major drivers of autoimmunity, and biol. agents targeting cytokines have revolutionized the treatment of immune-mediated diseases.  Despite the effectiveness of these drugs, they do not induce complete remission in all patients, prompting the development of alternative strategies - including targeting of intracellular signal transduction pathways downstream of cytokines.  Many cytokines that bind type I and type II cytokine receptors are crit. regulators of immune-mediated diseases and employ the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway to exert their effect.  Pharmacol. inhibition of JAKs blocks the actions of type I/II cytokines, and within the past 3 years therapeutic JAK inhibitors, or Jakinibs, have become available to rheumatologists.  Jakinibs have proven effective for the treatment of rheumatoid arthritis and other inflammatory diseases.  Adverse effects of these agents are largely related to their mode of action and include infections and hyperlipidemia.  Jakinibs are currently being investigated for a no. of new indications, and second-generation selective Jakinibs are being developed and tested.  Targeting STATs could be a future avenue for the treatment of rheumatol. diseases, although substantial challenges remain.  Nonetheless, the ability to therapeutically target intracellular signalling pathways has already created a new paradigm for the treatment of rheumatol. disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdr1Dh92dnLVg90H21EOLACvtfcHk0lilPoGJ_J1nXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ks7vJ&md5=e06f7ab6424f1fbdbf481c75fa9ebd23</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2015.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2015.167%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DBonelli%26aufirst%3DM.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DType%2520I%252FII%2520Cytokines%252C%2520JAKs%252C%2520and%2520New%2520Strategies%2520for%2520Treating%2520Autoimmune%2520Diseases%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2016%26volume%3D12%26spage%3D25%26epage%3D36%26doi%3D10.1038%2Fnrrheum.2015.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurence, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J.</span></span> <span> </span><span class="NLM_article-title">JAK Kinases in Health and Disease: An Update</span>. <i>Open Rheumatol. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.2174/1874312901206010232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.2174%2F1874312901206010232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=23028408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=232-244&author=A.+Laurenceauthor=M.+Pesuauthor=O.+Silvennoinenauthor=J.+O%E2%80%99Shea&title=JAK+Kinases+in+Health+and+Disease%3A+An+Update&doi=10.2174%2F1874312901206010232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">JAK kinases in health and disease: an update</span></div><div class="casAuthors">Laurence, Arian; Pesu, Marko; Silvennoinen, Olli; O'Shea, John</div><div class="citationInfo"><span class="NLM_cas:title">Open Rheumatology Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">232-244</span>CODEN:
                <span class="NLM_cas:coden">ORJPAP</span>;
        ISSN:<span class="NLM_cas:issn">1874-3129</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are crit. signaling elements for a large subset of cytokines.  As a consequence they play pivotal roles in the pathophysiol. of many diseases including neoplastic and autoimmune diseases.  Small mol. JAK inhibitors as therapeutic agents have become a reality and the palette of such inhibitors will likely expand.  This review will summarize our current knowledge on these key enzymes and their assocd. pharmaceutical inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjovQnlyAQvrVg90H21EOLACvtfcHk0li8qW-nNrB9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1equrjO&md5=ed5d20df39001bb27ca8556cae82c289</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1874312901206010232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1874312901206010232%26sid%3Dliteratum%253Aachs%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%26atitle%3DJAK%2520Kinases%2520in%2520Health%2520and%2520Disease%253A%2520An%2520Update%26jtitle%3DOpen%2520Rheumatol.%2520J.%26date%3D2012%26volume%3D6%26spage%3D232%26epage%3D244%26doi%3D10.2174%2F1874312901206010232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5023</span>– <span class="NLM_lpage">5038</span>, <span class="refDoi"> DOI: 10.1021/jm401490p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401490p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=5023-5038&author=J.+D.+Clarkauthor=M.+E.+Flanaganauthor=J.-B.+Telliez&title=Discovery+and+Development+of+Janus+Kinase+%28JAK%29+Inhibitors+for+Inflammatory+Diseases&doi=10.1021%2Fjm401490p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases</span></div><div class="casAuthors">Clark, James D.; Flanagan, Mark E.; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5023-5038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases.  As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnol. industries as therapeutic targets.  Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications.  Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3f7W5g8N6brVg90H21EOLACvtfcHk0li8qW-nNrB9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVCjsA%253D%253D&md5=6763ae2d46f52ddcda23e235a60634ae</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Fjm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401490p%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Janus%2520Kinase%2520%2528JAK%2529%2520Inhibitors%2520for%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D5023%26epage%3D5038%26doi%3D10.1021%2Fjm401490p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9030</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+Inhibitors+for+the+Treatment+of+Immunological+Disorders%3A+Recent+Advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0li8qW-nNrB9Ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Immunological%2520Disorders%253A%2520Recent%2520Advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, K.</span></span> <span> </span><span class="NLM_article-title">FDA Approves Tofacitinib for Rheumatoid Arthritis</span>. <i>Am. J. Health Syst. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2120</span>, <span class="refDoi"> DOI: 10.2146/news120088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.2146%2Fnews120088" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2120&author=K.+Traynor&title=FDA+Approves+Tofacitinib+for+Rheumatoid+Arthritis&doi=10.2146%2Fnews120088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2146%2Fnews120088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews120088%26sid%3Dliteratum%253Aachs%26aulast%3DTraynor%26aufirst%3DK.%26atitle%3DFDA%2520Approves%2520Tofacitinib%2520for%2520Rheumatoid%2520Arthritis%26jtitle%3DAm.%2520J.%2520Health%2520Syst.%2520Pharm.%26date%3D2012%26volume%3D69%26spage%3D2120%26doi%3D10.2146%2Fnews120088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di Lernia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardazzi, F.</span></span> <span> </span><span class="NLM_article-title">Profile of Tofacitinib Citrate and its Potential in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S82599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.2147%2FDDDT.S82599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26889081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BC28jitFemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=533-539&author=V.+Di+Lerniaauthor=F.+Bardazzi&title=Profile+of+Tofacitinib+Citrate+and+its+Potential+in+the+Treatment+of+Moderate-to-Severe+Chronic+Plaque+Psoriasis&doi=10.2147%2FDDDT.S82599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis</span></div><div class="casAuthors">Di Lernia V; Bardazzi F</div><div class="citationInfo"><span class="NLM_cas:title">Drug design, development and therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The outlook for patients with psoriasis has improved significantly over the last 10 years with the introduction of targeted therapies.  Cytokines exert their effects by activating intracellular signaling and transcription pathways, among which there are Janus kinases (JAKs) and signal transducers and activators of transcription (STAT) pathways.  JAKs are intracellular second messengers that are crucial for transmitting extracellular cytokine signals to the cell.  JAK inhibition interrupts intracellular signaling and can suppress immune cell activation and inflammation in T-cell-mediated disorders, such as psoriasis.  Consequently, JAKs are the subject of intensive research activity, since they represent possible therapeutic targets.  Tofacitinib is an orally available compound belonging to a novel category of nonbiologic drugs, the "JAK inhibitors", which target JAKs.  Recently, oral and topical formulations of tofacitinib have been demonstrated to be safe and effective for the treatment of plaque psoriasis in randomized clinical trials.  In particular, a 10 mg bid dose of tofacitinib was shown to be noninferior to etanercept 50 mg subcutaneously twice weekly.  Questions remain unresolved regarding the safety risk beyond the 5 mg bid dose.  This review, assessing the available scientific literature, focuses on the profile of tofacitinib, as investigational compound in the treatment of plaque psoriasis.  An overview of the efficacy and safety data from randomized clinical trials is provided.  In addition, the authors highlight future potential applications of tofacitinib in other skin diseases, in particular alopecia areata and vitiligo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7YQipRf1dUZcXNb62YGmbfW6udTcc2ea7kvKvFT0ntLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jitFemtg%253D%253D&md5=10cd4d4272d8e0dce01575df59f73662</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S82599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S82599%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLernia%26aufirst%3DV.%26aulast%3DBardazzi%26aufirst%3DF.%26atitle%3DProfile%2520of%2520Tofacitinib%2520Citrate%2520and%2520its%2520Potential%2520in%2520the%2520Treatment%2520of%2520Moderate-to-Severe%2520Chronic%2520Plaque%2520Psoriasis%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D533%26epage%3D539%26doi%3D10.2147%2FDDDT.S82599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elewski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buonanno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">and for the OPT Pivotal 1 and OPT Pivotal 2 Investigators. Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Results from Two, Randomised, Placebo-Controlled, Phase 3</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">961</span>, <span class="refDoi"> DOI: 10.1111/bjd.14018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1111%2Fbjd.14018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26149717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2015&pages=949-961&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Abeauthor=B.+Elewskiauthor=S.+R.+Feldmanauthor=A.+B.+Gottliebauthor=R.+Langleyauthor=T.+Lugerauthor=D.+Thaciauthor=M.+Buonannoauthor=P.+Guptaauthor=J.+Proulxauthor=S.+Lanauthor=R.+Wolk&title=and+for+the+OPT+Pivotal+1+and+OPT+Pivotal+2+Investigators.+Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+for+the+Treatment+of+Chronic+Plaque+Psoriasis%3A+Results+from+Two%2C+Randomised%2C+Placebo-Controlled%2C+Phase+3&doi=10.1111%2Fbjd.14018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Abe, M.; Elewski, B.; Feldman, S. R.; Gottlieb, A. B.; Langley, R.; Luger, T.; Thaci, D.; Buonanno, M.; Gupta, P.; Proulx, J.; Lan, S.; Wolk, R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-961</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.  Objectives : To det. the 16-wk efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.  Methods : Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily.  Coprimary efficacy end points (week 16) included the proportion of patients achieving Physician's Global Assessment (PGA) of 'clear' or 'almost clear' (PGA response) and the proportion achieving ≥ 75% redn. in Psoriasis Area and Severity Index (PASI 75).  Results : Across OPT Pivotal 1 and OPT Pivotal 2, 745 patients received tofacitinib 5 mg, 741 received tofacitinib 10 mg and 373 received placebo.  At week 16, a greater proportion of patients achieved PGA responses with tofacitinib 5 and 10 mg twice daily vs. placebo (OPT Pivotal 1, 41·9% and 59·2% vs. 9·0%; OPT Pivotal 2, 46·0% and 59·1% vs. 10·9%; all P < 0·001).  Higher PASI 75 rates were obsd. with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, resp., for tofacitinib 5 and 10 mg twice daily and placebo; OPT Pivotal 2, 46·0%, 59·6% and 11·4%; all P < 0·001 vs. placebo).  Adverse event (AE) rates appeared generally similar across groups; rates of serious AEs, infections, malignancies and discontinuations due to AEs were low.  Twelve patients reported herpes zoster across the tofacitinib treatment groups in both studies vs. none in the resp. placebo groups.  The most common AE across groups was nasopharyngitis.  Conclusions : Oral tofacitinib demonstrated significant efficacy vs. placebo during the initial 16 wk of treatment in patients with moderate-to-severe psoriasis.  Safety findings were consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTWaBXP7bJbLVg90H21EOLACvtfcHk0lgKmX4L3UyBkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyns73E&md5=2029ed12ccdeaeb36ab87425a8c534c1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14018%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DElewski%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DS.%2BR.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DLangley%26aufirst%3DR.%26aulast%3DLuger%26aufirst%3DT.%26aulast%3DThaci%26aufirst%3DD.%26aulast%3DBuonanno%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DLan%26aufirst%3DS.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3Dand%2520for%2520the%2520OPT%2520Pivotal%25201%2520and%2520OPT%2520Pivotal%25202%2520Investigators.%2520Tofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Plaque%2520Psoriasis%253A%2520Results%2520from%2520Two%252C%2520Randomised%252C%2520Placebo-Controlled%252C%2520Phase%25203%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2015%26volume%3D173%26spage%3D949%26epage%3D961%26doi%3D10.1111%2Fbjd.14018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gladman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigby, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azevedo, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaszuba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrikx, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanik, K. S.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1536</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1615977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1615977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29045207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGlt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1525-1536&author=D.+Gladmanauthor=W.+Rigbyauthor=V.+F.+Azevedoauthor=F.+Behrensauthor=R.+Blancoauthor=A.+Kaszubaauthor=E.+Kudlaczauthor=C.+Wangauthor=S.+Menonauthor=T.+Hendrikxauthor=K.+S.+Kanik&title=Tofacitinib+for+Psoriatic+Arthritis+in+Patients+with+an+Inadequate+Response+to+TNF+Inhibitors&doi=10.1056%2FNEJMoa1615977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors</span></div><div class="casAuthors">Gladman, Dafna; Rigby, William; Azevedo, Valderilio F.; Behrens, Frank; Blanco, Ricardo; Kaszuba, Andrzej; Kudlacz, Elizabeth; Wang, Cunshan; Menon, Sujatha; Hendrikx, Thijs; Kanik, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1525-1536</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis.  We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors. methods In this 6-mo randomized, placebo-controlled, double-blind, phase 3 trial, we randomly assigned 395 patients, in a 2:2:1:1 ratio, to four regimens: 5 mg of tofacitinib administered orally twice daily (132 patients); 10 mg of tofacitinib twice daily (132 patients); placebo, with a switch to 5 mg of tofacitinib twice daily at 3 mo (66 patients); or placebo, with a switch to 10 mg of tofacitinib twice daily at 3 mo (65 patients).  Data from the patients who received placebo during the first 3 mo of the trial were pooled.  The primary end points were the percentage of patients who had at least 20% improvement according to the criteria of the American College of Rheumatol. (ACR20 response) and the change from baseline score on the Health Assessment Questionnaire-Disability Index (HAQ-DI; scores range from 0 to 3, with higher scores indicating greater disability) at the month 3 anal. results At 3 mo, the rates of ACR20 response were 50% with the 5-mg dose of tofacitinib and 47% with the 10-mg dose, as compared with 24% with placebo (P<0.001 for both comparisons); the corresponding mean changes from baseline in HAQ-DI score were -0.39 and -0.35, as compared with -0.14 (P<0.001 for both comparisons).  Serious adverse events occurred in 4% of the patients who received the 5-mg dose of tofacitinib continuously and in 6% who received the 10-mg dose continuously.  Over the course of 6 mo, there were four serious infections, three herpes zoster infections, one myocardial infarction, and one ischemic stroke among the patients who received tofacitinib continuously.  Elevations of aspartate and alanine aminotransferase concns. of three or more times the upper limit of the normal range occurred in more patients who received tofacitinib continuously than in patients who received placebo followed by tofacitinib. conclusions In this trial involving patients with active psoriatic arthritis who had had an inadequate response to TNF inhibitors, tofacitinib was more effective than placebo over 3 mo in reducing disease activity.  Adverse events were more frequent with tofacitinib than with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbGiFUjTAPrVg90H21EOLACvtfcHk0lgKmX4L3UyBkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGlt7bE&md5=a38f9b9fc29590f98f94fe599a13df74</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1615977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1615977%26sid%3Dliteratum%253Aachs%26aulast%3DGladman%26aufirst%3DD.%26aulast%3DRigby%26aufirst%3DW.%26aulast%3DAzevedo%26aufirst%3DV.%2BF.%26aulast%3DBehrens%26aufirst%3DF.%26aulast%3DBlanco%26aufirst%3DR.%26aulast%3DKaszuba%26aufirst%3DA.%26aulast%3DKudlacz%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DMenon%26aufirst%3DS.%26aulast%3DHendrikx%26aufirst%3DT.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26atitle%3DTofacitinib%2520for%2520Psoriatic%2520Arthritis%2520in%2520Patients%2520with%2520an%2520Inadequate%2520Response%2520to%2520TNF%2520Inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1525%26epage%3D1536%26doi%3D10.1056%2FNEJMoa1615977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bachelez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van de Kerkhof, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakusevich, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimenti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papacharalambous, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawadrous, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolk, R.</span></span> <span> </span><span class="NLM_article-title">and for the OPT Compare Investigators. Tofacitinib versus Etanercept or Placebo in Moderate-to-Severe Chronic Plaque Psoriasis: a Phase 3 Randomised Non-Inferiority Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>386</i></span>,  <span class="NLM_fpage">552</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)62113-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0140-6736%2814%2962113-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26051365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2015&pages=552-561&author=H.+Bachelezauthor=P.+C.+Van+de+Kerkhofauthor=R.+Strohalauthor=A.+Kubanovauthor=F.+Valenzuelaauthor=J.-H.+Leeauthor=V.+Yakusevichauthor=S.+Chimentiauthor=J.+Papacharalambousauthor=J.+Proulxauthor=P.+Guptaauthor=H.+Tanauthor=M.+Tawadrousauthor=H.+Valdezauthor=R.+Wolk&title=and+for+the+OPT+Compare+Investigators.+Tofacitinib+versus+Etanercept+or+Placebo+in+Moderate-to-Severe+Chronic+Plaque+Psoriasis%3A+a+Phase+3+Randomised+Non-Inferiority+Trial&doi=10.1016%2FS0140-6736%2814%2962113-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial</span></div><div class="casAuthors">Bachelez, Herve; van de Kerkhof, Peter C. M.; Strohal, Robert; Kubanov, Alexey; Valenzuela, Fernando; Lee, Joo-Heung; Yakusevich, Vladimir; Chimenti, Sergio; Papacharalambous, Jocelyne; Proulx, James; Gupta, Pankaj; Tan, Huaming; Tawadrous, Margaret; Valdez, Hernan; Wolk, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">386</span>
        (<span class="NLM_cas:issue">9993</span>),
    <span class="NLM_cas:pages">552-561</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New therapeutic options are needed for patients with psoriasis.  Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis.  In this study, we aimed to compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.  In this phase 3, randomised, multicentre, double-dummy, placebo-controlled, 12-wk, non-inferiority trial, adult patients with chronic stable plaque psoriasis (for ≥12 mo) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index (PASI) score of 12 or higher and a Physician's Global Assessment (PGA) of moderate or severe, and had failed to respond to, had a contraindication to, or were intolerant to at least one conventional systemic therapy, were enrolled from 122 investigational dermatol. centers worldwide.  Eligible patients were randomly assigned in a 3:3:3:1 ratio to receive tofacitinib 5 mg or 10 mg twice daily at about 12 h intervals, etanercept 50 mg s.c. twice weekly at about 3-4 day intervals, or placebo.  Randomisation was done by a computer-generated randomisation schedule, and all patients and study personnel were masked to treatment assignment.  The co-primary endpoints were the proportion of patients at week 12 with at least a 75% redn. in the PASI score from baseline (PASI75 response) and the proportion of patients achieving a PGA score of "clear" or "almost clear" (PGA response), analyzed in the full anal. set (all patients who were randomised and received at least one dose of study drug).  This study is registered with ClinicalTrials.gov, no. NCT01241591.  Between Nov 29, 2010, and Sept 13, 2012, we enrolled 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four treatment groups (330 to tofacitinib 5 mg twice daily, 332 to tofacitinib 10 mg twice daily, 336 to etanercept 50 mg twice weekly, and 108 to placebo).  Of these patients, 1101 actually received their assigned study medication (329 in the tofactinib 5 mg group, 330 in the tofacitinib 10 mg group, 335 in the etanercept group, and 107 in the placebo group).  At week 12, PASI75 responses were recorded in 130 (39·5%) of 329 patients in the tofacitinib 5 mg group, 210 (63·6%) of 330 in the tofacitinib 10 mg group, 197 (58·8%) of 335 in the etanercept group, and six (5·6%) of 107 in the placebo group.  A PGA response was achieved by 155 (47·1%) of 329 patients in the tofacitinib 5 mg group, 225 (68·2%) of 330 in the tofacitinib 10 mg group, 222 (66·3%) of 335 in the etanercept group, and 16 (15·0%) of 107 in the placebo group.  The rate of adverse events was similar across the four groups, with serious adverse events occurring in seven (2%) of 329 patients in the tofacitinib 5 mg group, five (2%) of 330 in the tofacitinib 10 mg group, seven (2%) of 335 in the etanercept group, and two (2%) of 107 in the placebo group.  Three (1%) of 329 patients in the tofacitinib 5 mg group, ten (3%) of 330 in the tofacitinib 10 mg group, 11 (3%) of 335 in the etanercept group, and four (4%) of 107 patients in the placebo group discontinued their assigned treatment because of adverse events.  In patients with moderate-to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50 mg twice weekly.  The adverse event rates over 12 wk were similar for tofacitinib and etanercept.  This study indicates that in the future tofacitinib could provide a convenient and well-tolerated therapeutic option for patients with moderate-to-severe plaque psoriasis.Pfizer Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKYcpF-XDavrVg90H21EOLACvtfcHk0lhjPbEyIK9HIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgt77J&md5=797adf1a67423e82ce47d96aa87daa6b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2962113-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252962113-9%26sid%3Dliteratum%253Aachs%26aulast%3DBachelez%26aufirst%3DH.%26aulast%3DVan%2Bde%2BKerkhof%26aufirst%3DP.%2BC.%26aulast%3DStrohal%26aufirst%3DR.%26aulast%3DKubanov%26aufirst%3DA.%26aulast%3DValenzuela%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.-H.%26aulast%3DYakusevich%26aufirst%3DV.%26aulast%3DChimenti%26aufirst%3DS.%26aulast%3DPapacharalambous%26aufirst%3DJ.%26aulast%3DProulx%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DTawadrous%26aufirst%3DM.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DWolk%26aufirst%3DR.%26atitle%3Dand%2520for%2520the%2520OPT%2520Compare%2520Investigators.%2520Tofacitinib%2520versus%2520Etanercept%2520or%2520Placebo%2520in%2520Moderate-to-Severe%2520Chronic%2520Plaque%2520Psoriasis%253A%2520a%2520Phase%25203%2520Randomised%2520Non-Inferiority%2520Trial%26jtitle%3DLancet%26date%3D2015%26volume%3D386%26spage%3D552%26epage%3D561%26doi%3D10.1016%2FS0140-6736%2814%2962113-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asahina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imafuku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomochika, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyoizumi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtsuki, M.</span></span> <span> </span><span class="NLM_article-title">and study investigators. Oral Tofacitinib Efficacy, Safety and Tolerability in Japanese Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: A Randomized, Double-Blind, Phase 3 Study</span>. <i>J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1111/1346-8138.13258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1111%2F1346-8138.13258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26875540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ehtLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=869-880&author=A.+Asahinaauthor=T.+Etohauthor=A.+Igarashiauthor=S.+Imafukuauthor=H.+Saekiauthor=Y.+Shibasakiauthor=Y.+Tomochikaauthor=S.+Toyoizumiauthor=M.+Nagaokaauthor=M.+Ohtsuki&title=and+study+investigators.+Oral+Tofacitinib+Efficacy%2C+Safety+and+Tolerability+in+Japanese+Patients+with+Moderate-to-Severe+Plaque+Psoriasis+and+Psoriatic+Arthritis%3A+A+Randomized%2C+Double-Blind%2C+Phase+3+Study&doi=10.1111%2F1346-8138.13258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study</span></div><div class="casAuthors">Asahina, Akihiko; Etoh, Takafumi; Igarashi, Atsuyuki; Imafuku, Shinichi; Saeki, Hidehisa; Shibasaki, Yoshiyuki; Tomochika, Yukiko; Toyoizumi, Shigeyuki; Nagaoka, Makoto; Ohtsuki, Mamitaro; the study investigators</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-880</span>CODEN:
                <span class="NLM_cas:coden">JDMYAG</span>;
        ISSN:<span class="NLM_cas:issn">0385-2407</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis and psoriatic arthritis.  Japanese patients aged 20 years or more with moderate to severe plaque psoriasis and/or psoriatic arthritis were double-blindly randomized 1:1 to tofacitinib 5 or 10 mg b.i.d. for 16 wk, open-label 10 mg b.i.d. for 4 wk, then variable 5 or 10 mg b.i.d. to Week 52.  Primary end-points at Week 16 were the proportion of patients achieving at least a 75% redn. in Psoriasis Area and Severity Index (PASI75) and Physician's Global Assessment of "clear" or "almost clear" (PGA response) for psoriasis, and 20% or more improvement in American College of Rheumatol. criteria (ACR20) for patients with psoriatic arthritis.  Safety was assessed throughout.  Eighty-seven patients met eligibility criteria for moderate to severe plaque psoriasis (5 mg b.i.d., n = 43; 10 mg b.i.d., n = 44), 12 met eligibility criteria for psoriatic arthritis (5 mg b.i.d., n = 4; 10 mg b.i.d., n = 8) including five who met both criteria (10 mg b.i.d.).  At Week 16, 62.8% and 72.7% of patients achieved PASI75 with tofacitinib 5 and 10 mg b.i.d., resp.; 67.4% and 68.2% achieved PGA responses; all patients with psoriatic arthritis achieved ACR20.  Responses were maintained through Week 52.  Adverse events occurred in 83% of patients through Week 52, including four (4.3%) serious adverse events and three (3.2%) serious infections (all herpes zoster).  No malignancies, cardiovascular events or deaths occurred.  Tofacitinib (both doses) demonstrated efficacy in patients with moderate to severe plaque psoriasis and/or psoriatic arthritis through 52 wk; safety findings were generally consistent with prior studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNrigERixmbVg90H21EOLACvtfcHk0lhjPbEyIK9HIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ehtLzP&md5=b8151e6cdee3c1496b633e8b115156e4</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2F1346-8138.13258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1346-8138.13258%26sid%3Dliteratum%253Aachs%26aulast%3DAsahina%26aufirst%3DA.%26aulast%3DEtoh%26aufirst%3DT.%26aulast%3DIgarashi%26aufirst%3DA.%26aulast%3DImafuku%26aufirst%3DS.%26aulast%3DSaeki%26aufirst%3DH.%26aulast%3DShibasaki%26aufirst%3DY.%26aulast%3DTomochika%26aufirst%3DY.%26aulast%3DToyoizumi%26aufirst%3DS.%26aulast%3DNagaoka%26aufirst%3DM.%26aulast%3DOhtsuki%26aufirst%3DM.%26atitle%3Dand%2520study%2520investigators.%2520Oral%2520Tofacitinib%2520Efficacy%252C%2520Safety%2520and%2520Tolerability%2520in%2520Japanese%2520Patients%2520with%2520Moderate-to-Severe%2520Plaque%2520Psoriasis%2520and%2520Psoriatic%2520Arthritis%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Phase%25203%2520Study%26jtitle%3DJ.%2520Dermatol.%26date%3D2016%26volume%3D43%26spage%3D869%26epage%3D880%26doi%3D10.1111%2F1346-8138.13258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandborn, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Haens, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feagan, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinisch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niezychowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawendy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panés, J.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1736</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1606910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1606910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=28467869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOns7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=1723-1736&author=W.+J.+Sandbornauthor=C.+Suauthor=B.+E.+Sandsauthor=G.+R.+D%E2%80%99Haensauthor=S.+Vermeireauthor=S.+Schreiberauthor=S.+Daneseauthor=B.+G.+Feaganauthor=W.+Reinischauthor=W.+Niezychowskiauthor=G.+Friedmanauthor=N.+Lawendyauthor=D.+Yuauthor=D.+Woodworthauthor=A.+Mukherjeeauthor=H.+Zhangauthor=P.+Healeyauthor=J.+Pan%C3%A9s&title=Tofacitinib+as+Induction+and+Maintenance+Therapy+for+Ulcerative+Colitis&doi=10.1056%2FNEJMoa1606910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib as induction and maintenance therapy for ulcerative colitis</span></div><div class="casAuthors">Sandborn, William J.; Su, Chinyu; Sands, Bruce E.; D'Haens, Geert R.; Vermeire, Severine; Schreiber, Stefan; Danese, Silvio; Feagan, Brian G.; Reinisch, Walter; Niezychowski, Wojciech; Friedman, Gary; Lawendy, Nervin; Yu, Dahong; Woodworth, Deborah; Mukherjee, Arnab; Zhang, Haiying; Healey, Paul; Panes, Julian</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1723-1736</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Tofacitinib, an oral, small-mol. Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.  We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.  METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.  In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, resp., who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 wk.  The primary end point was remission at 8 wk.  In the OCTAVE Sustain trial, 593 patients who had a clin. response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 wk.  The primary end point was remission at 52 wk.  RESULTS: In the OCTAVE Induction 1 trial, remission at 8 wk occurred in 18.5% of the patients in the tofacitinib group vs. 8.2% in the placebo group (P = 0.007); in the OCTAVE Induction 2 trial, remission occurred in 16.6% vs. 3.6% (P<0.001).  In the OCTAVE Sustain trial, remission at 52 wk occurred in 34.3% of the patients in the 5-mg tofacitinib group and 40.6% in the 10-mg tofacitinib group vs. 11.1% in the placebo group (P<0.001 for both comparisons with placebo).  In the OCTAVE Induction 1 and 2 trials, the rates of overall infection and serious infection were higher with tofacitinib than with placebo.  In the OCTAVE Sustain trial, the rate of serious infection was similar across the three treatment groups, and the rates of overall infection and herpes zoster infection were higher with tofacitinib than with placebo.  Across all three trials, adjudicated nonmelanoma skin cancer occurred in five patients who received tofacitinib and in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none who received placebo; as compared with placebo, tofacitinib was assocd. with increased lipid levels.  CONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohzKgMAVSZh7Vg90H21EOLACvtfcHk0liWfIQ9bhvnrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOns7jP&md5=3e56aba6c1cba05688f4c59d8e66f0de</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1606910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1606910%26sid%3Dliteratum%253Aachs%26aulast%3DSandborn%26aufirst%3DW.%2BJ.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%2BR.%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DDanese%26aufirst%3DS.%26aulast%3DFeagan%26aufirst%3DB.%2BG.%26aulast%3DReinisch%26aufirst%3DW.%26aulast%3DNiezychowski%26aufirst%3DW.%26aulast%3DFriedman%26aufirst%3DG.%26aulast%3DLawendy%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DWoodworth%26aufirst%3DD.%26aulast%3DMukherjee%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHealey%26aufirst%3DP.%26aulast%3DPan%25C3%25A9s%26aufirst%3DJ.%26atitle%3DTofacitinib%2520as%2520Induction%2520and%2520Maintenance%2520Therapy%2520for%2520Ulcerative%2520Colitis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D1723%26epage%3D1736%26doi%3D10.1056%2FNEJMoa1606910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span> </span><span class="NLM_article-title">A Multicentre,
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
of Oral CP-690,550 as an Induction Therapy in Subjects with Moderate-to-Severe
Ulcerative Colitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT01465763</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT01465763?term=nct01465763&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT01465763?term=nct01465763&rank=1</a>   (first posted Oct. 21, 2011).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Multicentre%2C%0ARandomized%2C+Double-Blind%2C+Placebo-Controlled%2C+Parallel-Group+Study%0Aof+Oral+CP-690%2C550+as+an+Induction+Therapy+in+Subjects+with+Moderate-to-Severe%0AUlcerative+Colitis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT01465763%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01465763%3Fterm%3Dnct01465763%26rank%3D1+%28first+posted+Oct.+21%2C+2011%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Multicentre%252C%250ARandomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Parallel-Group%2520Study%250Aof%2520Oral%2520CP-690%252C550%2520as%2520an%2520Induction%2520Therapy%2520in%2520Subjects%2520with%2520Moderate-to-Severe%250AUlcerative%2520Colitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT01465763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span> </span><span class="NLM_article-title">Pfizer Announces FDA Approval
of Xeljanz (Tofacitinib) and Xeljanz XR for the Treatment of Active
Psoriatic Arthritis</span>.  <i>Pfizer Press Release</i>; <span class="NLM_publisher-name">Pfizer</span>, Dec 14, 2017; <a href="https://press.pfizer.com/press-release/pfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor" class="extLink">https://press.pfizer.com/press-release/pfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor</a> (accessed Aug 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Announces+FDA+Approval%0Aof+Xeljanz+%28Tofacitinib%29+and+Xeljanz+XR+for+the+Treatment+of+Active%0APsoriatic+Arthritis.+Pfizer+Press+Release%3B+Pfizer%2C+Dec+14%2C+2017%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor+%28accessed+Aug+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Announces%2520FDA%2520Approval%250Aof%2520Xeljanz%2520%2528Tofacitinib%2529%2520and%2520Xeljanz%2520XR%2520for%2520the%2520Treatment%2520of%2520Active%250APsoriatic%2520Arthritis%26jtitle%3DPfizer%2520Press%2520Release%26pub%3DPfizer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span> </span><span class="NLM_article-title">Pfizer Announces U.S. FDA Approves Xeljanz
(Tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative
Colitis</span>.  <i>Pfizer Press Release</i>; <span class="NLM_publisher-name">Pfizer</span>, May 30, 2018; <a href="https://press.pfizer.com/press-release/pfizer-announces-us-fda-approves-xeljanz-tofacitinib-treatment-moderately-severely-act" class="extLink">https://press.pfizer.com/press-release/pfizer-announces-us-fda-approves-xeljanz-tofacitinib-treatment-moderately-severely-act</a> (accessed Aug 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Announces+U.S.+FDA+Approves+Xeljanz%0A%28Tofacitinib%29+for+the+Treatment+of+Moderately+to+Severely+Active+Ulcerative%0AColitis.+Pfizer+Press+Release%3B+Pfizer%2C+May+30%2C+2018%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-announces-us-fda-approves-xeljanz-tofacitinib-treatment-moderately-severely-act+%28accessed+Aug+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Announces%2520U.S.%2520FDA%2520Approves%2520Xeljanz%250A%2528Tofacitinib%2529%2520for%2520the%2520Treatment%2520of%2520Moderately%2520to%2520Severely%2520Active%2520Ulcerative%250AColitis%26jtitle%3DPfizer%2520Press%2520Release%26pub%3DPfizer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span> </span><span class="NLM_article-title">Pfizer Receives Complete Response Letter
from FDA for Oral Xeljanz (Tofacitinib Citrate) Supplemental New Drug
Application for Moderate to Severe Chronic Plaque Psoriasis</span>.  <i>Pfizer Press Release</i>; <span class="NLM_publisher-name">Pfizer</span>, Oct 14, 2015; <a href="https://press.pfizer.com/press-release/pfizer-receives-complete-response-letter-fda-oral-xeljanz-tofacitinib-citrate-suppleme" class="extLink">https://press.pfizer.com/press-release/pfizer-receives-complete-response-letter-fda-oral-xeljanz-tofacitinib-citrate-suppleme</a> (accessed Dec 20, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Receives+Complete+Response+Letter%0Afrom+FDA+for+Oral+Xeljanz+%28Tofacitinib+Citrate%29+Supplemental+New+Drug%0AApplication+for+Moderate+to+Severe+Chronic+Plaque+Psoriasis.+Pfizer+Press+Release%3B+Pfizer%2C+Oct+14%2C+2015%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-receives-complete-response-letter-fda-oral-xeljanz-tofacitinib-citrate-suppleme+%28accessed+Dec+20%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Receives%2520Complete%2520Response%2520Letter%250Afrom%2520FDA%2520for%2520Oral%2520Xeljanz%2520%2528Tofacitinib%2520Citrate%2529%2520Supplemental%2520New%2520Drug%250AApplication%2520for%2520Moderate%2520to%2520Severe%2520Chronic%2520Plaque%2520Psoriasis%26jtitle%3DPfizer%2520Press%2520Release%26pub%3DPfizer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span> </span><span class="NLM_article-title">Efficacy and Safety of Tofacitinib in Subjects
with Active Ankylosing Spondylitis (AS)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03502616</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03502616?term=NCT03502616&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03502616?term=NCT03502616&rank=1</a> (first posted April 18, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Efficacy+and+Safety+of+Tofacitinib+in+Subjects%0Awith+Active+Ankylosing+Spondylitis+%28AS%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03502616%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03502616%3Fterm%3DNCT03502616%26rank%3D1+%28first+posted+April+18%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tofacitinib%2520in%2520Subjects%250Awith%2520Active%2520Ankylosing%2520Spondylitis%2520%2528AS%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03502616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span> </span><span class="NLM_article-title">Topical Tofacitinib for the Treatment
of Alopecia Areata and Variants</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02812342</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02812342?term=NCT02812342&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02812342?term=NCT02812342&rank=1</a> (first posted June 24, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Topical+Tofacitinib+for+the+Treatment%0Aof+Alopecia+Areata+and+Variants.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02812342%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02812342%3Fterm%3DNCT02812342%26rank%3D1+%28first+posted+June+24%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DTopical%2520Tofacitinib%2520for%2520the%2520Treatment%250Aof%2520Alopecia%2520Areata%2520and%2520Variants%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02812342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span> </span><span class="NLM_article-title">Tofacitinib for Inflammatory Eye
Disease</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03580343</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03580343?term=NCT03580343&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03580343?term=NCT03580343&rank=1</a> (first posted July 9, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tofacitinib+for+Inflammatory+Eye%0ADisease.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03580343%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03580343%3Fterm%3DNCT03580343%26rank%3D1+%28first+posted+July+9%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DTofacitinib%2520for%2520Inflammatory%2520Eye%250ADisease%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03580343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span> </span><span class="NLM_article-title">Oral Tofacitinib in Adult Subjects
with Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus
(SLE)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03159936</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03159936?term=NCT03159936&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03159936?term=NCT03159936&rank=1</a> (first posted May 19, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+Tofacitinib+in+Adult+Subjects%0Awith+Discoid+Lupus+Erythematosus+%28DLE%29+and+Systemic+Lupus+Erythematosus%0A%28SLE%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03159936%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03159936%3Fterm%3DNCT03159936%26rank%3D1+%28first+posted+May+19%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DOral%2520Tofacitinib%2520in%2520Adult%2520Subjects%250Awith%2520Discoid%2520Lupus%2520Erythematosus%2520%2528DLE%2529%2520and%2520Systemic%2520Lupus%2520Erythematosus%250A%2528SLE%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03159936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span> </span><span class="NLM_article-title">Evaluation of Tofacitinib in Early
Diffuse Cutaneous Systemic Sclerosis (dcSSc) (TOFA-SSc)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03274076</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03274076?term=NCT03274076&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03274076?term=NCT03274076&rank=1</a> (first posted Sept. 6, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Evaluation+of+Tofacitinib+in+Early%0ADiffuse+Cutaneous+Systemic+Sclerosis+%28dcSSc%29+%28TOFA-SSc%29.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03274076%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03274076%3Fterm%3DNCT03274076%26rank%3D1+%28first+posted+Sept.+6%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DEvaluation%2520of%2520Tofacitinib%2520in%2520Early%250ADiffuse%2520Cutaneous%2520Systemic%2520Sclerosis%2520%2528dcSSc%2529%2520%2528TOFA-SSc%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03274076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span> </span><span class="NLM_article-title">Study of Tofacitinib in Refractory
Dermatomyositis (STIR)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT03002649</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03002649?term=NCT03002649&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03002649?term=NCT03002649&rank=1</a> (first posted Dec. 20, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+of+Tofacitinib+in+Refractory%0ADermatomyositis+%28STIR%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT03002649%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03002649%3Fterm%3DNCT03002649%26rank%3D1+%28first+posted+Dec.+20%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520of%2520Tofacitinib%2520in%2520Refractory%250ADermatomyositis%2520%2528STIR%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT03002649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deisseroth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R. U.S.</span></span> <span> </span><span class="NLM_article-title">Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3212</span>– <span class="NLM_lpage">3217</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1158%2F1078-0432.CCR-12-0653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=22544377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3212-3217&author=A.+Deisserothauthor=E.+Kaminskasauthor=J.+Grilloauthor=W.+Chenauthor=H.+Saberauthor=H.+L.+Luauthor=M.+D.+Rothmannauthor=S.+Brarauthor=J.+Wangauthor=C.+Garnettauthor=J.+Bullockauthor=L.+B.+Burkeauthor=A.+Rahmanauthor=R.+Sridharaauthor=A.+Farrellauthor=R.+U.S.+Pazdur&title=Food+and+Drug+Administration+Approval%3A+Ruxolitinib+for+the+Treatment+of+Patients+with+Intermediate+and+High-Risk+Myelofibrosis&doi=10.1158%2F1078-0432.CCR-12-0653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis</span></div><div class="casAuthors">Deisseroth, Albert; Kaminskas, Edvardas; Grillo, Joseph; Chen, Wei; Saber, Haleh; Lu, Hong L.; Rothmann, Mark D.; Brar, Satjit; Wang, Jian; Garnett, Christine; Bullock, Julie; Burke, Laurie B.; Rahman, Atiqur; Sridhara, Rajeshwari; Farrell, Ann; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3212-3217</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On Nov. 16, 2011, the U.S.  Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis.  This approval was based on the results of 2 large randomized phase III trials that enrolled patients with intermediate-2 or high-risk myelofibrosis and compared ruxolitinib with placebo (study 1) or best available therapy (study 2).  The primary efficacy endpoint was the proportion of patients who experienced a redn. in spleen vol. of ≥35% at 24 wk (study 1) or 48 wk (study 2).  The key secondary endpoint in study 1 was the proportion of patients who experienced a ≥50% improvement from baseline in myelofibrosis total symptom score at 24 wk.  The results of these studies showed that a greater proportion of patients treated with ruxolitinib experienced a ≥35% redn. in spleen vol. as compared with those treated with placebo (42% vs. 1%, P < 0.0001) or best available therapy (29% vs. 0%, P < 0.0001).  A greater proportion of patients in study 1 experienced a ≥50% redn. in the myelofibrosis total symptom score during treatment with ruxolitinib than with placebo (46% vs. 5%, P < 0.0001).  Ruxolitinib treatment was assocd. with an increased incidence of grades III and IV anemia, thrombocytopenia, and neutropenia.  This is the first drug approved for myelofibrosis.  Clin Cancer Res; 18(12); 3212-7. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44NYcMOixiLVg90H21EOLACvtfcHk0lguBXlmW6im4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Olt7g%253D&md5=6ed7731730708b8a8cbdc5d766065ddb</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0653%26sid%3Dliteratum%253Aachs%26aulast%3DDeisseroth%26aufirst%3DA.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DGrillo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%2BL.%26aulast%3DRothmann%26aufirst%3DM.%2BD.%26aulast%3DBrar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGarnett%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DBurke%26aufirst%3DL.%2BB.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DFarrell%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%2BU.S.%26atitle%3DFood%2520and%2520Drug%2520Administration%2520Approval%253A%2520Ruxolitinib%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Intermediate%2520and%2520High-Risk%2520Myelofibrosis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3212%26epage%3D3217%26doi%3D10.1158%2F1078-0432.CCR-12-0653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span> </span><span class="NLM_article-title">A Study
of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory
Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation
(REACH3)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03112603</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03112603?term=NCT03112603&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03112603?term=NCT03112603&rank=1v</a> (first posted April 13, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+Ruxolitinib+vs+Best+Available+Therapy+%28BAT%29+in+Patients+With+Steroid-refractory%0AChronic+Graft+vs.+Host+Disease+%28GvHD%29+After+Bone+Marrow+Transplantation%0A%28REACH3%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03112603%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03112603%3Fterm%3DNCT03112603%26rank%3D1v+%28first+posted+April+13%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%250Aof%2520Ruxolitinib%2520vs%2520Best%2520Available%2520Therapy%2520%2528BAT%2529%2520in%2520Patients%2520With%2520Steroid-refractory%250AChronic%2520Graft%2520vs.%2520Host%2520Disease%2520%2528GvHD%2529%2520After%2520Bone%2520Marrow%2520Transplantation%250A%2528REACH3%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03112603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span> </span><span class="NLM_article-title">TRuE AD2—An Efficacy and
Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic
Dermatitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03745651</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03745651?term=NCT03745651&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03745651?term=NCT03745651&rank=1</a> (first posted November 19, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=TRuE+AD2%E2%80%94An+Efficacy+and%0ASafety+Study+of+Ruxolitinib+Cream+in+Adolescents+and+Adults+With+Atopic%0ADermatitis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03745651%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03745651%3Fterm%3DNCT03745651%26rank%3D1+%28first+posted+November+19%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DTRuE%2520AD2%25E2%2580%2594An%2520Efficacy%2520and%250ASafety%2520Study%2520of%2520Ruxolitinib%2520Cream%2520in%2520Adolescents%2520and%2520Adults%2520With%2520Atopic%250ADermatitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03745651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludivico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogulec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span> <span> </span><span class="NLM_article-title">Baricitinib in Patients with Refractory Rheumatoid Arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1507247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27028914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1243-1252&author=M.+C.+Genoveseauthor=J.+Kremerauthor=O.+Zamaniauthor=C.+Ludivicoauthor=M.+Krogulecauthor=L.+Xieauthor=S.+D.+Beattieauthor=A.+E.+Kochauthor=T.+E.+Cardilloauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=S.+de+Bonoauthor=D.+E.+Schlichtingauthor=J.+S.+Smolen&title=Baricitinib+in+Patients+with+Refractory+Rheumatoid+Arthritis&doi=10.1056%2FNEJMoa1507247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib in patients with refractory rheumatoid arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Kremer, Joel; Zamani, Omid; Ludivico, Charles; Krogulec, Marek; Xie, Li; Beattie, Scott D.; Koch, Alisa E.; Cardillo, Tracy E.; Rooney, Terence P.; Macias, William L.; de Bono, Stephanie; Schlichting, Douglas E.; Smolen, Josef S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1243-1252</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biol. disease-modifying antirheumatic drugs (DMARDs).  METHODS In this phase 3 study involving 527 patients with an inadequate response to or unacceptable side effects assocd. with one or more tumor necrosis factor inhibitors, other biol. DMARDs, or both, we randomly assigned the patients in a 1:1:1 ratio to baricitinib at a dose of 2 or 4 mg daily or placebo for 24 wk.  End points, tested hierarchically at week 12 to control type 1 error, were the American College of Rheumatol. 20% (ACR20) response (primary end point), the Health Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP), and a Simplified Disease Activity Index (SDAI) score of 3.3 or less (on a scale of 0.1 to 86.0, with a score of 3.3 or less indicating remission).  Comparisons with placebo were made first with the 4-mg dose of baricitinib and then with the 2-mg dose.  RESULTS Significantly more patients receiving baricitinib at the 4-mg dose than those receiving placebo had an ACR20 response at week 12 (55% vs. 27%, P<0.001).  Differences between the higher-dose baricitinib group and the placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score of 3.3 or less.  Adverse-event rates through 24 wk were higher for patients receiving the 2-mg dose of baricitinib and those receiving the 4-mg dose than for patients receiving placebo (71% and 77%, resp., vs. 64%), including infections (44% and 40%, vs. 31%).  The rates of serious adverse events were 4%, 10%, and 7% in the three groups, resp.  Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke, occurred in the higher-dose group.  Baricitinib was assocd. with a small redn. in neutrophil levels and increases in serum creatinine and low-d. lipoprotein cholesterol levels.  CONCLUSIONS In patients with rheumatoid arthritis and an inadequate response to biol. DMARDs, baricitinib at a daily dose of 4 mg was assocd. with clin. improvement at 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj72FQTLOsQLVg90H21EOLACvtfcHk0lguBXlmW6im4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E&md5=d7d317ee88fae38379b3b07c420349f6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507247%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZamani%26aufirst%3DO.%26aulast%3DLudivico%26aufirst%3DC.%26aulast%3DKrogulec%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DBaricitinib%2520in%2520Patients%2520with%2520Refractory%2520Rheumatoid%2520Arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1243%26epage%3D1252%26doi%3D10.1056%2FNEJMoa1507247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. M.</span></span> <span> </span><span class="NLM_article-title">A Randomized Phase 2b Trial of Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Moderate-to-Severe Psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1111/bjd.14403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1111%2Fbjd.14403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26800231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=1266-1276&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Ramanauthor=D.+Dischauthor=D.+E.+Schlichtingauthor=C.+Gaichauthor=W.+Maciasauthor=X.+Zhangauthor=J.+M.+Janes&title=A+Randomized+Phase+2b+Trial+of+Baricitinib%2C+an+Oral+Janus+Kinase+%28JAK%29+1%2FJAK2+Inhibitor%2C+in+Patients+with+Moderate-to-Severe+Psoriasis&doi=10.1111%2Fbjd.14403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Raman, M.; Disch, D.; Schlichting, D. E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.  Objectives : To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.  Methods : Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 wk (Part A).  Dose adjustment for 12 addnl. weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score.  The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 wk for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population.  Results : At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75.  All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 wk and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 wk.  More than 81% of PASI-75 responders maintained their scores through 24 wk.  During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, resp.  No opportunistic infections were obsd. in any treatment group.  Dose-dependent changes in lab. values were obsd.  Conclusions : Patients with moderate-to-severe psoriasis treated with baricitinib for 12 wk achieved significant improvements in PASI-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVPv2558vrrVg90H21EOLACvtfcHk0lgEKBrHGWeNTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN&md5=37df34807683b4742548f192f99654f6</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14403%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DDisch%26aufirst%3DD.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DGaich%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJanes%26aufirst%3DJ.%2BM.%26atitle%3DA%2520Randomized%2520Phase%25202b%2520Trial%2520of%2520Baricitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520%2528JAK%2529%25201%252FJAK2%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Moderate-to-Severe%2520Psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D174%26spage%3D1266%26epage%3D1276%26doi%3D10.1111%2Fbjd.14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span> </span><span class="NLM_article-title">A Study of Baricitinib (LY3009104) in Participants with Systemic
Lupus Erythematosus (SLE)</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02708095</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02708095?term=NCT02708095&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02708095?term=NCT02708095&rank=1</a>  (first posted Mar 15, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+Baricitinib+%28LY3009104%29+in+Participants+with+Systemic%0ALupus+Erythematosus+%28SLE%29.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02708095%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02708095%3Fterm%3DNCT02708095%26rank%3D1+%28first+posted+Mar+15%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520Baricitinib%2520%2528LY3009104%2529%2520in%2520Participants%2520with%2520Systemic%250ALupus%2520Erythematosus%2520%2528SLE%2529%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02708095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span> </span><span class="NLM_article-title">A Study of Baricitinib (LY3009104)
in Participants with Moderate-to-Severe Atopic Dermatitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National
Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2015</span>;  <span class="NLM_fpage">NCT02576938</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02576938?term=NCT02576938&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02576938?term=NCT02576938&rank=1</a> (first posted Oct 15, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study+of+Baricitinib+%28LY3009104%29%0Ain+Participants+with+Moderate-to-Severe+Atopic+Dermatitis.+ClinicalTrials.gov%3B+U.S.+National%0AInstitutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+NCT02576938%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02576938%3Fterm%3DNCT02576938%26rank%3D1+%28first+posted+Oct+15%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520Study%2520of%2520Baricitinib%2520%2528LY3009104%2529%250Ain%2520Participants%2520with%2520Moderate-to-Severe%2520Atopic%2520Dermatitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%250AInstitutes%2520of%2520Health%26date%3D2015%26spage%3DNCT02576938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span> </span><span class="NLM_article-title">FDA Approves Olumiant (Baricitinib)
2-mg tablets for the Treatment of Adults with Moderately-to-Severely
Active Rheumatoid Arthritis</span>.  <i>Lilly Press Release</i>; <span class="NLM_publisher-name">Eli Lilly and Company</span>, June 1, <span class="NLM_year">2018</span>; <a href="https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults" class="extLink">https://investor.lilly.com/news-releases/news-release-details/fda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults</a> (accessed Sept. 5, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+Approves+Olumiant+%28Baricitinib%29%0A2-mg+tablets+for+the+Treatment+of+Adults+with+Moderately-to-Severely%0AActive+Rheumatoid+Arthritis.+Lilly+Press+Release%3B+Eli+Lilly+and+Company%2C+June+1%2C+2018%3B+https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Ffda-approves-olumiantr-baricitinib-2-mg-tablets-treatment-adults+%28accessed+Sept.+5%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520Approves%2520Olumiant%2520%2528Baricitinib%2529%250A2-mg%2520tablets%2520for%2520the%2520Treatment%2520of%2520Adults%2520with%2520Moderately-to-Severely%250AActive%2520Rheumatoid%2520Arthritis%26jtitle%3DLilly%2520Press%2520Release%26pub%3DEli%2520Lilly%2520and%2520Company%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span> </span><span class="NLM_article-title">Oral JAK Inhibitor Smyraf Tablets Approved
in Japan for the Treatment of Rheumatoid Arthritis (including prevention
of structural joint damage) in Patients Who Have an Inadequate Response
to Conventional Therapies</span>.  <i>Astellas Press
Release</i>; <span class="NLM_publisher-name">Astellas Pharma, Inc.</span>, March 26, <span class="NLM_year">2019</span>; <a href="https://www.astellas.com/en/news/14651" class="extLink">https://www.astellas.com/en/news/14651</a> (accessed April 26, 2019).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Oral+JAK+Inhibitor+Smyraf+Tablets+Approved%0Ain+Japan+for+the+Treatment+of+Rheumatoid+Arthritis+%28including+prevention%0Aof+structural+joint+damage%29+in+Patients+Who+Have+an+Inadequate+Response%0Ato+Conventional+Therapies.+Astellas+Press%0ARelease%3B+Astellas+Pharma%2C+Inc.%2C+March+26%2C+2019%3B+https%3A%2F%2Fwww.astellas.com%2Fen%2Fnews%2F14651+%28accessed+April+26%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DOral%2520JAK%2520Inhibitor%2520Smyraf%2520Tablets%2520Approved%250Ain%2520Japan%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%2520%2528including%2520prevention%250Aof%2520structural%2520joint%2520damage%2529%2520in%2520Patients%2520Who%2520Have%2520an%2520Inadequate%2520Response%250Ato%2520Conventional%2520Therapies%26jtitle%3DAstellas%2520Press%250ARelease%26pub%3DAstellas%2520Pharma%252C%2520Inc%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrzycka-Sienkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardiel, M. H.</span></span> <span> </span><span class="NLM_article-title">Peficitinib, a JAK Inhibitor, in Combination with Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">932</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1002/art.40054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fart.40054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=28118538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=932-942&author=M.+C.+Genoveseauthor=M.+Greenwaldauthor=C.+Coddingauthor=A.+Zubrzycka-Sienkiewiczauthor=A.+J.+Kivitzauthor=A.+Wangauthor=K.+Shayauthor=X.+Wangauthor=J.+P.+Gargauthor=M.+H.+Cardiel&title=Peficitinib%2C+a+JAK+Inhibitor%2C+in+Combination+with+Limited+Conventional+Synthetic+Disease-Modifying+Antirheumatic+Drugs+in+the+Treatment+of+Moderate-to-Severe+Rheumatoid+Arthritis&doi=10.1002%2Fart.40054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Greenwald, Maria; Codding, Christine; Zubrzycka-Sienkiewicz, Anna; Kivitz, Alan J.; Wang, Annie; Shay, Kathyjo; Wang, Xuegong; Garg, Jay P.; Cardiel, Mario H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">932-942</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA).  Methods : In this randomized, double-blind, phase IIb trial, patients with RA (n = 289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 wk.  The primary end point was the percentage of patients who met the American College of Rheumatol. 20% improvement criteria (achieved an ACR20 response) at week 12.  Results : ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (P < 0.05), 56.3% (P < 0.01), and 29.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, resp.  Patients in the peficitinib 100 mg and 150 mg groups achieved a rapid and statistically significant ACR20 response compared with those in the placebo group (P < 0.05), reaching statistical significance by week 2.  Overall, the incidence of adverse events (AEs) was similar between patients receiving peficitinib and those receiving placebo.  The most common AEs were upper respiratory tract infection (5% [n = 15]), nausea (4% [n = 12]), and urinary tract infection (4% [n = 10]).  There was 1 case of herpes zoster in the placebo group, and 1 serious infection (limb abscess) in the peficitinib 25 mg group.  There were no incidences of grade 2 or higher neutropenia or lymphopenia.  Conclusion : In patients with moderate-to-severe RA, orally administered once-daily peficitinib in combination with limited csDMARDs resulted in a dose-dependent ACR20 response rate over 12 wk with satisfactory tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAtngQf8klmrVg90H21EOLACvtfcHk0lgEKBrHGWeNTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D&md5=761c5b89cdbbe60108a1bceb1d699ecd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fart.40054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40054%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DCodding%26aufirst%3DC.%26aulast%3DZubrzycka-Sienkiewicz%26aufirst%3DA.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DShay%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGarg%26aufirst%3DJ.%2BP.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26atitle%3DPeficitinib%252C%2520a%2520JAK%2520Inhibitor%252C%2520in%2520Combination%2520with%2520Limited%2520Conventional%2520Synthetic%2520Disease-Modifying%2520Antirheumatic%2520Drugs%2520in%2520the%2520Treatment%2520of%2520Moderate-to-Severe%2520Rheumatoid%2520Arthritis%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D932%26epage%3D942%26doi%3D10.1002%2Fart.40054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuro, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riese, R. J.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.3899/jrheum.130683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.3899%2Fjrheum.130683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=24692527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=837-852&author=J.+Wollenhauptauthor=J.+Silverfieldauthor=E.+B.+Leeauthor=J.+R.+Curtisauthor=S.+P.+Woodauthor=K.+Somaauthor=C.+I.+Nduakaauthor=B.+Bendaauthor=D.+Grubenauthor=H.+Nakamuraauthor=Y.+Komuroauthor=S.+H.+Zwillichauthor=L.+Wangauthor=R.+J.+Riese&title=Safety+and+Efficacy+of+Tofacitinib%2C+an+Oral+Janus+Kinase+Inhibitor%2C+for+the+Treatment+of+Rheumatoid+Arthritis+in+Open-label&doi=10.3899%2Fjrheum.130683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</span></div><div class="casAuthors">Wollenhaupt, Juergen; Silverfield, Joel; Lee, Eun Bong; Curtis, Jeffrey R.; Wood, Susan P.; Soma, Koshika; Nduaka, Chudy I.; Benda, Birgitta; Gruben, David; Nakamura, Hiroyuki; Komuro, Yoshihiro; Zwillich, Samuel H.; Wang, Lisy; Riese, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">837-852</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To describe the longterm safety and efficacy profile of tofacitinib in patients with moderate to severe active rheumatoid arthritis (RA).  Methods: Data were pooled from 2 open-label studies (NCT00413699, NCT00661661) involving patients who had participated in qualifying phase I, II, or III index studies of tofacitinib.  Safety data included over 60 mo of observation; efficacy data are reported up to Month 48.  Treatment was initiated with tofacitinib 5 or 10 mg twice daily.  Primary endpoints were adverse events (AE) and lab. safety data.  Secondary endpoints included American College of Rheumatol. (ACR) response rates, and Disease Activity Score (28 joints) (DAS28)-4[erythrocyte sedimentation rate (ESR)] and Health Assessment Questionnaire-Disability Index (HAQ-DI) assessments.  Results: Overall, 4102 patients were treated for 5963 patient-years; mean (max.) treatment duration was 531 (1844) days; 20.8% of patients discontinued treatment over 60 mo.  The most common AE were nasopharyngitis (12.7%) and upper respiratory tract infection (10.5%).  Serious AE were reported in 15.4% of patients with an exposure-estd. incidence rate of 11.1 events/100 patient-years.  Serious infections were reported in 4.5% of patients with an exposure-estd. incidence rate of 3.1 events/100 patient-years (95% CI: 2.66-3.55).  Mean values for lab. variables were stable over time and consistent with phase II and III studies.  Persistent efficacy was demonstrated through Month 48, as measured by ACR response rate (ACR20/50/70) DAS28-4-ESR, and HAQ-DI.  Safety and efficacy were similar for patients receiving tofacitinib as monotherapy or with background nonbiol. disease-modifying antirheumatic drugs.  Conclusion: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 mo in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Scjk1FOYMrVg90H21EOLACvtfcHk0lgqhECVkesgoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyiurbJ&md5=0c8cf68569627b3948b6c275ec69d8df</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.130683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.130683%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%2BP.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DNduaka%26aufirst%3DC.%2BI.%26aulast%3DBenda%26aufirst%3DB.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DNakamura%26aufirst%3DH.%26aulast%3DKomuro%26aufirst%3DY.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRiese%26aufirst%3DR.%2BJ.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Tofacitinib%252C%2520an%2520Oral%2520Janus%2520Kinase%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%2520in%2520Open-label%26jtitle%3DJ.%2520Rheumatol.%26date%3D2014%26volume%3D41%26spage%3D837%26epage%3D852%26doi%3D10.3899%2Fjrheum.130683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, W. C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Man, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chui, C. S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worsley, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. C. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span>. <i>BMC Musculoskelet. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi"> DOI: 10.1186/1471-2474-14-298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1186%2F1471-2474-14-298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=24139404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVWnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=298&author=Y.+Heauthor=A.Y.+S.+Wongauthor=E.+W.+Chanauthor=W.+C.+Y.+Lauauthor=K.+K.+C.+Manauthor=C.+S.+L.+Chuiauthor=A.+J.+Worsleyauthor=I.+C.+K.+Wong&title=Efficacy+and+Safety+of+Tofacitinib+in+the+Treatment+of+Rheumatoid+Arthritis%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1186%2F1471-2474-14-298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis</span></div><div class="casAuthors">He, Ying; Wong, Angel Y. S.; Chan, Esther W.; Lau, Wallis C. Y.; Man, Kenneth K. C.; Chui, Celine S. L.; Worsley, Alan J.; Wong, Ian C. K.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Musculoskeletal Disorders</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298/1-298/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">BMDMCE</span>;
        ISSN:<span class="NLM_cas:issn">1471-2474</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US Food and Drug Administration (FDA).  There are several randomized clin. trials (RCTs) that have investigated the efficacy and safety of tofacitinib in adult patients with rheumatoid arthritis (RA).  A systematic review with a meta-anal. of RCTs was undertaken to det. the efficacy and safety of tofacitinib in treating patients with RA.  Methods: Electronic and clin. trials register databases were searched for published RCTs of tofacitinib between 2009 and 2013.  Outcomes of interest include 20% and 50% improvement in the American College of Rheumatol. Scale (ACR20 and ACR50) response rates, rates of infection, the no. of immunol./haematol. adverse events (AEs), deranged lab. results (hepatic, renal, haematol. tests and lipoprotein level) and the incidence of drug withdrawal.  Results: Eight RCTs (n = 3,791) were reviewed.  Significantly greater ACR20 response rates were obsd. in patients receiving tofacitinib 5 and 10 mg bid (twice daily) vs. placebo at week 12, with risk ratios (RR) of 2.20 (95% CI 1.58, 3.07) and 2.38 (95% CI 1.81, 3.14) resp.  The effect was maintained at week 24 for 5 mg bid (RR 1.94; 95% CI 1.55, 2.44) and 10 mg bid (RR 2.20; 95% CI 1.76, 2.75).  The ACR50 response rate was also significantly higher for patients receiving tofacitinib 5 mg bid (RR 2.91; 95% CI 2.03, 4.16) and 10 mg bid (RR 3.32; 95% CI 2.33, 4.72) compared to placebo at week 12.  Patients in the tofacitinib group had significantly lower mean neutrophil counts, higher serum creatinine, higher percentage change of LDL/HDL and a higher risk of ALT/AST > 1 ULN (upper limit of normal) vs. placebo.  There were no significant differences in AEs and withdrawal due to AEs compared to placebo.  Conclusion: Tofacitinib is efficacious and well tolerated in patients with MTX-resistant RA up to a period of 24 wk.  However, haematol., liver function tests and lipoproteins should be monitored.  Long-term efficacy and pharmacovigilance studies are recommended.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUBb07WA5QhLVg90H21EOLACvtfcHk0lgqhECVkesgoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVWnsLk%253D&md5=91b198e3c0af406dee90bf105ee2a27c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2F1471-2474-14-298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2474-14-298%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DA.Y.%2BS.%26aulast%3DChan%26aufirst%3DE.%2BW.%26aulast%3DLau%26aufirst%3DW.%2BC.%2BY.%26aulast%3DMan%26aufirst%3DK.%2BK.%2BC.%26aulast%3DChui%26aufirst%3DC.%2BS.%2BL.%26aulast%3DWorsley%26aufirst%3DA.%2BJ.%26aulast%3DWong%26aufirst%3DI.%2BC.%2BK.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tofacitinib%2520in%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DBMC%2520Musculoskelet.%2520Disord.%26date%3D2013%26volume%3D14%26spage%3D298%26doi%3D10.1186%2F1471-2474-14-298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zerbini, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomonte, A. B.</span></span> <span> </span><span class="NLM_article-title">Tofacitinib for the Treatment of Rheumatoid Arthritis</span>. <i>Expert Rev. Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1586/eci.12.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1586%2Feci.12.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=22607178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=319-331&author=C.+A.+Zerbiniauthor=A.+B.+Lomonte&title=Tofacitinib+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1586%2Feci.12.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Tofacitinib for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Zerbini, Cristiano A. F.; Lomonte, Andrea Barranjard Vannucci</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">319-331</span>CODEN:
                <span class="NLM_cas:coden">ERCIBU</span>;
        ISSN:<span class="NLM_cas:issn">1744-666X</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects approx. 1% of the worldwide population.  It primarily targets the synovial membrane of joints, leading to a synovial proliferation, joint cartilage lesion and erosions in the adjacent bone tissue.  The disease is usually progressive and if the inflammatory process is not adequately suppressed, joint deformity takes place, leading to a significant functional disability and work incapacity.  Over the last decade, biol. therapy was established as a major step towards disease control in those patients who experienced failure after treatment with disease-modifying antirheumatic drugs.  Despite the growing no. of biol. agents with different immunol. targets, a significant no. of patients do not receive appropriate disease control, or have the use of these agents limited because of adverse events.  As such, the search for new mols. with a higher efficacy and better safety profile is ongoing.  This article focuses on a new drug, tofacitinib, which is a synthetic disease-modifying antirheumatic drug for treatment of RA.  Preclin. studies in arthritis and transplantation animal models are reviewed as a background for the possible use of tofacitinib treatment in humans.  Four Phase II (one A and three B dose-ranging) trials lasting from 6 to 24 wk in RA patients showed significant American College of Rheumatol. 20 improvements as early as week 2 and sustained at week 24 in two studies.  Tofacitinib Phase III studies in RA are included in a clin. program called ORAL Trials'.  Long-term follow-up from ongoing studies will contribute to a more accurate tofacitinib efficacy and safety profile.  Trials in other illness such as psoriasis, psoriatic arthritis, renal transplant rejection prevention, inflammatory bowel diseases and dry eye are underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHpLt7-aROnLVg90H21EOLACvtfcHk0lgqhECVkesgoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yqs78%253D&md5=ad557fe321ab93878f9eace579afcadf</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1586%2Feci.12.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Feci.12.19%26sid%3Dliteratum%253Aachs%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DLomonte%26aufirst%3DA.%2BB.%26atitle%3DTofacitinib%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Immunol.%26date%3D2012%26volume%3D8%26spage%3D319%26epage%3D331%26doi%3D10.1586%2Feci.12.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neubauer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffstadt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeffer, K.</span></span> <span> </span><span class="NLM_article-title">Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)81168-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0092-8674%2800%2981168-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=9590174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+Deficiency+Defines+an+Essential+Developmental+Checkpoint+in+Definitive+Hematopoiesis&doi=10.1016%2FS0092-8674%2800%2981168-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span></div><div class="casAuthors">Neubauer, Hans; Cumano, Ana; Muller, Mathias; Wu, Hong; Huffstadt, Ulrike; Pfeffer, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">397-409</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors.  A targeted inactivation of Jak2 was performed.  Jak2-/- embryos are anemic and die around day 12.5 postcoitum.  Primitive erythrocytes are found, but definitive erythropoiesis is absent.  Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe.  Fetal liver BFU-E and CFU-E colonies are completely absent.  However, multilineage hematopoietic stem cells (CD34low, c-kitpos) can be found, and B lymphopoiesis appears intact.  In contrast to IFNα stimulation, Jak2-/- cells do not respond to IFNγ.  Jak2-/- embryonic stem cells are competent for LIF signaling.  The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8oeTh0n3FcbVg90H21EOLACvtfcHk0lgHpD7COrInIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFCjtLk%253D&md5=74275b73c807331170c096145e69af94</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981168-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981168-X%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520Deficiency%2520Defines%2520an%2520Essential%2520Developmental%2520Checkpoint%2520in%2520Definitive%2520Hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409%26doi%3D10.1016%2FS0092-8674%2800%2981168-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Lommen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smits, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouannigot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deprez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciesielski, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span> <span> </span><span class="NLM_article-title">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9323</span>– <span class="NLM_lpage">9342</span>, <span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+Selective+JAK1+Inhibitors%3A+From+Hit+Identification+to+GLPG0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0lgHpD7COrInIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520Selective%2520JAK1%2520Inhibitors%253A%2520From%2520Hit%2520Identification%2520to%2520GLPG0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494)</span>. <i>BMC Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=23&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+Vitro+and+In+Vivo+Characterization+of+the+JAK1+Selectivity+of+Upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNγ, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2ebBzA-5vWXM4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Characterization%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520Upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatology%26date%3D2018%26volume%3D2%26spage%3D23%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+A+Selective+JAK1+Clinical+Candidate+for+the+Treatment+of+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lg4enf1VzM1OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520A%2520Selective%2520JAK1%2520Clinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westhovens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alten, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enriquez-Sosa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P.</span></span> <span> </span><span class="NLM_article-title">Filgotinib (GLPG0634/GS-6034), an Oral JAK1 Selective Inhibitor, is Effective in Combination with Methotrexate (MTX) in Patients with Active Rheumatoid Arthritis and Insufficient Response to MTX: Results from a Randomised, Dose-Finding Study (DARWIN 1)</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1008</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-210104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1136%2Fannrheumdis-2016-210104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27993829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=998-1008&author=R.+Westhovensauthor=P.+C.+Taylorauthor=R.+Altenauthor=D.+Pavlovaauthor=F.+Enriquez-Sosaauthor=M.+Mazurauthor=M.+Greenwaldauthor=A.+Van+der+Aaauthor=F.+Vanhoutteauthor=C.+Tassetauthor=P.+Harrison&title=Filgotinib+%28GLPG0634%2FGS-6034%29%2C+an+Oral+JAK1+Selective+Inhibitor%2C+is+Effective+in+Combination+with+Methotrexate+%28MTX%29+in+Patients+with+Active+Rheumatoid+Arthritis+and+Insufficient+Response+to+MTX%3A+Results+from+a+Randomised%2C+Dose-Finding+Study+%28DARWIN+1%29&doi=10.1136%2Fannrheumdis-2016-210104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)</span></div><div class="casAuthors">Westhovens, R.; Taylor, P. C.; Alten, R.; Pavlova, D.; Enriquez-Sosa, F.; Mazur, M.; Greenwald, M.; Van der Aa, A.; Vanhoutte, F.; Tasset, C.; Harrison, P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">998-1009</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.  In this 24-wk phase IIb study, patients with moderate-to-severe active RA receiving a stable dose of MTX were randomised (1:1:1:1:1:1:1) to receive placebo or 50, 100 or 200 mg filgotinib, administered once daily or twice daily.  Primary end point was the percentage of patients achieving a week 12 American College of Rheumatol. (ACR)20 response.  Overall, 594 patients were randomised and treated.  At week 12, significantly more patients receiving filgotinib 100 mg once daily or 200 mg daily (both regimens) achieved an ACR20 response vs. placebo.  For other key end points at week 12 (ACR50, ACR-N, Disease Activity Score based on 28 joints and C reactive protein value, Clin. Disease Activity Index, Simplified Disease Activity Index and Health Assessment Questionnaire-Disability Index), differences in favor of 100 or 200 mg filgotinib daily were seen vs. placebo; responses were maintained or improved through to week 24.  Rapid onset of action and dosedependent responses were obsd. for most efficacy end points and were assocd. with an increased Hb concn.  No significant differences between once-daily and twice-daily regimens were seen.  Treatment-emergent adverse event rates were similar in placebo and filgotinib groups.  Serious infections occurred in one and five patients in the placebo and filgotinib groups, resp.  No tuberculosis or opportunistic infections were reported.  Filgotinib as add-on to MTX improved the signs and symptoms of active RA over 24 wk and was assocd. with a rapid onset of action.  Filgotinib was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSL1GnhmEyfLVg90H21EOLACvtfcHk0lg4enf1VzM1OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOitr%252FM&md5=be3caaaf07ed3981f50545e651630b69</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-210104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-210104%26sid%3Dliteratum%253Aachs%26aulast%3DWesthovens%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26aulast%3DAlten%26aufirst%3DR.%26aulast%3DPavlova%26aufirst%3DD.%26aulast%3DEnriquez-Sosa%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DP.%26atitle%3DFilgotinib%2520%2528GLPG0634%252FGS-6034%2529%252C%2520an%2520Oral%2520JAK1%2520Selective%2520Inhibitor%252C%2520is%2520Effective%2520in%2520Combination%2520with%2520Methotrexate%2520%2528MTX%2529%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%2520and%2520Insufficient%2520Response%2520to%2520MTX%253A%2520Results%2520from%2520a%2520Randomised%252C%2520Dose-Finding%2520Study%2520%2528DARWIN%25201%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2017%26volume%3D76%26spage%3D998%26epage%3D1008%26doi%3D10.1136%2Fannrheumdis-2016-210104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kavanaugh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cseuz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reshetko, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P.</span></span> <span> </span><span class="NLM_article-title">Filgotinib (GLPG0634/GS-6034), an Oral Selective JAK1 Inhibitor, is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Randomised, Dose-Finding Study (DARWIN 2)</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2016-210105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1136%2Fannrheumdis-2016-210105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27993828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWgtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2017&pages=1009-1019&author=A.+Kavanaughauthor=J.+Kremerauthor=L.+Ponceauthor=R.+Cseuzauthor=O.+V.+Reshetkoauthor=M.+Stanislavchukauthor=M.+Greenwaldauthor=A.+Van+der+Aaauthor=F.+Vanhoutteauthor=C.+Tassetauthor=P.+Harrison&title=Filgotinib+%28GLPG0634%2FGS-6034%29%2C+an+Oral+Selective+JAK1+Inhibitor%2C+is+Effective+as+Monotherapy+in+Patients+with+Active+Rheumatoid+Arthritis%3A+Results+from+a+Randomised%2C+Dose-Finding+Study+%28DARWIN+2%29&doi=10.1136%2Fannrheumdis-2016-210105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)</span></div><div class="casAuthors">Kavanaugh, A.; Kremer, J.; Ponce, L.; Cseuz, R.; Reshetko, O. V.; Stanislavchuk, M.; Greenwald, M.; Van der Aa, A.; Vanhoutte, F.; Tasset, C.; Harrison, P.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1009-1020</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX).  Methods: In this 24-wk phase IIb study, patients with moderately to severely active RA were randomised (1:1:1:1) to receive 50, 100 or 200 mg filgotinib once daily, or placebo, after a ≥4-wk washout from MTX.  The primary end point was the percentage of patients achieving an American College of Rheumatol. (ACR)20 response at week 12.  Results: Overall, 283 patients were randomised and treated.  At week 12, significantly more patients receiving filgotinib at any dose achieved ACR20 responses vs. placebo (≥65% vs 29%, p<0.001).  For other key end points at week 12 (ACR50, ACR70, ACR-N, Disease Activity Score based on 28 joints and C reactive protein, Clin. Disease Activity Index, Simplified Disease Activity Index and Health Assessment Questionnaire-Disability Index) significant differences from baseline in favor of filgotinib 100 and 200 mg vs. placebo were seen; responses were maintained or improved through week 24.  Rapid onset of action was obsd. for most efficacy end points.  Dose-dependent increases in Hb were obsd.  The percentage of patients with treatment-emergent adverse events (TEAE) was similar in the placebo and filgotinib groups (∼40%).  Eight patients on filgotinib and one on placebo had a serious TEAE, and four patients, all of whom received filgotinib, experienced a serious infection.  No tuberculosis or opportunistic infections were reported.  Conclusions: Over 24 wk, filgotinib as monotherapy was efficacious in treating the signs and symptoms of active RA, with a rapid onset of action.  Filgotinib was generally well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLpycEqtJBZLVg90H21EOLACvtfcHk0lj0j57rpeWFTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWgtbvN&md5=157b24f3a339ba9837a7fa79d2a209b8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2016-210105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2016-210105%26sid%3Dliteratum%253Aachs%26aulast%3DKavanaugh%26aufirst%3DA.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DPonce%26aufirst%3DL.%26aulast%3DCseuz%26aufirst%3DR.%26aulast%3DReshetko%26aufirst%3DO.%2BV.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DP.%26atitle%3DFilgotinib%2520%2528GLPG0634%252FGS-6034%2529%252C%2520an%2520Oral%2520Selective%2520JAK1%2520Inhibitor%252C%2520is%2520Effective%2520as%2520Monotherapy%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%253A%2520Results%2520from%2520a%2520Randomised%252C%2520Dose-Finding%2520Study%2520%2528DARWIN%25202%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2017%26volume%3D76%26spage%3D1009%26epage%3D1019%26doi%3D10.1136%2Fannrheumdis-2016-210105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhoutte, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voloshyn, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanislavchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meuleners, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van’t Klooster, G.</span></span> <span> </span><span class="NLM_article-title">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective Janus Kinase 1 Inhibitor, after Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1949</span>– <span class="NLM_lpage">1959</span>, <span class="refDoi"> DOI: 10.1002/art.40186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fart.40186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=28622463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=1949-1959&author=F.+Vanhoutteauthor=M.+Mazurauthor=O.+Voloshynauthor=M.+Stanislavchukauthor=A.+Van+der+Aaauthor=F.+Namourauthor=R.+Galienauthor=L.+Meulenersauthor=G.+van%E2%80%99t+Klooster&title=Efficacy%2C+Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+Filgotinib%2C+a+Selective+Janus+Kinase+1+Inhibitor%2C+after+Short-Term+Treatment+of+Rheumatoid+Arthritis%3A+Results+of+Two+Randomized+Phase+IIa+Trials&doi=10.1002%2Fart.40186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials</span></div><div class="casAuthors">Vanhoutte, Frederic; Mazur, Minodora; Voloshyn, Oleksandr; Stanislavchuk, Mykola; Van der Aa, Annegret; Namour, Florence; Galien, Rene; Meuleners, Luc; van 't Klooster, Gerben</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1949-1959</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : JAK inhibitors have shown efficacy in rheumatoid arthritis (RA).  We undertook this study to test our hypothesis that selective inhibition of JAK-1 would combine good efficacy with a better safety profile compared with less selective JAK inhibitors.  Methods : In two 4-wk exploratory, double-blind, placebo-controlled phase IIa trials, 127 RA patients with an insufficient response to methotrexate (MTX) received filgotinib (GLPG0634, GS-6034) oral capsules (100 mg twice daily or 30, 75, 150, 200, or 300 mg once daily) or placebo, added onto a stable regimen of MTX, to evaluate safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of filgotinib.  The primary efficacy end point was the no. and percentage of patients in each treatment group meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 4.  Results : Treatment with filgotinib at 75-300 mg met the primary end point and showed early onset of efficacy.  ACR20 response rates progressively increased to week 4, and the Disease Activity Score in 28 joints using the C-reactive protein (CRP) level decreased.  Marked and sustained improvements were obsd. in serum CRP level and other PD markers.  The PK of filgotinib and its major metabolite was dose proportional over the 30-300 mg range.  Early side effects seen with other less selective JAK inhibitors were not obsd. (e.g., there was no worsening of anemia [JAK-2 inhibition related], no effects on liver transaminases, and no increase in low-d. lipoprotein or total cholesterol).  A limited decrease in neutrophils without neutropenia was consistent with immunomodulatory effects through JAK-1 inhibition.  There were no infections.  Overall, filgotinib was well tolerated.  Events related to study drug were mild or moderate and transient during therapy, and the most common such event was nausea.  Conclusion : Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7oTo2cM5so7Vg90H21EOLACvtfcHk0lj0j57rpeWFTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFyrurjP&md5=b704bd2b69231f1aa95815120b8cf922</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fart.40186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40186%26sid%3Dliteratum%253Aachs%26aulast%3DVanhoutte%26aufirst%3DF.%26aulast%3DMazur%26aufirst%3DM.%26aulast%3DVoloshyn%26aufirst%3DO.%26aulast%3DStanislavchuk%26aufirst%3DM.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DNamour%26aufirst%3DF.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DMeuleners%26aufirst%3DL.%26aulast%3Dvan%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26atitle%3DEfficacy%252C%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520Filgotinib%252C%2520a%2520Selective%2520Janus%2520Kinase%25201%2520Inhibitor%252C%2520after%2520Short-Term%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%253A%2520Results%2520of%2520Two%2520Randomized%2520Phase%2520IIa%2520Trials%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D1949%26epage%3D1959%26doi%3D10.1002%2Fart.40186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vermeire, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petryka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehbacher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebuterne, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roblin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klopocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewska-Jarosinska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baranovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sike, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoyanova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasset, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, P.</span></span> <span> </span><span class="NLM_article-title">Clinical Remission in Patients with Moderate-to-Severe Crohn’s Disease Treated with Filgotinib (the FITZROY Study): Results from a Phase 2, Double-Blind, Randomised</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(16)32537-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0140-6736%2816%2932537-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27988142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFSmu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=2017&pages=266-275&author=S.+Vermeireauthor=S.+Schreiberauthor=R.+Petrykaauthor=T.+Kuehbacherauthor=X.+Hebuterneauthor=X.+Roblinauthor=M.+Klopockaauthor=A.+Goldisauthor=M.+Wisniewska-Jarosinskaauthor=A.+Baranovskyauthor=R.+Sikeauthor=K.+Stoyanovaauthor=C.+Tassetauthor=A.+Van+der+Aaauthor=P.+Harrison&title=Clinical+Remission+in+Patients+with+Moderate-to-Severe+Crohn%E2%80%99s+Disease+Treated+with+Filgotinib+%28the+FITZROY+Study%29%3A+Results+from+a+Phase+2%2C+Double-Blind%2C+Randomised&doi=10.1016%2FS0140-6736%2816%2932537-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial</span></div><div class="casAuthors">Vermeire, Severine; Schreiber, Stefan; Petryka, Robert; Kuehbacher, Tanja; Hebuterne, Xavier; Roblin, Xavier; Klopocka, Maria; Goldis, Adrian; Wisniewska-Jarosinska, Maria; Baranovsky, Andrey; Sike, Robert; Stoyanova, Kremena; Tasset, Chantal; Van der Aa, Annegret; Harrison, Pille</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">10066</span>),
    <span class="NLM_cas:pages">266-275</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.  The FITZROY study examd. the efficacy and safety of filgotinib for the treatment of moderate-to-severe Crohn's disease.  We did a randomised, double-blind, placebo-controlled phase 2 study, which recruited patients from 52 centers in nine European countries.  We enrolled eligible patients aged 18-75 years with a documented history of ileal, colonic, or ileocolonic Crohn's disease for 3 mo or more before screening, as assessed by colonoscopy and supported by histol., and a Crohn's Disease Activity Index (CDAI) score during screening between 220 and 450 inclusive.  Patients were randomly assigned (3:1) to receive filgotinib 200 mg once a day or placebo for 10 wk.  Patients were stratified according to previous anti-tumor necrosis factor alpha exposure, C-reactive protein concn. at screening (≤10 mg/L or >10 mg/L), and oral corticosteroid use at baseline, using an interactive web-based response system.  The primary endpoint was clin. remission, defined as CDAI less than 150 at week 10.  After week 10, patients were assigned based on responder status to filgotinib 100 mg once a day, filgotinib 200 mg once a day, or placebo for an observational period lasting a further 10 wk.  The filgotinib and placebo treatment groups were compared using ANCOVA models and logistic regression models contg. baseline values and randomisation stratification factors as fixed effects.  Analyses were done on the intention-to-treat non-responder imputation set.  The trial was registered at ClinicalTrials.gov, no. NCT02048618.  Between Feb 3, 2014, and July 10, 2015, we enrolled 174 patients with active Crohn's disease confirmed by centrally read endoscopy (130 in the filgotinib 200 mg group and 44 in the placebo group).  In the intention-to-treat population, 60 (47%) of 128 patients treated with filgotinib 200 mg achieved clin. remission at week 10 vs. ten (23%) of 44 patients treated with placebo (difference 24 percentage points [95% CI 9-39], p=0·0077).  In a pooled anal. of all periods of filgotinib and placebo exposure over 20 wk, serious treatment-emergent adverse effects were reported in 14 (9%) of 152 patients treated with filgotinib and three (4%) of 67 patients treated with placebo.  Filgotinib induced clin. remission in significantly more patients with active Crohn's disease compared with placebo, and had an acceptable safety profile.Galapagos.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMvAPgtQG5WbVg90H21EOLACvtfcHk0ljtGVq5dhxjww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFSmu7jL&md5=1b70edfe4ba93e35a35974a0ca52b149</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2932537-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252932537-5%26sid%3Dliteratum%253Aachs%26aulast%3DVermeire%26aufirst%3DS.%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DPetryka%26aufirst%3DR.%26aulast%3DKuehbacher%26aufirst%3DT.%26aulast%3DHebuterne%26aufirst%3DX.%26aulast%3DRoblin%26aufirst%3DX.%26aulast%3DKlopocka%26aufirst%3DM.%26aulast%3DGoldis%26aufirst%3DA.%26aulast%3DWisniewska-Jarosinska%26aufirst%3DM.%26aulast%3DBaranovsky%26aufirst%3DA.%26aulast%3DSike%26aufirst%3DR.%26aulast%3DStoyanova%26aufirst%3DK.%26aulast%3DTasset%26aufirst%3DC.%26aulast%3DVan%2Bder%2BAa%26aufirst%3DA.%26aulast%3DHarrison%26aufirst%3DP.%26atitle%3DClinical%2520Remission%2520in%2520Patients%2520with%2520Moderate-to-Severe%2520Crohn%25E2%2580%2599s%2520Disease%2520Treated%2520with%2520Filgotinib%2520%2528the%2520FITZROY%2520Study%2529%253A%2520Results%2520from%2520a%2520Phase%25202%252C%2520Double-Blind%252C%2520Randomised%26jtitle%3DLancet%26date%3D2017%26volume%3D389%26spage%3D266%26epage%3D275%26doi%3D10.1016%2FS0140-6736%2816%2932537-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubbert-Roth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, M.-E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangan, A. L.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Upadacitinib in Patients with Active Rheumatoid Arthritis Refractory to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-BEYOND): a Double-Blind, Randomised Controlled Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">2513</span>– <span class="NLM_lpage">2524</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31116-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2FS0140-6736%2818%2931116-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29908670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=2513-2524&author=M.+C.+Genoveseauthor=R.+Fleischmannauthor=B.+Combeauthor=S.+Hallauthor=A.+Rubbert-Rothauthor=Y.+Zhangauthor=Y.+Zhouauthor=M.-E.+F.+Mohamedauthor=S.+Meerweinauthor=A.+L.+Pangan&title=Safety+and+Efficacy+of+Upadacitinib+in+Patients+with+Active+Rheumatoid+Arthritis+Refractory+to+Biologic+Disease-Modifying+Anti-Rheumatic+Drugs+%28SELECT-BEYOND%29%3A+a+Double-Blind%2C+Randomised+Controlled+Phase+3+Trial&doi=10.1016%2FS0140-6736%2818%2931116-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial</span></div><div class="casAuthors">Genovese, Mark C.; Fleischmann, Roy; Combe, Bernard; Hall, Stephen; Rubbert-Roth, Andrea; Zhang, Ying; Zhou, Yijie; Mohamed, Mohamed-Eslam F.; Meerwein, Sebastian; Pangan, Aileen L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10139</span>),
    <span class="NLM_cas:pages">2513-2524</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis.  We did this study to further assess the safety and efficacy of upadacitinib in patients with an inadequate response to biol. disease-modifying anti-rheumatic drugs (bDMARDs).  We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries.  Patients were aged 18 years or older, had active rheumatoid arthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs).  We randomly assigned patients (2:2:1:1) by interactive response technol. to receive once-daily oral extended-release upadacitinib 15 mg or 30 mg or placebo for 12 wk, followed by upadacitinib 15 mg or 30 mg from week 12 onwards.  The two sep. primary endpoints were the proportions of patients achieving a 20% improvement in American College of Rheumatol. criteria (ACR20) at week 12 and the proportion of patients achieving a 28-joint disease activity score using C-reactive protein (DAS28[CRP]) of 3·2 or less at week 12.  Efficacy and safety analyses were done in the modified intention-to-treat population of all patients who received at least one dose of study drug.  Data are presented up to week 24 of this ongoing study.  The trial is registered with ClinicalTrials.gov (NCT02706847).  Between March 15, 2016, and Jan 10, 2017, 499 patients were randomly assigned (n=165 upadacitinib 15 mg; n=165 upadacitinib 30 mg; n=85 placebo then upadacitinib 15 mg; and n=84 placebo then upadacitinib 30 mg) and one patient was withdrawn from the 15 mg upadacitinib group before the start of study treatment.  Mean disease duration was 13·2 years (SD 9·5); 235 (47%) of 498 patients had received one previous bDMARD, 137 (28%) had received two, and 125 (25%) had received at least three; 451 (91%) patients completed treatment up to week 12 and 419 (84%) patients completed treatment up to week 24.  At week 12, ACR20 was achieved by 106 (65%; 95% CI 57-72) of 164 patients receiving upadacitinib 15 mg and 93 (56%; 49-64) of 165 patients receiving upadacitinib 30 mg compared with 48 (28%; 22-35) of 169 patients receiving placebo (p<0·0001 for each dose vs placebo).  DAS28(CRP) of 3·2 or less was achieved by 71 (43%; 95% CI 36-51) of 164 patients receiving upadacitinib 15 mg and 70 (42%; 35-50) of 165 patients receiving upadacitinib 30 mg vs. 24 (14%; 9-20) of 169 patients receiving placebo (p<0·0001 for each dose vs placebo).  Up to week 12, overall nos. of patients with adverse events were similar for the placebo group (95 [56%] of 169) and the upadacitinib 15 mg group (91 [55%] of 164), but higher in the upadacitinib 30 mg group (111 [67%] of 165).  At week 12, the most common adverse events occurring in at least 5% of patients in any treatment group were upper respiratory tract infection (13 [8%] of 169 in the placebo group; 13 [8%] of 164 in the upadacitinib 15 mg group; ten [6%] of 165 in the upadacitinib 30 mg group), nasopharyngitis (11 [7%]; seven [4%]; nine [5%]), urinary tract infection (ten [6%]; 15 [9%]; nine [5%]), and worsening of rheumatoid arthritis (ten [6%]; four [2%]; six [4%]).  The no. of patients with serious adverse events was higher in the upadacitinib 30 mg group (12 [7%]) than in the upadacitinib 15 mg group (eight [5%]); no serious adverse events were reported in patients receiving placebo.  More patients in the upadacitinib 30 mg group had serious infections, herpes zoster, and adverse events leading to discontinuation than in the upadacitinib 15 mg and placebo groups.  During the placebo-controlled phase of the study, one case of pulmonary embolism, three malignancies, one major adverse cardiovascular event, and one death were reported in patients receiving upadacitinib; none were reported in patients receiving placebo.  Both doses of upadacitinib led to rapid and significant improvements compared with placebo over 12 wk in patients with refractory rheumatoid arthritis.AbbVie Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNKODcAMc3erVg90H21EOLACvtfcHk0ljtGVq5dhxjww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb3E&md5=d7bcea909b5dfb3a25fe64a22beca3a0</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931116-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931116-4%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCombe%26aufirst%3DB.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DRubbert-Roth%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMohamed%26aufirst%3DM.-E.%2BF.%26aulast%3DMeerwein%26aufirst%3DS.%26aulast%3DPangan%26aufirst%3DA.%2BL.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Upadacitinib%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%2520Refractory%2520to%2520Biologic%2520Disease-Modifying%2520Anti-Rheumatic%2520Drugs%2520%2528SELECT-BEYOND%2529%253A%2520a%2520Double-Blind%252C%2520Randomised%2520Controlled%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D2513%26epage%3D2524%26doi%3D10.1016%2FS0140-6736%2818%2931116-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span> </span><span class="NLM_article-title">Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842,
an Oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe
Atopic Dermatitis</span>.  <i>Pfizer News Release</i>; <span class="NLM_publisher-name">Pfizer</span>, Feb 14, <span class="NLM_year">2018</span>; <a href="https://press.pfizer.com/press-release/pfizer-receives-breakthrough-therapy-designation-fda-pf-04965842-oral-jak1-inhibitor-t" class="extLink">https://press.pfizer.com/press-release/pfizer-receives-breakthrough-therapy-designation-fda-pf-04965842-oral-jak1-inhibitor-t</a> (accessed Sep 6, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Receives+Breakthrough+Therapy+Designation+from+FDA+for+PF-04965842%2C%0Aan+Oral+JAK1+Inhibitor%2C+for+the+Treatment+of+Patients+with+Moderate-to-Severe%0AAtopic+Dermatitis.+Pfizer+News+Release%3B+Pfizer%2C+Feb+14%2C+2018%3B+https%3A%2F%2Fpress.pfizer.com%2Fpress-release%2Fpfizer-receives-breakthrough-therapy-designation-fda-pf-04965842-oral-jak1-inhibitor-t+%28accessed+Sep+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DPfizer%2520Receives%2520Breakthrough%2520Therapy%2520Designation%2520from%2520FDA%2520for%2520PF-04965842%252C%250Aan%2520Oral%2520JAK1%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Moderate-to-Severe%250AAtopic%2520Dermatitis%26jtitle%3DPfizer%2520News%2520Release%26pub%3DPfizer%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seneviratne, U. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Point, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorarensen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span> <span> </span><span class="NLM_article-title">PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1242</span>, <span class="refDoi"> DOI: 10.1021/acschembio.9b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.9b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlels70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1235-1242&author=H.+Xuauthor=M.+I.+Jessonauthor=U.+I.+Seneviratneauthor=T.+H.+Linauthor=M.+N.+Sharifauthor=L.+Xueauthor=C.+Nguyenauthor=R.+A.+Everleyauthor=J.+I.+Trujilloauthor=D.+S.+Johnsonauthor=G.+R.+Pointauthor=A.+Thorarensenauthor=I.+Kiltyauthor=J.-B.+Telliez&title=PF-06651600%2C+a+Dual+JAK3%2FTEC+Family+Kinase+Inhibitor&doi=10.1021%2Facschembio.9b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor</span></div><div class="casAuthors">Xu, Hua; Jesson, Michael I.; Seneviratne, Uthpala I.; Lin, Tsung H.; Sharif, M. Nusrat; Xue, Liang; Nguyen, Chuong; Everley, Robert A.; Trujillo, John I.; Johnson, Douglas S.; Point, Gary R.; Thorarensen, Atli; Kilty, Iain; Telliez, Jean-Baptiste</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1235-1242</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-06651600 was developed as an irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms.  A high level of selectivity toward JAK3 is achieved by the covalent interaction of PF-06651600 with a unique cysteine residue (Cys-909) in the catalytic domain of JAK3, which is replaced by a serine residue in the other JAK isoforms.  Importantly, 10 other kinases in the kinome have a cysteine at the equiv. position of Cys-909 in JAK3.  Five of those kinases belong to the TEC kinase family including BTK, BMX, ITK, RLK, and TEC and are also inhibited by PF-06651600.  Preclin. data demonstrate that inhibition of the cytolytic function of CD8+ T cells and NK cells by PF-06651600 is driven by the inhibition of TEC kinases.  On the basis of the underlying pathophysiol. of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, alopecia areata, and vitiligo, the dual activity of PF-06651600 toward JAK3 and the TEC kinase family may provide a beneficial inhibitory profile for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmeuSFXH1umLVg90H21EOLACvtfcHk0ljtGVq5dhxjww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlels70%253D&md5=6b687d02201c599e4e724885f5ecc93b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Facschembio.9b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.9b00188%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DSeneviratne%26aufirst%3DU.%2BI.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DSharif%26aufirst%3DM.%2BN.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DEverley%26aufirst%3DR.%2BA.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DPoint%26aufirst%3DG.%2BR.%26aulast%3DThorarensen%26aufirst%3DA.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26atitle%3DPF-06651600%252C%2520a%2520Dual%2520JAK3%252FTEC%2520Family%2520Kinase%2520Inhibitor%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2019%26volume%3D14%26spage%3D1235%26epage%3D1242%26doi%3D10.1021%2Facschembio.9b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span> </span><span class="NLM_article-title">Study to Evaluate the Efficacy
and Safety of Oral PF-06651600 and PF-06700841 in Subjects with Moderate
to Severe Crohn’s Disease</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">NCT03395184</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03395184?term=NCT03395184&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03395184?term=NCT03395184&rank=1</a>  (first posted Jan 10, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+to+Evaluate+the+Efficacy%0Aand+Safety+of+Oral+PF-06651600+and+PF-06700841+in+Subjects+with+Moderate%0Ato+Severe+Crohn%E2%80%99s+Disease.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2018%3B+NCT03395184%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03395184%3Fterm%3DNCT03395184%26rank%3D1+%28first+posted+Jan+10%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520to%2520Evaluate%2520the%2520Efficacy%250Aand%2520Safety%2520of%2520Oral%2520PF-06651600%2520and%2520PF-06700841%2520in%2520Subjects%2520with%2520Moderate%250Ato%2520Severe%2520Crohn%25E2%2580%2599s%2520Disease%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2018%26spage%3DNCT03395184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span> </span><span class="NLM_article-title">Study to Compare Oral PF-06651600,
PF-06700841 and Placebo in Subjects with Moderate to Severe Ulcerative
Colitis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02958865</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02958865?term=NCT02958865&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02958865?term=NCT02958865&rank=1</a>  (first posted Nov 8, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+to+Compare+Oral+PF-06651600%2C%0APF-06700841+and+Placebo+in+Subjects+with+Moderate+to+Severe+Ulcerative%0AColitis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02958865%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02958865%3Fterm%3DNCT02958865%26rank%3D1+%28first+posted+Nov+8%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520to%2520Compare%2520Oral%2520PF-06651600%252C%250APF-06700841%2520and%2520Placebo%2520in%2520Subjects%2520with%2520Moderate%2520to%2520Severe%2520Ulcerative%250AColitis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02958865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span> </span><span class="NLM_article-title">Study To Evaluate The Efficacy
And Safety Profile Of PF-06651600 And PF-06700841 In Subjects with
Alopecia Areata</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02974868</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02974868?term=NCT02974868&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02974868?term=NCT02974868&rank=1</a> (first posted Nov 29, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+To+Evaluate+The+Efficacy%0AAnd+Safety+Profile+Of+PF-06651600+And+PF-06700841+In+Subjects+with%0AAlopecia+Areata.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02974868%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02974868%3Fterm%3DNCT02974868%26rank%3D1+%28first+posted+Nov+29%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520To%2520Evaluate%2520The%2520Efficacy%250AAnd%2520Safety%2520Profile%2520Of%2520PF-06651600%2520And%2520PF-06700841%2520In%2520Subjects%2520with%250AAlopecia%2520Areata%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2016%26spage%3DNCT02974868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dendrou, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attfield, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jostins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttikkatte, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faergeman, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheeseman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawcer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compston, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpe, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVean, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fugger, L.</span></span> <span> </span><span class="NLM_article-title">Resolving TYK2 Locus Genotype-to-Phenotype Differences in Autoimmunity</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra149</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aag1974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1126%2Fscitranslmed.aag1974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27807284" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra149&author=C.+A.+Dendrouauthor=A.+Cortesauthor=L.+Shipmanauthor=H.+G.+Evansauthor=K.+E.+Attfieldauthor=L.+Jostinsauthor=T.+Barberauthor=G.+Kaurauthor=S.+B.+Kuttikkatteauthor=O.+A.+Leachauthor=C.+Deselauthor=S.+L.+Faergemanauthor=J.+Cheesemanauthor=M.+J.+Nevilleauthor=S.+Sawcerauthor=A.+Compstonauthor=A.+R.+Johnsonauthor=C.+Everettauthor=J.+I.+Bellauthor=F.+Karpeauthor=M.+Ultschauthor=C.+Eigenbrotauthor=G.+McVeanauthor=L.+Fugger&title=Resolving+TYK2+Locus+Genotype-to-Phenotype+Differences+in+Autoimmunity&doi=10.1126%2Fscitranslmed.aag1974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aag1974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aag1974%26sid%3Dliteratum%253Aachs%26aulast%3DDendrou%26aufirst%3DC.%2BA.%26aulast%3DCortes%26aufirst%3DA.%26aulast%3DShipman%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DH.%2BG.%26aulast%3DAttfield%26aufirst%3DK.%2BE.%26aulast%3DJostins%26aufirst%3DL.%26aulast%3DBarber%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DKuttikkatte%26aufirst%3DS.%2BB.%26aulast%3DLeach%26aufirst%3DO.%2BA.%26aulast%3DDesel%26aufirst%3DC.%26aulast%3DFaergeman%26aufirst%3DS.%2BL.%26aulast%3DCheeseman%26aufirst%3DJ.%26aulast%3DNeville%26aufirst%3DM.%2BJ.%26aulast%3DSawcer%26aufirst%3DS.%26aulast%3DCompston%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEverett%26aufirst%3DC.%26aulast%3DBell%26aufirst%3DJ.%2BI.%26aulast%3DKarpe%26aufirst%3DF.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DMcVean%26aufirst%3DG.%26aulast%3DFugger%26aufirst%3DL.%26atitle%3DResolving%2520TYK2%2520Locus%2520Genotype-to-Phenotype%2520Differences%2520in%2520Autoimmunity%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra149%26doi%3D10.1126%2Fscitranslmed.aag1974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.-Y.</span></span> <span> </span><span class="NLM_article-title">Selective Tyk2 Inhibitors as Potential Therapeutic Agents: A Patent Review (2015–2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1567713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1080%2F13543776.2019.1567713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30621465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=137-149&author=X.+Heauthor=X.+Chenauthor=H.+Zhangauthor=T.+Xieauthor=X.-Y.+Ye&title=Selective+Tyk2+Inhibitors+as+Potential+Therapeutic+Agents%3A+A+Patent+Review+%282015%E2%80%932018%29&doi=10.1080%2F13543776.2019.1567713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)</span></div><div class="casAuthors">He, Xingrui; Chen, Xiabin; Zhang, Hancheng; Xie, Tian; Ye, Xiang-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene.  Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family.  Before 2014, far more publications and patents appeared in public domain attributing to the development of selective Jak2 and Jak3 inhibitors than those for selective Tyk2 and Jak1 inhibitors.  This review sought to give an overview of patents related to small mol. selective Tyk2 inhibitors published from 2015 to 2018.  The article also covers clin. activities of small mol. selective Tyk2 inhibitors in recent years.  As a key component of the JAK-STAT signaling pathway, Tyk2 regulates INFα, IL12, and IL23.  Selective inhibition of Tyk2 can provide pharmacol. benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.  The selectivity against other Jak family subtypes (such as Jak2) is crucial in order to minimize the potential side effects and to maximize the desired pharmacol. effects.  In this context, this review of recent selective Tyk2 inhibitor patents may prove valid, interesting, and promising within the therapeutic paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrer4xPnKRtvrVg90H21EOLACvtfcHk0lizNmqYamosQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2kuro%253D&md5=cf7fa5e5f7a92eb951886f7951f7da4b</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1567713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1567713%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DX.-Y.%26atitle%3DSelective%2520Tyk2%2520Inhibitors%2520as%2520Potential%2520Therapeutic%2520Agents%253A%2520A%2520Patent%2520Review%2520%25282015%25E2%2580%25932018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26spage%3D137%26epage%3D149%26doi%3D10.1080%2F13543776.2019.1567713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span> <span> </span><span class="NLM_article-title">Toward Selective TYK2 Inhibitors as Therapeutic Agents for the Treatment of Inflammatory Diseases</span>. <i>Pharm. Pat. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.4155/ppa.14.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.4155%2Fppa.14.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=25291316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=449-466&author=C.+J.+Menet&title=Toward+Selective+TYK2+Inhibitors+as+Therapeutic+Agents+for+the+Treatment+of+Inflammatory+Diseases&doi=10.4155%2Fppa.14.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Menet, Christel J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Patent Analyst</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-466</span>CODEN:
                <span class="NLM_cas:coden">PPAHCN</span>;
        ISSN:<span class="NLM_cas:issn">2046-8954</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The family of JAK comprises four members and has received significant attention in recent years from the pharmaceutical industry as a therapeutic target.  The role of JAK is central to cytokine signaling pathways.  It is believed that selective modulation of one specific JAK can lead to the inhibition of a restricted set of cytokines, which should avoid undesired side effects and get closer to the profile of biol. therapies.  Consequently, selective JAK inhibition has become a major focus area of drug discovery research.  A review of the TYK2 patents indicates that industry attention has recently turned toward the development of specific inhibitors.  Importantly, despite the increasing no. of published patents, none of these drugs have yet made it to the clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmMgH3Z8Ff7Vg90H21EOLACvtfcHk0lh2gD8JeOsOkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslSkurjF&md5=0a79df697117246c840c559260d8e7ba</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.4155%2Fppa.14.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Fppa.14.23%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26atitle%3DToward%2520Selective%2520TYK2%2520Inhibitors%2520as%2520Therapeutic%2520Agents%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%26jtitle%3DPharm.%2520Pat.%2520Anal.%26date%3D2014%26volume%3D3%26spage%3D449%26epage%3D466%26doi%3D10.4155%2Fppa.14.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambler, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrencik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopalsamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knafels, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limburg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajdos, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Z.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)-pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8597</span>– <span class="NLM_lpage">8612</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8597-8612&author=A.+Fensomeauthor=C.+M.+Amblerauthor=E.+Arnoldauthor=M.+E.+Bankerauthor=M.+F.+Brownauthor=J.+Chrencikauthor=J.+D.+Clarkauthor=M.+E.+Dowtyauthor=I.+V.+Efremovauthor=A.+Flickauthor=B.+S.+Gerstenbergerauthor=A.+Gopalsamyauthor=M.+M.+Haywardauthor=M.+Hegenauthor=B.+D.+Hollingsheadauthor=J.+Jussifauthor=J.+D.+Knafelsauthor=D.+C.+Limburgauthor=D.+Linauthor=T.+H.+Linauthor=B.+S.+Pierceauthor=E.+Saiahauthor=R.+Sharmaauthor=P.+T.+Symanowiczauthor=J.-B.+Telliezauthor=J.+I.+Trujilloauthor=F.+F.+Vajdosauthor=F.+Vincentauthor=Z.-K.+Wanauthor=L.+Xingauthor=X.+Yangauthor=X.+Yangauthor=L.+Zhang&title=Dual+Inhibition+of+TYK2+and+JAK1+for+the+Treatment+of+Autoimmune+Diseases%3A+Discovery+of%28%28S%29-2%2C2-Difluorocyclopropyl%29%28%281R%2C5S%29-3-%282-%28%281-methyl-1H-pyrazol-4-yl%29amino%29-pyrimidin-4-yl%29-3%2C8-diazabicyclo%5B3.2.1%5Doctan-8-yl%29methanone+%28PF-06700841%29&doi=10.1021%2Facs.jmedchem.8b00917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)</span></div><div class="casAuthors">Fensome, Andrew; Ambler, Catherine M.; Arnold, Eric; Banker, Mary Ellen; Brown, Matthew F.; Chrencik, Jill; Clark, James D.; Dowty, Martin E.; Efremov, Ivan V.; Flick, Andrew; Gerstenberger, Brian S.; Gopalsamy, Ariamala; Hayward, Matthew M.; Hegen, Martin; Hollingshead, Brett D.; Jussif, Jason; Knafels, John D.; Limburg, David C.; Lin, David; Lin, Tsung H.; Pierce, Betsy S.; Saiah, Eddine; Sharma, Raman; Symanowicz, Peter T.; Telliez, Jean-Baptiste; Trujillo, John I.; Vajdos, Felix F.; Vincent, Fabien; Wan, Zhao-Kui; Xing, Li; Yang, Xiaojing; Yang, Xin; Zhang, Liying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8597-8612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cytokine signaling is an important characteristic of autoimmune diseases.  Many pro-inflammatory cytokines signal through the Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) pathway.  JAK1 is important for the γ-common chain cytokines, interleukin (IL)-6 and type-I interferon (IFN) family, while TYK2 in addn. to type-I IFN signaling also plays a role in IL-23 and IL-12 signaling.  Intervention with monoclonal antibodies (mAbs) or JAK1 inhibitors has demonstrated efficacy in Phase III psoriasis, psoriatic arthritis, inflammatory bowel disease and rheumatoid arthritis studies, leading to multiple drug approvals.  It is hypothesized that a dual JAK1/TYK2 inhibitor will provide addnl. efficacy, while managing risk by optimizing selectivity against JAK2 driven hematopoietic changes.  Our program began with a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor, subsequent work led to the discovery of PF-06700841 (compd. 23), which is in Phase II clin. development (NCT02969018, NCT02958865, NCT03395184, and NCT02974868).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWNhVkNWDMq7Vg90H21EOLACvtfcHk0lh2gD8JeOsOkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFWgtLfI&md5=c321512f524560cba445d070b9639e55</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00917%26sid%3Dliteratum%253Aachs%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DAmbler%26aufirst%3DC.%2BM.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChrencik%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DFlick%26aufirst%3DA.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DGopalsamy%26aufirst%3DA.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DHollingshead%26aufirst%3DB.%2BD.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DKnafels%26aufirst%3DJ.%2BD.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DTrujillo%26aufirst%3DJ.%2BI.%26aulast%3DVajdos%26aufirst%3DF.%2BF.%26aulast%3DVincent%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DZ.-K.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DDual%2520Inhibition%2520of%2520TYK2%2520and%2520JAK1%2520for%2520the%2520Treatment%2520of%2520Autoimmune%2520Diseases%253A%2520Discovery%2520of%2528%2528S%2529-2%252C2-Difluorocyclopropyl%2529%2528%25281R%252C5S%2529-3-%25282-%2528%25281-methyl-1H-pyrazol-4-yl%2529amino%2529-pyrimidin-4-yl%2529-3%252C8-diazabicyclo%255B3.2.1%255Doctan-8-yl%2529methanone%2520%2528PF-06700841%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8597%26epage%3D8612%26doi%3D10.1021%2Facs.jmedchem.8b00917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span> </span><span class="NLM_article-title">Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects
with Moderate to Severe Plaque Psoriasis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes
of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2016</span>;  <span class="NLM_fpage">NCT02969018</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT02969018?term=NCT02969018&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02969018?term=NCT02969018&rank=1</a> (first posted Nov 21, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Study+to+Evaluate+Safety+and+Efficacy+of+PF-06700841+in+Subjects%0Awith+Moderate+to+Severe+Plaque+Psoriasis.+ClinicalTrials.gov%3B+U.S.+National+Institutes%0Aof+Health%3A+Bethesda%2C+MD%2C+2016%3B+NCT02969018%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02969018%3Fterm%3DNCT02969018%26rank%3D1+%28first+posted+Nov+21%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DStudy%2520to%2520Evaluate%2520Safety%2520and%2520Efficacy%2520of%2520PF-06700841%2520in%2520Subjects%250Awith%2520Moderate%2520to%2520Severe%2520Plaque%2520Psoriasis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%250Aof%2520Health%26date%3D2016%26spage%3DNCT02969018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaramozza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieras, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fensome, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goteti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkle, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span> <span> </span><span class="NLM_article-title">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients with Plaque Psoriasis</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1002/jcph.1046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fjcph.1046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=29266308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=434-447&author=C.+Banfieldauthor=M.+Scaramozzaauthor=W.+Zhangauthor=E.+Kierasauthor=K.+M.+Pageauthor=A.+Fensomeauthor=M.+Vincentauthor=M.+E.+Dowtyauthor=K.+Gotetiauthor=P.+J.+Winkleauthor=E.+Peeva&title=The+Safety%2C+Tolerability%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+TYK2%2FJAK1+Inhibitor+%28PF-06700841%29+in+Healthy+Subjects+and+Patients+with+Plaque+Psoriasis&doi=10.1002%2Fjcph.1046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis</span></div><div class="casAuthors">Banfield, Christopher; Scaramozza, Matthew; Zhang, Weidong; Kieras, Elizabeth; Page, Karen M.; Fensome, Andrew; Vincent, Michael; Dowty, Martin E.; Goteti, Kosalaram; Winkle, Peter J.; Peeva, Elena</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">434-447</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06700841 were assessed in a randomized, double-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group study in healthy subjects and patients with plaque psoriasis.  The single ascending dose (1, 3, 10, 30, 100, or 200 mg) and multiple ascending dose (MAD; PF-06700841; up to 175 mg once daily or 50 mg twice daily for 10 days) periods included 54 healthy participants.  In addn., 30 patients with psoriasis received PF-06700841 30 or 100 mg or placebo once daily for 28 days.  Single PF-06700841 doses were rapidly absorbed, with peak plasma concns. ≤ 1 h, proportional exposure up to 100 mg, and mean half-life 3.8-7.5 h.  On day 10 of MAD, plasma concns. peaked at ≤1.5 h postdose (10-175 mg once daily).  Elimination half-life was 4.9-10.7 h; steady state was reached by day 8.  In psoriasis patients on day 28, peak plasma concns. occurred at 1-2 h.  Biomarkers IP-10 and high-sensitivity C-reactive protein were reduced and returned to near baseline levels after dosing.  Maximal mean percent change from baseline in the Psoriasis Area and Severity Index scores for PF-06700841 30 mg once daily and 100 mg once daily were -67.92% and -96.31%, resp., in week 4.  All adverse events were mild/moderate.  PF-06700841 was safe and well tolerated up to 200 mg once daily in healthy subjects and 100 mg once daily in patients with psoriasis, suggesting potential therapeutic utility in plaque psoriasis and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHMconrLwJf7Vg90H21EOLACvtfcHk0lh2gD8JeOsOkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVKrurw%253D&md5=a907c91ff2d50db9cba930c2249ed37b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1046%26sid%3Dliteratum%253Aachs%26aulast%3DBanfield%26aufirst%3DC.%26aulast%3DScaramozza%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKieras%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DK.%2BM.%26aulast%3DFensome%26aufirst%3DA.%26aulast%3DVincent%26aufirst%3DM.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DGoteti%26aufirst%3DK.%26aulast%3DWinkle%26aufirst%3DP.%2BJ.%26aulast%3DPeeva%26aufirst%3DE.%26atitle%3DThe%2520Safety%252C%2520Tolerability%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520TYK2%252FJAK1%2520Inhibitor%2520%2528PF-06700841%2529%2520in%2520Healthy%2520Subjects%2520and%2520Patients%2520with%2520Plaque%2520Psoriasis%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D434%26epage%3D447%26doi%3D10.1002%2Fjcph.1046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerstenberger, B. S.</span>; <span class="NLM_string-name">Arnold, E. P.</span>; <span class="NLM_string-name">Banker, M. E.</span>; <span class="NLM_string-name">Brown, M. F.</span>; <span class="NLM_string-name">Clark, J. D.</span>; <span class="NLM_string-name">Dermenci, A.</span>; <span class="NLM_string-name">Dowty, M.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Hayward, M. M.</span>; <span class="NLM_string-name">Hegen, M.</span>; <span class="NLM_string-name">Hollingshead, B. D.</span>; <span class="NLM_string-name">Knafels, J. D.</span>; <span class="NLM_string-name">Lin, D. W.</span>; <span class="NLM_string-name">Lin, T.</span>; <span class="NLM_string-name">Owen, D.</span>; <span class="NLM_string-name">Saiah, E.</span>; <span class="NLM_string-name">Sharma, R.</span>; <span class="NLM_string-name">Vajdos, F. F.</span>; <span class="NLM_string-name">Vincent, F.</span>; <span class="NLM_string-name">Wright, S. W.</span>; <span class="NLM_string-name">Xing, L.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of the TYK2 Selective Inhibitor PF-6826647 for the Treatment of Crohn’s Disease, and Other Autoimmune Conditions</span>.  <i>Presented at 256th ACS National Meeting, Boston, MA,, Aug. 19–23, 2018</i>; <span class="NLM_publisher-name">American Chemical Society</span>, <span class="NLM_year">2018</span>;  <span class="NLM_fpage">MEDI 319</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=MEDI+319&author=B.+S.+Gerstenberger&author=E.+P.+Arnold&author=M.+E.+Banker&author=M.+F.+Brown&author=J.+D.+Clark&author=A.+Dermenci&author=M.+Dowty&author=A.+Fensome&author=M.+M.+Hayward&author=M.+Hegen&author=B.+D.+Hollingshead&author=J.+D.+Knafels&author=D.+W.+Lin&author=T.+Lin&author=D.+Owen&author=E.+Saiah&author=R.+Sharma&author=F.+F.+Vajdos&author=F.+Vincent&author=S.+W.+Wright&author=L.+Xing&author=X.+Yang&author=X.+Yang&author=L.+Zhang&title=Discovery+of+the+TYK2+Selective+Inhibitor+PF-6826647+for+the+Treatment+of+Crohn%E2%80%99s+Disease%2C+and+Other+Autoimmune+Conditions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26atitle%3DDiscovery%2520of%2520the%2520TYK2%2520Selective%2520Inhibitor%2520PF-6826647%2520for%2520the%2520Treatment%2520of%2520Crohn%25E2%2580%2599s%2520Disease%252C%2520and%2520Other%2520Autoimmune%2520Conditions%26jtitle%3DPresented%2520at%2520256th%2520ACS%2520National%2520Meeting%252C%2520Boston%252C%2520MA%252C%252C%2520Aug.%252019%25E2%2580%259323%252C%25202018%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2018%26spage%3DMEDI%2520319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span>; <span class="NLM_string-name">Dermenci, A.</span>; <span class="NLM_string-name">Fensome, A.</span>; <span class="NLM_string-name">Gerstenberger, B. S.</span>; <span class="NLM_string-name">Hayward, M. M.</span>; <span class="NLM_string-name">Owen, D. R.</span>; <span class="NLM_string-name">Wright, S. W.</span>; <span class="NLM_string-name">Xing, L. H.</span>; <span class="NLM_string-name">Yang, X.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[l,5-<i>a</i>]pyrazin-4-yl Derivatives</span>. U.S. Patent <span class="NLM_patent">2017/0240552 A1</span>, Feb 21, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+F.+Brown&author=A.+Dermenci&author=A.+Fensome&author=B.+S.+Gerstenberger&author=M.+M.+Hayward&author=D.+R.+Owen&author=S.+W.+Wright&author=L.+H.+Xing&author=X.+Yang&title=Pyrazolo%5Bl%2C5-a%5Dpyrazin-4-yl+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DM.%2BF.%26atitle%3DPyrazolo%255Bl%252C5-a%255Dpyrazin-4-yl%2520Derivatives%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span> </span><span class="NLM_article-title">A First in Human Study to Evaluate
Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects
and Subjects with Plaque Psoriasis</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">NCT03210961</span>, <a href="https://clinicaltrials.gov/ct2/show/NCT03210961?term=NCT03210961&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03210961?term=NCT03210961&rank=1</a> (first posted July 7, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+First+in+Human+Study+to+Evaluate%0ASafety%2C+Tolerability%2C+and+Pharmacology+of+PF-06826647+in+Healthy+Subjects%0Aand+Subjects+with+Plaque+Psoriasis.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2017%3B+NCT03210961%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03210961%3Fterm%3DNCT03210961%26rank%3D1+%28first+posted+July+7%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520First%2520in%2520Human%2520Study%2520to%2520Evaluate%250ASafety%252C%2520Tolerability%252C%2520and%2520Pharmacology%2520of%2520PF-06826647%2520in%2520Healthy%2520Subjects%250Aand%2520Subjects%2520with%2520Plaque%2520Psoriasis%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2017%26spage%3DNCT03210961" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edavettal, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witmer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase 2-Mediated Signal Transduction in T Lymphocytes is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">11061</span>– <span class="NLM_lpage">11074</span>, <span class="refDoi"> DOI: 10.1074/jbc.M114.619502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1074%2Fjbc.M114.619502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=25762719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=11061-11074&author=J.+S.+Tokarskiauthor=A.+Zupa-Fernandezauthor=J.+A.+Tredupauthor=K.+Pikeauthor=C.+Changauthor=D.+Xieauthor=L.+Chengauthor=D.+Pedicordauthor=J.+Muckelbauerauthor=S.+R.+Johnsonauthor=S.+Wuauthor=S.+C.+Edavettalauthor=Y.+Hongauthor=M.+R.+Witmerauthor=L.+L.+Elkinauthor=Y.+Blatauthor=W.+J.+Pittsauthor=D.+S.+Weinsteinauthor=J.+R.+Burke&title=Tyrosine+Kinase+2-Mediated+Signal+Transduction+in+T+Lymphocytes+is+Blocked+by+Pharmacological+Stabilization+of+Its+Pseudokinase+Domain&doi=10.1074%2Fjbc.M114.619502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain</span></div><div class="casAuthors">Tokarski, John S.; Zupa-Fernandez, Adriana; Tredup, Jeffrey A.; Pike, Kristen; Chang, Chieh Ying; Xie, Dianlin; Cheng, Lihong; Pedicord, Donna; Muckelbauer, Jodi; Johnson, Stephen R.; Wu, Sophie; Edavettal, Suzanne C.; Hong, Yang; Witmer, Mark R.; Elkin, Lisa L.; Blat, Yuval; Pitts, William J.; Weinstein, David S.; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11061-11074</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Inhibition of signal transduction downstream of the IL-23 receptor represents an intriguing approach to the treatment of autoimmunity.  Using a chemogenomics approach marrying kinome-wide inhibitory profiles of a compd. library with the cellular activity against an IL-23-stimulated transcriptional response in T lymphocytes, a class of inhibitors was identified that bind to and stabilize the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of receptor-mediated activation of the adjacent catalytic domain.  These Tyk2 pseudokinase domain stabilizers were also shown to inhibit Tyk2-dependent signaling through the Type I interferon receptor but not Tyk2-independent signaling and transcriptional cellular assays, including stimulation through the receptors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high functional selectivity of this approach.  A crystal structure of the pseudokinase domain liganded with a representative example showed the compd. bound to a site analogous to the ATP-binding site in catalytic kinases with features consistent with high ligand selectivity.  The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions.  Tyk2 pseudokinase stabilizers, therefore, represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwSl_Zer56d7Vg90H21EOLACvtfcHk0liIR96sHSpEug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFSqt70%253D&md5=49e10a7c3e430c8be198c119b26bb16b</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.619502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.619502%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DPike%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DMuckelbauer%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DEdavettal%26aufirst%3DS.%2BC.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DWitmer%26aufirst%3DM.%2BR.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DTyrosine%2520Kinase%25202-Mediated%2520Signal%2520Transduction%2520in%2520T%2520Lymphocytes%2520is%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520Its%2520Pseudokinase%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D11061%26epage%3D11074%26doi%3D10.1074%2Fjbc.M114.619502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncia, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokarski, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedicord, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blat, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zupa-Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aranibar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of Imidazo[1,2-b]pyridazine TYK2 Pseudokinase Ligands as Potent and Selective Allosteric Inhibitors of TYK2 Signalling</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1039/C6MD00560H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1039%2FC6MD00560H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30108788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=700-712&author=R.+Moslinauthor=D.+Gardnerauthor=J.+Santellaauthor=Y.+Zhangauthor=J.+V.+Dunciaauthor=C.+Liuauthor=J.+Linauthor=J.+S.+Tokarskiauthor=J.+Strnadauthor=D.+Pedicordauthor=J.+Chenauthor=Y.+Blatauthor=A.+Zupa-Fernandezauthor=L.+Chengauthor=H.+Sunauthor=C.+Chaudhryauthor=C.+Huangauthor=C.+D%E2%80%99Arienzoauthor=J.+S.+Sackauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=J.+Tredupauthor=D.+Xieauthor=N.+Aranibarauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=D.+S.+Weinstein&title=Identification+of+Imidazo%5B1%2C2-b%5Dpyridazine+TYK2+Pseudokinase+Ligands+as+Potent+and+Selective+Allosteric+Inhibitors+of+TYK2+Signalling&doi=10.1039%2FC6MD00560H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling</span></div><div class="casAuthors">Moslin, R.; Gardner, D.; Santella, J.; Zhang, Y.; Duncia, J. V.; Liu, C.; Lin, J.; Tokarski, J. S.; Strnad, J.; Pedicord, D.; Chen, J.; Blat, Y.; Zupa-Fernandez, A.; Cheng, L.; Sun, H.; Chaudhry, C.; Huang, C.; D'Arienzo, C.; Sack, J. S.; Muckelbauer, J. K.; Chang, C.; Tredup, J.; Xie, D.; Aranibar, N.; Burke, J. R.; Carter, P. H.; Weinstein, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">700-712</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As a member of the Janus (JAK) family of non-receptor tyrosine kinases, TYK2 mediates the signaling of pro-inflammatory cytokines including IL-12, IL-23 and type 1 interferon (IFN), and therefore represents an attractive potential target for treating the various immuno-inflammatory diseases in which these cytokines have been shown to play a role.  Following up on our previous report that ligands to the pseudokinase domain (JH2) of TYK2 suppress cytokine-mediated receptor activation of the catalytic (JH1) domain, the imidazo[1,2-b]pyridazine (IZP) 7 was identified as a promising hit compd.  Through iterative modification of each of the substituents of the IZP scaffold, the cellular potency was improved while maintaining selectivity over the JH1 domain.  These studies led to the discovery of the JH2-selective TYK2 inhibitor 29, which provided encouraging systemic exposures after oral dosing in mice.  Phosphodiesterase 4 (PDE4) was identified as an off-target and potential liability of the IZP ligands, and selectivity for TYK2 JH2 over this enzyme was obtained by elaborating along selectivity vectors detd. from analyses of X-ray co-crystal structures of representative ligands of the IZP class bound to both proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobX5_XfvLHsLVg90H21EOLACvtfcHk0lhnIjzKz_3qbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyru7jN&md5=67b06413866ee6096810903f62edd901</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1039%2FC6MD00560H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00560H%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26aulast%3DGardner%26aufirst%3DD.%26aulast%3DSantella%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDuncia%26aufirst%3DJ.%2BV.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DPedicord%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBlat%26aufirst%3DY.%26aulast%3DZupa-Fernandez%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DTredup%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DAranibar%26aufirst%3DN.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DWeinstein%26aufirst%3DD.%2BS.%26atitle%3DIdentification%2520of%2520Imidazo%255B1%252C2-b%255Dpyridazine%2520TYK2%2520Pseudokinase%2520Ligands%2520as%2520Potent%2520and%2520Selective%2520Allosteric%2520Inhibitors%2520of%2520TYK2%2520Signalling%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D700%26epage%3D712%26doi%3D10.1039%2FC6MD00560H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Mertzman, M.</span>; <span class="NLM_string-name">Tokarski, J. S.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Gillooly, K.</span>; <span class="NLM_string-name">McIntyre, K. W.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Chaudhry, C.</span>; <span class="NLM_string-name">Huang, C.</span>; <span class="NLM_string-name">D’Arienzo, C.</span>; <span class="NLM_string-name">Heimrich, E.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Muckelbauer, J. K.</span>; <span class="NLM_string-name">Chang, C.-Y.</span>; <span class="NLM_string-name">Tredup, J.</span>; <span class="NLM_string-name">Mulligan, D.</span>; <span class="NLM_string-name">Xie, D.</span>; <span class="NLM_string-name">Aranibar, N.</span>; <span class="NLM_string-name">Chiney, M.</span>; <span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Lombardo, L.</span>; <span class="NLM_string-name">Carter, P. H.</span>; <span class="NLM_string-name">Weinstein, D. S.</span></span> <span> </span><span class="NLM_article-title">Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-carboxamide Pseudokinase Domain Ligands as Highly Selective Inhibitors of Tyrosine Kinase 2 (TYK2)</span>.  <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00443</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00443" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=R.+Moslin&author=Y.+Zhang&author=S.+T.+Wrobleski&author=S.+Lin&author=M.+Mertzman&author=J.+S.+Tokarski&author=J.+Strnad&author=K.+Gillooly&author=K.+W.+McIntyre&author=A.+Zupa-Fernandez&author=L.+Cheng&author=H.+Sun&author=C.+Chaudhry&author=C.+Huang&author=C.+D%E2%80%99Arienzo&author=E.+Heimrich&author=X.+Yang&author=J.+K.+Muckelbauer&author=C.-Y.+Chang&author=J.+Tredup&author=D.+Mulligan&author=D.+Xie&author=N.+Aranibar&author=M.+Chiney&author=J.+R.+Burke&author=L.+Lombardo&author=P.+H.+Carter&author=D.+S.+Weinstein&title=Identification+of+N-Methyl+Nicotinamide+and+N-Methyl+Pyridazine-3-carboxamide+Pseudokinase+Domain+Ligands+as+Highly+Selective+Inhibitors+of+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1021%2Facs.jmedchem.9b00443"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00443%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-Methyl%2520Nicotinamide%2520and%2520N-Methyl%2520Pyridazine-3-carboxamide%2520Pseudokinase%2520Domain%2520Ligands%2520as%2520Highly%2520Selective%2520Inhibitors%2520of%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26doi%3D10.1021%2Facs.jmedchem.9b00443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Gillooly, K. M.</span>; <span class="NLM_string-name">Strnad, J.</span>; <span class="NLM_string-name">Zupa-Fernandez, A.</span>; <span class="NLM_string-name">Catlett, I. M.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Heimrich, E. M.</span>; <span class="NLM_string-name">McIntyre, K. W.</span>; <span class="NLM_string-name">Cunningham, M. D.</span>; <span class="NLM_string-name">Carman, J. A.</span>; <span class="NLM_string-name">Zhou, X.</span>; <span class="NLM_string-name">Banas, D.</span>; <span class="NLM_string-name">Chaudhry, C.</span>; <span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">D’Arienzo, C.</span>; <span class="NLM_string-name">Chimalakonda, A.</span>; <span class="NLM_string-name">Yang, X.</span>; <span class="NLM_string-name">Xie, J. H.</span>; <span class="NLM_string-name">Pang, J.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Rose, S. M.</span></span>;; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>.; <span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span>; <span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Weinstein, D. S.</span>; <span class="NLM_string-name">Salter-Cid, L. M.</span></span> <span> </span><span class="NLM_article-title">Autoimmune Pathways in Mice and Humans are Blocked by Pharmacological Stabilization of the TYK2 Pseudokinase Domain</span>,  <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, in press.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1126%2Fscitranslmed.aaw1736" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+R.+Burke&author=L.+Cheng&author=K.+M.+Gillooly&author=J.+Strnad&author=A.+Zupa-Fernandez&author=I.+M.+Catlett&author=Y.+Zhang&author=E.+M.+Heimrich&author=K.+W.+McIntyre&author=M.+D.+Cunningham&author=J.+A.+Carman&author=X.+Zhou&author=D.+Banas&author=C.+Chaudhry&author=S.+Li&author=C.+D%E2%80%99Arienzo&author=A.+Chimalakonda&author=X.+Yang&author=J.+H.+Xie&author=J.+Pang&author=Q.+Zhao&author=S.+M.+Roseauthor=J.+Huangauthor=R.+M.+Moslin&author=S.+T.+Wrobleski&author=D.+S.+Weinstein&author=L.+M.+Salter-Cid&title=Autoimmune+Pathways+in+Mice+and+Humans+are+Blocked+by+Pharmacological+Stabilization+of+the+TYK2+Pseudokinase+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaw1736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaw1736%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAutoimmune%2520Pathways%2520in%2520Mice%2520and%2520Humans%2520are%2520Blocked%2520by%2520Pharmacological%2520Stabilization%2520of%2520the%2520TYK2%2520Pseudokinase%2520Domain%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaçi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girgis, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span> <span> </span><span class="NLM_article-title">Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1806382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1056%2FNEJMoa1806382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=30205746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=1313-1321&author=K.+Pappauthor=K.+Gordonauthor=D.+Tha%C3%A7iauthor=A.+Moritaauthor=M.+Gooderhamauthor=P.+Foleyauthor=I.+G.+Girgisauthor=S.+Kunduauthor=S.+Banerjee&title=Phase+2+Trial+of+Selective+Tyrosine+Kinase+2+Inhibition+in+Psoriasis&doi=10.1056%2FNEJMoa1806382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis</span></div><div class="casAuthors">Papp, Kim; Gordon, Kenneth; Thaci, Diamant; Morita, Akimichi; Gooderham, Melinda; Foley, Peter; Girgis, Ihab G.; Kundu, Sudeep; Banerjee, Subhashis</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1313-1321</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Tyrosine kinase 2 (TYK2) signaling pathways, which mediate cytokine signaling, are implicated in the pathophysiol. of psoriasis.  Selective inhibitors of TYK2 may be effective in treating psoriasis. methods We conducted a phase 2, double-blind trial of a TYK2 inhibitor, BMS-986165, in adults with moderate-to-severe psoriasis, excluding patients with a previous lack of response to agents targeting cytokine signaling through the same tyrosine kinase pathway.  Patients were randomly assigned to receive the drug orally at a dose of 3 mg every other day, 3 mg daily, 3 mg twice daily, 6 mg twice daily, or 12 mg daily or to receive placebo.  The primary end point was a 75% or greater redn. from baseline in the Psoriasis Area and Severity Index (PASI) score at week 12 (higher scores indicate greater severity of psoriasis). results A total of 267 patients received at least one dose in an intervention group of the trial.  At week 12, the percentage of patients with a 75% or greater redn. in the PASI score was 7% (3 of 45 patients) with placebo, 9% (4 of 44 patients) with 3 mg of BMS-986165 every other day (P = 0.49 vs. placebo), 39% (17 of 44 patients) with 3 mg daily (P<0.001 vs. placebo), 69% (31 of 45 patients) with 3 mg twice daily (P<0.001 vs. placebo), 67% (30 of 45 patients) with 6 mg twice daily (P<0.001 vs. placebo), and 75% (33 of 44 patients) with 12 mg daily (P<0.001 vs. placebo).  There were three serious adverse events in patients receiving the active drug, as well as one case of malignant melanoma 96 days after the start of treatment. conclusions Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher resulted in greater clearing of psoriasis than did placebo over a period of 12 wk.  Larger and longer-duration trials of this drug are required to det. its safety and durability of effect in patients with psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqWANKhDdt7Vg90H21EOLACvtfcHk0livGYb2BPdEzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFWlsrbE&md5=ededd5d925dd557cceacc472839a966a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1806382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1806382%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%26aulast%3DGordon%26aufirst%3DK.%26aulast%3DTha%25C3%25A7i%26aufirst%3DD.%26aulast%3DMorita%26aufirst%3DA.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DP.%26aulast%3DGirgis%26aufirst%3DI.%2BG.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DBanerjee%26aufirst%3DS.%26atitle%3DPhase%25202%2520Trial%2520of%2520Selective%2520Tyrosine%2520Kinase%25202%2520Inhibition%2520in%2520Psoriasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D1313%26epage%3D1321%26doi%3D10.1056%2FNEJMoa1806382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellegrini, S.</span></span> <span> </span><span class="NLM_article-title">The Janus Kinase Family of Protein Tyrosine Kinases and their Role in Signaling</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1534</span>, <span class="refDoi"> DOI: 10.1007/s000180050392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1007%2Fs000180050392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10526570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK1MXmtF2msLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=1523-1534&author=T.+C.+Yehauthor=S.+Pellegrini&title=The+Janus+Kinase+Family+of+Protein+Tyrosine+Kinases+and+their+Role+in+Signaling&doi=10.1007%2Fs000180050392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase family of protein tyrosine kinases and their role in signaling</span></div><div class="casAuthors">Yeh, T. C.; Pellegrini, S.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1523-1534</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review is given with 143 refs. on the Jaks with particular emphasis on structure-function studies aimed at revealing how this family of tyrosine kinases is regulated.  In the early 1990s, the search for protein kinases led to the discovery of a novel family of non-receptor Tyr kinases, the Janus kinases or JAKs.  These proteins were unusual because they contained 2 kinase homol. domains and no other known signaling modules.  It soon became clear that these were not 'just another' type of kinase.  Their ability to complement mutant cells insensitive to interferons and to be activated by a variety of cytokines demonstrated their central signaling function.  Now, as the authors approach the end of the decade, it is evident from biochem. studies to knockout mice that JAKs play non-redundant functions in development, differentiation, and host defense mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuWb3drPf_OrVg90H21EOLACvtfcHk0lifWWAIfEFigA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtF2msLo%253D&md5=f6887b6510043e3814c3fb1b3581c69f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1007%2Fs000180050392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000180050392%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DT.%2BC.%26aulast%3DPellegrini%26aufirst%3DS.%26atitle%3DThe%2520Janus%2520Kinase%2520Family%2520of%2520Protein%2520Tyrosine%2520Kinases%2520and%2520their%2520Role%2520in%2520Signaling%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D1999%26volume%3D55%26spage%3D1523%26epage%3D1534%26doi%3D10.1007%2Fs000180050392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maxwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillert, E.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eksterowicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">27261</span>– <span class="NLM_lpage">27270</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.672048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1074%2Fjbc.M115.672048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=26359499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=27261-27270&author=X.+Minauthor=D.+Ungureanuauthor=S.+Maxwellauthor=H.+Hammar%C3%A9nauthor=S.+Thibaultauthor=E.-K.+Hillertauthor=M.+Ayresauthor=B.+Greenfieldauthor=J.+Eksterowiczauthor=C.+Gabelauthor=N.+Walkerauthor=O.+Silvennoinenauthor=Z.+Wang&title=Structural+and+Functional+Characterization+of+the+JH2+Pseudokinase+Domain+of+JAK+Family+Tyrosine+Kinase+2+%28TYK2%29&doi=10.1074%2Fjbc.M115.672048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)</span></div><div class="casAuthors">Min, Xiaoshan; Ungureanu, Daniela; Maxwell, Sarah; Hammaren, Henrik; Thibault, Steve; Hillert, Ellin-Kristina; Ayres, Merrill; Greenfield, Brad; Eksterowicz, John; Gabel, Chris; Walker, Nigel; Silvennoinen, Olli; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">27261-27270</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation.  JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2).  The majority of disease-assocd. mutations in JAKs map to JH2, demonstrating its central regulatory function.  JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity.  Whether the other JAK JH2s share ATP binding and enzymic activity has been unclear.  Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5'-O-(thiotriphosphate) (ATP-γS) and characterize its nucleotide binding by biochem. and biophys. methods.  TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes.  Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling.  The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing mol. interactions around helix αAL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s.  The structural and biochem. data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2.  Finally, the co-crystal structure of TYK2 JH2 complexed with a small mol. inhibitor demonstrates that JH2 is accessible to ATP-competitive compds., which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ZJIkM0pXXbVg90H21EOLACvtfcHk0lifWWAIfEFigA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrtrnO&md5=2933fa07a5bdbea19f3d434591613070</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.672048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.672048%26sid%3Dliteratum%253Aachs%26aulast%3DMin%26aufirst%3DX.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DMaxwell%26aufirst%3DS.%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DHillert%26aufirst%3DE.-K.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DGreenfield%26aufirst%3DB.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGabel%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructural%2520and%2520Functional%2520Characterization%2520of%2520the%2520JH2%2520Pseudokinase%2520Domain%2520of%2520JAK%2520Family%2520Tyrosine%2520Kinase%25202%2520%2528TYK2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D27261%26epage%3D27270%26doi%3D10.1074%2Fjbc.M115.672048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallweber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bir Kohli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span> <span> </span><span class="NLM_article-title">Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition</span>. <i>Proc. Nat. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">8025</span>– <span class="NLM_lpage">8030</span>, <span class="refDoi"> DOI: 10.1073/pnas.1401180111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1073%2Fpnas.1401180111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=24843152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=8025-8030&author=P.+J.+Lupardusauthor=M.+Ultschauthor=H.+Wallweberauthor=P.+Bir+Kohliauthor=A.+R.+Johnsonauthor=C.+Eigenbrot&title=Structure+of+the+Pseudokinase-Kinase+Domains+from+Protein+Kinase+TYK2+Reveals+a+Mechanism+for+Janus+Kinase+%28JAK%29+Autoinhibition&doi=10.1073%2Fpnas.1401180111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition</span></div><div class="casAuthors">Lupardus Patrick J; Ultsch Mark; Wallweber Heidi; Eigenbrot Charles; Bir Kohli Pawan; Johnson Adam R</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8025-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Janus kinases (JAKs) are receptor-associated multidomain tyrosine kinases that act downstream of many cytokines and interferons.  JAK kinase activity is regulated by the adjacent pseudokinase domain via an unknown mechanism.  Here, we report the 2.8-ÅA structure of the two-domain pseudokinase-kinase module from the JAK family member TYK2 in its autoinhibited form.  We find that the pseudokinase and kinase interact near the kinase active site and that most reported mutations in cancer-associated JAK alleles cluster in or near this interface.  Mutation of residues near the TYK2 interface that are analogous to those in cancer-associated JAK alleles, including the V617F and "exon 12" JAK2 mutations, results in increased kinase activity in vitro.  These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsxgEXiV6j3TQLBVDQn4bCfW6udTcc2eZ2--a4XQxiqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjktFyntg%253D%253D&md5=47f1d528f736376c9e02add92839ac67</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1401180111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1401180111%26sid%3Dliteratum%253Aachs%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWallweber%26aufirst%3DH.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520Pseudokinase-Kinase%2520Domains%2520from%2520Protein%2520Kinase%2520TYK2%2520Reveals%2520a%2520Mechanism%2520for%2520Janus%2520Kinase%2520%2528JAK%2529%2520Autoinhibition%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D8025%26epage%3D8030%26doi%3D10.1073%2Fpnas.1401180111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungureanu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisouard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoda, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span> <span> </span><span class="NLM_article-title">ATP Binding to the Pseudokinase Domain of JAK2 is Critical for Pathogenic Activation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">4642</span>– <span class="NLM_lpage">4647</span>, <span class="refDoi"> DOI: 10.1073/pnas.1423201112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1073%2Fpnas.1423201112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=25825724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVOntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=4642-4647&author=H.+M.+Hammar%C3%A9nauthor=D.+Ungureanuauthor=J.+Grisouardauthor=R.+C.+Skodaauthor=S.+R.+Hubbardauthor=O.+Silvennoinen&title=ATP+Binding+to+the+Pseudokinase+Domain+of+JAK2+is+Critical+for+Pathogenic+Activation&doi=10.1073%2Fpnas.1423201112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation</span></div><div class="casAuthors">Hammaren, Henrik M.; Ungureanu, Daniela; Grisouard, Jean; Skoda, Radek C.; Hubbard, Stevan R.; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4642-4647</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Pseudokinases lack conserved motifs typically required for kinase activity.  Nearly half of pseudokinases bind ATP, but only few retain phosphotransfer activity, leaving the functional role of nucleotide binding in most cases unknown.  Janus kinases (JAKs) are nonreceptor tyrosine kinases with a tandem pseudokinase-kinase domain configuration, where the pseudokinase domain (JAK homol. 2, JH2) has important regulatory functions and harbors mutations underlying hematol. and immunol. diseases.  JH2 of JAK1, JAK2, and TYK2 all bind ATP, but the significance of this is unclear.  We characterize the role of nucleotide binding in normal and pathogenic JAK signaling using comprehensive structure-based mutagenesis.  Disruption of JH2 ATP binding in wild-type JAK2 has only minor effects, and in the presence of type I cytokine receptors, the mutations do not affect JAK2 activation.  However, JH2 mutants devoid of ATP binding ameliorate the hyperactivation of JAK2 V617F.  Disrupting ATP binding in JH2 also inhibits the hyperactivity of other pathogenic JAK2 mutants, as well as of JAK1 V658F, and prevents induction of erythrocytosis in a JAK2 V617F myeloproliferative neoplasm mouse model.  Mol. dynamic simulations and thermal-shift anal. indicate that ATP binding stabilizes JH2, with a pronounced effect on the C helix region, which plays a crit. role in pathogenic activation of JAK2.  Taken together, our results suggest that ATP binding to JH2 serves a structural role in JAKs, which is required for aberrant activity of pathogenic JAK mutants.  The inhibitory effect of abrogating JH2 ATP binding in pathogenic JAK mutants may warrant novel therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowpDHSf5yGQ7Vg90H21EOLACvtfcHk0li0vKcLV0YSSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVOntL8%253D&md5=7cb7b90a1978ef02628f9ce9e85622ad</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1423201112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1423201112%26sid%3Dliteratum%253Aachs%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DUngureanu%26aufirst%3DD.%26aulast%3DGrisouard%26aufirst%3DJ.%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26aulast%3DHubbard%26aufirst%3DS.%2BR.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DATP%2520Binding%2520to%2520the%2520Pseudokinase%2520Domain%2520of%2520JAK2%2520is%2520Critical%2520for%2520Pathogenic%2520Activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D4642%26epage%3D4647%26doi%3D10.1073%2Fpnas.1423201112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wityak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doweyko, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieven, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftheris, K.</span></span> <span> </span><span class="NLM_article-title">5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6261</span>– <span class="NLM_lpage">6270</span>, <span class="refDoi"> DOI: 10.1021/jm0503594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0503594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFSnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6261-6270&author=C.+Liuauthor=S.+T.+Wrobleskiauthor=J.+Linauthor=G.+Ahmedauthor=A.+Metzgerauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=D.+J.+Shusterauthor=K.+W.+McIntyreauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=H.+Zhangauthor=A.+M.+Doweykoauthor=D.+Dillerauthor=I.+Hendersonauthor=J.+C.+Barrishauthor=J.+H.+Doddauthor=G.+L.+Schievenauthor=K.+Leftheris&title=5-Cyanopyrimidine+Derivatives+as+a+Novel+Class+of+Potent%2C+Selective%2C+and+Orally+Active+Inhibitors+of+p38%CE%B1+MAP+Kinase&doi=10.1021%2Fjm0503594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase</span></div><div class="casAuthors">Liu, Chunjian; Wrobleski, Stephen T.; Lin, James; Ahmed, Gulzar; Metzger, Axel; Wityak, John; Gillooly, Kathleen M.; Shuster, David J.; McIntyre, Kim W.; Pitt, Sidney; Shen, Ding Ren; Zhang, Rosemary F.; Zhang, Hongjian; Doweyko, Arthur M.; Diller, David; Henderson, Ian; Barrish, Joel C.; Dodd, John H.; Schieven, Gary L.; Leftheris, Katerina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6261-6270</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of 5-cyanopyrimidine-based inhibitors of p38α MAP kinase has been investigated.  Analogs optimized through SAR iterations display low nanomolar enzymic and cellular activity.  The in vivo efficacy of this class of p38 inhibitors was demonstrated by 3a and 3b (>50% redn. in TNF levels when orally dosed at 5 mg/kg, 5 h prior to LPS administration in an acute murine model of inflammation).  For 3a and 3b, the previously identified N-methoxybenzamide moiety (1) was replaced with N-(isoxazol-3-yl)benzamide, thereby providing increased metabolic stability.  Cyanopyrimidine 3a demonstrated 100% oral bioavailability in mouse.  High p38 kinase selectivity vs. over 20 kinases was obsd. for analog 3b.  Direct hydrogen bonding of the cyano nitrogen of the 5-cyanopyrimidine core to the backbone NH of Met109 was confirmed by x-ray crystallog. anal. of 3a bound to p38α.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjJgNQ1DS8nrVg90H21EOLACvtfcHk0li0vKcLV0YSSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFSnu7Y%253D&md5=f293bdf26280ffe475eb22ba509488f1</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm0503594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0503594%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DAhmed%26aufirst%3DG.%26aulast%3DMetzger%26aufirst%3DA.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DDiller%26aufirst%3DD.%26aulast%3DHenderson%26aufirst%3DI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3D5-Cyanopyrimidine%2520Derivatives%2520as%2520a%2520Novel%2520Class%2520of%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Active%2520Inhibitors%2520of%2520p38%25CE%25B1%2520MAP%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6261%26epage%3D6270%26doi%3D10.1021%2Fjm0503594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">15403</span>– <span class="NLM_lpage">15411</span>, <span class="refDoi"> DOI: 10.1021/ja906058w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja906058w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=15403-15411&author=J.+Michelauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Energetics+of+Displacing+Water+Molecules+from+Protein+Binding+Sites%3A+Consequences+for+Ligand+Optimization&doi=10.1021%2Fja906058w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization</span></div><div class="casAuthors">Michel, Julien; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15403-15411</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy in drug design is to consider enhancing the affinity of lead mols. with structural modifications that displace water mols. from a protein binding site.  Because success of the approach is uncertain, clarification of the assocd. energetics was sought in cases where similar structural modifications yield qual. different outcomes.  Specifically, free-energy perturbation calcns. were carried out in the context of Monte Carlo statistical mechanics simulations to investigate ligand series that feature displacement of ordered water mols. in the binding sites of scytalone dehydratase, p38-αMAP kinase, and EGFR kinase.  The change in affinity for a ligand modification is found to correlate with the ease of displacement of the ordered water mol.  However, as in the EGFR example, the binding affinity may diminish if the free-energy increase due to the removal of the bound water mol. is not more than compensated by the addnl. interactions of the water-displacing moiety.  For accurate computation of the effects of ligand modifications, a complete thermodn. anal. is shown to be needed.  It requires identification of the location of water mols. in the protein-ligand interface and evaluation of the free-energy changes assocd. with their removal and with the introduction of the ligand modification.  Direct modification of the ligand in free-energy calcns. is likely to trap the ordered mol. and provide misleading guidance for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoULCMKgzc8SLVg90H21EOLACvtfcHk0limyAwhUflkVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOiu7%252FI&md5=598676ea350be074bc2adea75eae9948</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fja906058w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja906058w%26sid%3Dliteratum%253Aachs%26aulast%3DMichel%26aufirst%3DJ.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DEnergetics%2520of%2520Displacing%2520Water%2520Molecules%2520from%2520Protein%2520Binding%2520Sites%253A%2520Consequences%2520for%2520Ligand%2520Optimization%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D15403%26epage%3D15411%26doi%3D10.1021%2Fja906058w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl Effects in Protein–Ligand Binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4500</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-4500&author=C.+S.+Leungauthor=S.+S.+F.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+Effects+in+Protein%E2%80%93Ligand+Binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0limyAwhUflkVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%2BF.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520Effects%2520in%2520Protein%25E2%2580%2593Ligand%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D4500%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schönherr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span> <span> </span><span class="NLM_article-title">Profound Methyl Effects in Drug Discovery and a Call for New C–H Methylation Reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12256</span>– <span class="NLM_lpage">12267</span>, <span class="refDoi"> DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Sch%C3%B6nherrauthor=T.+Cernak&title=Profound+Methyl+Effects+in+Drug+Discovery+and+a+Call+for+New+C%E2%80%93H+Methylation+Reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span></div><div class="casAuthors">Schonherr Heike; Cernak Tim</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">12256-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The methyl group is one of the most commonly occurring carbon fragments in small-molecule drugs.  This simplest alkyl fragment appears in more than 67 % of the top-selling drugs of 2011 and can modulate both the biological and physical properties of a molecule.  This Review focuses on so-called magic methyl effects on binding potency, where the seemingly mundane change of C H to C Me improves the IC50  value of a drug candidate more than 100-fold.  This discussion is followed by a survey of recent advances in synthetic chemistry that allow the direct methylation of C(sp(2) ) H and C(sp(3) ) H bonds.  It is our hope that the relevance of the meager methyl group to drug discovery as presented herein will inspire reports on new C H methylation reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyoLZDDgvsMh0LsK7uFuY7fW6udTcc2eb39ZDdCL2yQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D&md5=ef08f80e55b2c530b49e4306da024902</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520Methyl%2520Effects%2520in%2520Drug%2520Discovery%2520and%2520a%2520Call%2520for%2520New%2520C%25E2%2580%2593H%2520Methylation%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span> <i>Small Molecule Drug Discovery Suite 2016-3, WaterMap</i>, <span class="NLM_edition">version 2.8</span>; <span class="NLM_publisher-name">Schrodinger, LLC</span>; <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Small+Molecule+Drug+Discovery+Suite+2016-3%2C+WaterMap%2C+version+2.8%3B+Schrodinger%2C+LLC%3B+New+York%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DSmall%2520Molecule%2520Drug%2520Discovery%2520Suite%25202016-3%252C%2520WaterMap%26pub%3DSchrodinger%252C%2520LLC%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilenko, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastham-Anderson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, W.</span></span> <span> </span><span class="NLM_article-title">Interleukin-22, a T(H)17 Cytokine, Mediates IL-23-Induced Dermal Inflammation and Acanthosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>445</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1038/nature05505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1038%2Fnature05505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=17187052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=445&publication_year=2007&pages=648-651&author=Y.+Zhengauthor=D.+M.+Danilenkoauthor=P.+Valdezauthor=I.+Kasmanauthor=J.+Eastham-Andersonauthor=J.+Wuauthor=W.+Ouyang&title=Interleukin-22%2C+a+T%28H%2917+Cytokine%2C+Mediates+IL-23-Induced+Dermal+Inflammation+and+Acanthosis&doi=10.1038%2Fnature05505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis</span></div><div class="casAuthors">Zheng, Yan; Danilenko, Dimitry M.; Valdez, Patricia; Kasman, Ian; Eastham-Anderson, Jeffrey; Wu, Jianfeng; Ouyang, Wenjun</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">445</span>
        (<span class="NLM_cas:issue">7128</span>),
    <span class="NLM_cas:pages">648-651</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Psoriasis is a chronic inflammatory skin disease characterized by hyperplasia of the epidermis (acanthosis), infiltration of leukocytes into both the dermis and epidermis, and dilation and growth of blood vessels.  The underlying cause of the epidermal acanthosis in psoriasis is still largely unknown.  Recently, interleukin (IL)-23, a cytokine involved in the development of IL-17-producing T helper cells (TH17 cells), was found to have a potential function in the pathogenesis of psoriasis.  Here the authors show that IL-22 is preferentially produced by TH17 cells and mediates the acanthosis induced by IL-23.  The authors found that IL-23 or IL-6 can directly induce the prodn. of IL-22 from both murine and human naive T cells.  However, the prodn. of IL-22 and IL-17 from TH17 cells is differentially regulated.  Transforming growth factor-β, although crucial for IL-17 prodn., actually inhibits IL-22 prodn.  Furthermore, IL-22 mediates IL-23-induced acanthosis and dermal inflammation through the activation of Stat3 (signal transduction and activators of transcription 3) in vivo.  The authors' results suggest that TH17 cells, through the prodn. of both IL-22 and IL-17, might have essential functions in host defense and in the pathogenesis of autoimmune diseases such as psoriasis.  IL-22, as an effector cytokine produced by T cells, mediates the crosstalk between the immune system and epithelial cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUsvRYRPqQbVg90H21EOLACvtfcHk0lgV-UuqGhzRfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOrtLk%253D&md5=492a413528aa035cbdc6a7ad683610c5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnature05505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05505%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDanilenko%26aufirst%3DD.%2BM.%26aulast%3DValdez%26aufirst%3DP.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DEastham-Anderson%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DOuyang%26aufirst%3DW.%26atitle%3DInterleukin-22%252C%2520a%2520T%2528H%252917%2520Cytokine%252C%2520Mediates%2520IL-23-Induced%2520Dermal%2520Inflammation%2520and%2520Acanthosis%26jtitle%3DNature%26date%3D2007%26volume%3D445%26spage%3D648%26epage%3D651%26doi%3D10.1038%2Fnature05505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, R.</span>; <span class="NLM_string-name">Sheriff, S.</span>; <span class="NLM_string-name">Wei, A.</span>; <span class="NLM_string-name">Ramamurthy, V.</span>; <span class="NLM_string-name">Bush, A.</span>; <span class="NLM_string-name">Russo, K. A.</span>; <span class="NLM_string-name">Engle, L.</span></span> <span> </span><span class="NLM_article-title">Fibronectin Based Scaffold Domain Proteins that Bind IL-23</span>. U.S. Patent <span class="NLM_patent">9,260,496 B2</span>, Dec 20, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=R.+Dasgupta&author=S.+Sheriff&author=A.+Wei&author=V.+Ramamurthy&author=A.+Bush&author=K.+A.+Russo&author=L.+Engle&title=Fibronectin+Based+Scaffold+Domain+Proteins+that+Bind+IL-23"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDasgupta%26aufirst%3DR.%26atitle%3DFibronectin%2520Based%2520Scaffold%2520Domain%2520Proteins%2520that%2520Bind%2520IL-23%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guram, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Aromatic Aminations with in Situ Generated Aminostannanes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">7901</span>– <span class="NLM_lpage">7902</span>, <span class="refDoi"> DOI: 10.1021/ja00096a059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00096a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK2cXmvVSgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=7901-7902&author=A.+S.+Guramauthor=S.+L.+Buchwald&title=Palladium-Catalyzed+Aromatic+Aminations+with+in+Situ+Generated+Aminostannanes&doi=10.1021%2Fja00096a059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Aromatic Aminations with in situ Generated Aminostannanes</span></div><div class="casAuthors">Guram, Anil S.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7901-2</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Aminostannes, generated in situ by the transamination reactions of N,N-diethylaminotributyltin with primary and secondary amines, undergo Pd-catalyzed reactions with aryl bromides to afford aryl amines in good yields.  Thus, e.g., in situ generation of Bu3SnNMeCH2Ph via transamination of Bu3SnNEt2 with HNMeCH2Ph, followed by reaction with 4-EtO2CC6H4Br in presence of PdCl2[P(o-tolyl)3]2 afforded 88% 4-EtO2CC6H4NMeCH2Ph.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbgxIJwAw2rVg90H21EOLACvtfcHk0lgV-UuqGhzRfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvVSgs74%253D&md5=01e7d965aef985f90b78c7c7bda73c9d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fja00096a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00096a059%26sid%3Dliteratum%253Aachs%26aulast%3DGuram%26aufirst%3DA.%2BS.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-Catalyzed%2520Aromatic%2520Aminations%2520with%2520in%2520Situ%2520Generated%2520Aminostannanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D7901%26epage%3D7902%26doi%3D10.1021%2Fja00096a059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J. F.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Formation of Carbon-Nitrogen Bonds. Reaction Intermediates and Catalyst Improvements in the Hetero Cross-Coupling of Aryl Halides and Tin Amides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">5969</span>– <span class="NLM_lpage">5970</span>, <span class="refDoi"> DOI: 10.1021/ja00092a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00092a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADyaK2cXltlCnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=5969-5970&author=F.+Paulauthor=J.+Pattauthor=J.+F.+Hartwig&title=Palladium-Catalyzed+Formation+of+Carbon-Nitrogen+Bonds.+Reaction+Intermediates+and+Catalyst+Improvements+in+the+Hetero+Cross-Coupling+of+Aryl+Halides+and+Tin+Amides&doi=10.1021%2Fja00092a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed formation of carbon-nitrogen bonds. Reaction intermediates and catalyst improvements in the hetero cross-coupling of aryl halides and tin amides</span></div><div class="casAuthors">Paul, Frederic; Patt, Joe; Hartwig, John F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5969-70</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The hetero cross-coupling of aryl bromides and Sn amides by Pd catalysts was studied to understand transition metal mediated C-N bond forming processes and to find more efficient and more general catalysts for this coupling process.  The Pd(II) compd. [(o-MeC6H4)3P]2PdX2 (X = Cl 1-Cl, Br 1-Br) is known to catalyze the hetero cross-coupling of Bu3SnNMe2 and phenyl- or p-alkylphenyl bromides at 90-110° in arene solvents to form N,N-dimethylanilines in 75-85% yields.  Three complexes were isolated and are kinetically competent intermediates in this catalytic process.  The mixed amine/phosphine complexes [(o-tolyl)3P](NHR2)PdCl2 (2) were formed by reaction of 1 with Sn dialkyl amides.  These amine complexes were sol. in toluene, catalyzed the coupling process in yields comparable to 1, and were characterized crystallog.  The Pd(0) species [(o-tolyl)3P]2Pd (3) was prepd. in pure form by addn. of (o-tolyl)3P to Pd(dba)2 and was also characterized crystallog.  This complex catalyzed the coupling chem. with rates that were faster than those involving 1 or 2.  The isolation of this pure Pd(0) species allowed a mechanistic anal. of the coupling process.  3 Reacted with aryl halides to yield the dimeric {[(o-tolyl)3P]Pd(Br)(Ar)}2 (4) which was also characterized spectroscopically, crystallog., and by soln. mol. wt.  The dimeric form appears to be retained in soln.  4 Reacted with Sn and Li amides to produce the arylamine products in yields comparable to those of the catalytic process.  This coupling step involved direct reaction of 4 with the main group amides, strongly suggesting that transmetalation and reductive elimination are the steps that provide coupled product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO5cbOkyGCp7Vg90H21EOLACvtfcHk0lgV-UuqGhzRfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXltlCnsrY%253D&md5=e322f59a309f7f377857fa5b61626aaf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fja00092a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00092a058%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DF.%26aulast%3DPatt%26aufirst%3DJ.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26atitle%3DPalladium-Catalyzed%2520Formation%2520of%2520Carbon-Nitrogen%2520Bonds.%2520Reaction%2520Intermediates%2520and%2520Catalyst%2520Improvements%2520in%2520the%2520Hetero%2520Cross-Coupling%2520of%2520Aryl%2520Halides%2520and%2520Tin%2520Amides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D5969%26epage%3D5970%26doi%3D10.1021%2Fja00092a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halford, B.</span></span> <span> </span><span class="NLM_article-title">Deuterium Switcheroo Breathes Life into Old Drugs</span>. <i>Chem. Eng. News</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">36</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=32-36&author=B.+Halford&title=Deuterium+Switcheroo+Breathes+Life+into+Old+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalford%26aufirst%3DB.%26atitle%3DDeuterium%2520Switcheroo%2520Breathes%2520Life%2520into%2520Old%2520Drugs%26jtitle%3DChem.%2520Eng.%2520News%26date%3D2016%26volume%3D94%26spage%3D32%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talele, T.
T.</span></span> <span> </span><span class="NLM_article-title">The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8712</span>– <span class="NLM_lpage">8756</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00472</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00472" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8712-8756&author=T.%0AT.+Talele&title=The+%E2%80%9CCyclopropyl+Fragment%E2%80%9D+is+a+Versatile+Player+that+Frequently+Appears+in+Preclinical%2FClinical+Drug+Molecules&doi=10.1021%2Facs.jmedchem.6b00472"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules</span></div><div class="casAuthors">Talele, Tanaji T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8712-8756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing use of the cyclopropyl ring in drug development to transition drug candidates from the preclin. to clin. stage.  Important features of the cyclopropane ring are, the (1) coplanarity of the three carbon atoms, (2) relatively shorter (1.51 Å) C-C bonds, (3) enhanced π-character of C-C bonds, and (4) C-H bonds are shorter and stronger than those in alkanes.  The present review will focus on the contributions that a cyclopropyl ring makes to the properties of drugs contg. it.  Consequently, the cyclopropyl ring addresses multiple roadblocks that can occur during drug discovery such as (a) enhancing potency, (b) reducing off-target effects, (c) increasing metabolic stability, (d) increasing brain permeability, (e) decreasing plasma clearance, (f) contributing to an entropically more favorable binding to the receptor, (g) conformational restriction of peptides/peptidomimetics to prevent proteolytic hydrolysis, and (h) altering drug pKa to reduce its P-glycoprotein efflux ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIJAG1XVRG7Vg90H21EOLACvtfcHk0lgxMd3hxScIJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpslWguro%253D&md5=b5586458ec4ab5e2d7586f5739663d1f</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00472%26sid%3Dliteratum%253Aachs%26aulast%3DTalele%26aufirst%3DT.%2BT.%26atitle%3DThe%2520%25E2%2580%259CCyclopropyl%2520Fragment%25E2%2580%259D%2520is%2520a%2520Versatile%2520Player%2520that%2520Frequently%2520Appears%2520in%2520Preclinical%252FClinical%2520Drug%2520Molecules%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8712%26epage%3D8756%26doi%3D10.1021%2Facs.jmedchem.6b00472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The Impact of Aromatic Ring Count on Compound Developability: Further Insights by Examining Carbo- and Hetero-Aromatic and -Aliphatic Ring Types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+Impact+of+Aromatic+Ring+Count+on+Compound+Developability%3A+Further+Insights+by+Examining+Carbo-+and+Hetero-Aromatic+and+-Aliphatic+Ring+Types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lgxMd3hxScIJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520Impact%2520of%2520Aromatic%2520Ring%2520Count%2520on%2520Compound%2520Developability%253A%2520Further%2520Insights%2520by%2520Examining%2520Carbo-%2520and%2520Hetero-Aromatic%2520and%2520-Aliphatic%2520Ring%2520Types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spyrakis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayden, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozzini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzarelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellogg, G. E.</span></span> <span> </span><span class="NLM_article-title">The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6781</span>– <span class="NLM_lpage">6827</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6781-6827&author=F.+Spyrakisauthor=M.+H.+Ahmedauthor=A.+S.+Baydenauthor=P.+Cozziniauthor=A.+Mozzarelliauthor=G.+E.+Kellogg&title=The+Roles+of+Water+in+the+Protein+Matrix%3A+A+Largely+Untapped+Resource+for+Drug+Discovery&doi=10.1021%2Facs.jmedchem.7b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery</span></div><div class="casAuthors">Spyrakis, Francesca; Ahmed, Mostafa H.; Bayden, Alexander S.; Cozzini, Pietro; Mozzarelli, Andrea; Kellogg, Glen E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6781-6827</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The value of thoroughly understanding the thermodn. specific to a drug discovery/design study is well known.  Over the past decade, the crucial roles of water mols. in protein structure, function, and dynamics have also become increasingly appreciated.  This Perspective explores water in the biol. environment by adopting its point of view in such phenomena.  The prevailing thermodn. models of the past, where water was seen largely in terms of an entropic gain after its displacement by a ligand, are now known to be much too simplistic.  We adopt a set of terminol. that describes water mols. as being "hot" and "cold", which we have defined as being easy and difficult to displace, resp.  The basis of these designations, which involve both enthalpic and entropic water contributions, are explored in several classes of biomols. and structural motifs.  The hallmarks for characterizing water mols. are examd., and computational tools for evaluating water-centric thermodn. are reviewed.  This Perspective's summary features guidelines for exploiting water mols. in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD8mT4Z7V7P7Vg90H21EOLACvtfcHk0lgxMd3hxScIJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVyru7s%253D&md5=1e6f76629bf2eeabf8b491f8814cfc69</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00057%26sid%3Dliteratum%253Aachs%26aulast%3DSpyrakis%26aufirst%3DF.%26aulast%3DAhmed%26aufirst%3DM.%2BH.%26aulast%3DBayden%26aufirst%3DA.%2BS.%26aulast%3DCozzini%26aufirst%3DP.%26aulast%3DMozzarelli%26aufirst%3DA.%26aulast%3DKellogg%26aufirst%3DG.%2BE.%26atitle%3DThe%2520Roles%2520of%2520Water%2520in%2520the%2520Protein%2520Matrix%253A%2520A%2520Largely%2520Untapped%2520Resource%2520for%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6781%26epage%3D6827%26doi%3D10.1021%2Facs.jmedchem.7b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krimmer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein-Bound Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10530</span>– <span class="NLM_lpage">10548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCjsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10530-10548&author=S.+G.+Krimmerauthor=J.+Cramerauthor=M.+Betzauthor=V.+Fridhauthor=R.+Karlssonauthor=A.+Heineauthor=G.+Klebe&title=Rational+Design+of+Thermodynamic+and+Kinetic+Binding+Profiles+by+Optimizing+Surface+Water+Networks+Coating+Protein-Bound+Ligands&doi=10.1021%2Facs.jmedchem.6b00998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein-Bound Ligands</span></div><div class="casAuthors">Krimmer, Stefan G.; Cramer, Jonathan; Betz, Michael; Fridh, Veronica; Karlsson, Robert; Heine, Andreas; Klebe, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10530-10548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A previously studied congeneric series of thermolysin inhibitors addressing the solvent-accessible S2' pocket with different hydrophobic substituents showed modulations of the surface water layers coating the protein-bound inhibitors.  Increasing stabilization of water mols. resulted in enthalpically more favorable binding signature, overall enhancing affinity.  Based on this observation, the authors optimized the series by designing tailored P2' substituents to improve and further stabilize the surface water network.  MD simulations were applied to predict the putative water pattern around the bound ligands.  Subsequently, the inhibitors were synthesized and characterized by high-resoln. crystallog., microcalorimetry and surface plasmon resonance.  One of the designed inhibitors established the most pronounced water network of all inhibitors tested so far, composed of several fused water polygons, and showed 50-fold affinity enhancement with respect to the original methylated parent ligand.  Notably, the inhibitor forming the most perfect water network also showed significantly prolonged residence time compared to the other tested inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKAWUpfEr2WbVg90H21EOLACvtfcHk0ljcDnFgBpuQMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCjsL%252FN&md5=37092339ddcbe5a1ec6a10572b1a3213</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00998%26sid%3Dliteratum%253Aachs%26aulast%3DKrimmer%26aufirst%3DS.%2BG.%26aulast%3DCramer%26aufirst%3DJ.%26aulast%3DBetz%26aufirst%3DM.%26aulast%3DFridh%26aufirst%3DV.%26aulast%3DKarlsson%26aufirst%3DR.%26aulast%3DHeine%26aufirst%3DA.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DRational%2520Design%2520of%2520Thermodynamic%2520and%2520Kinetic%2520Binding%2520Profiles%2520by%2520Optimizing%2520Surface%2520Water%2520Networks%2520Coating%2520Protein-Bound%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10530%26epage%3D10548%26doi%3D10.1021%2Facs.jmedchem.6b00998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bodnarchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Water, S.</span></span> <span> </span><span class="NLM_article-title">Water, Everywhere···It’s Time to Stop and Think</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1016%2Fj.drudis.2016.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=27210724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC28XoslWltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1139-1146&author=M.+Bodnarchukauthor=S.+Water&title=Water%2C+Everywhere%C2%B7%C2%B7%C2%B7It%E2%80%99s+Time+to+Stop+and+Think&doi=10.1016%2Fj.drudis.2016.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Water, water, everywhere... It's time to stop and think</span></div><div class="casAuthors">Bodnarchuk, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite the numerous methods available for predicting the location and affinity of water mols., there is still a degree of scepticism and reluctance towards using such information within a drug discovery program.  Here, I review some of the most common and popular methods to assess whether these apparent concerns are justified.  I suggest that the field is approaching maturity and that some methods are capable of giving quant. predictions, which are confirmed exptl.  This suggests that water-placement methods should be used more widely to help direct chem. efforts, although more successful examples are required to help validate the techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxfKWV5PXTkrVg90H21EOLACvtfcHk0ljcDnFgBpuQMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XoslWltb4%253D&md5=dc2a72fa764bb19cd0c0ca2921fc974a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DBodnarchuk%26aufirst%3DM.%26aulast%3DWater%26aufirst%3DS.%26atitle%3DWater%252C%2520Everywhere%25C2%25B7%25C2%25B7%25C2%25B7It%25E2%2580%2599s%2520Time%2520to%2520Stop%2520and%2520Think%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1139%26epage%3D1146%26doi%3D10.1016%2Fj.drudis.2016.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightstone, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. E.</span></span> <span> </span><span class="NLM_article-title">Approaches to Efficiently Estimate Solvation and Explicit Water Energetics in Ligand Binding: The Use of WaterMap</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.749853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1517%2F17460441.2013.749853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=23286874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtF2htb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=277-287&author=Y.+Yangauthor=F.+C.+Lightstoneauthor=S.+E.+Wong&title=Approaches+to+Efficiently+Estimate+Solvation+and+Explicit+Water+Energetics+in+Ligand+Binding%3A+The+Use+of+WaterMap&doi=10.1517%2F17460441.2013.749853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: the use of WaterMap</span></div><div class="casAuthors">Yang, Yue; Lightstone, Felice C.; Wong, Sergio E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-287</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Water displacement plays crit. role in several phases of drug discovery.  Proper treatment of displacing water could improve enrichment in virtual screening and could lead to more successes in lead optimization.  WaterMap has recently emerged as a promising approach in this regard; recent implementations of this protocol successfully explained various binding activity that were poorly understood previously, including the well-known super affinity assocd. with biotin binding to streptavidin.Areas covered: The review briefly discusses implicit and explicit solvent models and focuses on an application of inhomogeneous solvation theory - WaterMap.  Furthermore, the review discusses various successful cases where the use of WaterMap explained selectivity in protein-ligand binding and provides discussion of the fundamentals and recently successful implementations of WaterMap.  The authors also discuss the limitations of this protocol and list a few approaches that could extend its implementation to more cases.Expert opinion: WaterMap is a powerful tool for calcg. the cost of desolvation for structural waters.  In some cases, it proved useful in predicting relative binding free energy differences for congeneric ligands.  The practical utility of WaterMap hinges in adequate application of the results in the context of all the thermodn. contributions to binding.  Potential improvements as well as integration into methods such like MM-GB/SA could extend its success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTt0Lv5MkEN7Vg90H21EOLACvtfcHk0ljcDnFgBpuQMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtF2htb8%253D&md5=b63980bbfbea61c076be0d10704e2e91</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.749853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.749853%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLightstone%26aufirst%3DF.%2BC.%26aulast%3DWong%26aufirst%3DS.%2BE.%26atitle%3DApproaches%2520to%2520Efficiently%2520Estimate%2520Solvation%2520and%2520Explicit%2520Water%2520Energetics%2520in%2520Ligand%2520Binding%253A%2520The%2520Use%2520of%2520WaterMap%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D277%26epage%3D287%26doi%3D10.1517%2F17460441.2013.749853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightstone, F. C.</span></span> <span> </span><span class="NLM_article-title">Accounting for Water Molecules in Drug Design</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1517/17460441.2011.534452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=10.1517%2F17460441.2011.534452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=22646827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=65-74&author=S.+E.+Wongauthor=F.+C.+Lightstone&title=Accounting+for+Water+Molecules+in+Drug+Design&doi=10.1517%2F17460441.2011.534452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Accounting for water molecules in drug design</span></div><div class="casAuthors">Wong, Sergio E.; Lightstone, Felice C.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-74</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Water mols. often appear around ligands in protein crystal structures.  Reliable prediction of the effects of water on ligand binding remains a challenge.  Solvation effects are crucial for lead optimization where a 100-fold difference in binding affinity is significant but correspond to only ∼ 3 kcal/mol in binding free energy.  Well-known examples, such as nonpeptidic urea inhibitors of HIV protease, prove that careful examn. of water mols. and their energetics can contribute significantly to a successful drug design campaign.  Areas covered in this review: In this review, we examine methods to account for the effect of water in ligand binding at two stages of drug discovery: lead identification via docking calcns. and lead optimization.  We provide a survey of the models and techniques available to account for water in drug design.  What the reader will gain: The reader will become aware of common practices and pitfalls in dealing with water mols. in structure-based drug design.  Take home message: Although solvation effects are not fully understood, some pragmatic recommendations at the end of the article provide guidance for modelers in this area as well as new practitioners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp69CF6zImq0rVg90H21EOLACvtfcHk0lhlZrdCFdvBWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SrtbvN&md5=9dddf1105c78b0e29b416016a4e328ab</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.534452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.534452%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DS.%2BE.%26aulast%3DLightstone%26aufirst%3DF.%2BC.%26atitle%3DAccounting%2520for%2520Water%2520Molecules%2520in%2520Drug%2520Design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D65%26epage%3D74%26doi%3D10.1517%2F17460441.2011.534452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28PAINS%29+from+Screening+Libraries+and+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lhlZrdCFdvBWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528PAINS%2529%2520from%2520Screening%2520Libraries%2520and%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span> <span> </span><span class="NLM_article-title">One-Pot Synthesis of Hybrid Macrocyclic Pentamers with Variable Functionalizations around the Periphery</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2270</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1021/ol200538d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol200538d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlOls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=2270-2273&author=B.+Qinauthor=C.+Sunauthor=Y.+Liuauthor=J.+Shenauthor=R.+Yeauthor=J.+Zhuauthor=X.-F.+Duanauthor=H.+Zeng&title=One-Pot+Synthesis+of+Hybrid+Macrocyclic+Pentamers+with+Variable+Functionalizations+around+the+Periphery&doi=10.1021%2Fol200538d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">One-Pot Synthesis of Hybrid Macrocyclic Pentamers with Variable Functionalizations around the Periphery</span></div><div class="casAuthors">Qin, Bo; Sun, Chang; Liu, Ying; Shen, Jie; Ye, Ruijuan; Zhu, Jia; Duan, Xin-Fang; Zeng, Huaqiang</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2270-2273</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rather than four- or six-residue macrocycles, one-pot macrocyclization of m-anthranilic acid derivs. allows for the highly selective formation of five-residue macrocycles rigidified by intramol. hydrogen bonds.  Variable functionalizations around the pentameric periphery were achieved by reacting monomers with higher oligomers bearing different exterior side chains.  The formation of these hybrid pentamers suggests a chain-growth mechanism for the one-pot macrocyclization where the successive addn. of monomers onto higher oligomers is faster than those between two monomers or two higher oligomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz4Sn6GF_id7Vg90H21EOLACvtfcHk0lhlZrdCFdvBWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlOls74%253D&md5=e3479232a4b2bceec7909f0132d92d56</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fol200538d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol200538d%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DDuan%26aufirst%3DX.-F.%26aulast%3DZeng%26aufirst%3DH.%26atitle%3DOne-Pot%2520Synthesis%2520of%2520Hybrid%2520Macrocyclic%2520Pentamers%2520with%2520Variable%2520Functionalizations%2520around%2520the%2520Periphery%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D2270%26epage%3D2273%26doi%3D10.1021%2Fol200538d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moslin, R. M.</span>; <span class="NLM_string-name">Weinstein, D. S.</span>; <span class="NLM_string-name">Wrobleski, S. T.</span>; <span class="NLM_string-name">Tokarski, J. S.</span>; <span class="NLM_string-name">Spergel, S. H.</span>; <span class="NLM_string-name">Lin, S.</span>; <span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Amide-Substituted Heterocyclic Compounds Useful as Modulators of IL-12, IL-23 and/or IFNα Responses</span>. U.S. Patent <span class="NLM_patent">9,505,748 B2</span>, Nov 7, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+M.+Moslin&author=D.+S.+Weinstein&author=S.+T.+Wrobleski&author=J.+S.+Tokarski&author=S.+H.+Spergel&author=S.+Lin&author=Y.+Zhang&title=Amide-Substituted+Heterocyclic+Compounds+Useful+as+Modulators+of+IL-12%2C+IL-23+and%2For+IFN%CE%B1+Responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoslin%26aufirst%3DR.%2BM.%26atitle%3DAmide-Substituted%2520Heterocyclic%2520Compounds%2520Useful%2520as%2520Modulators%2520of%2520IL-12%252C%2520IL-23%2520and%252For%2520IFN%25CE%25B1%2520Responses%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZR','PDB','6NZR'); return false;">PDB: 6NZR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZQ','PDB','6NZQ'); return false;">PDB: 6NZQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZP','PDB','6NZP'); return false;">PDB: 6NZP</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i65"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00444">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_36327"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00444">10.1021/acs.jmedchem.9b00444</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray crystallographic data and refinement statistics for compounds <b>11</b>, <b>12</b>, and <b>29</b> in TYK2 JH2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings list (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_001.pdf">jm9b00444_si_001.pdf (146.23 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00444/suppl_file/jm9b00444_si_002.csv">jm9b00444_si_002.csv (2.96 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>11</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZP">6NZP</a>), <b>12</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZR">6NZR</a>), and <b>29</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6NZQ">6NZQ</a>) in TYK2 JH2 are available from the RCSB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00444&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00444%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00444" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0e2673ddcd94e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
